ABSTRACT

This material provides documentation for users of the 2006 National Ambulatory Medical Care Survey (NAMCS) public use micro-data file. The NAMCS is a national probability sample survey of visits to office-based physicians conducted by the National Center for Health Statistics, Centers for Disease Control and Prevention. It is a component of the National Health Care Survey which measures health care utilization across a variety of health care providers. Section I, "Description of the National Ambulatory Medical Care Survey," includes information on the scope of the survey, the sample, field activities, data collection procedures, medical coding procedures, population estimates, and sampling errors. Section II provides technical information, including a detailed description of the contents of each data record by location, and a list of physician specialties represented in the survey. Section III contains marginal data and estimates for selected items on the data record. The appendixes contain sampling errors, instructions and definitions for completing the Patient Record form, and lists of codes used in the survey.

SUMMARY OF CHANGES FOR 2006

The 2006 NAMCS public use micro-data file contains many of the same items as the 2005 file, but also reflects a few changes made to the 2006 Patient Record form and to the sample design itself. There are also new items that were created during data processing using recoded data collected on the Patient Record form as well as new items from the Physician Induction Interview. The items listed below were added or modified for 2006.

1. New/Modified Items

- **a. Does the patient now have:** The cancer checkbox for this item now has 5 checkboxes under it to indicate the stage.
- **b.** Diagnostic/Screening Services New checkboxes were added for pap test conventional; pap test liquid-based; and pap test unspecified. These replace the former single checkbox for pap test/cervical cytology. Also, a new checkbox for HPV DNA test was added.
- c. Non-Medication Treatment A radiation therapy checkbox was added.

The following data items were collected at the physician induction interview. The first nine are modifications made to items already collected and appearing on the public use file in 2005.

- d. If your practice's electronic medical record system includes computerized orders for prescriptions, are there warnings of drug interactions or contraindications provided?
- e. If your practice's electronic medical record system includes computerized orders for prescriptions, are prescriptions sent electronically to the pharmacy?
- f. If your practice's electronic medical record system includes computerized orders for tests, are orders sent electronically?
- g. If your practice's electronic medical record system includes lab results, are out of range levels highlighted?
- h. If your practice's electronic medical record system includes imaging results, are electronic images returned?
- i. If your practice's electronic medical record system includes clinical notes, do they include medical history and follow-up notes?
- j. If your practice's electronic medical record system includes clinical notes, do they include reminders for guideline-based interventions and/or screening tests?
- k. If your practice's electronic medical record system includes public health reporting, are notifiable diseases sent electronically?
- I. Are there plans for installing a new EMR system or replacing the current system within the next 3 years?
- m. Which of the following factors are taken into account for your patient care compensation (eg., base pay, bonuses, or withholds)?
 Your productivity (eg., number of cases seen per time period?)
 Patient satisfaction (eg., results of patient surveys)?
 Quality of care (eg., rates of preventive care services)?
 Practice profiling (patterns of using certain services, eg., laboratory tests, imaging, referrals, etc.)?
- n. Are performance measures on your practice available to the public?
- o. What percent of your patient care revenue is based on bonuses, returned withholds, or other performance-based payments?

- p. Roughly, what percent of your patient care revenue comes from each of the following methods of payment: Usual, customary and reasonable fee-for-service?
 - Discounted fee-for-service? Capitation? Case rates (eg., package pricing/episode of care)? Other?
- q. Does your practice offer any type of cervical cancer screening?

The following items are based on the patient's ZIP code of residence (which is not available on the public use file). ZIP code was used in conjunction with the NCHS Urban-Rural Classification Scheme for Counties (http://www.cdc.gov/nchs/r&d/rdc_urbanrural.htm) to determine the urban-rural status of the patient's residence. ZIP was used with data from the 2000 Census to determine education, income, and poverty measures. Cut-points for education and income were developed based on population quartiles (using ZIP code as the level of aggregation) for which the area measure fell. Poverty groupings were based on cut-points consistent with the "Public Health Geocoding Disparities Project" (American Journal of Epidemiol 2002;156(5):471-82.) Category 4, 20% or greater poverty, also corresponds to the Federal designation of a high poverty area established in the 1990 Census. See "Poverty Areas", Economics and Statistics Administration, U.S. Department of Commerce, June 1995. http://www.census.gov/population/socdemo/statbriefs/povarea.html.

- r Percent of poverty in patient's ZIP code
- s. Median household income in patient's ZIP code
- t. Percentage of adults with a Bachelor's Degree or higher in patient's ZIP code
- u. Urban-rural classification of the patient's ZIP code

The following section describes changes to the drug characteristics data.

v. One other change involves switching from the Food and Drug Administration's (FDA) National Drug Code Directory (NDC) to Lexicon Plus[®], a proprietary database of Cerner Multum, Inc., to code characteristics of drugs listed on the Patient Record. This switch was necessitated because the NDC was no longer being maintained by the FDA. The switch to Multum means that the NCHS generic codes (GEN1-GEN8) are no longer used to code NAMCS data. Instead, Multum codes for the generic composition of drugs have been adopted (see new items DRUGID1-DRUGID8). Each drug can have multiple therapeutic classes (termed drug categories in Multum) assigned to it; the public use file lists up to four categories for each drug.

Because each Multum code reflects all of a drug's ingredients, the separate ingredient fields for multi-ingredient drugs are no longer included on the public use file. The therapeutic classes (drug categories) included on the file for each drug will describe that drug, but for multi-ingredient drugs, one can not determine directly from the public use file the association between a particular ingredient and the therapeutic class. Therefore, a separate file for drug ingredients and their specific therapeutic classes is also available for downloading and merging with the public use data file, should users need this information. For a detailed description of the drug data changes on the public use file, please see page 22.

2. Deleted Items

None.

3. New Sampling Stratum of Community Health Centers (CHCs)

A sample of 104 Community Health Centers was selected based on information from the Health Resources Services Administration's Bureau of Primary Health Care Uniform Data System and the Indian Health Service. From each sampled CHC, a list of physicians and mid-level providers was obtained, which became the sampling frame for a selection of up to 3 health providers per CHC. Data on physicians working at CHCs are included in this public use data file; mid-level providers are not included. A separate file of mid-level provider data is expected to be released once two years of data for them are available.

4. New Sampling Stratum of Oncologists

A sample of 200 oncologists was added to the 2006 NAMCS, made possible through funding from the National Cancer Institute, National Institutes of Health.

Table of Contents

Page

Abstract	
Summary of Changes for 2006	
I. Description of the National Ambulatory Medical Care Survey	
A. Introduction	
B. Scope of the survey	
C. Sampling frame and size of sample	
D. Sample design	
E. Population figures	
F. Field activities	
G. Data collection	
H. Confidentiality	
I. Data processing	
J. Medical coding	
K. Estimation procedures	
L. Sampling errors	
M. Patient visit weight.	28
N. Physician code and patient code	
O. Use of the physician-level weight References	
II. Record Format and Physician Specialty List	30-81
A. Record format	
B. Physician specialty list	
C. AMA specialties regrouped into primary, medical and surgical	
III. Marginal Data	
A. Patient visits	
B. Drug mentions	
C. Physicians	
,	
Appendixes	
Appendix I	
A. Relative standard errors	
B. 2006 NAMCS Patient Record Form - Instructions and definitions	
C. Definitions of certain terms used in the NAMCS	105
Appendix II	
A. Reason for Visit Classification	107
Appendix III	
A. Generic codes and names in numeric order	
B. Drug entry codes and names in numeric order	
C. Multum Lexicon end-user license agreement	
D. Multum classification of therapeutic classes (drug categories)	

Page

Table of Contents (cont.)

List of Tables and Figures

Table I.	Number of physicians in the universe, total sample, sample response categories, and response rates by physician stratum	9
Table II.	U.S. population estimates used in computing annual visit rates for the National Ambulatory Medical Care Survey and the National Hospital Ambulatory Medical Care Survey, by selected characteristics: July 1, 2006	.14
Table III.	U.S. population estimates used in computing annual visit rates for the National Ambulatory Medical Care Survey and the National Hospital Ambulatory Medical Care Survey, by ethnicity, age, race, and sex: July 1, 2006	.16
Table IV	Coefficients appropriate for determining approximate relative standard errors by type of estimate and physician specialty: 2006 NAMCS	92
Figure 1.	2006 NAMCS Patient Record Form	.13

I. DESCRIPTION OF THE NATIONAL AMBULATORY MEDICAL CARE SURVEY

A. INTRODUCTION

This micro-data file contains data collected in the 2006 National Ambulatory Medical Care Survey (NAMCS). The NAMCS is a national probability sample survey conducted by the Division of Health Care Statistics, National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention (CDC). For 2006, a national sample of office-based and community health center (CHC)-based physicians provided data on patients' office and CHC visits. These data were weighted to produce national estimates that describe the utilization of ambulatory medical care services in the United States.

In 2006, a total of 29,392 Patient Record forms (PRFs) were received from the physicians who participated in the NAMCS. For a brief description of the survey design and data collection procedures, see below. A more detailed description of the survey design, data collection procedures, and the estimation process has been published (1,2).

Please note the following important points concerning analysis of NAMCS data on this micro-data file:

► PATIENT VISIT WEIGHT

Micro-data file users should be fully aware of the importance of the "patient visit weight" and how it must be used. Information about the patient visit weight is presented on page 27. If more information is needed, the staff of the Ambulatory and Hospital Care Statistics Branch can be consulted by calling (301) 458-4600 during regular working hours.

► RELIABILITY OF ESTIMATES

Users should also be aware of the reliability or unreliability of certain estimates, particularly the smaller estimates. The National Center for Health Statistics considers an estimate to be reliable if it has a relative standard error of 30 percent or less (i.e., the standard error is no more than 30 percent of the estimate). Therefore, it is important to know the value of the lowest possible estimate in this survey that is considered reliable, so as not to present data in a journal article or paper that may be unreliable. Most data file users can obtain an adequate working knowledge of relative standard errors from the information presented in Appendix I. It should be noted that estimates based on fewer than 30 records are also considered unreliable, regardless of the magnitude of the relative standard error. If you would like more information, do not hesitate to consult the staff of the Ambulatory and Hospital Care Statistics Branch.

B. SCOPE OF THE SURVEY

The basic sampling unit for the NAMCS is the physician-patient encounter or visit. Traditionally, only visits to the offices of nonfederally employed physicians classified by the American Medical Association (AMA) or the American Osteopathic Association (AOA) as "office-based, patient care" are included in the NAMCS. Physicians in the specialties of anesthesiology, pathology, and radiology are excluded from the physician universe. However, for 2006, in addition to the traditional sample, the NAMCS included a sample of community health centers, using information from the Health Resources Services Administration and the Indian Health Service to construct a sampling frame. From each sampled community health center, an additional sample of health care providers was selected, which could include physicians as well as mid-level health care providers such as physician assistants and nurse practitioners. Only visits to physicians are included on the 2006 public use file. Mid-level provider data is expected to be released as a separate file, combining data from 2006 and 2007.

Types of contacts not included in the 2006 NAMCS were those made by telephone, those made outside the physician's office (for example, house calls), visits made in hospital settings (unless the physician has a private office in a hospital and that office meets the NAMCS definition of "office"), visits made in institutional settings by patients for whom the institution has primary responsibility over time (for example, nursing homes), and visits to doctors' offices that are made for administrative purposes only (for example, to leave a specimen, pay a bill, or pick up insurance forms).

C. SAMPLING FRAME AND SIZE OF SAMPLE

The sampling frame for the 2006 NAMCS was composed of all physicians contained in the master files maintained by the AMA and AOA, at a point roughly 6 months prior to the start of the survey year, who met the following criteria:

- -- Office-based, as defined by the AMA and AOA;
- -- Principally engaged in patient care activities;
- -- Nonfederally employed;
- -- Not in specialties of anesthesiology, pathology, and radiology.

In addition, a sampling frame of community health centers (CHCs) was developed using data from the Health Resources and Services Administration's Bureau of Primary Health Care Uniform Data System and the Indian Health Service. Each participating CHC provided a list of physicians and mid-level health providers who would be available during the reporting period. This list became the frame for selection of a sample of physicians and mid-level providers in each CHC (see below for more details).

The 2006 NAMCS sample included 3,500 physicians: 3,276 Medical Doctors and 224 Doctors of Osteopathy. Sample physicians were screened at the time of the survey to assure that they met the above-mentioned criteria. A total of 1,232 physicians did not meet all of the criteria and were ruled out of scope (ineligible) for the study. The most frequent reasons for being out of scope were that the physician was retired, deceased, or employed in teaching, research, or administration. Of the 2,268 in-scope (eligible) physicians, 1,455 participated in the study. Of these, 1,269 completed a total of 29,392 Patient Record forms (PRFs), while 186 saw no patients during their assigned reporting period because of vacations, illness, or other reasons for being temporarily not in practice and hence did not submit PRFs. Of the 1,269 physicians who completed PRFs, 1,149 participated fully or adequately (i.e. at least half of the PRFs expected, based on the total number of visits during the reporting week, were submitted), and 120 participated minimally (i.e. fewer than half of the expected number of PRFs were submitted). The unweighted response rate was 58.9 percent, based on the number of full participants only. The physician universe, sample size, and response rates by physician specialty are shown in table I.

D. SAMPLE DESIGN

The 2006 NAMCS utilized a multistage probability design that involved probability samples of primary sampling units (PSUs), physician practices within PSUs, and patient visits within practices. The first-stage sample included 112 PSUs. A PSU consists of a county, a group of counties, county equivalents (such as parishes and independent cities), towns, townships, minor civil divisions (for some PSUs in New England), or a metropolitan statistical area (MSA). MSAs were defined by the U.S. Office of Management and Budget on the basis of the 1980 Census. The first-stage sample consisted of 112 PSUs that comprised a probability subsample of the PSUs used in the 1985-94 National Health Interview Survey (NHIS). The NAMCS PSU sample included with certainty the 26 NHIS PSUs with the largest populations. In addition, the NAMCS sample included one-half of the next 26 largest PSUs, and one PSU from each of the 73 PSU strata formed from the remaining PSUs for the NHIS sample.

PAGE 8

2006 NAMCS MICRO-DATA FILE DOCUMENTATION

				Sample					
Physician stratum	Universe (1)	Total	Out of Scope	In Scope	Nonres- pondents	Respon- dents	Response rate (2)		
Fotal	492,319	3,500	1,232	2,268	933	1,335	58.9		
General and family practice	69,099	361	125	236	94	142	60.2		
Osteopathy	28,909	224	83	141	49	92	65.2		
nternal medicine	73,567	217	101	116	46	70	60.3		
Pediatrics	49,856	197	82	115	43	72	62.6		
General surgery	19,504	199	86	113	51	62	54.9		
Obstetrics and gynecology	32,710	204	60	144	60	84	58.3		
Orthopedic surgery	18,599	137	36	101	42	59	58.4		
Cardiovascular diseases	16,635	208	57	151	73	78	51.7		
Dermatology	8,618	117	24	93	40	53	57.0		
Jrology	8,561	153	39	114	50	64	56.1		
Psychiatry	31,039	278	134	144	63	81	56.3		
Neurology	10,081	252	100	152	76	76	50.0		
Ophthalmology	15,313	126	30	96	41	55	57.3		
Otolaryngology	7,930	147	44	103	46	57	55.3		
All other specialties	93,711	306	147	159	71	88	55.3		
Oncology (new stratum)	8,187	200	84	116	64	52	44.8		
Community Health Center bhysicians (new stratum)(3)	774)	174	0	174	24	150	86.2		

Table I. Number of physicians in the universe, total sample, sample response categories, and response rate by physician strata: National Ambulatory Medical Care Survey, 2006

(1) Data are derived from the American Medical Association and the American Osteopathic Association and represent the total number of physicians who are eligible for the NAMCS.

(2) Response rate is number of respondents divided by number of in-scope physicians.

(3) A sample of community health centers was selected (see text for details), and lists of physicians and mid-level providers who would be available during the reporting period were obtained from sampled facilities. A selection of physicians was taken from these lists; therefore it does not reflect the universe of all community health center physicians. Mid-level providers were also sampled, but these data are not included on the 2006 NAMCS Public Use File. They may be released in combination with data on mid-level providers collected in 2007.

NOTE: An additional 120 physicians participated at a minimal level and are not included in the number of responding physicians.

The NHIS PSU sample was selected from approximately 1,900 geographically defined PSUs that covered the 50 States and the District of Columbia. The 1,900 PSUs were stratified by socioeconomic and demographic variables and then selected with a probability proportional to their size. Stratification was done within four geographical regions by MSA or non-MSA status. A detailed description of the 1985-94 NHIS PSU sample design is available (3).

Typically, the second stage consists of a probability sample of practicing physicians selected from the master files maintained by the American Medical Association (AMA) and American Osteopathic Association (AOA). Within each PSU, all eligible physicians are stratified into fifteen specialty groups: general and family practice, osteopathy, internal medicine, pediatrics, general surgery, obstetrics and gynecology, orthopedic surgery, cardiovascular diseases, dermatology, urology, psychiatry, neurology, ophthalmology, otolaryngology, and "all other" specialties. However, the NAMCS sample for 2006 was slightly larger than previous years, as the CDC's National Center for Chronic Disease and Prevention and Health Promotion sponsored the inclusion of an additional 150 primary care physicians (general/family practice, internal medicine, and obstetrics/gynecology), and the National Cancer Institute (NIH) sponsored a supplementary sample of 200 oncologists.

Also, this sample design typically includes too few community health center physicians for the estimates to be reliably presented. In order to improve the precision of CHC physician estimates, starting in 2006, a dual-sampling procedure was used to select CHC physicians and other providers. First, the "traditional" NAMCS sample of physicians was selected using established methods and sources. Second, a sample of 104 CHCs was selected, and within each center, up to three physicians, physician assistants, nurse midwives, or nurse practitioners were selected for survey participation. After selection, CHC providers followed the sampling procedure used by "traditional" NAMCS physicians in selecting patient visits. The list of CHCs is from the Health Resources and Services Administration and the Indian Health Service. To ensure that CHC physicians are included only once, all CHC physicians selected in the "traditional" NAMCS sample were omitted from the survey response and subsequent weighting. Only sample CHC physicians were included. Sampled mid-level providers were excluded as well, but data for these providers are expected to be released in a public use format once two full years of data for them are available.

The final stage was the selection of patient visits within the annual practices of sample physicians. This involved two steps. First, the total physician sample was divided into 52 random subsamples of approximately equal size, and each subsample was randomly assigned to 1 of the 52 weeks in the survey year. Second, a systematic random sample of visits was selected by the physician during the assigned week. The sampling rate varied for this final step from a 100-percent sample for very small practices to a 10-percent sample for very large practices as determined in a presurvey interview. The method by which the sampling rate was determined is available (4).

E. POPULATION FIGURES

The base population used in computing annual visit rates is presented in table II and table III. The denominators used in calculating 2006 visit rates for age, sex, race, ethnicity, and geographic region are Census 2000-based postcensal estimates of the civilian noninstitutional population of the United States. The population estimates are special tabulations developed by the Population Division, U.S. Census Bureau, from the July 1, 2006 set of state population estimates by age, sex, race, and ethnicity.

Population estimates of metropolitan statistical area status are based on data from the 2006 National Health Interview Survey (NHIS), National Center for Health Statistics, adjusted to the US Census Bureau definition of core-based statistical areas as of November 2004. See http://www.census.gov/population/www/estimates/metrodef.html for more about metropolitan statistical area definitions.

Estimates of visit rates for metropolitan and non-metropolitan statistical areas from 2003 on may differ somewhat from those reported in 2002 and previous years because of methodological differences in how the denominators were calculated. In survey years 1992-2002, the NHIS used a 1992 definition of MSAs and non-MSAs, and also used 1990-based Census estimates as controls. Because the NAMCS used Census 2000-based population estimates beginning in 2001, adjustments needed to be made to the MSA figures obtained from the NHIS in 2001 and 2002. For 2006, special tabulations were obtained from the Office of Analysis and Epidemiology, NCHS, where 2006 NHIS data were matched to the November 2004 U.S. Census Bureau definition of core-based statistical areas. The estimates were further adjusted based on the 2006 population estimates obtained from the Census Bureau.

Population estimates for race groups in the 2006 NAMCS are based on the 2000 U.S. Census in which respondents were able to indicate more than one race category. The multiple race indicator was adopted starting in the 1999 NAMCS but the population estimates that were available for calculating rates in 1999 and 2000 were based on estimates from the 1990 census, which used only single response race categories. The NAMCS had very few records for multiple race persons in those years, so rates for single race groups were calculated by dividing estimates by denominators that included some unidentifiable number of multiple race persons. Starting with 2001, the denominators used for calculating race-specific visit rates in NAMCS reports reflect the transition to multiple-race reporting. Specific race denominators reflect persons with a single race identification, and a separate denominator is now available for persons with more than one race designation.

Data indicate that multiple races are recorded for a patient less frequently in medical records compared to their numbers in the general population. The 2006 population estimates indicate that 1.6 percent of the total population identify themselves as being of multiple races. In contrast, multiple race patients account for 0.3 percent of NAMCS visits. This difference may exist partly because office staff are less likely to know and record the multiple race preference of the patient. It suggests that the race population rates calculated for 2006 may be slight overestimates for the single race categories and slight underestimates for the multiple race category.

F. FIELD ACTIVITIES

The first contact with the sample physician is through a letter from the Director, NCHS. After the physician receives the introductory letter (along with letters from professional medical societies which endorse the NAMCS), the Field Representative (FR) telephones the physician to establish basic eligibility and to schedule an appointment. At the appointment, the FR explains the survey to the physician and to any staff who may be involved in completing the forms. The FR also obtains the practice characteristics of up to four office locations where the physician sees patients during the reporting week. Typically, the FR will contact the physician's office just before, during and after the reporting week to remind him or her about the survey and to answer any questions that may arise. After the reporting period, the FR makes another visit to the practice to collect the forms and reviews them briefly to ensure that there are no large errors or information gaps. During this last visit, the physician is given a certificate of appreciation for her or his participation.

G. DATA COLLECTION

The actual data collection for the NAMCS was carried out by the physician aided by his/her office staff when possible. Physicians were instructed to keep a daily listing of all patient visits during the assigned reporting week using an arrival log, optional worksheet, or similar method. This list was the sampling frame to indicate the visits for which data were to be recorded. It was to include both scheduled and unscheduled patients, but not cancellations or no-shows. Visits were selected from the list using a random start and a predetermined sampling interval based on the physician's estimated visits for the week and the number of days the physician was expected to see patients that week. In this way, a systematic random sample of visits was obtained. The sampling procedures were designed so that about 30 Patient Record forms were completed during the assigned reporting week. This minimized the data collection workload and maintained about equal reporting levels among sample physicians regardless of practice size.

PAGE 12

Data for sampled visits were recorded on Patient Record forms. The Patient Record form was printed on one side of an 8 x 14 inch sheet (Figure 1). At the top of each form, physicians could record the patient's name and record number. However, this information was detached by the physician prior to submitting the completed forms and was never given to Census personnel. It was used only to assist physicians in clarifying missing or ambiguous responses that may have been found during the data editing process.

Terms and definitions relating to the Patient Record form are included in Appendix I. Nearly half of the NAMCS Patient Record forms (49.1 percent) were abstracted by Census Bureau staff rather than by the physician or medical office personnel.

H. CONFIDENTIALITY

In April 2003, the Privacy Rule of the Health Insurance Portability and Accountability Act (HIPAA) was implemented to establish minimum Federal standards for safeguarding the privacy of individually identifiable health information. No personally identifying information, such as patient's name or address or Social Security number, is collected in the NAMCS. Data collection is authorized by Section 306 of the Public Health Service Act (Title 42, U.S. Code, 242k). All information collected is held in the strictest confidence according to law [Section 308(d) of the Public Health Service Act (42, U.S. Code, 242m(d))] and the Confidential Information Protection and Statistical Efficiency Act (Title 5 of PL 107-347). The NAMCS protocol has been approved by the NCHS Research Ethics Review Board annually starting in February 2003. Waivers of the requirements to obtain informed consent of patients and patient authorization for release of patient medical record data by health care providers were granted.

In the Spring of 2003, the NAMCS implemented additional data collection procedures to help providers assure patient confidentiality. Census Bureau Field Representatives were trained on how the Privacy Rule allows physicians to make disclosures of protected health information without patient authorization for public health purposes and for research that has been approved by a Research Ethics Review Board. Physicians were encouraged to accept a data use agreement between themselves and CDC/NCHS, since the Privacy Rule allows physicians to disclose limited data sets (i.e., data sets with no direct patient identifiers) for research and public health purposes if such an agreement exists.

Assurance of confidentiality was provided to all physicians according to Section 308 (d) of the Public Health Service Act (42 USC 242m). Strict procedures were utilized to prevent disclosure of NAMCS data. All information which could identify the physician was confidential and was seen only by persons engaged in the NAMCS, and was not disclosed or released to others for any other purpose. Names or other identifying information for individual patients were not removed from the physician's office.

I. DATA PROCESSING

1. Edits

In addition to the completeness checks made by the field staff, clerical edits were performed upon receipt of the data for central processing. Detailed editing instructions were provided to manually review the patient records and to reclassify or recode ambiguous entries. Computer edits for code ranges and inconsistencies were also performed.

Please note: Figure 1 has been omitted from this version of the documentation in order to minimize file size and download time. You may view or download the 2006 NAMCS Patient Record form from this web address:

http://www.cdc.gov/nchs/about/major/ahcd/surinst.htm#Survey Instrument NAMCS

PAGE 14

2006 NAMCS MICRO-DATA FILE DOCUMENTATION

Table II. U.S. population estimates used in computing annual visit rates for the National Ambulatory Medical Care Survey and the National Hospital Ambulatory Medical Care Survey, by selected characteristics: July 1, 2006

			Age in years			
Race and sex	All ages	Under 1	1-4	5-14	15-24	25-34
All races	294,180,154	4,126,516	16,284,756	40,292,354	41,429,759	39,302,445
Male	143,993,599	2,111,047	8,327,334	20,608,619	20,964,790	19,584,180
Female	150,186,555	2,015,469	7,957,422	19,683,735	20,464,969	19,718,265
White Only	236,072,127	3,129,024	12,415,782	30,737,173	32,125,713	30,703,091
Male	116,526,447	1,601,742	6,358,240	15,763,747	16,379,104	15,573,907
Female	119,545,680	1,527,282	6,057,542	14,973,426	15,746,609	15,129,184
Black Only	36,980,547	627,030	2,444,703	6,198,567	6,129,859	5,128,689
Male	17,178,374	319,673	1,240,853	3,142,448	2,983,394	2,312,052
Female	19,802,173	307,357	1,203,850	3,056,119	3,146,465	2,816,637
Asian Only	13,090,211	181,344	708,130	1,620,370	1,704,371	2,362,275
Male	6,327,472	93,021	362,851	821,280	866,622	1,150,045
Female	6,762,739	88,323	345,279	799,090	837,749	1,212,230
NHOPI* Only	519,943	8,098	29,937	85,406	89,632	93,614
Male	261,965	4,187	15,599	43,725	45,575	48,423
Female	257,978	3,911	14,338	41,681	44,057	45,191
AIAN* Only	2,849,566	41,620	161,111	477,327	521,555	429,836
Male	1,412,234	21,274	81,774	242,546	262,684	219,482
Female	1,437,332	20,346	79,337	234,781	258,871	210,354
Multiple Races	4,667,760	139,400	525,093	1,173,511	858,629	584,940
Male	2,287,107	71,150	268,017	594,873	427,411	280,271
Female	2,380,653	68,250	257,076	578,638	431,218	304,669

*NHOPI is Native Hawaiian/Other Pacific Islander. AIAN is American Indian/Alaska Native.

Geographic R	Region totals	Metropolitan Statistical Area totals		
Northeast	53,924,831	MSA 244,770,063		
Midwest	65,204,235	Non-MSA 49,410,091		
South	106,797,883			
West	68,253,205			

SOURCE: These are U.S. Bureau of the Census postcensal estimates of the civilian noninstitutionalized population of the United States as of July 1, 2006. The estimates of age, sex, race and region are from special tabulations developed by the Population Division, U.S. Census Bureau using the July 1, 2006 set of state population estimates, and reflect Census 2000 data. More information may be obtained from the Census website at <u>www.census.gov</u>. The 2006 MSA population estimates are based on data from the 2006 National Health Interview Survey (NHIS), National Center for Health Statistics, adjusted to the U.S. Census Bureau definition of core-based statistical areas as of November 2004. See <u>www.census.gov/population/www/estimates/metrodef.html</u> for more about MSA definitions.

Table II. U.S. population estimates used in computing annual visit rates for the National Ambulatory Medical Care Survey and the National Hospital Ambulatory Medical Care Survey, by selected characteristics: July 1, 2006 - con.

Age in years						
Race and sex	35-44	45-54	55-64	65-74	75 and	
Race and sex	55-44	40-04	55-04	05-74	over	
All races	42,773,272	42,927,829	31,423,419	18,672,985	16,946,819	
Male	21,071,307	20,997,919	15,114,947	8,557,918	6,655,538	
Female	21,701,965	21,929,910	16,308,472	10,115,067	10,291,281	
White Only	34,222,908	35,236,749	26,525,466	15,980,009	14,996,212	
Male	17,131,444	17,463,418	12,906,932	7,404,991	5,942,922	
Female	17,091,464	17,773,331	13,618,534	8,575,018	9,053,290	
Black Only	5,295,305	5,001,397	3,138,649	1,740,688	1,275,660	
Male	2,361,718	2,264,397	1,389,767	721,144	442,928	
Female	2,933,587	2,737,000	1,748,882	1,019,544	832,732	
Asian Only	2,292,584	1,837,102	1,220,043	679,097	484,895	
Male	1,109,864	861,231	562,410	305,837	194,311	
Female	1,182,720	975,871	657,633	373,260	290,584	
NHOPI* Only	79,566	63,149	38,390	19,856	12,295	
Male	39,737	31,412	18,856	9,386	5,065	
Female	39,829	31,737	19,534	10,470	7,230	
AIAN* Only	409,845	375,573	235,730	118,449	78,520	
Male	202,985	181,098	113,607	54,951	31,833	
Female	206,860	194,475	122,123	63,498	46,687	
Multiple Races	473,064	413,859	265,141	134,886	99,237	
Male	225,559	196,363	123,375	61,609	38,479	
Female	247,505	217,496	141,766	73,277	60,758	

HISPANIC			Age in years			
Race and sex	All ages	Under 1	1-4	5-14	15-24	25-34
All races	43,796,437	970,373	3,733,162	8,026,491	7,220,233	7,924,872
Male	22,476,295	495,851	1,905,539	4,105,028	3,767,211	4,304,136
Female	21,320,142	474,522	1,827,623	3,921,463	3,453,022	3,620,736
White Only	40,532,363	897,245	3,488,705	7,343,490	6,629,587	7,364,586
Male	20,858,151	458,487	1,780,805	3,758,345	3,468,693	4,020,948
Female	19,674,212	438,758	1,707,900	3,585,145	3,160,894	3,343,638
Black Only	1,615,034	38,701	118,008	323,504	280,542	277,634
Male	780,702	19,818	60,317	164,198	140,360	133,000
Female	834,332	18,883	57,691	159,306	140,182	144,634
Asian Only	274,325	6,551	20,704	55,851	47,809	47,792
Male	135,014	3,322	10,445	28,459	24,217	23,851
Female	139,311	3,229	10,259	27,392	23,592	23,941
NHOPI* Only	115,188	2,519	7,923	22,876	21,310	22,978
Male	60,236	1,294	4,111	11,717	11,152	12,986
Female	54,952	1,225	3,812	11,159	10,158	9,992
AIAN* Only	637,600	5,583	21,588	120,055	127,372	123,459
Male	334,670	2,859	10,956	61,175	65,958	69,528
Female	302,930	2,724	10,632	58,880	61,414	53,931
Multiple Races	621,927	19,774	76,234	160,715	113,613	88,423
Male	307,522	10,071	38,905	81,134	56,831	43,823
Female	314,405	9,703	37,329	79,581	56,782	44,600

Table III. U.S. population estimates used in computing annual visit rates for the National Ambulatory Medical Care Survey and the National Hospital Ambulatory Medical Care Survey, by ethnicity, age, race, and sex: July 1, 2006

SOURCE: These are U.S. Bureau of the Census postcensal estimates of the civilian noninstitutionalized population of the United States as of July 1, 2006. They were developed by the Population Division, U.S. Census Bureau using the July 1, 2006 set of state population estimates, and reflect Census 2000 data. More information may be obtained from the Census website at <u>www.census.gov.</u>

2006 NAMCS MICRO-DATA FILE DOCUMENTATION

Table III. U.S. population estimates used in computing annual visit rates for the National Ambulatory Medical Care Survey and the National Hospital Ambulatory Medical Care Survey, by ethnicity, age, race, and sex: July 1, 2006 - con.

HISPANIC		A	ge in years			
					75 and	
Race and sex	35-44	45-54	55-64	65-74	over	
All races	6,555,986	4,480,738	2,527,506	1,364,347	992,729	
Male	3,432,138	2,254,164	1,207,463	610,087	394,678	
Female	3,123,848	2,226,574	1,320,043	754,260	598,051	
White Only	6,089,875	4,152,245	2,350,918	1,278,766	936,946	
Male	3,204,521	2,095,712	1,124,686	572,613	373,341	
Female	2,885,354	2,056,533	1,226,232	706,153	563,605	
Black Only	237,175	167,545	92,366	47,914	31,645	
Male	110,472	78,184	42,243	20,540	11,570	
Female	126,703	89,361	50,123	27,374	20,075	
Asian Only	40,115	28,769	15,221	7,089	4,424	
Male	19,230	13,681	7,030	3,122	1,657	
Female	20,885	15,088	8,191	3,967	2,767	
NHOPI* Only	17,318	10,718	5,410	2,522	1,614	
Male	9,070	5,461	2,633	1,137	675	
Female	8,248	5,257	2,777	1,385	939	
AIAN* Only	102,291	73,532	37,126	16,365	10,229	
Male	55,098	38,532	18,699	7,555	4,310	
Female	47,193	35,000	18,427	8,810	5,919	
Multiple Races	69,212	47,929	26,465	11,691	7,871	
Male	33,747	22,594	12,172	5,120	3,125	
Female	35,465	25,335	14,293	6,571	4,746	

PAGE 18

Table III. U.S. population estimates used in computing annual visit rates for the National Ambulatory Medical Care Survey and the National Hospital Ambulatory Medical Care Survey, by ethnicity, age, race, and sex: July 1, 2006 – con.

NON- HISPANIC			Age in years			
Race and sex	All ages	Under 1	1-4	5-14	15-24	25-34
All races	250,383,717	3,156,143	12,551,594	32,265,863	34,209,526	31,377,573
Male	121,517,304	1,615,196	6,421,795	16,503,591	17,197,579	15,280,044
Female	128,866,413	1,540,947	6,129,799	15,762,272	17,011,947	16,097,529
White Only	195,539,764	2,231,779	8,927,077	23,393,683	25,496,126	23,338,505
Male	95,668,296	1,143,255	4,577,435	12,005,402	12,910,411	11,552,959
Female	99,871,468	1,088,524	4,349,642	11,388,281	12,585,715	11,785,546
Black Only	35,365,513	588,329	2,326,695	5,875,063	5,849,317	4,851,055
Male	16,397,672	299,855	1,180,536	2,978,250	2,843,034	2,179,052
Female	18,967,841	288,474	1,146,159	2,896,813	3,006,283	2,672,003
Asian Only	12,815,886	174,793	687,426	1,564,519	1,656,562	2,314,483
Male	6,192,458	89,699	352,406	792,821	842,405	1,126,194
Female	6,623,428	85,094	335,020	771,698	814,157	1,188,289
NHOPI* Only	404,755	5,579	22,014	62,530	68,322	70,636
Male	201,729	2,893	11,488	32,008	34,423	35,437
Female	203,026	2,686	10,526	30,522	33,899	35,199
AIAN* Only	2,211,966	36,037	139,523	357,272	394,183	306,377
Male	1,077,564	18,415	70,818	181,371	196,726	149,954
Female	1,134,402	17,622	68,705	175,901	197,457	156,423
Multiple Races	4,045,833	119,626	448,859	1,012,796	745,016	496,517
Male	1,979,585	61,079	229,112	513,739	370,580	236,448
Female	2,066,248	58,547	219,747	499,057	374,436	260,069

2006 NAMCS MICRO-DATA FILE DOCUMENTATION

NON-						
HISPANIC	Age in years					
					75 and	
Race and sex	35-44	45-54	55-64	65-74	over	
All races	36,217,286	38,447,091	28,895,913	17,308,638	15,954,090	
Male	17,639,169	18,743,755	13,907,484	7,947,831	6,260,860	
Female	18,578,117	19,703,336	14,988,429	9,360,807	9,693,230	
White Only	28,133,033	31,084,504	24,174,548	14,701,243	14,059,266	
Male	13,926,923	15,367,706	11,782,246	6,832,378	5,569,581	
Female	14,206,110	15,716,798	12,392,302	7,868,865	8,489,685	
Black Only	5,058,130	4,833,852	3,046,283	1,692,774	1,244,015	
Male	2,251,246	2,186,213	1,347,524	700,604	431,358	
Female	2,806,884	2,647,639	1,698,759	992,170	812,657	
Asian Only	2,252,469	1,808,333	1,204,822	672,008	480,471	
Male	1,090,634	847,550	555,380	302,715	192,654	
Female	1,161,835	960,783	649,442	369,293	287,817	
NHOPI* Only	62,248	52,431	32,980	17,334	10,681	
Male	30,667	25,951	16,223	8,249	4,390	
Female	31,581	26,480	16,757	9,085	6,291	
AIAN* Only	307,554	302,041	198,604	102,084	68,291	
Male	147,887	142,566	94,908	47,396	27,523	
Female	159,667	159,475	103,696	54,688	40,768	
Multiple Races	403,852	365,930	238,676	123,195	91,366	
Male	191,812	173,769	111,203	56,489	35,354	
Female	212,040	192,161	127,473	66,706	56,012	

2. Quality Control

All medical and drug coding and keying operations were subject to quality control procedures. Quality control for the medical and drug coding operation, as well as straight-key items, involved a two-way 10-percent independent verification procedure. As an additional quality control, all Patient Record forms with differences between coders or illegible entries for the reason for visit, diagnosis, procedures, diagnosis, and medication items were reviewed and adjudicated at NCHS. For nonmedical coding items, the error rate was 0.4 percent. For items which required medical coding, coding error rates ranged between 0.2 and 1.4 percent for various survey items.

3. Adjustments for Item Nonresponse

Unweighted item nonresponse rates were 5.0 percent or less for all data items with the following exceptions: is female patient pregnant? (28.5 percent of visits by females ages 10-54), if pregnant, gestation week (31.0 percent), ethnicity (28.3 percent), race (26.9 percent), does patient use tobacco? (33.6 percent), for "not current" smoker, is "never" or "former" applicable? (18.7 percent), is visit related to injury/poisoning/adverse effect? (8.4 percent), was patient referred for this visit? (20.7 percent), how many past visits in last 12 months? (7.3 percent), status of patient enrollment in a chronic disease management program for any of the chronic conditions in item 5b of Patient Record form (48.1 percent), stage of patient's cancer (54.3 percent), time spent with physician (24.2 percent of visits where a physician was seen), during physician's last normal week of practice, did physician -- make hospital visits (8.6 percent), conduct telephone consults (8.3 percent), conduct email consults (5.6 percent); what percent of physician's practice revenue from patient care comes from -- Medicare (8.0 percent), Medicaid (8.1 percent), private insurance (8.1 percent), patient payment (8.2 percent), managed care (26.8 percent), other source (8.2 percent); are performance measures on practice available to public (33.7 percent). percent of practice care revenue based on bonuses, returned withholds, or other performance-based payments (22.7 percent), percent of patient care revenue from: usual, customary and reasonable fee-forservice (16.5 percent), discounted fee for service (16.7 percent), capitation (16.0 percent), case rates (16.4 percent), other (16.4 percent); does your practice's electronic medical records system include imaging results (5.9 percent), public health reporting (15.3 percent); if your practice's EMR system includes computerized orders for prescriptions, are there warnings of drug interactions/contraindications provided (10.76 percent) and are prescriptions sent electronically to the pharmacy (8.8 percent), if your practice's EMR system includes computerized orders for tests, are orders sent electronically (19.8 percent), if your practice's EMR system includes lab results, are out of range levels highlighted (25.6 percent), if your practice's EMR system includes clinical notes, do they include medical history and followup notes (11.6 percent) and do they include reminders for guideline-based interventions and/or screening tests (18.7 percent), if your practice's EMR system includes public health reporting, are notifiable diseases sent electronically (48.9 percent), are there plans for installing a new EMR system or replacing the current system within the next 3 years (10.0 percent), for new patients, does physician accept the following types of payment - private insurance - capitated (8.2 percent), private insurance - non-capitated - (8.9 percent), Worker's Compensation (5.2 percent), no charge (10.6 percent); and has your practice experienced any difficulty, in the last 12 months, in referring patients with the following types of health insurance for specialty consultations: Medicaid (10.3 percent), Medicare (9.9 percent), private insurance (8.8 percent), uninsured (12.9 percent). Denominators for the above rates were adjusted to account for skip patterns on the data collection forms. For example, only pregnant females were included in the response rate for gestation week.

Some missing data items were imputed by randomly assigning a value from a Patient Record form with similar characteristics; imputations were based on physician specialty, geographic region, and 3-digit ICD-9-CM codes for primary diagnosis. For ethnicity, state was used instead of geographic region. The following variables were imputed: birth year (2.7 percent), sex (1.3 percent), race (26.9 percent), ethnicity (28.3 percent), have you or anyone in your practice seen patient before? (3.1 percent), how many past visits in last 12 months (7.3 percent of visits by established patients), and time spent with physician (24.2 percent of visits where a physician was seen). Blank or otherwise missing responses are so noted in the data.

J. MEDICAL CODING

The Patient Record form contains several medical items requiring three separate coding systems. The three coding systems are described briefly below. Quality control for the NAMCS medical and drug coding operations involved a two-way 10 percent independent verification procedure. A dependent verification procedure was used to review and adjudicate all records with coding discrepancies. Definitions of the medical items can be found in Appendix I.

1. <u>Patient's Complaint(s), Symptoms(s) or Other Reason(s) for this Visit</u>: Information collected in item 3 of the Patient Record form was coded according to <u>A Reason for Visit Classification for Ambulatory</u> <u>Care</u> (RVC) (5). The updated classification is available (6), and the list of codes is shown in Appendix II. The classification was updated to incorporate several new codes as well as changes to existing codes. The system continues to utilize a modular structure. The digits 1 through 8 precede the 3-digit RVC codes to identify the various modules as follows:

Prefix Module

- "1" = Symptom module
- "2" = Disease module
- "3" = Diagnostic, screening, and preventive module
- "4" = Treatment module
- "5" = Injuries and adverse effects module
- "6" = Test results module
- "7" = Administrative module
- "8" = Uncodable entries
- "9" = Special code = blank

Up to three reasons for visit were coded from item 3 in sequence; coding instructions for this item are contained in the Reason for Visit Classification and Coding Manual (6).

2. <u>Physician's Diagnoses</u>: Diagnostic information in item 5 of the Patient Record form was coded according to the <u>International Classification of Diseases</u>, <u>9th Revision</u>, <u>Clinical Modification</u> (ICD-9-CM) (7). The ICD-9-CM codes are provided in two formats, character and numeric. Please see page 73 in the Record Format section for information on the background, purpose, and appearance of the numeric recodes. The rest of this paragraph describes the format of the character version.

The character version ICD-9-CM codes are not prefixed or zerofilled on the public use file. For example, 38100 = 381.00 = Acute nonsuppurative otitis media, unspecified.

There is an implied decimal between the third and fourth digits. For inapplicable fourth or fifth digits, a dash has been inserted. For example, 4011- = 401.1 = Essential hypertension, benign.

Supplementary classification codes are not prefixed or zerofilled. For example, V700- = V70.0 = Routine general medical examination at a health care facility

In addition to the diagnostic codes from the ICD-9-CM the following unique codes in the diagnostic fields were developed by AHCSB staff:

- V990- = noncodable diagnosis, insufficient information for coding, illegible diagnosis
- V991- = left before being seen, patient walked out, not seen by doctor, left against medical advice
- V992- = transferred to another facility, sent to see specialist
- V993- = HMO will not authorize treatment
- V997- = entry of "none," "no diagnosis," "no disease," "healthy"
- 00000 = blank

A maximum of three diagnoses were coded in sequence. Coding instructions concerning diagnoses are contained in the NAMCS Coding Requirements Manual, volume 1 (8).

3. <u>Diagnostic/Screening Services and Non-Medication Treatment</u>: Open-ended responses for "Scope procedure" and "Other test/service" from item 7 on the Patient Record form (Diagnostic/Screening Services) as well as open-ended responses for "Procedures" from item 9 (Non-Medication Treatment) were coded according to the <u>International Classification of Diseases</u> (ICD-9-CM) using the procedure codes in Volume III. Up to 2 scope procedures, 2 other diagnostic/screening tests/services, and up to 4 procedures in the non-medication treatment item could be coded for each office visit.

Character format codes have an implied decimal between the second and third position and do not use prefixes or zerofills. Codes without an applicable 4th digit have a dash inserted. Please note that, as with the diagnosis codes described above, the file also contains numeric recodes for procedures at the end of the record format. These are described in the Record Format section.

It should be noted that some respondents reported procedures in item 7, while others may have reported the same procedure in item 9. For this reason, when analyzing procedures, it is recommended that all of the possible procedure fields be taken into account regardless of item location.

4. <u>Medications/Injections</u>: The NAMCS drug data collected in item 10 have been classified and coded using the entry name (the entry made on the Patient Record form) according to a unique classification scheme developed at NCHS (9). The medical classification system of drugs by entry name uses a five-digit coding scheme which is updated regularly to include new products. It includes the following special codes:

90000 = blank 99980 = unknown entry, other 99999 = illegible entry

Up to 8 medications could be recorded for each visit. A list of drug codes by entry name is included in Appendix III.

In addition to drugs coded by entry name, this file contains the following drug information:

a. Generic drug code: Beginning with the 2006 data release, NAMCS no longer uses the NCHS 5digit code which had been assigned to each official generic name assigned to every drug entity by the United States Pharmacopeia or other responsible authority. Instead, drugs are coded in terms of their generic components and therapeutic classifications using Lexicon Plus[®], a proprietary database of Cerner Multum, Inc., also used by the National Health and Nutrition Examination Survey, NCHS. The Lexicon Plus is a comprehensive database of all prescription and some nonprescription drug products available in the U.S. drug market.

In accordance with the license agreement, NCHS publications, tabulations, and software applications should cite the Multum Lexicon as the source and basis for the coding and classification of NAMCS drug data. For additional information on the Multum Lexicon Drug Database, please refer to the following Web site: <u>http://www.multum.com/Lexicon.htm</u>.

Starting with the 2006 data release, all drug codes based on entry name (using NCHS' classification system as cited above) were also assigned a unique generic drug code from Multum's Lexicon Drug Database where possible. The structure of the Multum database is such that multiple ingredient drugs are assigned a single generic drug code encompassing all of a drug's ingredients rather than being assigned generic drug codes for each ingredient, as in past years of NAMCS drug data.

For example, prior to 2006, if Tylenol No. 3 was reported in the NAMCS, it was assigned a drug entry code of 32920 to reflect the entry of Tylenol No. 3. Using the NCHS generic classification, it was also given a code of 51380 in the generic code field to represent a combination product, and then

received separate ingredient codes for acetaminophen and codeine. Under Multum, there is a single generic code that reflects the combination of acetaminophen with codeine.

The format of the generic drug code (now called DRUGID rather than GEN) has also changed from previous years. Rather than a 5 digit numeric code, the generic drug code is 6 digits, beginning with the letters "a", "c" or "d". All Multum codes begin with the letter "d", but there were some drug names reported by NAMCS participants that were not found in the Lexicon Drug Database. These have been assigned unique drug codes beginning with an "a" where a drug's ingredients could be determined, or a "c" in the case where a drug's ingredients could not be determined. The variables DRUGID1 through DRUGID8 reflect the generic codes for each drug reported.

b. Prescription status code: A code designed to identify the legal status (prescription or nonprescription) of the drug entry.

c. Controlled substance status code: A code used to denote the degree of potential abuse and federal control of a drug entry.

d. Composition status code: A code used to distinguish between single-ingredient and combination drugs.

e. Therapeutic category code: In data years prior to 2006, a 4-digit code was used to identify up to three therapeutic classes to which the drug entry might belong. (Prior to 2002 only a single therapeutic class was listed, but additional classes can be added for those years using tools available at the NAMCS website.) These were based on the standard drug classifications used in the National Drug Code Directory, 1995 edition (10).

However, beginning with the 2006 data year, Multum's therapeutic classification system is being used. The Multum Lexicon provides a 3-level nested category system that assigns a therapeutic classification to each drug and each ingredient of the drug (e.g., for naproxen: the broadest category is central nervous system agents [level 1]; the more detailed category is analgesics [level 2]; and the most detailed category is nonsteroidal anti-inflammatory agents [level 3]). Not all drugs have three classification levels; some may only have two [e.g. for digoxin: cardiovascular agents [level 1]; inotropic agents [level 2]), others only have one. See Appendix III for the complete Multum category scheme.

Each drug may have up to four therapeutic categories on the public use file. The variables RX1CAT1 through RX8CAT4 reflect the unique Multum drug categories for a particular drug; these are character values with codes from '001' through '341'. **This variable will always show the most detailed therapeutic level available of a particular drug.** For example, psychotherapeutic agents in Multum are further classified into a second more detailed level as antidepressants or antipsychotics. Antidepressants are further classified into seven subcategories (miscellaneous antidepressants, SSRI antidepressants, tricyclic antidepressants, and SSNRI antidepressants); antipsychotics are further classified into five subcategories. For a drug categorized as a tricyclic antidepressant, it would have a drug category code of '307', reflecting the Level 3 code.

Other drugs may have only two levels available, such as immunologic agents. There are seven level 2 categories of immunologic agents, and no further breakdowns into a third level in the Multum system. Therefore, RX1CAT1 would reflect only a second level code in that case. So, using RX1CAT1-RX8CAT4 will allow one to identify the most specific level of a drug, but will not, by itself, identify whether that code reflects the first, second, or third level.

In order to understand each level in terms of the Multum hierarchy, we have also placed on the file additional variables that show the full first, second, and third levels, if applicable, for each drug category for each drug. For example, in the case of the tricyclic antidepressant mentioned earlier, RX1CAT1='307'. But there are three additional variables corresponding to that drug's first therapeutic category. RX1V1C1 (meaning Drug 1, Level 1 of Therapeutic Category 1) would be '242'

(psychotherapeutic agents), RX1V2C1 (Drug 1, Level 2 of Therapeutic Category 1) would be '249' (antidepressants), and RX1V3C1 (Drug 1, Level 3 of Therapeutic Category 1) would be '307' (tricyclic antidepressants). If there were no second or third level for a particular category, the entry would be blank (' '). This is repeated for each of the drug's maximum of four therapeutic categories. The three levels can easily be concatenated by data users if they wish to obtain a complete code showing the full level structure applicable to each drug's therapeutic categories. An advantage of having separate levels is that it allows data users to aggregate drugs at any level desired. SAS code is provided at the website for micro-data users who wish to group therapeutic categories in various ways.

All drugs were coded using Multum drug categories, even those drugs not found in Multum's drug database. "Unspecified" drugs were assigned to their respective therapeutic category (e.g., hormones – unspecified: category id=97, category name=hormones). Drugs that could not be assigned to any drug entry name (MED1-8 = 99980, 99999) were not assigned a therapeutic drug category.

In some cases, NCHS was able to categorize a drug's therapeutic class at the first or second Multum level, but not at the more detailed level. When this occurred, the undetermined levels are designated as '999' in the data.

Multum uses a "combination" category for some multiple ingredient drugs. These include antihypertensive combinations, antiasthmatic combinations, upper respiratory combinations, psychotherapeutic combinations, bronchodilator combinations, sex hormone combinations, skeletal muscle relaxant combinations, and narcotic analgesic combinations. This categorization may be sufficient for certain analyses but not for others because it lacks information about the therapeutic effect of the individual ingredients that make up the combination. For example, the drug HYDROCHLOROTHIAZIDE; LOSARTAN is identified as an antihypertensive combination. Therefore, we know that this drug has an antihypertensive drug effect. However, based on this combination category we do not know that the drug's single ingredients have the therapeutic effects of a diuretic and angiotensin II inhibitor, which is relevant for some analyses.

As a result, NCHS decided that, in addition to assigning therapeutic categories to each drug, a separate file would be provided listing the ingredients for each drug along with the therapeutic classes for each ingredient. In the case of single ingredient drugs, the ingredient therapeutic categories would be the same as the drug therapeutic categories. This separate downloadable file (INGRED-2006) can be matched to the main file using the DRUGID code. For each DRUGID on the main file, the supplemental file contains up to 5 ingredients and up to 3 therapeutic category codes for each ingredient. In past years, codes used to identify the active generic ingredients of combination drugs were included on the public use file.

IMPORTANT: In 2006, we have continued to update and revise the drug characteristics in our ambulatory care drug database, which underwent substantial revision in 2002. In 2002, many drugs had ingredient lists reviewed, and non-active ingredients were removed. Duplicate codes caused by misspellings or other variant entries were eliminated, and incorrect codes (for example, for non-medications) were removed. From 2002-2005, each drug entry had up to three therapeutic classes associated with it, compared with a single therapeutic class in prior years. These factors made trend analysis more problematic, and the solution was to provide researchers with our Drug Characteristics file, which is updated annually, at our Ambulatory Health Care Data website. The characteristics from this file could be applied by matching on drug codes to previous years of data in order to get the most accurate results when doing analysis of drug trends. A SAS program for applying drug characteristics from the current drug database to previous years of public use data was also available for downloading.

For 2006, however, with the adoption of the Multum Lexicon for coding drugs according to generic ingredients and therapeutic categories, a new solution for trend analysis was necessary. Therefore, for the 2006 data release, we are also providing a separate downloadable mapping file (DRUGMAP-06), which will allow data users to match all of the drug codes used in previous years (for example, MED1-MED8 in 2005) with the corresponding Multum DRUGID code for generic composition of the drug and its

corresponding therapeutic categories. Once that is accomplished, users can also if they wish match to the drug ingredient file as described above.

For users who are interested in analyzing drug data, one method involves the isolation of those records with drugs, or drug mentions, and the creation of a separate data file of drug mentions. Each Patient Record form for 2006 can have up to eight drug mentions recorded in item 10, so whatever file is created would need to include all of them. This method can be used for obtaining estimates of drug mentions, but is not recommended for variance estimation. Rather, the structure of the visit file should be kept intact when estimating variance. In order to do this, estimates of drug mentions can be obtained by creating a new weight variable (called DRUGWT in this example). This variable is created by multiplying PATWT (the patient visit weight) by NUMMED (the number of medications recorded at the sampled visit) or DRUGWT=PATWT*NUMMED. DRUGWT can then be used in place of PATWT to weight one's data; it produces the estimated number of drug mentions rather than visits. (See Record Format for more on PATWT and NUMMED.)

This documentation contains some marginal data for drug mentions. Should the data user need additional assistance in analyzing data on drug mentions, the staff of the Ambulatory and Hospital Care Statistics Branch is available by calling (301) 458-4600. Our website can be accessed at: http://www.cdc.gov/nchs/namcs.htm

K. ESTIMATION PROCEDURES

Statistics produced from the 2006 National Ambulatory Medical Care Survey were derived by a multistage estimation procedure. The procedure produces essentially unbiased national estimates and has basically four components: 1) inflation by reciprocals of the probabilities of selection, 2) adjustment for nonresponse, 3) a ratio adjustment to fixed totals, and 4) weight smoothing. Each of these components is described below.

1. Inflation of Reciprocals by Sampling Probabilities

Since the survey utilized a three-stage sample design, there were three probabilities:

- a) the probability of selecting the PSU;
- b) the probability of selecting a physician within the PSU; and
- c) the probability of selecting a patient visit within the physician's practice.

The last probability was defined to be the exact number of office visits during the physician's specified reporting week divided by the number of Patient Record forms completed. All weekly estimates were inflated by a factor of 52 to derive annual estimates.

2. Adjustment for Nonresponse

Estimates from NAMCS data were adjusted to account for in-scope physicians who did not provide PRFs (non-PRF physicians) either because they saw no patients during their sample week or failed to provide PRFs for visits by patients they did see during their sample week.

Beginning with 2004 data, changes were made to the nonresponse adjustment factor to account for the seasonality of the reporting period. Extra weights for nonresponding physicians were shifted to responding physicians in reporting periods within the same quarter of the year. The shift in nonresponse adjustment did not significantly affect any of the overall annual estimates.

Beginning with 2003 data, the adjustment for non-PRF physicians differs from the adjustment used in prior years. Previously the adjustment accounted for non-response by physician specialty, geographic region, and metropolitan statistical area status. The revised non-response adjustment also accounts for non-response from physicians by practice size, as measured by number of weekly

visits, and for variability in number of weeks that participating physicians saw patients during the year.

Previously, these characteristics were assumed to be the same for physicians providing patient encounter information and those not providing such information. However, research done for the first time with 2003 data showed that these two assumptions are not always true. In general, the weekly visit volume for non-PRF physicians was larger than for PRF physicians. Also, physicians who saw no patients during their sample week tended to see patients fewer weeks annually than did physicians who saw patients during their week. To minimize understatement (and in some cases, overstatement) of visits, the non-response adjustment factor was revised to include information on the number of weeks physicians actually practiced during a typical year and the number of visits physicians reported during a week. Both data items were collected for responding and nonresponding physicians during the induction interview starting with the 2001 survey.

The 2003 weight with the revised non-response adjustment increased the overall visit estimate by 12 percent over the same estimate obtained using the original weight. For this reason, 2003 and subsequent year visit estimates are not entirely comparable to visit estimates computed using the previous weighting strategy. If researchers are presenting data with estimates or rates across these years, we recommend including a footnote such as the following:

3. Ratio Adjustment

A postratio adjustment was made within each of the sixteen physician specialty groups. The ratio adjustment is a multiplication factor which had as its numerator the number of physicians in the universe in each physician specialty group and as its denominator the estimated number of physicians in that particular specialty group. The numerator was based on figures obtained from the AMA and AOA master files, and the denominator was based on data from the sample.

A postratio adjustment was also made within each type of community health center. (For sampling purposes, CHCs were divided into federally funded facilities, "look-alike" facilities (add definition), and Indian Health Centers [IHC].) For visit level estimates, the ratio adjustment for the IHC and the "look-alikes" is a multiplication factor which had as its numerator the number of CHCs in each region, per CHC type and as its denominator the estimated number of CHCs in each region per CHC type. The ratio adjustment for the federally funded CHCs is a multiplication factor which has as its numerator the number of visits in each region and as its denominator the estimated number of cHCs in each region.

K. WEIGHT SMOOTHING

Each year there are a few sample physicians whose final visit weights are large relative to those for the rest of the sample. There is a concern that those few may adversely affect the ability of the resulting statistics to reflect the universe, especially if the sampled patient visits to some of those few physicians should be unusual relative to the universe. Extremes in final weights also increase the resulting variances. Extreme weights can be truncated, but this leads to an understatement of the total visit count. The technique of weight smoothing is used instead, because it preserves the total estimated visit count within each specialty by shifting the "excess" from visits with the largest weights to visits with smaller weights.

Excessively large visit weights were truncated, and a ratio adjustment was performed. For non-CHC physicians, the ratio adjustment is a multiplication factor that uses as its numerator the total visit count in each physician specialty group before the largest weights are truncated, and, as its denominator, the total visit count in the same specialty group after the largest weights are truncated. The ratio adjustment was made within each of the sixteen physician specialty groups and yields the same estimated total visit count as the unsmoothed weights.

For CHC physicians, the ratio adjustment is a multiplication factor that uses as its numerator the total

visit count for each type of CHC (federally qualified, Indian Health Centers, and look-alikes) within geographic region before the largest weights are truncated, and, as its denominator, the total visit count for each group after the largest weights are truncated. The ratio adjustment was made within each of the CHC types within each region and yields the same estimated total visit count as the unsmoothed weights.

L. SAMPLING ERRORS

Procedures for calculating sampling errors as well as estimates of standard errors of statistics derived from the NAMCS are described in the technical notes of other documents (2,11) as well as in Appendix I of this document.

M. PATIENT VISIT WEIGHT

The "patient visit weight" is a vital component in the process of producing national estimates from sample data, and its use should be clearly understood by all micro-data file users. The statistics contained on the micro-data file reflect data concerning only a sample of patient visits, not a complete count of all the visits that occurred in the United States. Each record on the data file represents one visit in the sample of 29,392 visits. In order to obtain national estimates from the sample, each record is assigned an inflation factor called the "patient visit weight." By aggregating the patient visit weights on the 29,392 sample records for 2006, the user can obtain the estimated total of 901,954,225 office visits made in the United States.

The marginal tables on pages 82-88 contain data on numbers of records for selected variables as well as the corresponding national estimated number of visits and drug mentions obtained by aggregating the "patient visit weights" on those records. Similar tables are also provided for physician-level estimates.

N. PHYSICIAN CODE and PATIENT CODE

The purpose of these codes is to allow for greater analytical depth by permitting the user to link individual Patient Record forms on the public use file with individual physicians' practices. This linkage will enable users to conduct more comprehensive analysis without violating the confidentiality of patients or physicians.

To uniquely identify a record, both the physician code and the patient code must be used. Patient codes are merely a sequential numbering of the visits recorded by the physician and alone will not uniquely identify visit records. In order to do so, both the unique 4-digit physician code and the 3-digit patient code must be used.

O. USE OF THE PHYSICIAN-LEVEL WEIGHT

A physician-level weight (PHYSWT) was first added to the 2005 NAMCS public use file. These weights allow data users to calculate physician-level estimates. There is one weight for each physician which appears on the first visit record only for that physician. When running an analysis of physician-level characteristics using PHYSWT, it is recommended to select only those records where PHYSWT is greater than 0. This will result in correct sample counts of variables, which is useful for assessing reliability. Weighted estimates will be correct either way, because of the one weight per physician format.

Items on the file which are appropriate for physician-level estimates include the following: type of office setting [RETYPOFF], solo or group practice [SOLO], employment status of physician [EMPSTAT], who owns this practice [OWNS], is lab testing performed at this office [LAB], during last normal week of practice, did physician make any home visits [HOMVISR], hospital visits [HOSVISR], telephone consults [TELCONR], email consults [ECONR]; does practice submit claims electronically EBILLREC], does

practice use electronic medical records (EMR) (not including billing records) [EMEDREC], does practice's EMR system include: patient demographics [EDEMOG], computerized prescription orders [ECPOE], warnings of drug interactions [EWARN], prescriptions sent electronically [ESCRIP], computerized test orders [ECTOE], orders for tests sent electronically [EORDER], lab results [ERESULT], highlighted out of range values [ERANGE], imaging results [EIMGRES], electronic images returned [EIMAGE], clinical notes [EPNOTES], medical history and follow-up notes [EHXFU], reminders for interventions/tests [EREMIND], public health reporting [EPUBHLTH], notifiable diseases sent electronically [ENOTDIS]; percent of patient care revenue from Medicare [PRMCARER], from Medicaid [PRMAIDR], from private insurance [PRPRVTR], from patient payment [PRPATR], or from other sources [PROTHR]; number of managed care contracts [MANCAREC], percent of patient care revenue from managed care contracts [PRMANR]; is productivity taken into account for patient care compensation [PCCPROD], is patient satisfaction taken into account for patient care compensation [PCCSAT], is guality of care taken into account for patient care compensation [PCCQOC], is practice profiling taken into account for patient care compensation [PCCPPROF], are performance measures on practice available to the public [MEASPUB], percent of patient care revenue that is based on bonuses, returned withholds, or other performance-based payments [PRP4P], percent of patient care revenue from the following methods of payment; usual, customary and reasonable fee-for service [REVFFS], discounted fee for service [REVDISC], capitation [REVCAP], case rates [REVCASE], other [REVOTH]; is physician currently accepting new patients [ACEPTNEW], for new patients, does physician accept capitated private insurance [CAPITATE], noncapitated private insurance [NOCAP], Medicare [NMEDCARE], Medicaid [NMEDCAID], Worker's Compensation [NWORKCMP], selfpay [NSELFPAY], no charge [NNOCHRGE]; difficulty in referring patients with the following forms of payment for specialty consultation: Medicaid [REFMDCAD], Medicare [REFMDCAR], private insurance [REFPRIV], uninsured [REFUNINS]; does practice offer any type of cervical cancer screening [CRVCANSC], specialty group (15 strata) SPECR], specialty category (primary, medical, surgical) [SPECCAT], specialty (SPEC), geographic region [REGION], and metropolitan statistical area [MSA]. These variables all pertain to the physician or the physician's practice characteristics. Also see the Marginal Data section (page 82) which includes some marginal tables of physician-level estimates. Appendix I ("Relative Standard Errors") provides further information.

In addition to generating estimates for physician characteristics at the physician level, the addition of PHYSWT also means that one can link visit data with physician data. For example, one could examine average time spent with physicians across physicians rather than simply across visits. This type of analysis is slightly complicated; a description along with sample SAS code is available at the Ambulatory Health Care Data website.

For more information, contact the Ambulatory and Hospital Care Statistics Branch at 301-458-4600.

REFERENCES

- 1. Tenney JB, White KL, Williamson JW. National Ambulatory Medical Care Survey: Background and Methodology. National Center for Health Statistics. Vital Health Stat 2(61). 1974.
- 2. Schappert SM., Nelson CR. National Ambulatory Medical Care Survey, 1995-96 Summary. National Center for Health Statistics. Vital Health Stat 13(142). 2000.
- Massey JT, Moore TF, Parsons VL, Tadros W. Design and estimation for the National Health Interview Survey, 1985-94. National Center for Health Statistics. Vital Health Stat 2(110).1989.
- 4. Physician Induction Interview Form. National Ambulatory Medical Care Survey. OMB No. 0920-0234.
- 5. Schneider D, Appleton L, McLemore T. A Reason for Visit Classification for Ambulatory Care. National Center for Health Statistics. Vital Health Stat 2(78). 1979.
- 6. National Ambulatory Medical Care Survey and National Hospital Ambulatory Medical Care Survey Reason for Visit Classification and Coding Manual: (updated annually). Ambulatory and Hospital Care Statistics Branch, Division of Health Care Statistics, National Center for Health Statistics.
- U.S. Dept. of Health and Human Services, Centers for Disease Control and Prevention, Health Care Financing Administration. International Classification of Diseases, 9th Revision, Clinical Modification. Sixth Edition. October 2006.
- 8. National Ambulatory Medical Care Survey: Coding Requirements (updated annually). Ambulatory and Hospital Care Statistics Branch, Division of Health Care Statistics, National Center for Health Statistics.
- Koch H, Campbell W. The Collection and Processing of Drug Information. National Ambulatory Medical Care Survey, 1980. National Center for Health Statistics. Vital Health Stat 2(90). 1982.
- 10. Food and Drug Administration. National Drug Code Directory, 1995 edition. Washington: Public Health Service. 1995.
- Cherry D, Woodwell DA, Hing E, Rechtsteiner E. National Ambulatory Medical Care Survey, 2006 summary. National Health Statistics Report, no. 3. Hyattsville, Maryland: National Center for Health Statistics. 2008.

II. RECORD FORMAT AND PHYSICIAN SPECIALTY LIST

A. RECORD FORMAT

Number of records = 29,392

This section consists of a detailed breakdown of each data record. For each item on the record, the user is provided with a sequential item number, field length, file location, and brief description of the item, along with valid codes. Most data are from the Patient Record form (PRF). Such items are so noted in the description below. The American Medical Association (AMA), the American Osteopathic Association (AOA) and the induction interview (reference 3) are alternate sources of data. Some information is obtained by recoding selected data from these sources.

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
			DATE OF VISIT (from PRF Q1.a)
1	2	1-2	[VMONTH] MONTH OF VISIT 01-12: January-December
2	4	3-6	[VYEAR] YEAR OF VISIT 2004, 2006 (Survey dates were 12/27/2004-12/25/2006.)
3	1	7	[VDAYR] DAY OF WEEK OF VISIT 1 = Sunday 2 = Monday 3 = Tuesday 4 = Wednesday 5 = Thursday 6 = Friday 7 = Saturday
4	3	8-10	[AGE] PATIENT AGE (IN YEARS; DERIVED FROM DATE OF BIRTH) (from PRF Q1.c) 000 = Under 1 year 001-099 100 = 100 years or over
5	1	11	[SEX] SEX (from PRF Q1.d) 1 = Female 2 = Male

2006 NAMCS MICRO-DATA FILE DOCUMENTATION

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
6	1	12	[PREGNANT] If female, is patient pregnant? (from PRF Q1.d)
			NOTE: It was discovered that this variable, along with GESTWK, was often completed incorrectly by survey respondents. This was because, in many cases where the patient's last menstrual period was known, that date was reported and the pregnancy box was checked, even though the patient was not pregnant. Much editing was done to correct these errors, but in some cases it was not possible to determine if the patient was really pregnant. The last menstrual period date was used to calculate GESTWK (or to corroborate a reported GESTWK) and is not included on the public use file. PREGNANT and GESTWK should be used with some caution.
			1 = Yes 2 = No 3 = Unknown 8 = Not applicable (patient is not female) 9 = Blank
7	2	13-14	[GESTWEEK] Week of gestation (from PRF Q1.d) 01-44 88 = Not applicable (patient is male, or patient is female with unknown or negative pregnancy status) 99 = Blank
8	1	15	[ETHNIC] ETHNICITY (from PRF Q1.e) 1 = Hispanic or Latino 2 = Not Hispanic or Latino
9	1	16	[RACE] RACE (from PRF Q1.f)
			Data users should be aware that some records may have masked race values. This was required for disclosure avoidance. 1 = White 2 = Black/African American 3 = Asian 4 = Native Hawaiian/Other Pacific Islander 5 = American Indian/Alaska Native 6 = More than one race reported
10	17		[USETOBAC] TOBACCO USE (from PRF Q1.g) 0 = Blank 1 = Not current 2 = Current 3 = Unknown

PAGE 32

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
11		18	[NOTOBAC] NON-CURRENT TOBACCO USE (from PRF Q1.g) 1 = Never 2 = Former 8 = Not Applicable 9 = Blank
12	1	19	[PAYPRIV] EXPECTED SOURCE OF PAYMENT: PRIVATE INSURANCE (from PRF Q1.h) 0 = No 1 = Yes
13	1	20	[PAYMCARE] EXPECTED SOURCE OF PAYMENT: MEDICARE (from PRF Q1.h) 0 = No 1 = Yes
14	1	21	[PAYMCAID] EXPECTED SOURCE OF PAYMENT: MEDICAID/SCHIP (from PRF Q1.h) 0 = No 1 = Yes
15	1	22	[PAYWKCMP] EXPECTED SOURCE OF PAYMENT: WORKER'S COMPENSATION (from PRF Q1.h) 0 = No 1 = Yes
16	1	23	[PAYSELF] EXPECTED SOURCE OF PAYMENT: SELF PAY (from PRF Q1.h) 0 = No 1 = Yes
17	1	24	[PAYNOCHG] EXPECTED SOURCE OF PAYMENT: NO CHARGE/CHARITY (from PRF Q1.h) 0 = No 1 = Yes
18	1	25	[PAYOTH] EXPECTED SOURCE OF PAYMENT: OTHER (from PRF Q1.h) 0 = No 1 = Yes

2006 NAMCS MICRO-DATA FILE DOCUMENTATION

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
19	1	26	[PAYUNK] EXPECTED SOURCE OF PAYMENT: UNKNOWN (from PRF Q1.h) 0 = No 1 = Yes
20	1	27	[PAYTYPE] PRIMARY EXPECTED SOURCE OF PAYMENT FOR THIS VISIT (Recoded from PRF Q1.h using this hierarchy of payment categories: Medicaid/SCHIP, Medicare, Private Insurance, Worker's Compensation, Self- Pay, No Charge/Charity, Other, Unknown) 0 = Blank 1 = Private insurance 2 = Medicare 3 = Medicaid/SCHIP 4 = Worker's Compensation 5 = Self-pay 6 = No charge/charity 7 = Other 8 = Unknown
21	1	28	 [INJDET] (INJURY/POISONING/ADVERSE EFFECT) Is this visit related to any of the following: (from PRF Q2) 1 = Unintentional injury/poisoning 2 = Intentional injury/poisoning 3 = Adverse effect of medical/surgical care or adverse effect of medicinal drug 4 = None of the above 5 = Unknown 9 = Blank
22	1	29	[INJURY] Is this visit related to an injury, poisoning, or adverse effect of medical treatment? (recoded from PRF Q2, PRF Q3 and PRF Q5) 0 = No 1 = Yes
23			PATIENT'S REASON(S) FOR VISIT (See page 21 in Section I and Coding List in Appendix II.) (from PRF Q3)
23.1	5	30-34	[RFV1] REASON # 1 10050-89990 = 1005.0-8999.0 90000 = Blank
23.2	5	35-39	[RFV2] REASON # 2 10050-89990 = 1005.0-8999.0 90000 = Blank

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
23.3	5	40-44	[RFV3] REASON # 3 10050-89990 = 1005.0-8999.0 90000 = Blank
24	1	45	[PRIMCARE] ARE YOU THE PATIENT'S PRIMARY CARE PHYSICIAN? (from PRF Q4.a) 0 = Blank 1 = Yes 2 = No 3 = Unknown
25	1	46	[REFER] WAS PATIENT REFERRED FOR THIS VISIT? (from PRF Q4.a) 0 = Blank 1 = Yes 2 = No 3 = Unknown 8 = Not applicable
26	1	47	[SENBEFOR] HAS THE PATIENT BEEN SEEN IN YOUR PRACTICE BEFORE? (from PRF Q4.b) 1 = Yes, established patient 2 = No, new patient
27	1	48	[PASTVIS] HOW MANY PAST VISITS IN THE LAST 12 MONTHS? (from PRF Q4.b) 1 = None 2 = 1-2 3 = 3-5 4 = 6 or more 5 = Unknown 8 = Not applicable
28	1	49	[MAJOR] MAJOR REASON FOR THIS VISIT (from PRF Q4.c) 0 = Blank 1 = New problem (<3 mos. onset) 2 = Chronic problem, routine 3 = Chronic problem, flare up 4 = Pre-/Post-surgery 5 = Preventive care (e.g. routine prenatal, well-baby, screening, insurance, general exams)

2006 NAMCS MICRO-DATA FILE DOCUMENTATION

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
29			PHYSICIAN'S DIAGNOSES (See page 21, Section 1 for explanation of coding.) (from PRF Q5a)
29.1	5	50-54	[DIAG1] DIAGNOSIS # 1 (ICD-9-CM) There is an implied decimal between the third and fourth digits; for inapplicable fourth or fifth digits, a dash is inserted.
			 0010[-] - V829[-] = 001.0[0]-V82.9[0] V990- = Noncodable, insufficient information for coding, illegible V991- = Left before being seen; patient walked out; not seen by doctor; left against medical advice V992- = Transferred to another facility; sent to see specialist V993- = HMO will not authorize treatment V997- = Entry of "none," "no diagnosis," "no disease," or "healthy" 00000 = Blank
29.2	5	55-59	[DIAG2] DIAGNOSIS # 2 (ICD-9-CM) There is an implied decimal between the third and fourth digits; for inapplicable fourth or fifth digits, a dash is inserted. See DIAGNOSIS #1 for details.
29.3	5	60-64	[DIAG3] DIAGNOSIS # 3 (ICD-9-CM) There is an implied decimal between the third and fourth digits; for inapplicable fourth or fifth digits, a dash is inserted. See DIAGNOSIS #1 for details.
30			PROBABLE, QUESTIONABLE, AND RULE OUT DIAGNOSES
30.1	1	65	[PRDIAG1] IS DIAGNOSIS #1 PROBABLE, QUESTIONABLE, OR RULE OUT? (derived from PRF Q5.a) 0 = No 1 = Yes 8 = Not applicable
30.2	1	66	[PRDIAG2] IS DIAGNOSIS #2 PROBABLE, QUESTIONABLE, OR RULE OUT? (derived from PRF Q5.a) 0 = No 1 = Yes 8 = Not applicable
30.3	1	67	[PRDIAG3] IS DIAGNOSIS #3 PROBABLE, QUESTIONABLE, OR RULE OUT? (derived from PRF Q5.a) 0 = No 1 = Yes 8 = Not applicable

PAGE 36			2006 NAMCS MICRO-DATA FILE DOCUMENTATION
ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
31			REGARDLESS OF THE DIAGNOSES WRITTEN IN 5A, DOES THE PATIENT NOW HAVE: (from PRF Q5.b) 0 = No 1 = Yes
31.1 31.2 31.3 31.3a	1 1 1 1	68 69 70 71	[ARTHRTIS] Arthritis [ASTHMA] Asthma [CANCER] Cancer [CASTAGE] Stage of patient's cancer 0=In situ 1=Local 2=Regional 3=Distant
31.4 31.5 31.6 31.7 31.8 31.9 31.10 31.11 31.12 31.13 31.14	1 1 1 1 1 1 1 1 1 1	72 73 74 75 76 77 78 79 80 81 82	4=Unknown 8=Not applicable [CEBVD] Cerebrovascular disease [CHF] Congestive heart failure [CRF] Chronic renal failure [COPD] Chronic obstructive pulmonary disease [DEPRN] Depression [DIABETES] Diabetes [HYPLIPID] Hyperlipidemia [HTN] Hypertension [IHD] Ischemic heart disease [OBESITY] Obesity [OSTPRSIS] Osteoporosis
31.15	1	83	[NOCHRON] None of the above 0 = "None" not checked 1 = "None" checked 2 = Entire item blank
31.16	2	84-85	[TOTCHRON] TOTAL NUMBER OF CHRONIC CONDITIONS (derived from PRF Q5.b) 0-14 99 = Entire item blank
32	1	86	[DMP] STATUS OF PATIENT ENROLLMENT IN A DISEASE MANAGEMENT PROGRAM FOR CONDITION(S) MARKED IN 5B (from PRF Q5.c) 1 = Currently enrolled 2 = Ordered/advised to enroll at this visit 3 = Not enrolled 4 = Unknown 8 = Not applicable 9 = Blank

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
33			VITAL SIGNS (from PRF Q6)
33.1	2	87-88	[HTIN] PATIENT'S HEIGHT (inches) 5-84 inches 99 = Blank
33.2	3	89-91	[WTLB] PATIENT'S WEIGHT (pounds) 3-492 999 = Blank
33.2a	6	92-97	[BMI] Body-Mass Index This was calculated from Patient's Height and Weight during data processing. It contains a decimal point and up to 2 decimal places. BMI was not calculated for pregnant females or patients under age 2. 10.33-85.33 999=Unknown/Not Applicable
33.3	4	98-101	[TEMPF] Temperature (Fahrenheit) There is an implied decimal between the third and fourth digits. 0000 = Blank 0600-1112 = 60.0 – 111.2 Fahrenheit
33.4a	3	102-104	[BPSYS] Blood pressure - systolic 0-290 999 = Blank
33.4b	3	105-107	[BPDIAS] Blood pressure – diastolic 0-190 998 = P, Palp, DOP, or DOPPLER 999 = Blank
34			DIAGNOSTIC/SCREENING SERVICES (from PRF Q7)
34.1	1	108	[DIAGSCRN] Were any diagnostic/screening services ordered or provided at this visit? 0 = No 1 = Yes 2 = No answer (Entire item blank, including "None" box.)
			0 = No, 1 = Yes (excludes write-ins)
34.2 34.3 34.4 34.5 34.6	1 1 1 1	109 110 111 112 113	EXAMINATIONS: [BREAST] Breast exam [PELVIC] Pelvic exam [RECTAL] Rectal exam [SKIN] Skin exam [DEPRESS] Depression screening exam

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
34.7	1	114	IMAGING: [ANYIMAGE] (derived from PRF Q7, boxes 7-12) This item was created during data processing and indicates whether any of the imaging boxes were checked.
34.8 34.9 34.10 34.11 34.12 34.13	1 1 1 1 1	115 116 117 118 119 120	[BONEDENS] Bone density exam [MAMMO] Mammography [MRI] MRI/CT/PET [ULTRASND] Ultrasound [XRAY] X-ray [OTHIMAGE] Other imaging
34.14 34.15 34.16 34.17 34.18 34.19 34.20	1 1 1 1 1 1	121 122 123 124 125 126 127	BLOOD TESTS: [CBC] Complete blood count [ELECTROL] Electrolytes [GLUCOSE] Glucose [HGBA] HgbA1C (glycohemoglobin) [CHOLEST] Cholesterol [PSA] PSA (Prostate specific antigen) [OTHERBLD] Other blood test
24.04	1	100	OTHER TESTS:
34.21 34.22	1	128 129	[SCOPPROC] Any scope procedure [SIGCOLON] (derived from PRF Q7, box 20) This item was created during data processing and indicates whether any type of sigmoidoscopy/colonoscopy was ordered or performed at the visit, based on write-in procedure entries. It is a summary variable only and should not be added to results from the write-in procedure fields.
34.23.a	a 4	130-133	[SCOPEWI1] Scope procedure write-in #1 (ICD-9-CM, Vol.3, Procedure Classification) A left-justified alphanumeric code with an implied decimal after the first two digits; inapplicable fourth digits have a dash inserted. 0101-999 = 01.01-99.99 0000 = Not applicable/blank
34.23.t	5 4	134-137	[SCOPEWI2] Scope procedure write-in #2 (ICD-9-CM, Vol.3, Procedure Classification) A left-justified alphanumeric code with an implied decimal after the first two digits; inapplicable fourth digits have a dash inserted. 0101-999 = 01.01-99.99 0000 = Not applicable/blank
34.24 34.25	1 1	138 139	[BIOPSY] Biopsy [CHLAMYD] Chlamydia test

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
34.26 34.27 34.28 34.29 34.30 34.31 34.32 34.33 34.34 34.35 34.36 34.37	1 1 1 1 1 1 1 1 1 1	140 141 142 143 144 145 146 147 148 149 150 151	[PAPCONV] PAP test - conventional [PAPLIQ] PAP test - liquid-based [PAPUNSP] PAP test - unspecified [HPVDNA] HPV DNA test [EKG] EKG/ECG [SPIRO] Spirometry/Pulmonary function test [URINE] Urinalysis [HTTAKE] Height taken (derived from PRF Q6) [WTTAKE] Weight taken (derived from PRF Q6) [TEMPTAKE] Temperature taken (derived from PRF Q6) [BLODPRES] Blood pressure taken (derived from PRF Q6) [OTHDIAG] Other test/service
34.38.a	a 4	152-155	[DIAGSC1] Other diagnostic service write-in #1 (ICD-9-CM, Vol.3, Procedure Classification) A left-justified alphanumeric code with an implied decimal after the first two digits; inapplicable fourth digits have a dash inserted. 0101-999 = 01.01-99.99 0000 = Not applicable/blank
34.38.t	o 4	156-159	[DIAGSC2] Other diagnostic service write-in #2 (ICD-9-CM, Vol.3, Procedure Classification) A left-justified alphanumeric code with an implied decimal after the first two digits; inapplicable fourth digits have a dash inserted. 0101-999 = 01.01-99.99 0000 = Not applicable/blank
34.39	2	160-161	[TOTDIAG] Total number of diagnostic/screening services ordered or provided 0-31 99 = Entire Item blank
35			HEALTH EDUCATION (from PRF Q8)
35.1	1	162	[HLTHED] Was any health education ordered or provided at this visit? 0 = No 1 = Yes 2 = No answer (Entire item blank, including "None" box.)
			0 = No, 1 = Yes
35.2 35.3 35.4 35.5 35.6 35.7	1 1 1 1 1	163 164 165 166 167 168	[ASTHMAED] Asthma education DIETNUTR] Diet/Nutrition [EXERCISE] Exercise [GRWTHDEV] Growth/Development [INJPREV] Injury prevention [STRESMGT] Stress management

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
35.8 35.9 35.10	1 1 1	169 170 171	[TOBACED] Tobacco use/exposure [WTREDUC] Weight reduction [OTHLTHED] Other health education
35.11	2	172-173	[TOTHLTED] Total health education ordered or provided 0-9 99 = Entire item blank
36			NON-MEDICATION TREATMENT (from PRF Q9)
36.1	1	174	[NONMED] Was any non-medication treatment ordered or provided at this visit?
			0 = No 1 = Yes 2 = Entire item blank, including "None" box
			0 = No, 1 = Yes
36.2 36.3 36.4 36.5 36.6 36.7 36.8 36.9 36.10 36.11 36.12 36.13 36.14	1 1 1 1 1 1 1 1 1	175 176 177 178 179 180 181 182 183 184 185 186 187	[CAM] Complementary alternative medicine [DME] Durable medical equipment [HOMEHLTH] Home health care [HOSPICE] Hospice care [PT] Physical therapy [RADTHER] Radiation therapy [SPOCTHER] Speech/Occupational therapy [SYCHOTH] Psychotherapy [OTHMNTL] Other mental health counseling [EXCISION] Excision [ORTHO] Orthopedic care [WOUND] Wound care [OTHPROC] Other surgical or non-surgical procedures This created checkbox combines data from items 9.14 and 9.15 on the Patient Record form. Procedures written in these items are listed below.
36.15.a	a 4	188-191	[OTHPROC1] Procedure #1 (ICD-9-CM, Vol.3, Procedure Classification) A left-justified alphanumeric code with an implied decimal after the first two digits; inapplicable fourth digits have a dash inserted. 0101-999 = 01.01-99.99 0000 = Not applicable/blank

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
36.15.b	4	192-195	[OTHPROC2] Procedure # 2 (ICD-9-CM, Vol.3, Procedure Classification) A left-justified alphanumeric code with an implied decimal after the first two digits; inapplicable fourth digits have a dash inserted. 0101-999 = 01.01-99.99 0000 = Not applicable/blank
36.15.c	4	196-199	[OTHPROC3] Procedure # 3 (ICD-9-CM, Vol.3, Procedure Classification) A left-justified alphanumeric code with an implied decimal after the first two digits; inapplicable fourth digits have a dash inserted. 0101-999 = 01.01-99.99 0000 = Not applicable/blank
36.15.d	4	200-203	[OTHPROC4] Procedure #4 (ICD-9-CM, Vol.3, Procedure Classification) A left-justified alphanumeric code with an implied decimal after the first two digits; inapplicable fourth digits have a dash inserted. 0101-999 = 01.01-99.99 0000 = Not applicable/blank
36.16	2	204-205	[TOTNONMED] Total number of non-medication treatments 0-16 99 = Entire item blank
37			MEDICATIONS & IMMUNIZATIONS (See page 22 for more information. See Appendix III for Code List.) (from PRF Q10)
37.1	1	206	[MED] WERE MEDICATIONS OR IMMUNIZATIONS ORDERED OR PROVIDED AT THIS VISIT? 0 = No 1 = Yes 2 = Entire item blank, including "None" box
37.2	5	207-211	[MED1] MEDICATION #1 00001-99227 = 00001-99227 90000 = Blank 99980 = Unknown Entry; Other 99999 = Illegible Entry
37.3	5	212-216	[MED2] MEDICATION #2 00001-99227 = 00001-99227 90000 = Blank 99980 = Unknown Entry; Other 99999 = Illegible Entry

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
37.4	5	217-221	[MED3] MEDICATION #3 00001-99227 = 00001-99227 90000 = Blank 99980 = Unknown Entry; Other 99999 = Illegible Entry
37.5	5	222-226	[MED4] MEDICATION #4 00001-99227 = 00001-99227 90000 = Blank 99980 = Unknown Entry; Other 99999 = Illegible Entry
37.6	5	227-231	[MED5] MEDICATION #5 00001-99227 = 00001-99227 90000 = Blank 99980 = Unknown Entry; Other 99999 = Illegible Entry
37.7	5	232-236	[MED6] MEDICATION #6 00001-99227 = 00001-99227 90000 = Blank 99980 = Unknown Entry; Other 99999 = Illegible Entry
37.8	5	237-241	[MED5] MEDICATION #7 00001-99227 = 00001-99227 90000 = Blank 99980 = Unknown Entry; Other 99999 = Illegible Entry
37.9	5	242-246	[MED5] MEDICATION #8 00001-99227 = 00001-99227 90000 = Blank 99980 = Unknown Entry; Other 99999 = Illegible Entry
37.10	1	247	[NCMED1] Was medication #1 new or continued? 1 = New 2 = Continued 3 = Both "New" and "Continued" were checked 8 = Not Applicable (no drug listed) 9 = Blank
37.11	1	248	[NCMED2] Was medication #2 new or continued? See NCMED1.
37.12	1	249	[NCMED3] Was medication #3 new or continued? See NCMED1.
37.13	1	250	[NCMED4] Was medication #4 new or continued? See NCMED1.

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
37.14	1	251	[NCMED5] Was medication #5 new or continued? See NCMED1.
37.15	1	252	[NCMED6] Was medication #6 new or continued? See NCMED1.
37.16	1	253	[NCMED7] Was medication #7 new or continued? See NCMED1.
37.17	1	254	[NCMED8] Was medication #8 new or continued? See NCMED1
37.18	1	255	[NUMNEW] NUMBER OF NEW MEDICATIONS CODED 0 – 8
37.19	1	256	[NUMCONT] NUMBER OF CONTINUED MEDICATIONS CODED 0 – 8
			NOTE: For NUMNEW and NUMCONT, the value '0' can reflect the following situations: for NUMNEW, a) no drug listed; b) drug listed as continued medication only; or c) drug listed but unknown whether new or continued; for NUMCONT, a) no drug listed; b) drug listed as new medication only, or c) drug listed but unknown whether new or continued
37.20	1	257	[NUMMED] NUMBER OF MEDICATIONS CODED 0 – 8
38			PROVIDERS SEEN (from PRF Q11)
			0 = No, 1 = Yes
38.1 38.2 38.3 38.4 38.5 38.6	1 1 1 1 1	258 259 260 261 262 263	[NOPROVID] No answer to item [PHYS] Physician [PHYSASST] Physician assistant [NPNMW] Nurse practitioner/Midwife [RNLPN] RN/LPN [OTHPROV] Other provider
39			VISIT DISPOSITION (from PRF Q12)
			0 = No, 1 = Yes
39.1 39.2 39.3 39.4 39.5 39.6 39.7	1 1 1 1 1 1	264 265 266 267 268 269 270	[NODISP] No answer to item [NOFU] No follow-up planned [RETPRN] Return if needed, P.R.N [REFOTHMD] Refer to other physician [RETAPPT] Return at specified time [TELEPHON] Telephone follow-up planned [REFERED] Refer to emergency department

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
39.8 39.9	1 1	271 272	[ADMITHOS] Admit to hospital [OTHDISP] Other visit disposition
40	3	273-275	[TIMEMD] TIME SPENT WITH MD (in minutes) (from PRF Q13) 0-240
41	6	276-281	[PATWT] PATIENT VISIT WEIGHT (See page 27 in Section I) A right-justified integer developed by NCHS staff for the purpose of producing national estimates from sample data.
42	1	282	[REGION] GEOGRAPHIC REGION (Based on actual location of the practice.)
			1= Northeast 2= Midwest 3= South 4= West
43	1	283	[MSA] METROPOLITAN/NON-METROPOLITAN STATUS
			(Based on actual location in conjunction with the definition of the Bureau of the Census and the U.S. Office of Management and Budget.)
			1 = MSA (Metropolitan Statistical Area) 2 = Non-MSA (includes micropolitan statistical areas)
44	3	284-286	[SPEC] PHYSICIAN SPECIALTY COLLECTED FROM INDUCTION INTERVIEW (REFERENCE 3)
			(See "Physician Specialty List" on page 78.)
45	1	287	[MDDO] TYPE OF DOCTOR 1 = M.D Doctor of Medicine 2 = D.O Doctor of Osteopathy
46	4	288-291	[PHYCODE] PHYSICIAN CODE - A unique code assigned to all records from a particular physician. 13-3010
47	3	292-294	[PATCODE] PATIENT CODE - A number assigned to identify each individual record from a particular physician. 1-107

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
**** TH	IE FOLLOWING	G FIELDS SHOW	WHETHER DATA WERE IMPUTED TO REPLACE BLANKS ****
48			IMPUTED FIELDS
			0 = Not imputed 1 = Imputed
			•
48.1	1	295	[BDATEFL] Patient birth date
48.2	1	296	[SEXFL] Patient sex
48.3	1	297	[ETHNICFL] Patient ethnicity
48.4	1	298	[RACEFL] Patient race
48.5	1	299	[SENBEFL] Has patient been seen in your practice before?
48.6	1	300	[PASTFL] If yes, how many past visits in last 12 months?
48.7	1	301	[TIMEMDFL] Time spent with physician (minutes)

CONTINUED ON NEXT PAGE.

PAGE 46			2006 NAMCS MICRO-DATA FILE DOCUMENTATION
ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
49			DRUG-RELATED INFO FOR MEDICATION #1
si L ra d c c c o	tandard classific exicon Drug Da igredient drugs ather than being ata. All Multum buld not be assi buld be determin	cation system) wer tabase, where pos are assigned a sin assigned generic codes start with th gned a code in Mu ned) or "c" (when i	release, all drug codes based on entry name (using NCHS' re also assigned a unique generic drug code from Multum's ssible. The structure of the Multum database is such that multiple agle generic drug code encompassing all of a drug's ingredients drug codes for each ingredient, as in past years of NAMCS drug he letter "d" but there were some drugs reported in NAMCS that ultum. These received a prefix of either "a" (when ingredients ingredients could not be determined). For more on the structure formation on therapeutic class and drug ingredients, please see
49.1	6	302-307	[DRUGID1] DRUG ID (See p. 144 for more information.)
			a10001-a71037 = NCHS code (for drugs not found in Multum but for which ingredients could be determined) c00012-c00899 = NCHS code (for drugs not found in Multum and with undetermined ingredients) d00001-d06848 = Multum code
49.2	1	308	[PRESCR1] PRESCRIPTION STATUS CODE 1 = Prescription Drug 2 = Nonprescription Drug 3 = Undetermined
49.3	1	309	[CONTSUB1] CONTROLLED SUBSTANCE STATUS CODE 1 = Schedule I (Research Only) 2 = Schedule II 5 = Schedule V 3 = Schedule III 6 = No Control 4 = Schedule IV 7 = Undetermined
49.4	1	310	[COMSTAT1] COMPOSITION STATUS CODE 1 = Single Entity Drug 2 = Combination Drug 3 = Undetermined
49.5a	3	311-313	[RX1CAT1] MULTUM DRUG CATEGORY # 1 Reflects the most detailed therapeutic level to which the drug can be classified. For some drugs, Multum Level 1 (broadest level) is the most detailed, while others can be coded to Level 2, but the majority can be coded to Level 3 (most detailed level). For more on the Multum classification system, please see page 22. The complete Multum classification is shown in Appendix III. " " = Blank/Not applicable 001 - 899 = Drug category 999 = Undetermined category

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
49.6a	3	314-316	[RX1CAT2] MULTUM DRUG CATEGORY # 2 See RX1CAT1.
49.7a	3	317-319	[RX1CAT3] MULTUM DRUG CATEGORY # 3 See RX1CAT1.
49.8a	3	320-322	[RX1CAT4] MULTUM DRUG CATEGORY # 4 See RX1CAT1.
			DRUG CATEGORY LEVELS
			See RX1CAT1 for general coding conventions that apply to all Multum drug categories. Complete Multum classification scheme is shown in Appendix III.
49.5a1 49.6a1 49.7a1 49.8a1	3 3	323-325 326-328 329-331 332-334	[RX1V1C1] Level 1 of MULTUM DRUG CATEGORY # 1 [RX1V1C2] Level 1 of MULTUM DRUG CATEGORY # 2 [RX1V1C3] Level 1 of MULTUM DRUG CATEGORY # 3 [RX1V1C4] Level 1 of MULTUM DRUG CATEGORY # 4
49.5a2 49.6a2 49.7a2 49.8a2	3 3	335-337 338-340 341-343 344-346	[RX1V2C1] Level 2 of MULTUM DRUG CATEGORY # 1 [RX1V2C2] Level 2 of MULTUM DRUG CATEGORY # 2 [RX1V2C3] Level 2 of MULTUM DRUG CATEGORY # 3 [RX1V2C4] Level 2 of MULTUM DRUG CATEGORY # 4
49.5a3 49.6a3 49.7a3 49.8a3	3 3	347-349 350-352 353-355 356-358	[RX1V3C1] Level 3 of MULTUM DRUG CATEGORY # 1 [RX1V3C2] Level 3 of MULTUM DRUG CATEGORY # 2 [RX1V3C3] Level 3 of MULTUM DRUG CATEGORY # 3 [RX1V3C4] Level 3 of MULTUM DRUG CATEGORY # 4

PAGE 48			2006 NAMCS MICRO-DATA FILE DOCUMENTATION
ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
50			DRUG-RELATED INFO FOR MEDICATION #2
50.1	6	359-364	[DRUGID2] Drug ID (See p. 144 for more information.) a10001-a71037 = NCHS code (for drugs not found in Multum but for which ingredients could be determined) c00012-c00899 = NCHS code (for drugs not found in Multum and with undetermined ingredients) d00001-d06848 = Multum code
50.2	1	365	[PRESCR2] PRESCRIPTION STATUS CODE 1 = Prescription Drug 2 = Nonprescription Drug 3 = Undetermined
50.3	1	366	[CONTSUB2] CONTROLLED SUBSTANCE STATUS CODE1 = Schedule I (Research Only)2 = Schedule II5 = Schedule V3 = Schedule III6 = No Control4 = Schedule IV7 = Undetermined
50.4	1	367	[COMSTAT2] COMPOSITION STATUS CODE 1 = Single Entity Drug 2 = Combination Drug 3 = Undetermined
50.5a	3	368-370	[RX2CAT1] MULTUM DRUG CATEGORY # 1
			Reflects the most detailed therapeutic level to which the drug can be classified. For some drugs, Multum Level 1 (broadest level) is the most detailed, while others can be coded to Level 2, but the majority can be coded to Level 3 (most detailed level). For more on the Multum classification system, please see page 22. The complete Multum classification is shown in Appendix III.
			 " = Blank/Not applicable 001 - 899 = Drug category 999 = Undetermined category
50.6a	3	371-373	[RX2CAT2] MULTUM DRUG CATEGORY # 2 See RX2CAT1.
50.7a	3	374-376	[RX2CAT3] MULTUM DRUG CATEGORY # 3 See RX2CAT1.
50.8a	3	377-379	[RX2CAT4] MULTUM DRUG CATEGORY # 4 See RX2CAT1.

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
			DRUG CATEGORY LEVELS See RX2CAT1 for general coding conventions that apply to all Multum drug categories. Complete Multum classification
50.5a1 50.6a1	3	380-382 383-385	scheme is shown in Appendix III. [RX2V1C1] Level 1 of MULTUM DRUG CATEGORY # 1 [RX2V1C2] Level 1 of MULTUM DRUG CATEGORY # 2
50.7a1 50.8a1	•	386-388 389-391	[RX2V1C3] Level 1 of MULTUM DRUG CATEGORY # 3 [RX2V1C4] Level 1 of MULTUM DRUG CATEGORY # 4
50.5a2 50.6a2 50.7a2 50.8a2	3 3	392-394 395-397 398-400 401-403	[RX2V2C1] Level 2 of MULTUM DRUG CATEGORY # 1 [RX2V2C2] Level 2 of MULTUM DRUG CATEGORY # 2 [RX2V2C3] Level 2 of MULTUM DRUG CATEGORY # 3 [RX2V2C4] Level 2 of MULTUM DRUG CATEGORY # 4
50.5a3 50.6a3 50.7a3 50.8a3	3 3	404-406 407-409 410-412 413-415	[RX2V3C1] Level 3 of MULTUM DRUG CATEGORY # 1 [RX2V3C2] Level 3 of MULTUM DRUG CATEGORY # 2 [RX2V3C3] Level 3 of MULTUM DRUG CATEGORY # 3 [RX2V3C4] Level 3 of MULTUM DRUG CATEGORY # 4

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
51			DRUG-RELATED INFO FOR MEDICATION #3
51.1	6	416-421	[DRUGID3] Drug ID (See p. 144 for more information.) a10001-a71037 = NCHS code (for drugs not found in Multum but for which ingredients could be determined) c00012-c00899 = NCHS code (for drugs not found in Multum and with undetermined ingredients) d00001-d06848 = Multum code
51.2	1	422	[PRESCR3] PRESCRIPTION STATUS CODE 1 = Prescription Drug 2 = Nonprescription Drug 3 = Undetermined
51.3	1	423	[CONTSUB3] CONTROLLED SUBSTANCE STATUS CODE1 = Schedule I (Research Only)2 = Schedule II5 = Schedule V3 = Schedule III6 = No Control4 = Schedule IV7 = Undetermined
51.4	1	424	[COMSTAT3] COMPOSITION STATUS CODE 1 = Single Entity Drug 2 = Combination Drug 3 = Undetermined
51.5a	3	425-427	[RX3CAT1] MULTUM DRUG CATEGORY # 1
			Reflects the most detailed therapeutic level to which the drug can be classified. For some drugs, Multum Level 1 (broadest level) is the most detailed, while others can be coded to Level 2, but the majority can be coded to Level 3 (most detailed level). For more on the Multum classification system, please see page 22. The complete Multum classification is shown in Appendix III.
			 " = Blank/Not applicable 001 - 899 = Drug category 999 = Undetermined category
51.6a	3	428-430	[RX3CAT2] MULTUM DRUG CATEGORY # 2 See RX3CAT1.
51.7a	3	431-433	[RX3CAT3] MULTUM DRUG CATEGORY # 3 See RX3CAT1.
51.8a	3	434-436	[RX3CAT4] MULTUM DRUG CATEGORY # 4 See RX3CAT1.

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
			DRUG CATEGORY LEVELS See RX3CAT1 for general coding conventions that apply to all Multum drug categories. Complete Multum classification
			scheme is shown in Appendix III.
51.5a1	3	437-439	[RX3V1C1] Level 1 of MULTUM DRUG CATEGORY # 1
51.6a1	3	440-442	[RX3V1C2] Level 1 of MULTUM DRUG CATEGORY # 2
51.7a1	3	443-445	RX3V1C3 Level 1 of MULTUM DRUG CATEGORY # 3
51.8a1	3	446-448	[RX3V1C4] Level 1 of MULTUM DRUG CATEGORY # 4
51.5a2	-	449-451	[RX3V2C1] Level 2 of MULTUM DRUG CATEGORY # 1
51.6a2	-	452-454	[RX3V2C2] Level 2 of MULTUM DRUG CATEGORY # 2
51.7a2		455-457	[RX3V2C3] Level 2 of MULTUM DRUG CATEGORY # 3
51.8a2	3	458-460	[RX3V2C4] Level 2 of MULTUM DRUG CATEGORY # 4
51.5a3	-	461-463	[RX3V3C1] Level 3 of MULTUM DRUG CATEGORY # 1
51.6a3	-	464-466	[RX3V3C2] Level 3 of MULTUM DRUG CATEGORY # 2
51.7a3	-	467-469	[RX3V3C3] Level 3 of MULTUM DRUG CATEGORY # 3
51.8a3	3	470-472	[RX3V3C4] Level 3 of MULTUM DRUG CATEGORY # 4

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
52			DRUG-RELATED INFO FOR MEDICATION #4
52.1	6	473-478	[DRUGID4] Drug ID (See p. 144 for more information.) a10001-a71037 = NCHS code (for drugs not found in Multum but for which ingredients could be determined) c00012-c00899 = NCHS code (for drugs not found in Multum and with undetermined ingredients) d00001-d06848 = Multum code
52.2	1	479	[PRESCR4] PRESCRIPTION STATUS CODE 1 = Prescription Drug 2 = Nonprescription Drug 3 = Undetermined
52.3	1	480	[CONTSUB4] CONTROLLED SUBSTANCE STATUS CODE1 = Schedule I (Research Only)2 = Schedule II5 = Schedule V3 = Schedule III6 = No Control4 = Schedule IV7 = Undetermined
52.4	1	481	[COMSTAT4] COMPOSITION STATUS CODE 1 = Single Entity Drug 2 = Combination Drug 3 = Undetermined
52.5a	3	482-484	[RX4CAT1] MULTUM DRUG CATEGORY # 1 Reflects the most detailed therapeutic level to which the drug can be classified. For some drugs, Multum Level 1 (broadest level) is the most detailed, while others can be coded to Level 2, but the majority can be coded to Level 3 (most detailed level). For more on the Multum classification system, please see page 22. The complete Multum classification is shown in Appendix III.
			 " = Blank/Not applicable 001 - 899 = Drug category 999 = Undetermined category
52.6a	3	485-487	[RX4CAT2] MULTUM DRUG CATEGORY # 2 See RX4CAT1.
52.7a	3	488-490	[RX4CAT3] MULTUM DRUG CATEGORY # 3 See RX4CAT1.
52.8a	3	491-493	[RX4CAT4] MULTUM DRUG CATEGORY # 4 See RX4CAT1.

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
			DRUG CATEGORY LEVELS See RX4CAT1 for general coding conventions that apply to all Multum drug categories. Complete Multum classification
52.5a1 52.6a1 52.7a1	3	494-496 497-499 500-502	scheme is shown in Appendix III. [RX4V1C1] Level 1 of MULTUM DRUG CATEGORY # 1 [RX4V1C2] Level 1 of MULTUM DRUG CATEGORY # 2 [RX4V1C3] Level 1 of MULTUM DRUG CATEGORY # 3
52.8a1	3	503-505	[RX4V1C4] Level 1 of MULTUM DRUG CATEGORY # 4
52.5a2 52.6a2 52.7a2 52.8a2	3 3	506-508 509-511 512-514 515-517	[RX4V2C1] Level 2 of MULTUM DRUG CATEGORY # 1 [RX4V2C2] Level 2 of MULTUM DRUG CATEGORY # 2 [RX4V2C3] Level 2 of MULTUM DRUG CATEGORY # 3 [RX4V2C4] Level 2 of MULTUM DRUG CATEGORY # 4
52.5a3 52.6a3 52.7a3 52.8a3	3	518-520 521-523 524-526 527-529	[RX4V3C1] Level 3 of MULTUM DRUG CATEGORY # 1 [RX4V3C2] Level 3 of MULTUM DRUG CATEGORY # 2 [RX4V3C3] Level 3 of MULTUM DRUG CATEGORY # 3 [RX4V3C4] Level 3 of MULTUM DRUG CATEGORY # 4

PAGE 54	PA	GE	54
---------	----	----	----

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
53			DRUG-RELATED INFO FOR MEDICATION #5
53.1	6	530-535	[DRUGID5] Drug ID (See p. 144 for more information.) a10001-a71037 = NCHS code (for drugs not found in Multum but for which ingredients could be determined) c00012-c00899 = NCHS code (for drugs not found in Multum and with undetermined ingredients) d00001-d06848 = Multum code
53.2	1	536	[PRESCR5] PRESCRIPTION STATUS CODE 1 = Prescription Drug 2 = Nonprescription Drug 3 = Undetermined
53.3	1	537	[CONTSUB5] CONTROLLED SUBSTANCE STATUS CODE1 = Schedule I (Research Only)2 = Schedule II5 = Schedule V3 = Schedule III6 = No Control4 = Schedule IV7 = Undetermined
53.4	1	538	[COMSTAT5] COMPOSITION STATUS CODE 1 = Single Entity Drug 2 = Combination Drug 3 = Undetermined
53.5a	3	539-541	[RX5CAT1] MULTUM DRUG CATEGORY # 1 Reflects the most detailed therapeutic level to which the drug can be classified. For some drugs, Multum Level 1 (broadest level) is the most detailed, while others can be coded to Level 2, but the majority can be coded to Level 3 (most detailed level). For more on the Multum classification system, please see page 22. The complete Multum classification is shown in Appendix III.
			 " = Blank/Not applicable 001 - 899 = Drug category 999 = Undetermined category
53.6a	3	542-544	[RX5CAT2] MULTUM DRUG CATEGORY # 2 See RX3CAT1.
53.7a	3	545-547	[RX5CAT3] MULTUM DRUG CATEGORY # 3 See RX3CAT1.
53.8a	3	548-550	[RX5CAT4] MULTUM DRUG CATEGORY # 4 See RX3CAT1.

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
			DRUG CATEGORY LEVELS See RX5CAT1 for general coding conventions that apply to all Multum drug categories. Complete Multum classification
53.5a1 53.6a1 53.7a1 53.8a1	3 3	551-553 554-556 557-559 560-562	scheme is shown in Appendix III. [RX5V1C1] Level 1 of MULTUM DRUG CATEGORY # 1 [RX5V1C2] Level 1 of MULTUM DRUG CATEGORY # 2 [RX5V1C3] Level 1 of MULTUM DRUG CATEGORY # 3 [RX5V1C4] Level 1 of MULTUM DRUG CATEGORY # 4
53.5a2 53.6a2 53.7a2 53.8a2	3 3	563-565 566-568 569-571 572-574	[RX5V2C1] Level 2 of MULTUM DRUG CATEGORY # 1 [RX5V2C2] Level 2 of MULTUM DRUG CATEGORY # 2 [RX5V2C3] Level 2 of MULTUM DRUG CATEGORY # 3 [RX5V2C4] Level 2 of MULTUM DRUG CATEGORY # 4
53.5a3 53.6a3 53.7a3 53.8a3	3	575-577 578-580 581-583 584-586	[RX5V3C1] Level 3 of MULTUM DRUG CATEGORY # 1 [RX5V3C2] Level 3 of MULTUM DRUG CATEGORY # 2 [RX5V3C3] Level 3 of MULTUM DRUG CATEGORY # 3 [RX5V3C4] Level 3 of MULTUM DRUG CATEGORY # 4

PAGE 56	PA	GE	56
---------	----	----	----

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
54			DRUG-RELATED INFO FOR MEDICATION #6
54.1	6	587-592	[DRUGID6] Drug ID (See p. 144 for more information.) a10001-a71037 = NCHS code (for drugs not found in Multum but for which ingredients could be determined) c00012-c00899 = NCHS code (for drugs not found in Multum and with undetermined ingredients) d00001-d06848 = Multum code
54.2	1	593	[PRESCR6] PRESCRIPTION STATUS CODE 1 = Prescription Drug 2 = Nonprescription Drug 3 = Undetermined
54.3	1	594	[CONTSUB6] CONTROLLED SUBSTANCE STATUS CODE1 = Schedule I (Research Only)2 = Schedule II5 = Schedule V3 = Schedule III6 = No Control4 = Schedule IV7 = Undetermined
54.4	1	595	[COMSTAT6] COMPOSITION STATUS CODE 1 = Single Entity Drug 2 = Combination Drug 3 = Undetermined
54.5a	3	596-598	[RX6CAT1] MULTUM DRUG CATEGORY # 1
			Reflects the most detailed therapeutic level to which the drug can be classified. For some drugs, Multum Level 1 (broadest level) is the most detailed, while others can be coded to Level 2, but the majority can be coded to Level 3 (most detailed level). For more on the Multum classification system, please see page 22. The complete Multum classification is shown in Appendix III.
			 " = Blank/Not applicable 001 - 899 = Drug category 999 = Undetermined category
54.6a	3	599-601	[RX6CAT2] MULTUM DRUG CATEGORY # 2 See RX6CAT1.
54.7a	3	602-604	[RX6CAT3] MULTUM DRUG CATEGORY # 3 See RX6CAT1.
54.8a	3	605-607	[RX6CAT4] MULTUM DRUG CATEGORY # 4 See RX6CAT1.

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
			DRUG CATEGORY LEVELS See RX6CAT1 for general coding conventions that apply to all Multum drug categories. Complete Multum classification
54.5a1 54.6a1 54.7a1	3	608-610 611-613 614-616	scheme is shown in Appendix III. [RX6V1C1] Level 1 of MULTUM DRUG CATEGORY # 1 [RX6V1C2] Level 1 of MULTUM DRUG CATEGORY # 2 [RX6V1C3] Level 1 of MULTUM DRUG CATEGORY # 3
54.8a1	3	617-619	[RX6V1C4] Level 1 of MULTUM DRUG CATEGORY # 4
54.5a2 54.6a2 54.7a2 54.8a2	3 3	620-622 623-625 626-628 629-631	[RX6V2C1] Level 2 of MULTUM DRUG CATEGORY # 1 [RX6V2C2] Level 2 of MULTUM DRUG CATEGORY # 2 [RX6V2C3] Level 2 of MULTUM DRUG CATEGORY # 3 [RX6V2C4] Level 2 of MULTUM DRUG CATEGORY # 4
54.5a3 54.6a3 54.7a3 54.8a3	3 3	632-634 635-637 638-640 641-643	[RX6V3C1] Level 3 of MULTUM DRUG CATEGORY # 1 [RX6V3C2] Level 3 of MULTUM DRUG CATEGORY # 2 [RX6V3C3] Level 3 of MULTUM DRUG CATEGORY # 3 [RX6V3C4] Level 3 of MULTUM DRUG CATEGORY # 4

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
55			DRUG-RELATED INFO FOR MEDICATION #7
55.1	6	644-649	[DRUGID7] Drug ID (See p. 144 for more information.) a10001-a71037 = NCHS code (for drugs not found in Multum but for which ingredients could be determined) c00012-c00899 = NCHS code (for drugs not found in Multum and with undetermined ingredients) d00001-d06848 = Multum code
55.2	1	650	[PRESCR7] PRESCRIPTION STATUS CODE 1 = Prescription Drug 2 = Nonprescription Drug 3 = Undetermined
55.3	1	651	[CONTSUB7] CONTROLLED SUBSTANCE STATUS CODE1 = Schedule I (Research Only)2 = Schedule II5 = Schedule V3 = Schedule III6 = No Control4 = Schedule IV7 = Undetermined
55.4	1	652	[COMSTAT7] COMPOSITION STATUS CODE 1 = Single Entity Drug 2 = Combination Drug 3 = Undetermined
55.5a	3	653-655	[RX7CAT1] MULTUM DRUG CATEGORY # 1
			Reflects the most detailed therapeutic level to which the drug can be classified. For some drugs, Multum Level 1 (broadest level) is the most detailed, while others can be coded to Level 2, but the majority can be coded to Level 3 (most detailed level). For more on the Multum classification system, please see page 22. The complete Multum classification is shown in Appendix III.
			 " = Blank/Not applicable 001 - 899 = Drug category 999 = Undetermined category
55.6a	3	656-658	[RX7CAT2] MULTUM DRUG CATEGORY # 2 See RX7CAT1.
55.7a	3	659-661	[RX7CAT3] MULTUM DRUG CATEGORY # 3 See RX7CAT1.
55.8a	3	662-664	[RX7CAT4] MULTUM DRUG CATEGORY # 4 See RX7CAT1.

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
			DRUG CATEGORY LEVELS See RX7CAT1 for general coding conventions that apply to all Multum drug categories. Complete Multum classification
55.5a1 55.6a1	•	665-667 668-670	scheme is shown in Appendix III. [RX7V1C1] Level 1 of MULTUM DRUG CATEGORY # 1 [RX7V1C2] Level 1 of MULTUM DRUG CATEGORY # 2
55.7a1 55.8a1	•	671-673 674-676	[RX7V1C3] Level 1 of MULTUM DRUG CATEGORY # 3 [RX7V1C4] Level 1 of MULTUM DRUG CATEGORY # 4
55.5a2 55.6a2 55.7a2 55.8a2	3 3	677-679 680-682 683-685 686-688	[RX7V2C1] Level 2 of MULTUM DRUG CATEGORY # 1 [RX7V2C2] Level 2 of MULTUM DRUG CATEGORY # 2 [RX7V2C3] Level 2 of MULTUM DRUG CATEGORY # 3 [RX7V2C4] Level 2 of MULTUM DRUG CATEGORY # 4
55.5a3 55.6a3 55.7a3 55.8a3	3 3	689-691 692-694 695-697 698-700	[RX7V3C1] Level 3 of MULTUM DRUG CATEGORY # 1 [RX7V3C2] Level 3 of MULTUM DRUG CATEGORY # 2 [RX7V3C3] Level 3 of MULTUM DRUG CATEGORY # 3 [RX7V3C4] Level 3 of MULTUM DRUG CATEGORY # 4

PAGE 60	AGE 60
---------	--------

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
56			DRUG-RELATED INFO FOR MEDICATION #8
56.1	6	701-706	[DRUGID8] Drug ID (See p. 144 for more information.) a10001-a71037 = NCHS code (for drugs not found in Multum but for which ingredients could be determined) c00012-c00899 = NCHS code (for drugs not found in Multum and with undetermined ingredients) d00001-d06848 = Multum code
56.2	1	707	[PRESCR8] PRESCRIPTION STATUS CODE 1 = Prescription Drug 2 = Nonprescription Drug 3 = Undetermined
56.3	1	708	[CONTSUB8] CONTROLLED SUBSTANCE STATUS CODE1 = Schedule I (Research Only)2 = Schedule II5 = Schedule V3 = Schedule III6 = No Control4 = Schedule IV7 = Undetermined
56.4	1	709	[COMSTAT8] COMPOSITION STATUS CODE 1 = Single Entity Drug 2 = Combination Drug 3 = Undetermined
56.5a	3	710-712	[RX8CAT1] MULTUM DRUG CATEGORY # 1
			Reflects the most detailed therapeutic level to which the drug can be classified. For some drugs, Multum Level 1 (broadest level) is the most detailed, while others can be coded to Level 2, but the majority can be coded to Level 3 (most detailed level). For more on the Multum classification system, please see page 22. The complete Multum classification is shown in Appendix III.
			 " = Blank/Not applicable 001 - 899 = Drug category 999 = Undetermined category
56.6a	3	713-715	[RX8CAT2] MULTUM DRUG CATEGORY # 2 See RX8CAT1.
56.7a	3	716-718	[RX8CAT3] MULTUM DRUG CATEGORY # 3 See RX8CAT1.
56.8a	3	719-721	[RX8CAT4] MULTUM DRUG CATEGORY # 4 See RX8CAT1.

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
			DRUG CATEGORY LEVELS See RX8CAT1 for general coding conventions that apply to all
			Multum drug categories. Complete Multum classification scheme is shown in Appendix III.
56.5a1	3	722-724	[RX8V1C1] Level 1 of MULTUM DRUG CATEGORY # 1
56.6a1	3	725-727	[RX8V1C2] Level 1 of MULTUM DRUG CATEGORY # 2
56.7a1	3	728-730	[RX8V1C3] Level 1 of MULTUM DRUG CATEGORY # 3
56.8a1	3	731-733	[RX8V1C4] Level 1 of MULTUM DRUG CATEGORY # 4
56.5a2	3	734-736	[RX8V2C1] Level 2 of MULTUM DRUG CATEGORY # 1
56.6a2	3	737-739	[RX8V2C2] Level 2 of MULTUM DRUG CATEGORY # 2
56.7a2	3	740-742	[RX8V2C3] Level 2 of MULTUM DRUG CATEGORY # 3
56.8a2	3	743-745	[RX8V2C4] Level 2 of MULTUM DRUG CATEGORY # 4
56.5a3 56.6a3	-	746-748 749-751	[RX8V3C1] Level 3 of MULTUM DRUG CATEGORY # 1 [RX8V3C2] Level 3 of MULTUM DRUG CATEGORY # 2
56.7a3		752-754	[RX8V3C3] Level 3 of MULTUM DRUG CATEGORY # 3
56.8a3		755-757	[RX8V3C4] Level 3 of MULTUM DRUG CATEGORY # 4

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
The fol	llowing items w	ere collected using	g the Physician Induction Interview form at the start of the surv of the physician's practice.
57	1	758	 [RETYPOFF] TYPE OF OFFICE SETTING FOR THIS VIS 1 = Private solo or group practice 2 = Free standing clinic/urgicenter (not part of hospital emergency department or outpatient department) 3 = Community health center 4 = Mental health center 5 = Non-Federal government clinic 6 = Family planning clinic 7 = Health maintenance organization (HMO) or other prepaid practice 8 = Faculty Practice Plan 9 = Other
58	1	759	[SOLO] IS THIS A SOLO PRACTICE? 1 = Yes 2 = No 3 = Blank
59	1	760	[EMPSTAT] EMPLOYMENT STATUS OF PHYSICIAN 1 = Owner 2 = Employee 3 = Contractor 4 = Blank
60	1	761	[OWNS] WHO OWNS THE PRACTICE? 1 = Physician or physician group 2 = Health Maintenance Organization (HMO) 3 = Community health center 4 = Medical/Academic health center 5 = Other hospital 6 = Other health care corporation 7 = Other 9 = Blank
61	1	762	[LAB] IS ANY LAB TESTING PERFORMED AT THE OFFI 1 = Yes 2 = No 3 = Unknown 9 = Blank
62	1	763	[PATEVEN] DOES PHYSICIAN SEE PATIENTS IN THE OFFICE DURING THE EVENING OR ON WEEKENDS? 1 = Yes 2 = No 3 = Don't know 9 = Blank

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
63	1	764	[HOMVISR] DURING LAST NORMAL WEEK OF PRACTICE, DID PHYSICIAN MAKE ANY HOME VISITS (INCLUDING NURSING HOMES)? 0 = No 1 = Yes 2 = Unknown
64	1	765	[HOSVISR] DURING LAST NORMAL WEEK OF PRACTICE, DID PHYSICIAN MAKE ANY HOSPITAL VISITS? 0 = No 1 = Yes 2 = Unknown
65	1	766	[TELCONR] DURING LAST NORMAL WEEK OF PRACTICE, DID PHYSICIAN DO ANY TELEPHONE CONSULTS WITH PATIENTS? 0 = No 1 = Yes 2 = Unknown
66	1	767	[ECONR] DURING LAST NORMAL WEEK OF PRACTICE, DID PHYSICIAN DO ANY INTERNET/EMAIL CONSULTS WITH PATIENTS? 0 = No 1 = Yes 2 = Unknown
67	1	768	[EBILLREC] DOES THIS PRACTICE SUBMIT CLAIMS ELECTRONICALLY? (ELECTRONIC BILLING) 0 = Blank 1 = Yes 2 = No 3 = Unknown
68	1	769	[EMEDREC] DOES THIS PRACTICE USE ELECTRONIC MEDICAL RECORDS (NOT INCLUDING BILLING RECORDS)? 0 = Blank 1 = Yes, all electronic 2 = Yes, part paper and part electronic 3 = No 4 = Don't know

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
69	1	770	[EDEMOG] DOES THIS PRACTICE'S ELECTRONIC MEDICAL RECORD SYSTEM INCLUDE PATIENT DEMOGRAPHIC INFORMATION? 1= Yes 2= No 3= Unknown 4= Turned off 8= Not applicable 9= Blank
70	1	771	[ECPOE] DOES THIS PRACTICE'S ELECTRONIC MEDICAL RECORD SYSTEM INCLUDE COMPUTERIZED ORDERS FOR PRESCRIPTIONS? 1= Yes 2= No 3= Unknown 4= Turned off 8= Not applicable 9= Blank
71	1	772	[EWARN] IF THIS PRACTICE'S ELECTRONIC MEDICAL RECORD SYSTEM INCLUDES COMPUTERIZED ORDERS FOR PRESCRIPTIONS, ARE THERE WARNINGS OF DRUG INTERACTIONS/CONTRAINDICATIONS PROVIDED? 1= Yes 2= No 3= Unknown 4= Turned off 8= Not applicable 9= Blank
72	1	773	[ESCRIP] IF THIS PRACTICE'S ELECTRONIC MEDICAL RECORD SYSTEM INCLUDES COMPUTERIZED ORDERS FOR PRESCRIPTIONS, ARE PRESCRIPTIONS SENT ELECTRONICALLY TO THE PHARMACY? 1= Yes 2= No 3= Unknown 4= Turned off 8= Not applicable 9= Blank
73	1	774	[ECTOE] DOES THIS PRACTICE'S ELECTRONIC MEDICAL RECORD SYTEM INCLUDE COMPUTERIZED ORDERS FOR TESTS? 1= Yes 2= No 3= Unknown 4= Turned off 8= Not applicable 9= Blank

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
74	1	775	[EORDER] IF THIS PRACTICE'S ELECTRONIC MEDICAL RECORD SYTEM INCLUDES COMPUTERIZED ORDERS FOR TESTS, ARE ORDERS SENT ELECTRONICALLY? 1= Yes 2= No 3= Unknown 4= Turned off 8= Not applicable 9= Blank
75	1	776	[ERESULT] DOES THIS PRACTICE'S ELECTRONIC MEDICAL RECORD SYTEM INCLUDE LAB RESULTS? 1= Yes 2= No 3= Unknown 4= Turned off 8= Not applicable 9= Blank
76	1	777	[ERANGE] IF THIS PRACTICE'S ELECTRONIC MEDICAL RECORD SYSTEM INCLUDES TEST RESULTS, ARE OUT OF RANGE LEVELS HIGHLIGHTED? 1= Yes 2= No 3= Unknown 4= Turned off 8= Not applicable 9= Blank
77	1	778	[EIMGRES] DOES THIS PRACTICE'S ELECTRONIC MEDICAL RECORD SYTEM INCLUDE IMAGING RESULTS? 1= Yes 2= No 3= Unknown 4= Turned off 8= Not applicable 9= Blank
78	1	779	[EIMAGE] IF THIS PRACTICE'S ELECTRONIC MEDICAL RECORD SYTEM INCLUDES IMAGING RESULTS, ARE ELECTRONIC IMAGES RETURNED? 1= Yes 2= No 3= Unknown 4= Turned off 8= Not applicable 9= Blank

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
79	1	780	[EPNOTES] DOES THIS PRACTICE'S ELECTRONIC MEDICAL RECORD SYTEM INCLUDE CLINICAL NOTES? 1= Yes 2= No 3= Unknown 4= Turned off 8= Not applicable 9= Blank
80	1	781	[EHXFU] IF THIS PRACTICE'S ELECTRONIC MEDICAL RECORD SYSTEM INCLUDES CLINICAL NOTES, DO THEY INCLUDE MEDICAL HISTORY AND FOLLOW-UP NOTES? 1= Yes 2= No 3= Unknown 4= Turned off 8= Not applicable 9= Blank
81	1	782	[EREMIND] IF THIS PRACTICE'S ELECTRONIC MEDICAL RECORD SYSTEM INCLUDES CLINICAL NOTES, DO THEY INCLUDE REMINDERS FOR GUIDELINE-BASED INTERVENTIONS AND/OR SCREENING TESTS? 1= Yes 2= No 3= Unknown 4= Turned off 8= Not applicable 9= Blank
82	1	783	[EPUBHLTH] DOES THIS PRACTICE'S ELECTRONIC MEDICAL RECORD SYSTEM INCLUDE PUBLIC HEALTH REPORTING? 1= Yes 2= No 3= Unknown 4= Turned off 8= Not applicable 9= Blank
83	1	784	[ENOTDIS] IF THIS PRACTICE'S ELECTRONIC MEDICAL RECORD SYSTEM INCLUDES PUBLIC HEALTH REPORTING, ARE NOTIFIABLE DISEASES SENT ELECTRONICALLY? 1= Yes 2= No 3= Unknown 4= Turned off 8= Not applicable 9= Blank

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
84	1	785	[EMRNEW] ARE THERE PLANS FOR INSTALLING A NEW ELECTONIC MEDICAL RECORD SYSTEM OR REPLACING THE CURRENT SYSTEM WITHIN THE NEXT THREE YEARS? 1 = Yes 2 = No 3 = Maybe 4 = Unknown 9 = Blank
85	1	786	[PRMCARER] Roughly, what percent of your patient care revenue comes from Medicare? 1 = Less than or equal to 25 percent 2 = 26-50 percent 3 = 51-75 percent 4 = More than 75 percent 9 = Blank
86	1	787	[PRMAIDR] Roughly, what percent of your patient care revenue comes from Medicaid? 1 = Less than or equal to 25 percent 2 = 26-50 percent 3 = 51-75 percent 4 = More than 75 percent 9 = Blank
87	1	788	[PRPRVTR] Roughly, what percent of your patient care revenue comes from private insurance? 1 = Less than or equal to 25 percent 2 = 26-50 percent 3 = 51-75 percent 4 = More than 75 percent 9 = Blank
88	1	789	[PRPATR] Roughly, what percent of your patient care revenue comes from patient payments? 1 = Less than or equal to 25 percent 2 = 26-50 percent 3 = 51-75 percent 4 = More than 75 percent 9 = Blank
89	1	790	[PROTHR] Roughly, what percent of your patient care revenue comes from other sources? (including charity, research, Champus, VA, etc.) 1 = Less than or equal to 25 percent 2 = 26-50 percent 3 = 51-75 percent 4 = More than 75 percent 9 = Blank

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
90	1	791	[MANCAREC] Roughly, how many managed care contracts does this practice have, such as HMOs, PPOs, IPAs, and point-of-service plans? 0 = Blank 1 = None 2 = Less than 3 3 = 3-10 4 = More than 10
91	1	792	[PRMANR] Roughly, what percentage of the patient care revenue received by this practice comes from (these) managed care contracts? 1 = Less than or equal to 25 percent 2 = 26-50 percent 3 = 51-75 percent 4 = More than 75 percent 9 = Blank
			The following 4 items are all possible responses to this question asked of physicians: Which of the following factors are taken into account for your patient care compensation (e.g., base pay, bonuses, or withholds)?
92	1	793	[PCCPROD] Your productivity (e.g., number of case seen per time period)? 1 = Yes 2 = No 3 = Don't know 9 = Blank
93	1	794	[PCCSAT] Patient satisfaction (e.g., results of patient surveys)? 1 = Yes 2 = No 3 = Don't know 9 = Blank
94	1	795	[PCCQOC] Quality of care (e.g. rates of preventive care services)? 1 = Yes 2 = No 3 = Don't know 9 = Blank
95	1	796	[PCCPPROF] Practice profiling (patterns of using certain services, e.g., laboratory tests, imaging, referrals, etc.)? 1 = Yes 2 = No 3 = Don't know 9 = Blank

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
96	1	797	[MEASPUB] Are performance measures on your practice available to the public? 1 = Yes 2 = No 3 = Don't know 8 = Not applicable 9 = Blank
97	1	798	[PRP4PR] What percent of your practice care revenue is based on bonuses, returned withholds or other performance- based payments? 1 = Less than or equal to 25 percent 2 = 26-50 percent 3 = 51-75 percent 4 = More than 75 percent 9 = Blank
98	1	799	[REVFFSR] Roughly, what percent of your patient care revenue comes from usual, customary, and reasonable fee-for- service? 1 = Less than or equal to 25 percent 2 = 26-50 percent 3 = 51-75 percent 4 = More than 75 percent 9 = Blank
99	1	800	[REVDISCR] Roughly, what percent of your patient care revenue comes from discounted fee-for-service? 1 = Less than or equal to 25 percent 2 = 26-50 percent 3 = 51-75 percent 4 = More than 75 percent 9 = Blank
100	1	801	[REVCAPR] Roughly, what percent of your patient care revenue comes from capitation? 1 = Less than or equal to 25 percent 2 = 26-50 percent 3 = 51-75 percent 4 = More than 75 percent 9 = Blank
101	1	802	[REVCASER] Roughly, what percent of your patient care revenue comes from case rates? 1 = Less than or equal to 25 percent 2 = 26-50 percent 3 = 51-75 percent 4 = More than 75 percent 9 = Blank

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
102	1	803	[REVOTHR] Roughly, what percent of your patient care revenue comes from other sources? 1 = Less than or equal to 25 percent 2 = 26-50 percent 3 = 51-75 percent 4 = More than 75 percent 9 = Blank
103	1	804	[ACETPNEW] Are you currently accepting "new" patients into your practice? 0 = Blank 1 = Yes 2 = No 3 = Unknown
104	1	805	[CAPITATE] From those "new" patients, which of the following types of payment do you accept? - Capitated private insurance 0 = Blank 1 = Yes 2 = No 3 = Unknown 4 = Not applicable
105	1	806	[NOCAP] From those "new" patients, which of the following types of payment do you accept? – Non-capitated private insurance 0 = Blank 1 = Yes 2 = No 3 = Unknown 4 = Not applicable
106	1	807	[NMEDCARE] From those "new" patients, which of the following types of payment do you accept? – Medicare 0 = Blank 1 = Yes 2 = No 3 = Unknown 4 = Not applicable
107	1	808	[NMEDCAID] From those "new" patients, which of the following types of payment do you accept? – Medicaid 0 = Blank 1 = Yes 2 = No 3 = Unknown 4 = Not applicable

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
108	1	809	NWORKCMP] From those "new" patients, which of the following types of payment do you accept? – Workers compensation 0 = Blank 1 = Yes 2 = No 3 = Unknown 4 = Not applicable
109	1	810	[NSELFPAY] From those "new" patients, which of the following types of payment do you accept? – Self-pay 0 = Blank 1 = Yes 2 = No 3 = Unknown 4 = Not applicable
110	1	811	[NNOCHRGE] From those "new" patients, which of the following types of payment do you accept? – No charge 0 = Blank 1 = Yes 2 = No 3 = Unknown 4 = Not applicable
111	1	812	[REFMDCAD] In the last 12 months, has your practice experienced difficulty in referring patients with the following types of health insurance for specialty consultations? – Medicaid 0 = Blank 1 = A lot of difficulty 2 = Some difficulty 3 = Little difficulty 4 = No difficulty 5 = Unknown 6 = Not applicable
112	1	813	[REFMDCAR] In the last 12 months, has your practice experienced difficulty in referring patients with the following types of health insurance for specialty consultations? – Medicare 0 = Blank 1 = A lot of difficulty 2 = Some difficulty 3 = Little difficulty 4 = No difficulty 5 = Unknown 6 = Not applicable

PAGE 7	72		2006 NAMCS MICRO-DATA FILE DOCUMENTATION		
ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES		
113	1	814	[REFPRIV] In the last 12 months, has your practice experienced difficulty in referring patients with the following types of health insurance for specialty consultations? – Private insurance 0 = Blank 1 = A lot of difficulty 2 = Some difficulty 3 = Little difficulty 4 = No difficulty 5 = Unknown 6 = Not applicable		
114	1	815	[REFUNINS] In the last 12 months, has your practice experienced difficulty in referring patients with the following types of health insurance for specialty consultations? – Uninsured 0 = Blank 1 = A lot of difficulty 2 = Some difficulty 3 = Little difficulty 4 = No difficulty 5 = Unknown 6 = Not applicable		
115	1	816	[CRVCANSC] Do you offer any type or cervical cancer screening? 1= Yes 2 = No 3 = Don't know 9 = Blank		
	****** THE FOLLOWING ITEMS ARE RECODED FROM PREVIOUS ITEMS ******				
116	1	817	[RACER] RACE RECODE 1 = White 2 = Black 3 = Other		
117	1	818	[RACEETH] RACE/ETHNICITY 1 = White Only, Non-Hispanic 2 = Black Only, Non-Hispanic 3 = Hispanic 4 = Asian Only 5 = Native Hawaiian, Other Pacific Islander Only 6 = American Indian/Alaska Native Only 7 = Multiple Races		

*** THE FOLLOWING ITEM WAS ADDED TO ENABLE USERS TO CREATE TABLES USING THE PHYSICIAN SPECIALTY GROUPS SHOWN ON PAGES 78-79 OF SECTION II. THIS WILL PRODUCE TABLES BY SPECIALTY SIMILAR TO THOSE SHOWN IN NAMCS PUBLISHED REPORTS ***

2006 NAMCS MICRO-DATA FILE DOCUMENTATION

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND	CODES
118	2	819-820	[SPECR] PHYSICIAN SPECIALTY F	RECODE
			 01 = General and family practice 03 = Internal medicine 04 = Pediatrics 05 = General surgery 06 = Obstetrics and gynecology 07 = Orthopedic surgery 08 = Cardiovascular diseases 	09 = Dermatology 10 = Urology 11 = Psychiatry 12 = Neurology 13 = Ophthalmology 14 = Otolaryngology 15 = All other 16 = Oncology

(Note: For SPECR, doctors of osteopathy (stratum 02) as well as Community Health Center physicians (stratum 17 in Table 1) have been aggregated with doctors of medicine according to their self-designated practice specialty, and therefore are not differentiated in the variable range. To isolate doctors of osteopathy from medical doctors using the Physician Specialty Recode, it is necessary to crosstabulate it with Type of Doctor located in position 287.) Community Health Center physicians can be identified by crosstabulating with RETYPOFF (Type of Office Setting for this Visit) in position 758.

119 1		821	[SPECCAT] PHYSICIAN SPECIALTY GROUP		
			(Recoded from SPEC using categories shown on page 80.)		
			1 = Primary care specialty		
			2 = Surgical care specialty		
			3 = Medical care specialty		

*** THE FOLLOWING ITEM WAS ADDED TO ENABLE USERS TO CREATE SUBSETS OF VISITS BY PATIENTS UNDER ONE YEAR OF AGE ***

120 3 822-824 [AGEDAYS] AGE IN DAYS

001-365 = 001-365 days 999 = More than 365 days

*** THE FOLLOWING ITEM WAS ADDED TO FACILITATE ANALYSIS OF AGE DATA, USING THE CATEGORIES FOUND IN NAMCS REPORTS.

121	1	825	[AGER] AGE RECODE
			1 = Under 15 years
			2 = 15-24 years
			3 = 25-44 years
			4 = 45-64 years
			5 = 65-74 years
			6 = 75 years and over

NUMERIC RECODES FOR DIAGNOSIS AND PROCEDURES

The following items were included on the public use file to facilitate analysis of visits using ICD-9-CM codes. Prior to the 1995 public use file, all ICD-9-CM diagnosis codes on the NAMCS micro-data file were converted from alphanumeric to numeric fields according to the following coding conventions: A prefix of '1' was added to ICD-9-CM codes in the range of 001.0[-] through 999.9[-]. A prefix of '20' was substituted for the letter 'V' for codes in the range of V01.0[-] through V82.9[-]. Inapplicable fourth or fifth

PAGE 74			2006 NAMCS MICRO-DATA FILE DOCUMENTATION
ITEM	FIELD	FILE	
NO.	LENGTH	LOCATION	[ITEM NAME], DESCRIPTION, AND CODES

digits were zerofilled. This conversion was done to facilitate analysis of ICD-9-CM data using Ambulatory Care Statistics software systems. Similar conversions were made for ICD-9-CM procedure codes and external cause of injury codes. Specific coding conventions are discussed in the public use documentation for each data year.

In 1995, however, the decision was made to use actual ICD-9-CM codes on the public use data file. Codes were not prefixed, and a dash was inserted for inapplicable fourth or fifth digits. For specific details pertaining to each type of code (diagnosis, procedure, cause of injury), refer to the documentation for the survey year of interest. This had the advantage of preserving actual codes and avoiding possible confusion over the creation of some artificial codes due to zerofilling.

It had come to our attention that some users of NAMCS data find it preferable to use the numeric field recodes rather than the alphanumeric fields in certain data applications. Therefore, since data year 1997, we have included numeric recodes for any ICD-9-CM codes on our datasets. These are in addition to the actual codes for these variables which appear earlier on the public use file. Users can make their own choice about which format best suits their needs.

122.1	6	826-831	 [DIAG1R] DIAGNOSIS # 1 (Recode to Numeric Field) 100100-208290 = 001.0[0]-V82.9[0] 209900 = Noncodable, insufficient information for coding, illegible 209910 = Left before being seen; patient walked out; not seen by doctor; left against medical advice 209920 = Transferred to another facility; sent to see specialist 209930 = HMO will not authorize treatment 209970 = Entry of "none," "no diagnosis," "no disease," or "healthy" 900000 = Blank
122.2	6	832-837	 [DIAG2R] DIAGNOSIS # 2 (Recode to Numeric Field) 00100-208290 = 001.0[0]-V82.9[0] 09900 = Noncodable, insufficient information for coding, illegible 09910 = Left before being seen; patient walked out; not seen by doctor; left against medical advice 09920 = Transferred to another facility; sent to see specialist 09930 = HMO will not authorize treatment 09970 = Entry of "none," "no diagnosis," "no disease," or "healthy" 900000 = Blank

2006 NAMCS MICRO-DATA FILE DOCUMENTATION

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
122.3	6	838-843	 [DIAG3R] DIAGNOSIS # 3 (Recode to Numeric Field) 100100-208290 = 001.0[0]-V82.9[0] 209900 = Noncodable, insufficient information for coding, 209910 = Left before being seen; patient walked out; not seen by doctor; left against medical advice 209920 = Transferred to another facility; sent to see specialist 209930 = HMO will not authorize treatment 209970 = Entry of "none," "no diagnosis," "no disease," or "healthy" 900000 = Blank
123.1	4	844-847	[SCOPWI1R] SCOPE PROCEDURE WRITE-IN #1 (Recode to Numeric Field) 0101-999 = 01.01 - 99.99 0000 = Not applicable/Blank
123.2	4	848-851	[SCOPWI2R] SCOPE PROCEDURE WRITE-IN #2 (Recode to Numeric Field) 0101-999 = 01.01 - 99.99 0000 = Not applicable/Blank
124.1	4	852-855	[DIAGSC1R] OTHER DIAGNOSTIC/SCREENING SERVICE WRITE-IN #1 (Recode to Numeric Field) 0101-999 = 01.01 - 99.99 0000 = Not applicable/Blank
124.2	4	856-859	[DIAGSC2R] OTHER DIAGNOSTIC/SCREENING SERVICE WRITE-IN #2 (Recode to Numeric Field) 0101-999 = 01.01 - 99.99 0000 = Not applicable/Blank
125.1	4	860-863	[OTHPROC1R] PROCEDURE WRITE-IN #1 (Recode to Numeric Field) 0101-999 = 01.01 - 99.99 0000 = Not applicable/Blank
125.2	4	864-867	[OTHPROC2R] PROCEDURE WRITE-IN #2 (Recode to Numeric Field) 0101-999 = 01.01 - 99.99 0000 = Not applicable/Blank
125.3	4	868-871	[OTHPROC3R] PROCEDURE WRITE-IN #3 (Recode to Numeric Field) 0101-999 = 01.01 - 99.99 0000 = Not applicable/Blank

PAGE 76			2006 NAMCS MICRO-DATA FILE DOCUMENTATION
ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
125.4	4	872-875	[OTHPROC4R] PROCEDURE WRITE-IN #4 (Recode to Numeric Field) 0101-999 = 01.01 - 99.99 0000 = Not applicable/Blank
	*****	END OF NUI	MERIC RECODES *******
126	1	876	[WHOCOMP] WHO COMPLETED THE PATIENT RECORD FORMS?
			 1 = Physician 2 = Office Staff 3 = Census Field Representative (abstraction from record) 4 = Other 5 = Multiple categories checked 6 = Unknown
127	1	877	[SETTYPE] SETTING TYPE This item is intended for use when combining data from the NAMCS and NHAMCS. 1 = Physician office (NAMCS) 2 = Hospital outpatient department (NHAMCS) 3 = Hospital emergency departments (NHAMCS)
128	4	878-881	[YEAR] SURVEY YEAR 2006

NAMCS DESIGN VARIABLES

NAMCS sampling design variables (in masked format) were first added to the 2000 public use file, and data years from 1993-1999 were re-released to include them. These variables were for use with statistical software such as SUDAAN that takes into account the complex sampling design of the survey. However, for those running versions of SAS, Stata, SPSS and other software that assumes a single stage of sampling, the multi-stage design variables provided on the public use files could not be used without modification. Therefore, in 2002, two new variables, CSTRATM and CPSUM, were developed, that could be used in such programs instead of the multi-stage variables. In 2003, the decision was made to include on the public use file just these two variables and not the multi-stage design variables that appeared in the past.

Until such time as the older public use files may be re-released to include these variables, data users wishing to combine data from 2003 and later years with data from earlier years will find it necessary to create CSTRATM and CPSUM for the earlier files. A technical paper, *Using Ultimate Cluster Models with NAMCS and NHAMCS Public Use Files,* is available for downloading at the Ambulatory Health Care Data website: http://www.cdc.gov/nchs/about/major/ahcd/ahcd1.htm. This paper gives instructions on how to configure data files prior to 2002 for variance estimation based on 1-stage sampling models, such as those used in SAS proc surveymeans, Stata, SPSS, and the SUDAAN with-replacement option, and how to handle instances of single-case strata in the data on the older files. Please also see the section in on

2006 NAMCS MICRO-DATA FILE DOCUMENTATION

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
	ve Standard Error PSU is primary s		ocument for more information on these variables and how to use
129	8	882-889	[CSTRATM] CLUSTERED PSU STRATUM MARKER (masked) 20105101-40400000
130	6	890-905	[CPSUM] CLUSTERED PSU MARKER (masked) 5-102987
131	6	906-911	[PHYSWT] PHYSICIAN WEIGHT Physician weight enables data users to make physician-level estimates. See also "Description of the NAMCS," Marginal Data, and Appendix I.
132	1	912	[PCTPOVR] PERCENT POVERTY IN PATIENT'S ZIP CODE 1 = Quartile 1 (Less than 5.00 percent) 2 = Quartile 2 (5.00-9.99 percent) 3 = Quartile 3 (10.00-19.99 percent) 4 = Quartile 4 (20.00 percent or more) 9 = Missing data
133	1	913	[HINCOMER] MEDIAN HOUSEHOLD INCOME IN PATIENT'S ZIP CODE 1 = Quartile 1 (Below \$32,793) 2 = Quartile 2 (\$32,794-\$40,626) 3 = Quartile 3 (\$40,627-\$52,387) 4 = Quartile 4 (\$52,388 or more) 9 = Missing data
134	1	914	[PBAMORER] PERCENT OF ADULTS WITH BACHELOR'S DEGREE OR HIGHER IN PATIENT'S ZIP CODE 1 = Quartile 1 (Less than 12.84 percent) 2 = Quartile 2 (12.84-19.66 percent) 3 = Quartile 3 (19.67-31.68 percent) 4 = Quartile 4 (31.69 percent or more) 9 = Missing data
135	1	915	[URBANRUR] URBAN-RURAL CLASSIFICATION OF PATIENT'S ZIP CODE 1 = Large central metro 2 = Large fringe metro 3 = Medium metro 4 = Small metro 5 = Non-metro (micropolitan and non-core) 9 = Missing data

B. PHYSICIAN SPECIALTY LIST

The 2006 NAMCS survey design grouped physicians into 16 strata, or specialty groups, for sampling purposes. These included the standard 15 groups used in previous years in addition to a separate stratum for oncologists. One stratum, doctors of osteopathy, was based on information from the American Osteopathic Association. The other groups were developed based on information from the American Medical Association (AMA). Below is a list of the AMA physician specialties comprising each of these sample strata. Some small specialties were masked on the public use file for confidentiality purposes.

GENERAL AND FAMILY PRACTICE

FP - Family Practice FPG - Family Practice, Geriatric Medicine FSM - Sports Medicine (Family Practice) GP - General Practice

INTERNAL MEDICINE

IM - Internal Medicine

PEDIATRICS

ADL - Adolescent Medicine **CCP** - Critical Care Pediatrics DBP - Developmental - Behavioral Pediatrics MPD - Internal Medicine/Pediatrics NDN - Neurodevelopmental Disabilities NPM - Neonatal-Perinatal Medicine PD - Pediatrics PDA - Pediatric Allergy PDC - Pediatric Cardiology PDE - Pediatric Endocrinology PDI - Pediatric Infectious Diseases PDP - Pediatric Pulmonology PDT - Medical Toxicology PEM - Pediatric Emergency Medicine PG - Pediatric Gastroenterology PN - Pediatric Nephrology PPR - Pediatric Rheumatology PSM - Sports Medicine (Pediatrics) **GENERAL SURGERY**

GS - General Surgery

OBSTETRICS AND GYNECOLOGY

GYN - Gynecology MFM - Maternal & Fetal Medicine OBG - Obstetrics & Gynecology OBS - Obstetrics OCC -Critical Care Medicine (Obstetrics & Gynecology) REN - Reproductive Endocrinology

ORTHOPEDIC SURGERY

OAR - Adult Reconstructive Orthopedics

OFA - Foot and Ankle Orthopedics

OP - Pediatric Orthopedics

ORS - Orthopedic Surgery

- OSM Sports Medicine (Orthopedic Surgery)
- OSS Orthopedic Surgery of the Spine
- OTR Orthopedic Trauma

CARDIOVASCULAR DISEASES

CD - Cardiovascular Diseases

DERMATOLOGY

D - Dermatology

UROLOGY

U - Urology UP - Pediatric Urology

PSYCHIATRY

ADP - Addiction Psychiatry CHP - Child Psychiatry NUP - Neuropsychiatry P - Psychiatry PFP - Forensic Psychiatry PYA - Psychoanalysis PYG - Geriatric Psychiatry PYM – Psychosomatic Medicine

NEUROLOGY

CHN - Child Neurology CN -Clinical Neurophysiology ESN – Endovascular Surgical Neuroradiology N - Neurology NRN - Neurology (Diagnostic Radiology) VN – Vascular Neurology

OPHTHALMOLOGY

OPH - Ophthalmology PO - Pediatric Ophthalmology

OTOLARYNGOLOGY

NO - Otology - Neurotology OTO - Otolaryngology PDO - Pediatric Otolaryngology

ONCOLOGY (new stratum for 2006)

GO - Gynecological Oncology HO - Hematology/Oncology OMO - Musculoskeletal Oncology ON - Medical Oncology PHO - Pediatric Hematology/Oncology SO - Surgical Oncology

ALL OTHER

A - Allergy ADM - Addiction Medicine AI - Allergy and Immunology ALI - Allergy & Immunology/ Diagnostic Lab. Immunology AM - Aerospace Medicine AMI - Adolescent Medicine (Internal Medicine) AS - Abdominal Surgery **CBG - Clinical Biochemical Genetics** CCG - Clinical Cytogenetics CCM - Critical Care Medicine CCS - Critical Care Surgery CFS - Craniofacial Surgery CG - Clinical Genetics CMG - Clinical Molecular Genetics CRS - Colon and Rectal Surgery CS - Cosmetic Surgery DDL - Dermatological Immunology/ Diagnostic Lab. Immunology **DIA - Diabetes** DS - Dermatologic Surgery **EM - Emergency Medicine END** - Endocrinology **EP** - Epidemiology ESM - Sports Medicine (Emergency Medicine) ETX - Medical Toxicology (Emergency Medicine) **FPS - Facial Plastic Surgery** GE - Gastroenterology **GPM - General Preventive Medicine** HEM - Hematology HEP - Hepatology HNS - Head and Neck Surgery HS - Hand Surgery HSP - Hand Surgery (Plastic Surgery) HSS - Hand Surgery (Surgery) IC - Interventional Cardiology ICE - Cardiac Electrophysiology **ID** - Infectious Diseases IG - Immunology

ALL OTHER (cont.)

ILI - Internal Medicine/Diagnostic Lab. Immunology IMG - Geriatric Medicine (Internal Medicine) ISM - Sports Medicine (Internal Medicine) LM - Legal Medicine MDM - Medical Management MG - Medical Genetics NC - Nuclear Cardiology **NEP** - Nephrology NS - Neurological Surgery NSP - Pediatric Surgery (Neurology) NTR - Nutrition **OM - Occupational Medicine** OMF - Oral & Maxillofacial Surgery OMM - Osteopathic Manipulative Medicine PA - Clinical Pharmacology PCC - Pulmonary Critical Care Medicine PCS - Pediatric Cardiothoracic Surgery PDS - Pediatric Surgery PE - Pediatric Emergency Medicine (Emergency Medicine) PHL - Phlebology PHM - Pharmaceutical Medicine PHP - Public Health/General Preventive Medicine PLI - Pediatric/Diagnostic Lab. Immunology PLM - Palliative Medicine PM - Physical Medicine and Rehabilitation PMD - Pain Medicine PMM - Sports Medicine (Physical Medicine and Rehabilitation) PPN - Pain Medicine PRD – Procedural Dermatology PRM - Pediatric Rehabilitation Medicine PRO - Proctology PS - Plastic Surgery PSH – Plastic Surgery within the Head & Neck PTX - Medical Toxicology (Preventive Medicine) PUD - Pulmonary Diseases RHU - Rheumatology SCI - Spinal Cord Injury SME - Sleep Medicine TRS - Traumatic Surgery TS - Thoracic Surgery TTS - Transplant Surgery UCM - Urgent Care Medicine UM - Undersea Medicine VM - Vascular Medicine VS - Vascular Surgery OS - Other Specialty

US - Unspecified

C. AMA SPECIALTIES REGROUPED INTO PRIMARY CARE, SURGICAL, AND MEDICAL SPECIALTIES

Below is a list of the AMA physician specialties comprising the NAMCS sample strata, regrouped into primary care, surgical, and medical specialties for analytic purposes (see SPECCAT variable on file layout).

PRIMARY CARE SPECIALTIES

- ADL Adolescent Medicine
- AMI Adolescent Medicine (Internal Medicine)
- FP Family Practice
- FPG Family Practice, Geriatric Medicine
- FSM Sports Medicine (Family Practice)
- GP General Practice
- GYN Gynecology
- IM Internal Medicine
- IMG Geriatric Medicine (Internal Medicine)
- MPD Internal Medicine/Pediatrics
- MFM Maternal & Fetal Medicine
- OBG Obstetrics & Gynecology
- OBS Obstetrics
- PD Pediatrics
- PSM Sports Medicine (Pediatrics)

SURGICAL SPECIALTIES

- AS Abdominal Surgery
- OAR Adult Reconstructive Orthopedics
- CRS Colon and Rectal Surgery
- CS Cosmetic Surgery
- CFS Craniofacial Surgery
- OCC Critical Care Medicine (Obstetrics & Gynecology)
- CCS Critical Care Surgery
- DS Dermatologic Surgery
- ESN Endovascular Surgical Neuroradiology
- FPS Facial Plastic Surgery
- OFA Foot and Ankle Orthopedics
- GS General Surgery
- GO Gynecological Oncology
- HS Hand Surgery
- HSP Hand Surgery (Plastic Surgery)
- HSS Hand Surgery (Surgery)
- HNS Head and Neck Surgery
- OMO Musculoskeletal Oncology
- NS Neurological Surgery
- OPH Ophthalmology
- OMF Oral & Maxillofacial Surgery
- OTO Otolaryngology
- NO Otology Neurotology
- ORS Orthopedic Surgery
- OSS Orthopedic Surgery of the Spine
- OTR Orthopedic Trauma

SURGICAL SPECIALTIES (cont.)

- PCS Pediatric Cardiothoracic Surgery
- OP Pediatric Orthopedics
- PO Pediatric Ophthalmology
- PDO Pediatric Otolaryngology
- NSP Pediatric Surgery (Neurology)
- PDS Pediatric Surgery
- UP Pediatric Urology
- PRD Procedural Dermatology
- PS Plastic Surgery
- PSH Plastic Surgery within the Head & Neck
- OSM Sports Medicine (Orthopedic Surgery)
- SO Surgical Oncology
- TS Thoracic Surgery
- TTS Transplant Surgery
- TRS Traumatic Surgery
- U Urology
- VS Vascular Surgery

MEDICAL SPECIALTIES

- A Allergy
- ADM Addiction Medicine
- ADP Addiction Psychiatry
- AI Allergy and Immunology
- ALI Allergy & Immunology/
 - Diagnostic Lab. Immunology
- AM Aerospace Medicine
- CBG Clinical Biochemical Genetics
- CCG Clinical Cytogenetics
- CCM Critical Care Medicine
- **CCP** Critical Care Pediatrics
- CD Cardiovascular Diseases
- CG Clinical Genetics
- CMG Clinical Molecular Genetics
- CHN Child Neurology
- CHP Child Psychiatry
- CN -Clinical Neurophysiology
- D Dermatology
- DBP Developmental Behavioral Pediatrics
- DDL Dermatological Immunology/ Diagnostic Lab. Immunology
- DIA Diabetes
- EM Emergency Medicine
- END Endocrinology
- EP Epidemiology

MEDICAL SPECIALTIES (cont.)

ESM - Sports Medicine (Emergency Medicine) ETX - Medical Toxicology (Emergency Medicine) GE - Gastroenterology **GPM - General Preventive Medicine** HEM - Hematology HEP - Hepatology HO - Hematology/Oncology IC - Interventional Cardiology ICE - Cardiac Electrophysiology **ID** - Infectious Diseases IG - Immunology ILI - Internal Medicine/Diagnostic Lab. ISM - Sports Medicine (Internal Medicine) LM - Legal Medicine MDM - Medical Management MG - Medical Genetics NDN - Neurodevelopmental Disabilities N - Neurology NC - Nuclear Cardiology NEP - Nephrology NPM - Neonatal-Perinatal Medicine NRN - Neurology (Diagnostic Radiology) NTR - Nutrition NUP - Neuropsychiatry PHM - Pharmaceutical Medicine PHP - Public Health/General Preventive Medicine PHO - Pediatric Hematology/Oncology **OM - Occupational Medicine** OMM - Osteopathic Manipulative Medicine ON - Medical Oncology P - Psvchiatrv PA - Clinical Pharmacology PCC - Pulmonary Critical Care Medicine PDA - Pediatric Allergy PDC - Pediatric Cardiology PDE - Pediatric Endocrinology PDI - Pediatric Infectious Diseases PDP - Pediatric Pulmonology PDT - Medical Toxicology PE - Pediatric Emergency Medicine (Emergency Medicine) PEM - Pediatric Emergency Medicine PFP - Forensic Psychiatry

PG - Pediatric Gastroenterology

- PHL Phlebology PLI - Pediatric/Diagnostic Lab. Immunology PLM - Palliative Medicine PM - Physical Medicine and Rehabilitation PMD - Pain Medicine PMM - Sports Medicine (Physical Medicine and Rehabilitation) PN - Pediatric Nephrology PPN – Pain Medicine PPR - Pediatric Rheumatology PRM - Pediatric Rehabilitation Medicine PRO - Proctology PTX - Medical Toxicology (Preventive Medicine) PUD - Pulmonary Diseases PYA - Psychoanalysis PYG - Geriatric Psychiatry PYM – Psychosomatic Medicine REN - Reproductive Endocrinology Immunology RHU - Rheumatology SCI - Spinal Cord Injury SME - Sleep Medicine UCM - Urgent Care Medicine UM - Undersea Medicine VM - Vascular Medicine VN - Vascular Neurology OS - Other Specialty
 - US Other Specia
 - US Unspecified

III. MARGINAL DATA

A. PATIENT VISITS

PATIENT AGE

CATEGORY	RECORDS	WEIGHTED VISITS	PERCENT	
Total	29,392	901,954,225	100.000	
1 - Under 15 years	4,334	157,906,085	17.507	
2 - 15-24 years	2,457	72,411,350	8.028	
3 - 25-44 years	6,408	185,304,981	20.545	
4 - 45-64 years	8,742	256,494,356	28.438	
5 - 65-74 years	3,550	108,062,975	11.981	
6 - 75 years and over	3,901	121,774,478	13.501	

PATIENT SEX

2 - Male	12,028	368,662,151	40.874
1 - Female	17,364	533,292,074	59.126
Total	29,392	901,954,225	100.000
CATEGORY	RECORDS	WEIGHTED VISITS	PERCENT

PATIENT RACE

CATEGORY RECORDS WEIGHTED VISITS PERCENT 29,392 Total 901,954,225 100.000 1 - White Only 24,227 764,635,852 84.775 2 - Black/African American Only 3,287 87,040,331 9.650 3 - Asian Only 1,230 38,682,687 4.289 4 - Native Hawaiian/Oth Pac Isl Only 3,017,623 115 0.335 5 - American Indian/Alaska Native Only 435 6,172,986 0.684 6 - More than one race reported 98 2,404,746 0.267

EXPECTED PRIMARY SOURCE OF PAYMENT

CATEGORY	RECORDS	WEIGHTED VISITS	PERCE
Total	29,392	901,954,225	100.0
0 - Blank	724	22,265,505	2.4
1 - Private insurance	13,707	456,649,643	50.
2 - Medicare	6,410	193,268,957	21.
3 - Medicaid	4,545	126,391,978	14.
4 $_{\overline{\mathrm{T}}}$ Worker's compensation	351	15,084,366	1.
5 - Self-pay	1,608	35,655,610	3.
6 - No charge	295	4,536,360	0.
7 - Other	716	19,897,176	2.
8 - Unknown	1,036	28,204,630	3.

MAJOR REASON FOR VISIT

CATEGORY	RECORDS	WEIGHTED VISITS	PERCENT
Total	29,392	901,954,225	100.000
O - Blank	474	15,702,421	1.741
1 - Acute problem	9,160	319,405,786	35.413
2 - Chronic problem, routine	9,955	262,652,939	29.120
3 - Chronic problem, flare-up	2,538	71,319,773	7.907
4 - Pre/Post-surgery	2,064	59,531,285	6.600
5 - Preventive care	5,201	173,342,021	19.218

HAS THE PATIENT BEEN SEEN IN YOUR PRACTICE BEFORE?

CATEGORY	RECORDS	WEIGHTED VISITS	PERCENT
Total	29,392	901,954,225	100.000
1 - Yes, established patient	25,305	791,498,896	87.754
2 - No, new patient	4,087	110,455,329	12.246

CATEGORY	RECORDS	WEIGHTED VISITS	PERCENT
Total	29,392	901,954,225	100.000
0	8,585	265,246,656	29.408
1	6,826	214,094,104	23.737
2	4,544	142,213,791	15.767
3	2,714	87,076,981	9.654
4	1,821	54,441,962	6.036
5	1,307	37,581,489	4.167
6	966	28,691,915	3.181
7	762	21,423,089	2.375
8	1,867	51,184,238	5.675

NUMBER OF MEDICATION CODES THIS VISIT

PHYSICIAN SPECIALTY

CATEGORY	RECORDS	WEIGHTED VISITS	PERCENT
Total	29,392	901,954,225	100.000
1 - General/family practice	6,563	208,475,329	23.114
3 - Internal medicine	2,819	125,398,034	13.903
4 - Pediatrics	2,886	122,343,757	13.564
5 - General surgery	1,318	24,057,081	2.497
6 - Obstetrics and gynecology	2,236	69,435,646	7.698
7 - Orthopedic surgery	1,284	48,066,139	5.329
8 - Cardiovascular diseases	1,485	25,790,231	2.859
9 - Dermatology	1,309	25,256,401	2.800
10 - Urology	1,302	18,306,542	2.030
11 - Psychiatry	1,393	25,150,175	2.788
12 - Neurology	1,583	12,532,101	1.389
13 - Ophthalmology	1,373	57,814,712	6.410
14 - Otolaryngology	1,316	17,507,639	1.941
15 - Other specialties	1,861	116,958,490	12.967
16 - Oncology	1,045	14,871,087	1.649

B. DRUG MENTIONS

PATIENT AGE

CATEGORY	RECORDS	WEIGHTED MENTIONS	PERCENT	
Total	63,941	1,897,014,939	100.000	
1 - Under 15 years	5,529	199,023,658	10.491	
2 - 15-24 years	3,036	84,544,072	4.457	
3 - 25-44 years	10,607	290,328,934	15.305	
4 - 45-64 years	21,547	610,828,065	32.199	
5 - 65-74 years	10,941	328,334,383	17.308	
6 - 75 years and over	12,281	383,955,827	20.240	

PATIENT SEX

CATEGORY	RECORDS	WEIGHTED MENTIONS	PERCENT	
Total	63,941	1,897,014,939	100.000	
1 - Female	37,874	1,126,027,917	59.358	
2 - Male	26,067	770,987,022	40.642	

PHYSICIAN SPECIALTY

CATEGORY	RECORDS	WEIGHTED MENTIONS	PERCENT
CATEGORY Total 1 - General/family practice 3 - Internal medicine 4 - Pediatrics 5 - General surgery 6 - Obstetrics and gynecology 7 - Orthopedic surgery 8 - Cardiovascular diseases 9 - Dermatology 10 - Urology 11 - Psychiatry	RECORDS 63,941 16,561 9,562 4,000 1,342 2,321 1,341 7,415 1,885 2,474 2,817	WEIGHTED MENTIONS 1,897,014,939 513,141,302 432,584,857 158,409,471 22,912,294 66,467,948 49,635,868 130,148,006 36,925,681 32,659,498 52,550,872	PERCENT 100.000 27.050 22.803 8.350 1.208 3.504 2.617 6.861 1.947 1.722 2.770
12 - Neurology	4,056	32,319,343	1.704
10 - Urology	2,474	32,659,498	1.722
12 - Neurology 13 - Ophthalmology	4,056 1,371	32,319,343 57,243,845	1.704 3.018
14 - Otolaryngology 15 - Other specialties 16 - Oncology	1,452 4,079 3,265	19,176,922 247,268,210 45,570,822	1.011 13.035
	3,205	45,570,622	2.402

DRUG THERAPEUTIC CATEGORIES (USING LEVEL 1 CODES)

CATEGORY	RECORDS	WEIGHTED MENTIONS	PERCENT
Total	68,406	2,020,673,256	100.000
'OO1'=Anti-infectives	4,157	147,017,945	7.276
'020'=Antineoplastics	883	19,185,678	0.949
'O28'=Biologicals	165	6,943,300	0.344
'040'=Cardiovascular agents	10,950	313,438,744	15.512
'057'=Central nervous system agents	13,434	369,478,821	18.285
'081'=Coagulation modifiers	3,007	83,260,693	4.120
'087'=Gastrointestinal agents	3,399	107,000,492	5.295
'097'=Hormones	4,031	127,003,133	6.285
'105'=Miscellaneous agents	2,579	74,136,776	3.669
<pre>'115'=Nutritional products</pre>	3,724	107,018,464	5.296
'122'=Respiratory agents	5,145	175,815,477	8.701
'133'=Topical agents	4,015	130,515,864	6.459
ʻ153'=Plasma expanders	2	51,633	0.003
'218'=Alternative medicines	455	11,701,301	0.579
'242'=Psychotherapeutic agents	4,345	101,509,988	5.024
'254'=Immunological agents	1,922	66,412,892	3.287
'331'=Radiologic agents	13	232,543	0.012
'358'=Metabolic agents	6,099	177,248,693	8.772
'899'=Pharmaceutical aids	81	2,700,819	0.134

Therapeutic categories are based on Lexicon Plus®, a proprietary database of Cerner Multum, Inc. The Lexicon Plus is a comprehensive database of all prescription and some nonprescription drug products available in the U.S. drug market. For additional information on the Multum Lexicon Drug Database, please refer to the following Web site: <u>http://www.multum.com/Lexicon.htm</u>. For more information on coding therapeutic categories in the NAMCS, see page 22.

C. PHYSICIAN ESTIMATES

PHYSICIAN SPECIALTY

CATEGORY	RECORDS	WEIGHTED PHYSICIANS	PERCENT
Total	1,268	301,270 100	0.000
General/family practice	249	•	3.928
Internal medicine	117	•	3.045
Pediatrics	109	•	0.239
General surgery	57	10,658 3	3.538
Obstetrics and gynecology	98	23,840 7	7.913
Orthopedic surgery	56	14,984 4	1.974
Cardiovascular diseases	56	14,984 4	1.974
Dermatology	48	7,245 2	2.405
Urology	48	7,245 2	2.405
Psychiatry	82	17,011 5	5.646
Neurology	73	6,231 2	2.068
Ophthalmology	49	12,340 4	1.096
Otolaryngology	54	5,664	.880
Oncology	48	5,472 1	1.816
Other specialties	94	50,831 16	5.872
IS THIS A SOLO PRACTICE?			
CATEGORY	RECORDS	WEIGHTED PHYSICIANS	PERCENT
Total	4 000		
Yes	1,268	301,270	100.000
	1,268 385	301,270 97,776	100.000 32.455
No	-	-	
No Blank	385	97,776	32.455
	385 881	97,776 202,872	32.455 67.339
Blank	385 881	97,776 202,872	32.455 67.339
Blank SPECIALTY TYPE	385 881 2 RECORDS	97,776 202,872 622 WEIGHTED PHYSICIANS	32.455 67.339 0.206
Blank SPECIALTY TYPE CATEGORY Total	385 881 2	97,776 202,872 622	32.455 67.339 0.206 PERCENT
Blank SPECIALTY TYPE CATEGORY Total Primary care specialty	385 881 2 RECORDS 1,268	97,776 202,872 622 WEIGHTED PHYSICIANS 301,270	32.455 67.339 0.206 PERCENT 100.000
Blank SPECIALTY TYPE CATEGORY Total	385 881 2 RECORDS 1,268 571	97,776 202,872 622 WEIGHTED PHYSICIANS 301,270 150,467	32.455 67.339 0.206 PERCENT 100.000 49.944

APPENDIX I

A. RELATIVE STANDARD ERRORS

The standard error is primarily a measure of the sampling variability that occurs by chance because only a sample is surveyed, rather than the entire universe. The relative standard error (RSE) of an estimate is obtained by dividing the standard error of the estimate by the estimate itself and is expressed as a percentage of the estimate. Standard errors and other measures of sampling variability are best determined by using a statistical software package that takes into account the sample designs of surveys to produce such measures.

Using computer software like SUDAAN to produce standard errors will, in general, yield results that are more accurate than those produced using the generalized variance curve described below. This is especially true for clustered variables like race, provider seen, or expected source of payment. The standard errors produced with such software using masked design variables, while improving substantially over the generalized variance curve results, will not always be as accurate as those produced using unmasked data. However, data files containing unmasked variables are confidential and are only available through the NCHS Research Data Center.

NAMCS (and NHAMCS) public use files for 1993-2002 included masked multi-stage design variables used to estimate variance with software such as SUDAAN's full sample without replacement design option. In 2002, two new sample design variables (CSTRATM and CPSUM) were added to the file for use with software utilizing a "between PSU" variance estimator or "ultimate cluster" sampling design.

Ultimate cluster variance estimates depend only on the first stage of the sample design, so that only first-stage cluster and first-stage stratum identification are required. Starting with 2003 data, the NAMCS public use files include only these first-stage design variables, CSTRATM and CPSUM. They differ from the STRATM and PSUM variables on 1993-2002 files in that providers are the first-stage sampling units in certainty areas (geographic areas selected with certainty), while geographic areas are the first-stage sampling units in non-certainty areas.

Examples using CSTRATM and CPSUM in Stata, SUDAAN's 1-stage WR (with replacement) design option, and SAS's PROC surveymeans applications are presented below:

<u>Stata</u>

The pweight (PATWT), strata (CSTRATM), and PSU (CPSUM) are set with the svyset command as follows:

<u>Stata 8:</u> svyset [pweight=patwt], psu(cpsum) strata(cstratm)

<u>Stata 9 and Stata 10:</u> svyset cpsum [pweight=patwt], strata(cstratm)

SUDAAN 1-stage WR Option

The program below provides a with replacement ultimate cluster (1-stage) estimate of standard errors for a cross-tabulation.

PROC CROSSTAB DATA=COMB1 DESIGN=WR FILETYPE=SAS; NEST CSTRATM CPSUM/MISSUNIT;

SAS - PROC SURVEYMEANS

PROC SURVEYMEANS DATA=COMB1; CLUSTER CPSUM; STRATA CSTRATM;

<u>SPSS</u>

This code pertains to SPSS Inc.'s Complex Samples 12.0 module. It would be used with the "Analysis Preparation Wizard" component of that module. The PLAN FILE statement would be invoked in statistical runs, as in the example for CSTABULATE shown below.

CSPLAN ANALYSIS /PLAN FILE='DIRECTORY\PLANNAME.CSAPLAN' /PLAN VARS ANALYSISWEIGHT=PATWT /PRINT PLAN /DESIGN STAGELABEL= 'ANY LABEL' STRATA=CSTRATM CLUSTER=CPSUM /ESTIMATOR TYPE=WR.

CSTABULATE /PLAN FILE='DIRECTORY\PLANNAME.CSAPLAN' /TABLES VARIABLES = var1 var2 /CELLS POPSIZE /STATISTICS SE /MISSING SCOPE = TABLE CLASSMISSING = EXCLUDE.

If researchers wish to combine data from 2003 and later years of NAMCS public use files with earlier years, it will be necessary to create the CSTRATM and CPSUM variables and to consider the possibility of single case strata in the data, in order to estimate variances. A technical paper, *Using Ultimate Cluster Models with NAMCS and NHAMCS Public Use Files*, is available for downloading at the Ambulatory Health Care Data website: <u>http://www.cdc.gov/nchs/namcs.htm</u>. This paper gives instructions on how to configure data files prior to 2002 for variance estimation based on 1-stage sampling models and how to handle instances of single-case strata in the data on the older files.

IMPORTANT NOTE: These examples can be used when producing visit or drug estimates. For physician-level estimates, the statements are the same, but replace PATWT with PHYSWT. The PHYSWT variable is only placed on the first record for each physician. When running purely physician level analysis, it is recommended that only records with PHYSWT > 0 be selected; this will give the correct sample counts and will not affect estimation of variance. Weighted estimates will be correct either way.

In addition to generating estimates for physician characteristics at the physician level, the addition of PHYSWT also means that one can link visit data with physician data. For example, one could examine average time spent with physicians across physicians rather than simply across visits. This type of analysis is slightly complicated; a description along with sample SAS code is available at the Ambulatory Health Care Data website. For more information, contact the Ambulatory and Hospital Care Statistics Branch at 301-458-4600.

For data users who do not wish to use SUDAAN or similar programs to produce measures of sampling variability, we may make available upon request tables which contain relative standard errors based on generalized variance curves for a wide range of visit estimates and drug mention estimates by physician specialty. (Estimates with a relative standard error greater than 30 percent are considered unreliable by the standards of the National Center for Health Statistics. It should also be noted here that estimates based on fewer than 30 sample records are considered unreliable, regardless of the magnitude of the relative standard

error.) The following formulas may be used to calculate approximate relative standard errors for visit estimates and drug mention estimates.

For aggregate estimates, approximate relative standard errors can be calculated using the following general formula, where "x" is the aggregate of patient visits or drug mentions in thousands, and coefficients "A" and "B" are obtained from Table IV:

$$RSE(x) = 100 \cdot \sqrt{A + \frac{B}{x}}$$

For estimates of percents, approximate relative standard errors can be calculated using the following general formula, where "p" is the percent of visits or mentions, "x" is the denominator of the percent in thousands, and coefficient "B" is obtained from Table IV:

$$RSE(p) = 100 \cdot \sqrt{\frac{B \cdot (1-p)}{p \cdot x}}$$

For estimates of visit rates in which the numerator is the number of visits for a particular characteristic and the denominator is the total U.S. population or one of the age-sex-race groups of the total population, the relative standard error is equivalent to the relative standard error of the numerator, as shown above in the paragraph on aggregate estimates. For additional information, contact the Ambulatory and Hospital Care Statistics Branch at (301) 458-4600.

Type of estimate and physician specialty	Coefficier with estimate		Lowest reliable estimate (in thousands)
	A	в	
Visits			
Overall totals	0.00203	90.48011	1,028
General and family practice	0.00526	59.59612	703
nternal medicine	0.01329	102.74054	1,339
Pediatrics	0.01512	102.94240	1,375
General surgery	0.02055	30.20181	435
Dbstetrics and gynecology	0.01088	47.00114	594
Drthopedic surgery	0.01722	76.49871	1,051
Cardiovascular diseases	0.01326	29.25321	381
Dermatology	0.01216	44.12225	567
Jrology	0.01536	22.54109	302
Psychiatry	0.01275	50.54269	654
Veurology	0.01113	12.58419	160
Dphthalmology	0.01948	103.90094	1,473
Dtolaryngology	0.01910	19.07683	269
Dncology	0.02911	24.43601	401
All other specialties	0.01504	176.08394	2,349
Drug mentions			
Overall totals	0.00326	224.09874	2,584
General and family practice	0.00710	154.36587	1,862
nternal medicine	0.02052	333.25297	4,796
Pediatrics	0.02071	146.19938	2,110
General surgery	0.05640	83.28006	2,479
Obstetrics and gynecology	0.01159	108.60022	1,385
Orthopedic surgery	0.04881	71.61719	1,739
Cardiovascular diseases	0.01730	118.36779	1,628
Dermatology	0.02279	85.43735	1,271
Jrology	0.02507	57.85796	891
Psychiatry	0.01488	124.37847	1,656
Neurology	0.01510	49.65797	663
Dphthalmology	0.04529	93.34521	2,088
Dtolaryngology	0.03228	36.96110	640
Dncology	0.03100	219.28880	1,835
All other specialties	0.04605	80.63259	3,717

Table IV. Coefficients appropriate for determining approximate relative standard errors by type of estimate and physician specialty: National Ambulatory Medical Care Survey, 2006

(NOTE: FOOTNOTE is on next page)

2006 NAMCS MICRO-DATA FILE DOCUMENTATION

B. 2006 NAMCS PATIENT RECORD FORM - INSTRUCTIONS AND DEFINITIONS

1. PATIENT INFORMATION

ITEM 1a. DATE OF VISIT

The month, day and year should be recorded in figures, for example, 05/17/2006 for May 17, 2006. Enter the last digit in the pre-filled 4-digit year.

ITEM 1b. ZIP CODE

Enter 5-digit ZIP code from patient's mailing address.

ITEM 1c. DATE OF BIRTH

The month, day, and year of the patient's birth should be recorded here, in the same fashion as Date of Visit above. In the rare event the date of birth is unknown, the year of birth should be estimated as closely as possible. Enter 4-digit year.

ITEM 1d. SEX

Please check the appropriate category. If "*female*" is marked, please answer the sub-question: "Is patient pregnant?" If "Yes" is marked, specify gestation week. If gestation week is unknown, then record LMP (last menstrual period) date in same fashion as Date of Visit.

ITEM 1e. ETHNICITY

Ethnicity refers to a person's national or cultural group. The Patient Record form has two categories for ethnicity, Hispanic or Latino and Not Hispanic or Latino.

Mark the appropriate category according to your knowledge of the patient or from information in the medical record. You are not expected to ask the patient for this information. If the patient's ethnicity is not known and is not obvious, mark the box which in your judgment is most appropriate. The definitions of the categories are listed below. Do not determine the patient's ethnicity from their last name.

	Ethnicity	Definition
1	Hispanic or Latino	A person of Cuban, Mexican, Puerto Rican, South or Central American, or other Spanish culture or origin, regardless of race.
2	Not Hispanic or Latino	All other persons.

ITEM 1f. RACE

Mark *all* appropriate categories based on observation, or your knowledge of the patient, or from information in the medical record. You are not expected to ask the patient for this information. If the patient's race is not known or not obvious, mark the box(es) which in your judgment is (are) most appropriate. Do not determine the patient's race from their last name.

Race		Definition
1	White	A person having origins in any of the original peoples of Europe, the Middle East or North Africa.
_		
2	Black/African American	A person having origins in any of the black racial groups of Africa.
3	Asian	A person having origins in any of the original peoples of the Far
		East, Southeast Asia, or the Indian subcontinent including, for
		example, Cambodia, China, India, Japan, Korea, Malaysia,
		Pakistan, the Philippine Islands, Thailand, and Vietnam.
4	Native Hawaiian/	A person having origins in any of the original peoples of Hawaii,
	Other Pacific Islander	Guam, Samoa, or other Pacific Islands.
5	American Indian/ Alaskan Native	A person having origins in any of the original peoples of North America, and who maintains cultural identification through tribal
		affiliation or community recognition.

ITEM 1g. TOBACCO USE

Tobacco use is defined as smoking cigarettes/cigars, using snuff, or chewing tobacco. Mark "Not current" if the patient does not currently use tobacco. If "Not current" is marked, then mark "Never" if the patient has never used tobacco or "Former" if the patient formerly used tobacco. Mark "Current" if the patient uses tobacco. Mark "Unknown" if it cannot be determined whether the patient currently uses or does not use tobacco.

1 Not current	2 Current
1 Never	3 Unknown
2 Former	

ITEM 1h. EXPECTED SOURCE OF PAYMENT FOR THIS VISIT

Mark (X) ALL appropriate expected source(s) of payment.

Expected Source				
of Payment	Definition			
1 Private insurance	Charges paid in-part or in-full by a private insurer (e.g., Blue Cross/Blue Shield) either directly to the physician or reimbursed to the patient. Include charges covered under a private insurance sponsored prepaid plan.			
2 Medicare	Charges paid in-part or in-full by a Medicare plan. Includes payments directly to the physician as well as payments reimbursed to the patient. Include charges covered under a Medicare sponsored prepaid plan.			
3 Medicaid/SCHIP	Charges paid in-part or in-full by a Medicaid plan. Includes payments made directly to the physician as well as payments reimbursed to the patient. Include charges covered under a Medicaid sponsored prepaid plan or the State Children's Health Insurance Program (SCHIP).			
4 Worker's compensation	Includes programs designed to enable employees injured on the job to receive financial compensation regardless of fault.			
5 Self-pay	Charges, to be paid by the patient or patient's family, which will not be			
5 Gen-pay	reimbursed by a third party. "Self-pay" is perhaps a poor choice of wording since we really have no interest in whether the patient actually pays the bill. This category is intended to include visits for which the patient is expected to be ultimately responsible for most of the bill. DO NOT check this box for a copayment or deductible.			
6 No charge/Charity	Visits for which no fee is charged (e.g., charity, special research, or teaching). Do not include visits paid for as part of a total package (e.g., prepaid plan visits, post-operative visits included in a surgical fee, and pregnancy visits included in a flat fee charged for the entire pregnancy). Mark the box or boxes that indicate how the services were originally paid.			
7 Other	Any other sources of payment not covered by the above categories, such as CHAMPUS, state and local governments, private charitable organizations, and other liability insurance (e.g., automobile collision policy coverage).			
8 Unknown	The primary source of payment is not known.			

2. INJURY/POISONING/ADVERSE EFFECT

ITEM 2. IS THIS VISIT RELATED TO ANY OF THE FOLLOWING?

If ANY PART of this visit was related to an injury or poisoning or adverse effect of medical or surgical care or an adverse effect of a medicinal drug, then mark (X) the appropriate box. Indicate whether the injury or poisoning was intentional (i.e., self -inflicted or an assault) or unintentional. The injury/poisoning/adverse effect does not need to be recent. It can include those visits for follow up of previously treated injuries and visits for flare-ups of problems due to old injuries. This not only includes injuries or poisonings, but also adverse effects of medical treatment or surgical procedures (e.g., unintentional cut during a surgical procedure, foreign object left in body during procedure, and adverse drug events). Include any prescription

or over-the-counter medication involved in an adverse drug event (e.g., allergies, overdose, medication error, drug interactions).

If the visit was not related to an injury, or poisoning or adverse effect of medical or surgical care or an adverse effect of a medicinal drug, then mark (X) "None of the above" and if it could not be determined mark (X) "Unknown."

3. REASON FOR VISIT

ITEM 3. PATIENT'S COMPLAINT(S), SYMPTOM(S), OR OTHER REASON(S) FOR THIS VISIT (in patient's own words.)

Enter the patient's complaint(s), symptom(s), or other reason(s) for this visit *in the Patient's own words*. Space has been allotted for the "most important" and two "other" complaints, symptoms, and reasons as indicated below.

- (1) Most important
- (2) Other
- (3) Other

The *Most Important* reasons should be entered in (1). Space is available for two other reasons in (2) and (3). By "most important" we mean the problem or symptom which in the physician's judgment, was most responsible for the patient making this visit. Since we are interested only in the patient's *most important complaints/symptoms/reasons*, it is not necessary to record more than three.

This is one of the most important items on the Patient Record form. No similar data on office based physician visits are available in any other survey and there is tremendous interest in the findings. Please take the time to be sure you understand what is wanted--especially the following three points: We want the patient's principal complaint(s), symptom(s) or other reason(s) in the patient's own words. The physician may recognize right away, or may find out after the examination, that the real problem is something entirely different. In item 3 we are interested in how the patient defines the reason for the visit (e.g., "cramps after eating," or "fell and twisted my ankle").

The item refers to the patient's complaint, symptom, or other reason for *this visit*. Conceivably, the patient may be undergoing a course of treatment for a serious illness, but if his/her principal reason for this visit is a cut finger or a twisted ankle, then that is the information we want.

There will be visits by patients for reasons other than some complaint or symptom. Examples might be well baby check-up or routine prenatal care. In such cases, simply record the *reason for the visit*.

Reminder: If the reason for a patient's visit is to pay a bill, ask the physician to complete an insurance form, or drop off a specimen, then the patient is not eligible for the sample. A Patient Record form should not be completed for this patient.

4. CONTINUITY OF CARE

ITEM 4a. ARE YOU THE PATIENT'S PRIMARY CARE PHYSICIAN/PROVIDER ?

The primary care physician/provider plans and provides the comprehensive primary health care of the patient. Mark "Yes" if the health care provided to the patient during this visit was from his/her primary care physician/provider and skip to Item 4b. If the physician/provider seen at this visit was substituting for the primary care physician/provider, also check "Yes." Mark "No" if care was not from the primary care physician/provider or "Unknown" if it is not known.

If "No" or "Unknown" is checked, also indicate whether the patient was referred for this visit by another physician or health care provider. This item provides an idea of the "flow" of ambulatory patients from one physician/provider to another . Mark the "Yes," "No," or "Unknown" category, as appropriate.

Notice that this item concerns referrals to the sample physician by a *different* physician/provider. The interest is in referrals for this visit and not in referrals for any prior visit.

Referrals are any visits that are made because of the advice or direction of a clinic or physician/provider other than the physician/provider being visited.

ITEM 4b. HAVE YOU OR ANYONE IN YOUR PRACTICE SEEN THIS PATIENT BEFORE?

"Seen" means "provided care for" at any time in the past. In group practices, mark "Yes, established patient" if the patient was seen before by any physician or staff member in the group. Exclude this visit.

Mark "No, new patient" if the patient has not been seen by the physician or her/his office.

If "Yes" is checked, also indicate approximately how many past visits the patient has made to your practice within the last 12 months using the check boxes provided. Do not include the current visit in your total. If you cannot determine how many past visits were made, then please mark "Unknown." Include all visits to other physicians or health care providers under a physician's supervision in this practice/department.

ITEM 4c. MAJOR REASON FOR THIS VISIT

Mark the major reason for the patient's current visit. Be sure to *check only one* of the following "Major Reasons."

	Problem	Definition
1	New problem	A visit for a condition, illness, or injury having a relatively sudden or recent onset (within three months of this visit).
2	Chronic Problem, Routine	A visit primarily to receive care or examination for a pre-existing chronic condition, illness, or injury (onset of condition was three months or more before this visit).
3	Chronic Problem, Flare up	A visit primarily due to sudden exacerbation of a pre-existing chronic condition.
4	Pre- or Post- Surgery	A visit scheduled primarily for care required prior to or following surgery (e.g., pre-surgery tests, removing sutures).
5	Preventive Care	General medical examinations and routine periodic examinations. Includes prenatal and postnatal care, annual physicals, well-baby exams, screening, and insurance examinations.

5. PHYSICIAN'S DIAGNOSIS FOR THIS VISIT

ITEM 5a. AS SPECIFICALLY AS POSSIBLE, LIST DIAGNOSES RELATED TO THIS VISIT INCLUDING CHRONIC CONDITIONS.

- (1) Primary diagnosis
- (2) Other
- (3) Other

This is one of the most important items on the Patient Record form. Item 5a(1) refers to the physician's primary diagnosis for this visit. While the diagnosis may be tentative, provisional, or definitive it should represent the physician's best judgment at this time, expressed in acceptable medical terminology including "problem" terms. If the patient was not seen by a physician, then the diagnosis by the main medical provider should be recorded.

If a patient appears for *postoperative* care (follow up visit after surgery), record the postoperative diagnosis as well as any other. The postoperative diagnosis should be indicated with the letters "P.O."

Space has been allotted for two "other" diagnoses. In Items 5a(2) and 5a(3) list the diagnosis of other conditions related to this visit. Include chronic conditions (e.g., hypertension, depression, etc.) if related to this visit.

ITEM 5b. REGARDLESS OF THE DIAGNOSES WRITTEN IN 5a, DOES PATIENT NOW HAVE:

The intent of this item is to supplement the diagnosis reported in item 5a(1), 5a(2), and 5a(3). Mark all of the selected condition(s) regardless if it is already reported in item 5a. Even if the condition is judged to be not clinically significant for this visit, it should still be checked. General descriptions for each condition are listed below.

Condition		Description
1	Arthritis	Includes those types of rheumatic diseases in which there is an
		inflammation involving joints (e.g., osteoarthritis, rheumatoid arthritis,
		acute arthritis, juvenile chronic arthritis, hypertrophic arthritis, Lyme
		arthritis, and psoriatic arthritis).
2	Asthma	Includes extrinsic, intrinsic, and chronic obstructive asthma.
3	Cancer (ca)	Includes any type of cancer (ca), such as, carcinoma, sarcoma,
		leukemia, and lymphoma.

Several cancer staging systems exist. A cancer patient's prognosis and treatment is determined using the American Joint Committee on Cancer (AJCC) *Cancer Staging Handbook*. For comparability of stage and treatment results over time, the Surveillance, Epidemiology and End Results (SEER) Summary State is still collected and used. Below is a scheme of how the staging systems compare.

Comparability between AJCC staging system and SEER Summary Stage with the exception of prostate cancer

AJCC Stage	SEER Summary Stage	In item 5b(3), mark box:
0 (In-situ)	In-situ	0 – In situ
1	Localized	1 - Local
П	Regional (by direct extension or	2 - Regional
111	positive lymph nodes)	
IV	Distant (cancer found in other organs)	3 - Distant
Unknown	Unknown	4 - Unknown

Comparability between AJCC staging system and SEER Summary Stage for prostate cancer

Prostate cancer represents a special situation as most patients do not undergo surgery. The table below provides a summary of the equivalent correlations between the staging systems.

Prostate Cancer (AJCC)	Prostate Cancer SEER Summary Stage	In item 5b(3), mark box:
0 (In-situ)	In-situ	0 – In situ
I (T1) no extension (Stage A) II (T2) no extension, no lymph nodes involved (Stage B)	Localized (confined to prostate gland)	1 - Local
III (T3) negative lymph nodes involved (Stage C)	Regional (extends to other organs, no lymph nodes involved)	2 - Regional
IV (T4) positive lymph nodes (Stage D) Distant metastasises	Regional (extends to other organs, positive lymph nodes involved) Distant metastasises	3 - Distant
Unknown	Unknown	4 - Unknown

- 4 Cerebrovascular disease
- Includes stroke and transient ischemic attacks (TIAs)
- 5 CHF (congestive heart failure)
- 6 Chronic renal failure
- 7 COPD (chronic obstructive pulmonary disease)
- 8 Depression
- 9 Diabetes
- 10 Hyperlipidemia
- 11 Hypertension
- 12 Ischemic heart disease

Includes end-stage renal disease (ESRD) and chronic kidney failure due to diabetes or hypertension. Includes chronic bronchitis and emphysema. Excludes asthma.

Includes affective disorders and major depressive disorders, such as episodes of depression reaction, psychogenic depression, and reactive depression.

Includes both diabetes mellitus and diabetes insipidus.

Includes hyperlipoproteinemva and hypercholesterolemia.

Includes essential (primary or idiopathic) and secondary hypertension. Includes angina pectoris, coronary atherosclerosis, acute myocardial infarction, and other forms of ischemic heart disease.

PAGE 100	2006 NAMCS MICRO-DATA FILE DOCUMENTATION
13 Obesity	Includes body weight 20% over the standard optimum weight

- 13 Obesity
 14 Osteoporosis
 Includes body weight 20% over the standard optimum weight.
- 15 None of the above Mark (X) if none of the conditions above exist.

ITEM 5c. STATUS OF PATIENT ENROLLMENT IN A DISEASE MANAGEMENT PROGRAM FOR ANY OF THE CONDITIONS MARKED IN 5b

A disease management program is defined as a set of interventions designed to improve the health of individuals by working more directly with them and their physicians and support-service providers on their treatment plans regarding diet, adherence to medicine schedules, and other self-management techniques. Other components of the program include outcomes measurement and a routine reporting/feedback loop which may involve communication with the patient, physician, health plan, and ancillary providers.

6. VITAL SIGNS

(1)	Height	Record the patient's height if measured at this visit. If it was not measured at this visit and the patient is 21 years of age or over,
		then review the chart for the last time that height was recorded
(2)	W/aight	and enter that value. Mark the appropriate box (ft/in or cm).
(2)	Weight	Record the patient's weight if measured at this visit. If it was not measured at this visit and the patient is 21 years of age or over,
		then review the chart for the last time that weight was recorded and enter that value. Mark the appropriate box (lbs or kg).
(3)	Temperature	Record the patient's temperature if measured at this visit. Mark the appropriate box (degrees C or F).
(4)	Blood pressure	Record the patient's blood pressure if measured at this visit.

7. DIAGNOSTIC/SCREENING SERVICES

Mark all services that were ordered or provided during this visit for the purpose of screening (i.e., early detection of health problems in asymptomatic individuals) or diagnosis (i.e., identification of health problems causing individuals to be symptomatic). EACH SERVICE ORDERED OR PROVIDED SHOULD BE MARKED. At visits for a complete physical exam, several tests may be ordered prior to the visit, so that the results can be reviewed during the visit. Since these services are related to the visit, the appropriate box(es) should be marked.

Mark the "NONE" box if no Diagnostic/Screening Services were ordered or provided.

For "Electrolytes," include any of the following tests: electrolytes, sodium (Na), chloride (Cl), potassium (K), calcium (Ca), or magnesium (Mg).

For "Lipids/Cholesterol," include any of the following tests: cholesterol, LDL, HDL, cholesterol/HDL ratio, triglycerides, coronary risk profile, or lipid profile.

For "Biopsy," include any form of open or closed biopsy of lesions or tissues.

2006 NAMCS MICRO-DATA FILE DOCUMENTATION

For "Chlamydia test," only include the following tests if chlamydia is specifically mentioned: enzyme-linked immunosorbent assay (ELISA, EIA), direct fluorescent antibody test (DFA), nucleic acid amplification test (NAAT), nucleic acid hybridization test (DNA probe testing), or chlamydia culture.

"Pap test – conventional" refers to a smear spread on a glass slide and fixed.

"Pap test – liquid-based cytology" refers to a specimen suspended in a liquid solution. "HPV DNA test" detects the presence in women of human papillomavirus and is performed by collecting cells from the cervix.

If a scope procedure was ordered or provided, mark the "Scope procedure - Specify" box and write-in the type in the space provided.

If services were ordered or provided, but are not listed on the form, mark the "Other test/service - Specify" box and write-in the service(s) in the space provided.

8. HEALTH EDUCATION

Mark all appropriate boxes for any of the following types of health education ordered or provided to the patient during the visit. Exclude medications.

Mark the "NONE" box if no counseling, educational, or therapeutic services were provided.

Heal Educ	th ation	Definition
2	Asthma Education	Information regarding the elimination of allergens that may exacerbate asthma, or other activities that could lead to an asthma attack or instruction on the use of medication, such as an inhaler.
3	Diet/Nutrition	Any topic related to the foods and/or beverages consumed by the patient. Examples include general dietary guidelines for health promotion and disease prevention, dietary restrictions to treat or control a specific medical problem or condition, and dietary instructions related to medications. Includes referrals to other health professionals, for example, dietitians and nutritionists.
4	Exercise	Any topics related to the patient's physical conditioning or fitness. Examples include information aimed at general health promotion and disease prevention and information given to treat or control a specific medical condition. Includes referrals to other health and fitness professionals. Does not include referrals for physical therapy. Physical therapy ordered or provided at the visit is listed as a separate check box in Item 9.
5	Growth/ Development	Any topics related to human growth and development.
6	Injury Prevention	Any topic aimed at minimizing the chances of injury in one's daily life. May include issues as diverse as drinking and driving, seat belt use, child safety, avoidance of injury during various physical activities, and use of smoke detectors.
7	Stress Management	Information intended to help patients reduce stress through exercise, biofeedback, yoga, etc. Includes referrals to other health professionals for the purpose of coping with stress.

Health Education		Definition
8	Tobacco use/exposure	Information given to the patient on issues related to tobacco use in any form, including cigarettes, cigars, snuff, and chewing tobacco, and on the exposure to tobacco in the form of "secondhand smoke." Includes information on smoking cessation as well as prevention of tobacco use. Includes referrals to other health professionals for smoking cessation programs.
9	Weight reduction	Information given to the patient to assist in the goal of weight reduction. Includes referrals to other health professionals for the purpose of weight reduction.
10	Other	Check if there were other types of health or education ordered or provided that were not listed above.

9. NON-MEDICATION TREATMENT

Mark (X) all non-medication treatments ordered or provided at this visit.

Non-Medication Treatment		Definition
1	NONE	No non-medication treatments were ordered, scheduled, or performed at this visit.
2	Complementary or Alternative medicine	Includes medical interventions neither widely taught in medical schools nor generally available in physician offices or hospitals (e.g., acupuncture, chiropractic, homeopathy, massage, or herbal therapies).
3	Durable medical equipment	Equipment which can withstand repeated use (i.e., could normally be rented and used by successive patients); is primarily used to serve a medical purpose; generally is not useful to a person in the absence of illness or injury; and is appropriate for use in the patient's home (e.g., cane, crutch, walker, and wheelchair.)
4	Home health care	Includes services provided to individuals and families in their places of residence for the purpose of promoting, maintaining, or restoring health or for maximizing the level of independence while minimizing the effects of disability and illness, including terminal illness. Services may include skilled nursing care; help with bathing, using the toilet, or dressing provided by home health aides; and physical therapy, speech language pathology services, and occupational therapy.
5	Hospice care	A program of palliative care (i.e., care which serves to relieve or alleviate without curing) and supportive care services providing physical, psychological, social, and spiritual care for dying persons, their families, and other loved ones. Hospice services are available in both the home and inpatient settings. Home hospice care is provided on a part-time, intermittent, regularly scheduled, and around-the-clock basis. Bereavement services and other types of counseling are available to the family and other loved ones.

2006 NAMCS MICRO-DATA FILE DOCUMENTATION

6	Physical therapy	Physical therapy includes treatments using heat, light, sound, or physical pressure or movement, (e.g., ultrasonic, ultraviolet, infrared, whirlpool, diathermy, cold, or manipulative therapy).
7	Radiation therapy	The use of high-energy penetrating rays or subatomic particles to treat disease.
8	Speech/ Occupational therapy	Speech therapy includes the treatment of defects and disorders of the voice and of spoken and written communication. Occupational therapy includes the therapeutic use of work, self- care, and play activities to increase independent function, enhance development, and prevent disability.
9	Psychotherapy	All treatments involving the intentional use of verbal techniques to explore or alter the patient's emotional life in order to effect symptom reduction or behavior change.
10	Other mental health counseling	General advise and counseling about mental health issues and education about mental disorders. Includes referrals to other mental health professionals for mental health counseling.
11	Excision of tissue	Includes any excision of tissue such as polyps, cysts, or moles. Excludes would care and biopsy.
12	Orthopedic care	Includes reduction, casting, wrapping, splinting, and aspiration of fluid from joints.
13	Wound care	Includes cleaning, debridement, and dressing of burns; repair of lacerations with skin tape or sutures; removal of foreign bodies; and incision and draining of wounds.
14	Other non-surgical procedures	Write-in any non-surgical procedure ordered or performed at this visit that was not previously recorded.
15	Other surgical procedures	Write-in any surgical procedure ordered or performed at this visit that was not previously recorded. Surgical procedures may be simple (e.g., insertion of intrauterine contraceptive device) or complex (e.g., cataract extraction, hernia repair, hip replacement, etc.).

10. MEDICATIONS & IMMUNIZATIONS

If medications or immunizations were ordered, supplied, administered, or continued at this visit, please list them (up to 8) in the space provided using either the brand or generic names. Record the exact drug name (brand or generic) written on any prescription or on the medical record. Do not enter broad drug classes, such as "laxative," "cough preparation," "analgesic," "antacid," "birth control pill," or "antibiotic." The one exception is "allergy shot." If no medication was prescribed, provided, or continued then mark (X) the "NONE" box and continue.

Medication, broadly defined, includes the specific name of any:

•prescription and over-the-counter medications, anesthetics, hormones, vitamins, immunizations, allergy shots, and dietary supplements.

•medication and immunizations which the physician ordered or provided *prior to this visit* and *instructs or expects* the patient to continue taking regardless of whether a "refill" is provided at the time of visit.

For each medication, record if it was new or continued.

11. PROVIDERS

Mark all providers seen during this visit. If care was provided, at least in part, by a person not represented in the four categories, mark the "Other" box.

12. VISIT DISPOSITION

Mark all that apply.

Visi	t Disposition	Definition
1	No follow-up planned	No return visit or telephone contact was scheduled or planned for the patient's problem.
2	Return if needed, PRN	The patient was instructed to return to the office as needed.
3	Refer to other physician	The patient was instructed to consult or seek care from another physician. The patient may or may not return to this office at a later date.
4	Return at specified time	The patient was told to schedule an appointment or was given an appointment to return to the office at a particular time.
5	Telephone follow-up planned	The patient was instructed to telephone the physician or physician's staff on a particular day to report on his or her progress, or a member of the office staff plans to call the patient to check on his or her condition.
6	Refer to emergency department	The patient was instructed to go to the emergency department for further evaluation and care immediately.
7	Admit to hospital	The patient was instructed that further care or treatment will be provided as an inpatient in the hospital.
8	Other	Any other disposition not included in the above list.

13. TIME SPENT WITH PHYSICIAN

Include here the length of time the physician spent with the patient. DO NOT include the time the patient spent waiting to see the physician or receiving care from someone other than the physician. For example, DO NOT include the time the nurse spent giving the patient an inoculation or the time a technician spent administering an electrocardiogram. It is entirely possible that for visits such as these, the patient would not see the doctor at all. In that case, "0" minutes should be recorded. DO NOT include physician's time spent preparing for a patient such as reviewing the patient's medical records or test results <u>before</u> seeing the patient.

If more than one patient is seen by the doctor at the same time, apply the following rule:

If the doctor can easily separate the time spent with each (e.g., 3 minutes with one and 27 minutes with the other), he/she should record that on the Patient Record forms. If the doctor cannot easily estimate how much time was spent with each, he/she should divide the total time equally among the patients seen together.

C. DEFINITIONS OF CERTAIN TERMS USED IN THE NAMCS

Ambulatory patient --An individual presenting for personal health services, neither bedridden nor currently admitted to any health care institution on the premises.

Continuity of care -- Continuity of care is a goal of health care achieved through an interdisciplinary process involving patients, families, health care professionals, and providers in the management of a coordinated plan of care. Based on changing needs and available resources, the process optimizes quality outcomes in the health status of patients. It may involve professionals from many different disciplines within multiple systems.

Drug mention(s) --The physician's entry of a pharmaceutical agent ordered or provided--by any route of administration--for prevention, diagnosis, or treatment. Generic as well as brand-name drugs are included. Along with all new drugs, the physician also records continued medications if the patient was specifically instructed or expected to continue the medication.

Drug visit -- A drug visit is a visit at which medication was prescribed or provided by the physician.

Office(s) --Premises that the physician identifies as locations for his or her ambulatory practice. Responsibility over time for patient care and professional services rendered there generally resides with the individual physician rather than with any institution.

Visit --A direct, personal exchange between ambulatory patient and the physician (or members of his/her staff) for the purpose of seeking care and rendering health services.

PATIENTS

In-scope -- All patients seen by the physician or members of his/her staff in the physician's office(s).

Out-of-scope -- Patients seen by the physician in a hospital, nursing home, or other extended care institution, or the patient's home. Note: If the doctor has a private office (which fits definition of "office") located in a hospital, the ambulatory patients seen there would be considered "in-scope." The following types of patients are also considered out-of-scope:

• patients seen by the physician in any institution (including outpatient clinics of hospitals) for which the institution has the primary responsibility for the care of the patient over time;

 patients who telephone and receive advice from the physician; patients who come to the office only to leave a specimen, pick up insurance forms, or pay their bills;

• patients who come to the office only to pick up medications previously prescribed by the physician.

PHYSICIANS

In-Scope -- All duly licensed doctors of medicine and doctors of osteopathy currently in practice who have regularly scheduled time for seeing ambulatory patients at an office location.

Out-of-Scope -- Those physicians who treat patients only indirectly, including specialists in anesthesiology, pathology, forensic pathology, radiology, therapeutic radiology, and diagnostic radiology, and the following physicians:

- physicians who are federally employed or who are in military service;
- physicians who treat patients only in an institutional setting (e.g., patients in nursing homes and hospitals);
- physicians employed full time by an industry or institution and having no private practice (e.g., physicians who work for the VA, the Ford Motor Company, etc.);
- physicians who spend no time seeing ambulatory patients.

Physician specialty -- Principal specialty (including general practice) as designated by the physician at the time of the survey. Those physicians for whom a specialty was not obtained were assigned the principal specialty recorded in the Master Physician files maintained by the AMA or AOA.

Metropolitan status — Physicians are classified by their location in metropolitan statistical area as follows:

Metropolitan statistical area (MSA)—As defined by the U.S. Office of Management and Budget, the definition of an individual MSA involves two considerations: first, a city or cities of specified population, that constitute the central city and identify the county in which it is located as the central county; second, economic and social relationships with "contiguous" counties that are metropolitan in character so that the periphery of the specific metropolitan area may be determined. MSAs may cross state lines. In New England, MSAs consist of cities and towns rather counties.

Non-MSA—Non-MSA areas are those not defined as MSAs, including rural and micropolitan areas.

Region of practice location -- The four geographic regions which correspond to those used by the U.S. Bureau of the Census, are as follows:

<u>Region</u>	States Included
Northeast	Connecticut, Maine, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, Vermont
Midwest	Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri, Nebraska, North Dakota, Ohio, South Dakota, Wisconsin
South	Alabama, Arkansas, Delaware, District of Columbia, Florida, Georgia, Kentucky, Louisiana, Maryland, Mississippi, North Carolina, Oklahoma, South Carolina, Tennessee, Texas, Virginia, West Virginia
West	Arizona, California, Colorado, Idaho, Montana, Nevada, New Mexico, Oregon, Utah, Washington, Wyoming, Alaska, Hawaii

APPENDIX II **REASON FOR VISIT CLASSIFICATION**

A. SUMMARY OF CODES

MODULE

CODE NUMBER

SYMPTOM MODULE

General Symptoms	1001-1099
Symptoms Referable to Psychological and Mental Disorders	1100-1199
Symptoms Referable to the Nervous System (Excluding Sense Organs)	1200-1259
Symptoms Referable to the Cardiovascular and Lymphatic Systems	1260-1299
Symptoms Referable to the Eyes and Ears	1300-1399
Symptoms Referable to the Respiratory System	1400-1499
Symptoms Referable to the Digestive System	1500-1639
Symptoms Referable to the Genitourinary System	1640-1829
Symptoms Referable to the Skin, Nails, and Hair	1830-1899
Symptoms Referable to the Musculoskeletal System	1900-1999
DISEASE MODULE	

Infective and Parasitic Diseases 2001-2099 Neoplasms 2100-2199 Endocrine, Nutritional, Metabolic, and Immunity Diseases 2200-2249 Diseases of the Blood and Blood-forming Organs 2250-2299 Mental Disorders 2300-2349 Diseases of the Nervous System 2350-2399 Diseases of the Eye 2400-2449 Diseases of the Ear 2450-2499 Diseases of the Circulatory System 2500-2599 Diseases of the Respiratory System 2600-2649 Diseases of the Digestive System 2650-2699 Diseases of the Genitourinary System 2700-2799 Diseases of the Skin and Subcutaneous Tissue 2800-2899 Diseases of the Musculoskeletal System and Connective Tissue 2900-2949 **Congenital Anomalies** 2950-2979 Perinatal Morbidity and Mortality Conditions 2980-2999

DIAGNOSTIC, SCREENING AND PREVENTIVE MODULE

General Examinations	3100-3199
Special Examinations	3200-3299
Diagnostic Tests	3300-3399
Other Screening and Preventive Procedures	3400-3499
Family Planning	3500-3599

TREATMENT MODULE

Medications	4100-4199
Preoperative and Postoperative Care	4200-4299
Specific Types of Therapy	4400-4499
Specific Therapeutic Procedures	4500-4599
Medical Counseling	4600-4699
Social Problem Counseling	4700-4799
Progress Visit, NEC	4800-4899

MODULE

CODE NUMBER

INJURIES AND ADVERSE EFFECTS MODULE

Injury by Type and/or Location Injury, NOS Poisoning and Adverse Effects	5001-5799 5800-5899 5900-5999
TEST RESULTS MODULE	6100-6700
ADMINISTRATIVE MODULE	7100-7140
UNCODABLE ENTRIES	8990-8999
BLANK	9000

NOTE: NOS = Not otherwise specified; NEC = not elsewhere classified

B. REASON FOR VISIT CLASSIFICATION TABULAR LISTING

SYMPTOM MODULE GENERAL SYMPTOMS (1001-1099)		1035.0	Symptoms of fluid abnormalities Includes: Fluid retention	
1005.0	Chills		Holding water	
1010.0	Fever Includes: High temperature		1035.1 Edema Includes: Ankles swelling (both) Bloated	
1012.0	Other symptoms of body temperature Excludes: Chills (1005.0) Fever (1010.0)		Dropsy Legs (both) Peripheral Swollen with water	
	1012.1 Feeling cold 1012.2 Feeling hot 1012.3 Feeling hot and cold		Excludes: Swelling of one ankle (1930.5) Swelling of one leg (1920.5)	
1015.0	Tiredness, exhaustion Includes:		1035.2 Excessive sweating, perspiration Includes: Diaphoresis	
	Exercise intolerance Fatigue Lack of energy		1035.3 Excessive thirst	
	No energy Run down Worn out	1040.0	Weight gain Includes:	
1020.0	General weakness		Fat pads (localized) Fatty deposits Obesity	
1025.0	General ill feeling		Overweight Too fat	
	Includes: Diffuse Cx Illness, NOS Malaise		Excludes: Counseling for weight problem (4600.0)	
	Not feeling well Multiple complaints	1045.0	Weight loss 1045.1 Recent weight loss	
	Sick, NOS		1045.2 Underweight	
1030.0	Fainting (syncope)	1046.0	Symptoms of face, NEC	
	Includes: Blacking out Fainting spells Passing out		Excludes: Facial pain 1055.4 Facial paralysis 1230.0	
	Excludes: Unconsciousness (5840.0)	1050.0	Chest pain and related symptoms (not referable to a specific body system)	
			1050.1 Chest pain	
			Excludes: Heart pain (1265.0)	
			1050.2 Chest discomfort, pressure, tightness, heaviness	
			Includes	

C - pressure

1050.3 Burning sensation in the chest

2006 NAMCS MICRO-DATA FILE DOCUMENTATION

1055.0	Pain, specified site n system	not referable to a specific body	1075.0	Symptoms of growth	h and developmental disorders
	Includes Buttoc		Includes: Developmental regression		
Glutes			1075.1	Lack of growth	
	Exclude Abdon Chest Phanto	es: ninal pain (see 1545.1-1545.3) pain (1050.1) pm leg/limb (2307.0)			Includes: Failure to thrive Immaturity, physical Poor weight gain Slowness, physical Too short
	1055.1	Rib pain		1075.2	Excessive growth
	1055.2	Side pain, flank pain			Includes:
	1055.3	Groin pain			Development, early (physical) Too big for age
		Includes:			Too tall
		Pubic pain	1000.0	a 1	
	1055.4	Facial pain	1080.0	NEC	of infants (under 1 year of age),
		Includes:		1080.1	Cranky, crying too much, fussy, fidgety, irritable
		Jaw pain Pain over eye		1080.2	Regurgitation, spitting up
1060.0	Pain and related sym	nptoms, NEC			Excludes:
					Vomiting (1530.0)
	1060.1	Pain, unspecified		1000.2	
		T 1 1		1080.3	Feeding problem, eating difficulty
		Includes: Ache all over (generalized) Incisions	1085.0	General or unspecifi	ed nonviral infection
		mensions		Include	s.
	1060.2	Cramps, spasms, site unspecified			on, NOS
		Excludes: Menstrual cramps (1745.2)	1090.0	Allergy, NOS	
		Mensulai cramps (1743.2)		Include	s.
	1060.3	Stiffness, site unspecified			edema
1065.0	Tumor or mass, site	unspecified			ic reaction, NOS allergy, NOS
	1065.1	Internal mass, NOS			llergy, NOS
	1005.1	Internar mass, 1005		Exclude	26.
1066.0	Lesion. Internal NO	S (excludes brain and skin)			ic skin reaction (2825.0)
	,	,			y to medications (5905.0)
1070.0	Bleeding, multiple o	r unspecified sites		Nasal	allergy (2635.0)
			1095.0	Disorders of motor f	functions
				Include	s:
				Ataxia	
				Clums	iness

Difficulty in walking Dyskinesia Fall, NOS Limping Staggering Stumbling Uncoordinated Unsteady gait

1096.0 Dyslexia, NOS

SYMPTOMS REFERABLE TO PSYCHOLOGICAL AND MENTAL DISORDERS (1100-1199)

			Includes	:
1100.0	Anxiety and nervousness		Can't r	est
			Hypera	activity
	Includes:		Overac	ctivity
	Apprehension			
	Bad nerves	1130.0	Behavioral disturbar	ices
	Jittery			
	Panicky feeling		Includes	
	Stress		Behav	ior problem
	Tension		Gamb	ling problem
	Upset		Lack o	of self control
	Worried		Starin	g spells
1105.0	Fears and phobias		1130.1	Antisocial behavior
	Includes:			Includes:
	General fearfulness			Avoiding people
	Agoraphobia			Excessive shyness
				Lying
1110.0	Depression			Social isolation
	*			Withdrawal
	Includes:			
	Crying excessively		1130.2	Hostile behavior
	Dejected			
	Distress (NOS)			Includes:
	Feeling down			Aggressiveness
	Feeling low			Child abuser
	Grief			Child neglecter
	Hopelessness			Combative
	Sadness			Criminality
	Tension			Cruelty
	Tension headache			Destructiveness
	(also code 1210.0)			Elder abuser
	Unhappy			Homicidal
	FFJ			Negativism
1115.0	Anger			Parent abuser
	8			Quarrelsome
	Includes:			Spouse abuser
	Bitterness			Spouse batterer
	Hostile feelings			
	en e		1130.3	Hysterical behavior
	Excludes:			,
	Temper problems (1130.4)		1130.4	Temper problems
				I I I I I I I
1120.0	Problems with identity and self-esteem			Includes:
				Blowing up
	Includes:			Fussy
	Co-dependency			Irritability
	Dependency			Losing temper
	Don't like myself			Temper tantrums
	Guilt			
	Helpless			Excludes:
	Identity crisis			Fussy infants (1080.1)
	Insecurity, emotional			
	Lack of motivation		1130.5	Obsessions and
	Loss of identity			compulsions
	No confidence			*
	No goals			
	Poor boundaries			
	Too much is expected of me			

1125.0 Restlessness

1135.0	Disturbances of slee	р	1155.0	Delusions or halluci	nations
	Include: Night t			Include: Flashb Grandi	ack
	1135.1	Insomnia			g voices of reference
		Includes: Can't sleep			ine is poisoned things
		Sleeplessness Trouble falling asleep	1160.0	Psychosexual disord	ers
	1135.2	Sleepiness (hypersomnia)		1160.1	Frigidity, loss of sex drive, lack of response, lack of libido
		Includes:			response, new or nordo
		Can't stay awake		1160.2	Homosexuality, concerns with
		Drowsiness			57
		Groggy		1160.3	Impotence, Erectile dysfunction
	1135.3 1135.4	Nightmares Sleepwalking		1160.4	Premature ejaculation
	1135.5	Apnea		1160.5	Masturbation excessive, concerns about
		Includes: Sleep apnea (use additional code 1420.0 if breathing		1160.6	Orgasm, problem with
		problem)		1160.7	Preoccupation with sex
1140.0	Smoking problems		1165.0	* 1 1	problems relating to psychological al disorders, NEC
	Includes				
		luit smoking		Includes	5:
	Smoki	ng too much		Blunte Can't c	d affect cope
	Exclude				cal imbalance
		al symptoms of smoking (see			icted affect
		cular symptom)			r to self
	Зтоке	er's cough (1440.0)		Deja v Disorie	u feelings
1145.0	Alcohol-related prob	blems			alty concentrating
	Include	s:		Going	
		ol abuse			verybody
	Drinki	ng problem		Inhibit	ed
					ng disability
	Exclude			-	g my mind
		se effects of alcohol (5915.0) olism (2320.0)		Mood	fluctuation swings
1150.0					ommunicative ar thinking
1150.0	Abnormal drug usag	,e			blogical problems, NOS
	Include	s:			wn syndrome
	Drug a	lbuse		Troubl	e concentrating
		ent or excessive use of stimulants,		Wande	ering around
	halluc	inogens, depressants, etc.			
	Exclude			Exclude	es: exter disorder (2315.0)
		uddiction (2321.0)			ality disorder (2315.0)
		lependence (2321.0)		1 61301	
		cation with drugs (5910.0)		1165.1	Nailbiting
		ose, intentional (5820.1)			
	Overde	ose, unintentional, NOS (5910.0)		1165.2	Thumbsucking

SYMPTOMS REFERABLE TO THE NERVOUS SYSTEM (EXCLUDING SENSE ORGANS) (1200 - 1259)

1220.0

1225.0

1230.0

1200.0 Abnormal	involuntary	movements
-----------------	-------------	-----------

Includes: Jerking Shaking Tics Tremors Twitch

Excludes: Eye movements (see 1325.0-1325.4) Eyelid twitch (1340.4)

1205.0 Convulsions

Includes: Febrile convulsions Fits Seizures Spells

Excludes: Fainting (1030.0)

1207.0 Symptoms of head, NEC

Excludes: Headache, pain in head (1210.0)

1210.0 Headache, pain in head Includes: Post-traumatic (also code 5575.0) Excludes: Migraine (2365.0) Sinus headache (1410.1) Symptoms of head, NEC (1207.0)

1215.0 Memory, disturbances of

Includes: Amnesia Forgetfulness Lack or loss of memory Temporary loss of memory PAG

Disturbances of sensation 1220.1 Loss of feeling (anesthesia) Includes: Lack of sensation No response to pain Numbness Stunned Excludes: Post-op complications of anesthesia Note: Use additional code to identify body part. 1220.2 Increased sensation (hyperesthesia) 1220.3 Abnormal sensation (paresthesia) Includes: Burning legs Burning, tingling sensation Needles and pins Prickly feeling 1220.4 Other disturbances of sense, including smell and taste Vertigo - dizziness Includes: Falling sensation Giddiness (dizziness) Lightheadedness Loss of sense of equilibrium or balance Room spinning Weakness (neurologic) Includes:

> Right- or left-sided weakness Excludes:

Excludes: General weakness (1020.0)

Drooping, facial or NOS

1235.0 Disorders of speech, speech disturbance

Includes: Groping for words Speech/verbal apraxia Unable to speak

1235.1 Stuttering, stammering

1235.2 Slurring

1240.0 Other symptoms referable to the nervous system

Includes: Brain lesion Confusion Cognitive decline Damaged nerves Neuralgia Pinched nerve

Excludes: Nerve block 4560.0

1240.1 Apraxia

Excludes: Speech/verbal apraxia 1235.0

SYMPTOMS REFERABLE TO THE CARDIOVASCULAR AND LYMPHATIC SYSTEMS (1260-1299)

1260.0 Abnormal pulsations and palpitations

1260.1 Increased heartbeat

Includes: Pulse too fast Rapid heartbeat

1260.2 Decreased heartbeat

Includes: Pulse too slow Slow heart

1260.3 Irregular heartbeat

Includes: Fluttering Jumping Racing Skipped beat

1265.0 Heart pain

Includes: Anginal pain Heart distress Pain over heart

Excludes: Angina pectoris (2515.0) Chest pain (1050.1)

1270.0 Other symptoms of the heart

Includes: Bad heart Heart condition Poor heart Weak heart

2006 NAMCS MICRO-DATA FILE DOCUMENTATION

1275.0	Symptoms of lymph glands (or nodes)	
--------	-------------------------------------	--

	1275.1	Swollen or enlarged glands
	1275.2	Sore glands
1280.0	Other symptoms refe cardiovascular/lymp	
		Includes: Telangiectasia
	1280.1	Poor circulation
	1280.2	Pallor, paleness

SYMPTOMS REFERABLE TO THE EYES AND EARS (1300-1399)

Flushed, blushing

1280.3

1305.0	Vision dysfunctions	
	Excludes Refract	s: ive errors (2405.0)
	1305.1	Blindness and half vision Includes: Visual field deficit
	1305.2	Diminished vision
		Includes: Blurred vision Can't see distances Difficulty reading Focus, Eyes won't (other than Infant 1335.0) Obstruction, Vision Poor vision Scotoma Trouble seeing Weak eyes
	1305.3	Extraneous vision
		Includes: Cloudy vision Hazy vision Spots in front of eyes (floaters)
	1305.4	Double vision (diplopia)
1310.0	Discharge from eye	
	1310.1	Bleeding
	1310.2	Tearing, watering (lacrimation)
	1310.3	Pus, matter, white discharge

1315.0	Eye infection and in	flammation	1340.0	Symptoms of eyelids	
	1315.1	Pinkeye			Includes: Can't close eye
1320.0	Abnormal sensations	s of the eye			Lesion Rash
	Includes			1340.1	Infection, inflammation, swelling
	-	n body sensation		1340.2	Itching
	1320.1	Pain		1340.3	Mass or growth
		Includes: Irritation		1340.4	Abnormal movement
	1320.2	Itching			Includes:
	1320.3	Burning, stinging			Blinking Drooping Squinting
	1320.4	Strain			Twitching
1325.0	Abnormal eye move	ments	1345.0	Hearing dysfunctions	
	1325.1	Abnormal retraction		1345.1	Diminished hearing
	1325.2	Cross-eyed			Includes: Deafness
	1325.3	Pupils unequal			Hearing loss Trouble hearing
	1325.4	Deviation		1345.2	Heightened or acute hearing
1330.0	Abnormal appearance	ce of eyes		1345.3	Extraneous hearing
	1330.1	Abnormal color			Includes: Ringing (tinnitus)
		Includes: Bloodshot			Excludes: Hearing things (1155.0)
		Red	1350.0	Discharge from ear	
		Excludes: Yellow (1610.2)		Includes:	
	1330.2	Protrusion (exophthalmos)		Fluid in	ear
	1330.3	Cloudy, dull, hazy appearance		1350.1	Bleeding
1335.0	Other and unspecifie	ed symptoms referable to eye, NEC		1350.2	Pus (purulent drainage)
	Include	• •		1350.3	Swimmer's ear
	Defect		1355.0	Earache, or ear infect	ion
	1335.1	Contact lens problems		1355.1	Earache, pain
	1335.2	Allergy		1355.2	Ear infection
	1335.3	Swelling	1360.0	Plugged feeling in ear	r
		Excludes: Foreign body (5600.0) Injury (5510.0) Abrasion (5410.0)		Crackin Ear feel	l tion in ear g s full ed cleaning

1365.0	-	ed symptoms referable to the ears,	1410.0	Sinus problems	
	NEC Includes red, redness			Includes	
	1365.1	Itching		Sinus o Sinus o	cyst drainage
	1365.2	Growths or mass		1410.1	Pain and pressure
	1365.3	Pulling at ears, picking at ears			Includes: Sinus headache
	1365.4	Abnormal size or shape, "ears stick out"		1410.2	Sinus inflammation, infection
		Excludes: Foreign body in ear (5620.0)		1410.3	Sinus congestion
SYMPTO	OMS REFERABLE T	O THE RESPIRATORY SYSTEM	1415.0	Shortness of breath	
(1400-14		o militadi mari oni di di lini		Include	
1400.0	Nasal congestion			Out of	lessness breath ion of suffocation
	Include				
	Drippy Excess	y nose s mucus	1420.0	Labored or difficult	breathing (dyspnea)
	Nasal	obstruction		Include	
	Post-n Runny	asal drip		Anoxi Can't b	
	Sniffle			Нурох	
	Stuffy	nose		Smoth	
1405.0	Other symptoms of	nose			atory distress e breathing
	Exclude Nasal	es: allergy (2635.0)	1425.0	Wheezing	
	1405.1	Nosebleed (epistaxis)		Include: Sighin	s: g respiration
	1405.2	Sore in nose	1430.0	Breathing problems,	NEC
	1405.3	Inflammation and swelling		Include	
		Includes:		Hurts	o breathe
		Infection Red nose Sore nose		1430.1	Disorders of respiratory sound, NEC
	1405.4	Problem with appearance of nose			Includes: Abnormal breathing sounds
		Includes:			Snoring Rales
		Bump(s)			Rattles
		Too large			Stridor
		Undesirable appearance		1430.2	Rapid breathing (hyperventilation)
			1435.0	Sneezing	
			1440.0	Cough	
				Includes	
				Conge	
					y cough r's cough
				Shioke	

1445.0	Head cold, upper	respiratory	infection	(coryza)
--------	------------------	-------------	-----------	----------

Includes: Cold, NOS

Excludes: Chest cold (1475.0)

1450.0 General viral infection

1450.1 Flu

Includes: Grip Influenza

Excludes: Croup (2600.0)

1455.0 Symptoms referable to throat

1455.1 Soreness

- Includes: Throat hurts
- 1455.2 Pain
- 1455.3 Infection
 - Includes: Throat virus
 - Excludes: Strep throat (2010.0)
- 1455.4 Irritation, scratch, tickle, itch
- 1455.5 Swelling
- 1455.6 Lump or mass

Includes: Sensation of something in throat

Excludes: Foreign body in throat (5615.0)

1460.0 Symptoms referable to tonsils

Includes: Hypertrophy Infection Inflammation

1470.0 Abnormalities of sputum or phlegm

1470.1 Coughing up blood

Includes:

Hemoptysis

1470.2 Pus in sputum

1470.3 Excessive sputum

Includes: Productive

Congestion in chest

1475.0

1480.0

Includes: Lung congestion Chest cold

Disorders of voice

1480.1 Hoarseness, loss of voice

Includes: Croaky

1480.2 Hypernasality

1485.0 Other symptoms referable to the respiratory system, NEC

Includes: Drainage in throat

1485.1 Lung pain

1485.2 Lung infection

SYMPTOMS REFERABLE TO THE DIGESTIVE SYSTEM (1500-1639)

1500.0 Symptoms of teeth and gums

Includes: Loose tooth (no injury) Tooth infection

1500.1	Toothache
1500.2	Gum pain
1500.3	Bleeding gums

1501.0 Symptoms of the jaw, NOS

Includes: Jaw problem, unspecified

1501.1 Swelling

1501.2 Lump or mass

1505.0	Symptoms referable	to lips	1540.0	Gastrointestinal infe	ction
	1505.1 1505.2	Cracked, bleeding, dry Abnormal color		Stoma	nal virus
	1505.3	Cold sore			gastroenteritis
1510.0	Symptoms referable	to mouth	1545.0	Stomach and abdom	inal pain, cramps and spasms
		ng at the mouth too thick		Include: Gastric Exclude Groin	e pain
	1510.1 1510.2 1510.3 1510.4	Pain, burning, soreness Bleeding Dryness Ulcer, sore		1545.1	Abdominal pain, cramps, spasms, NOS
1515.0	Symptoms referable	to tongue			Includes: Abdominal discomfort, NO Gas pains Intestinal colic
		s: on tongue n tongue		1545.2	Lower abdominal pain, cramps, spasms,
	1515.1	Pain			Includes: Right lower quadrant (RLQ) pain
	1515.2 1515.3	Bleeding Inflammation, infection, swelling			Left lower quadrant (LLQ) pain Inguinal pain
	1515.4	Abnormal color, ridges, coated		1545.3	Upper abdominal pain, cramps, spasms
1520.0	Difficulty in swallow	-			Includes:
	Includes Chokir Inabili				Epigastric pain Left upper quadrant (LUQ) pain Pain in umbilical region Right upper quadrant (RUQ) pain
1525.0	Nausea		1565.0	Change in abdomina	ıl size
	Nervou Sick to	s: ke throwing up is stomach stomach stomach		1565.1	Distention, fullness, NOS Includes: Abdominal bloating Stomach fullness
1530.0	Vomiting			1565.2	Mass or tumor
	Dry he Retchi	eep food down aves ng			Includes: Mass in groin Mass, inguinal
				1565.3	Abdominal swelling, NOS
1535.0	Heartburn and indige	estion (dyspepsia)			
	Includes Acid in st Excessive				

1570.0	Appetite, abnormal 1570.1	Excessive appetite Eats too much	1605.0	Symptoms referable 1605.1	to anus-rectum Pain
	1570.2	Always hungry Decreased appetite			Includes: Burning
		Not hungry Loss of appetite			Irritation
		Decreased fluid intake		1605.2	Bleeding
1575.0	Difficulty eating			1605.3	Swelling or mass
1580.0	Gastrointestinal blee Includes: Bowel	ding		1605.4	Itching
	1580.1	Blood in stool (melena)	1610.0	Symptoms of liver, g	allbladder, and biliary tract
	1580.2	Vomiting blood (hematemesis)		1610.1	Pain
1585.0	Flatulence			1610.2	Jaundice
	Excess Gas Exclude	l, gas ion due to gas ive gas	1615.0 system	Includes	
1590.0	Constipation			Bad brea	
1595.0	Diarrhea				tric distress intestinal distress sis
	Includes: Loose The run	stools		Stomac	ighs itation (adult) ch problem ch trouble
1600.0	Other symptoms or c	hanges in bowel function	SYMPTO		TO THE GENITOURINARY
	1600.1	Discharge in stools		I (1640-1829)	
		Includes: Guaiac positive Hemocult positive Mucus	1640.0	Abnormalities of urin Exclude	
		Pus		1640.1	Blood in urine (hematuria)
	1600.2	Worms		1640.2	Pus in urine
	1600.3	Changes in size, color, shape, or odor		1640.3	Unusual color or odor
		Includes:	1645.0	Frequency and urgen	ncy of urination
		Bulky stools Too narrow Unusual odor or color		1645.1	Excessive urination, night (nocturia)
	1600.4	Incontinence of stool	1650.0	Painful urination	·
		Includes: Dirty pants (encopresis) Leaking stools		Includes Burnin	:: g, discomfort

PAGE 119

2006 NAMCS MICRO-DATA FILE DOCUMENTATION

1655.0	Incontinence of uri	ne (enuresis)	1700.0	Symptoms of penis	
	1655.1	Involuntary urination, can't hold urine, dribbling, wetting pants		1700.1	Pain, aching, soreness, tenderness, painful erection
	1655.2	Bedwetting		1700.2	Infection, inflammation, swelling
1660.0	Other urinary dysfu	-		1700.3	Lumps, bumps, growths, warts
1000.0					Lumps, bumps, growins, wans
	Include Troub	es: ole going	1705.0	Penile discharge	
	Weak	Stream	1710.0	Symptoms of prosta	te
	1660.1	Retention of urine		Include Prosta	s: te trouble
		Includes: Can't urinate		1710.1	Swelling
	1660.2	Hesitancy		1710.2	Infection
		Includes: Difficulty in starting stream	1715.0	Symptoms of the scr	rotum and testes
	1660.3	Large volume		1715.1	Pain, aching, tenderness
	1000.5	Includes:		1715.2	Swelling, inflammation
		Polyuria		1715.3	Growths, warts, lumps, bumps
	1660.4	Small volume		1715.4	Itching, jock itch
1665.0 Symptoms of bladder			1720.0 Other symptoms of male reproductive system Includes:		
	Include Bladd	es: ler trouble		Painf	ul ejaculation
	1665.1	Pain		Exclude Psyche	es: osexual problems (1160.0-1160.6)
	1665.2	Infection	1730.0	Absence of menstru	ation (amenorrhea)
	1665.3	Mass		Exclude	
1670.0	Symptoms of the ki	dneys		Missee	cted pregnancy (3200.0) d a period (3200.0) late (3200.0)
	Include		1525.0		
		ey trouble	1735.0	Irregularity of mens	
	1670.1 1670.2	Pain Infection		1735.1	Frequent
	1670.3	Mass		1735.2	Infrequent
1675.0	Urinary tract infecti	ion, NOS		1735.3	Unpredictable
	Include		1740.0	Irregularity of mens	trual flow
		ourinary infection infection		1740.1	Excessively heavy (menorrhagia)
1680.0	Other symptoms ref	ferable to urinary tract		1740.2	Scanty flow (oligomenorrhea)
	Ureth Urina Exclud	d stones ral bleeding ry irritation		1740.3	Abnormal material, including clots

Kidney stones or bladder stones (2705.0)

1745.0	Menstrual	l symptoms,	other and unspecified	1770.0	Vulvar dis	sorders			
		Includes: Long pe				1770.1 1770.2 1770.3	Mass, lump	irritation, sw rt, cyst, ulcer	C
		1745.1	Premenstrual symptoms, PMS	1775.0	Pelvic syn	nptoms	,		,
			Includes: Bloating before periods			1775.1	Pain		
			Premenstrual tension or irritability			1775.2	Pressure or	dropping sen	sation
	1745.2	Painful me	enstruation (dysmenorrhea)				Includes: Feeling o	f uterus fallir	ng out
			Includes:						8
			Menstrual cramps			1775.3	Infection, in	flammation	
			Pain in legs and back						
			during menstruation	1790.0		of pregnanc	сy		
1750.0	Menopaus	sal symptom	IS		Include Fetal	movement			
		1750.1	Early or late onset of menopause			Excludes Routine	: prenatal visi	ts (3205.0)	
		1750.2	Vasomotor symptoms-hot flashes			1700 1	Dain dunin a		
		1750.3	Emotional symptoms, change of			1790.1	Pain during	pregnancy	
		170010	life problems			1790.2	Spotting,	bleeding	during
				pregnancy	r				
1755.0	Uterine ar	nd vaginal b	leeding			1790.3	Symptoms	of onset of lal	oor
		Excludes	:			1790.5	Symptoms (n onset of fa	501
	Bleeding during pr		g during pregnancy (1790.2)				Includes: Water bro	oke	
		1755.1	Intermenstrual bleeding (metrorrhagia)					membranes n, contractio	ns
			Includes: Bleeding between periods Breakthrough bleeding	1791.0	Postpartur	n problems			
		1755.2	Postmenopausal bleeding			Includes: Bleedin Pain			
		1755.3	Postcoital bleeding, female						
1760.0	Vaginal d	ischarge				Excludes Postpart	: tum examinat	tion, routine	(3215.0)
			brown, white (leukorrhea),	1795.0	Other sym	ptoms refer system	able to the fe	male reprodu	ictive
		excessi	lve	1800.0	Pain or so	reness of br	east		
1765.0	Other vag	inal sympto	ms	1000.0	i uni or sor	Includes: Tenderr			
	1765.1 Pain 1765.2 Infection		Pain	1905.0	I	noos of t-	t		
			Infection	1805.0 Lun		nass of brea			
		1765.3	Itching, burning	Includes: Bump					
		1765.4	Vaginal dryness			Knot Nodule Cyst			

1810.0	Other symptoms refe	erable to breast	1835.0	Discoloration or abn	ormal pigmentation
	1810.1	Bleeding or discharge from nipple or breast		Includes Birthm Blotch	ark
	1810.2	Postpartum problems			s under eyes
		Includes: Engorgement		Rednes Spots	55
		Postpartum infection Nursing difficulties		Exclude Blushi	es: ng (1280.3)
	1810.3	Problems with shape or size		Bruise Flushir	(see 5405.0-5430.0) ng (1280.3)
		Includes: Too large Too small	1840.0	Jaundie Infections of skin, N	ce (1610.2)
		Sagging Uneven development	10+0.0	Includes	s:
1815.0	Symptoms of inferti	lity		Infecte	ng wound d blister d wound
		get pregnant ty to conceive			s: s' foot (2025.0) l drainage (as treatment)
1820.0	Hormone deficiency	or problem		1840.1	Infection of skin of head or neck area
1825.0	Symptoms of sexual			1840.2	Infection of skin of arm, hand, or
	Include Dyspa Painfu			1840.3	finger Infection of skin of leg, foot, or
	Exclude		1045.0	G ()	toe
	1160.	blogical disorders (see 1160.0- 6)	1845.0	Symptoms of skin m	
SYMPTO	OMS REFERABLE 1	O THE SKIN, NAILS, AND HAIR			nole, NOS
(1830-18	99)			1845.1	Change in size or color
1830.0	Acne or pimples			1845.2	Bleeding mole
		omplexion	1850.0	Warts, NOS	
	Blackt Blemis Breaki	shes ng out		Includes: Condyloma Condyloma acuminatum	
	White	lexion, NOS heads		Exclude Plantar	es: e's warts (2015.0)
			1855.0	Other growths of ski	n
				Includes Callus Corns	
				Cysts, Cyst, s	
					rowth, NOS

1860.0	Skin rash Includes Rash Skin er		1890.0	Symptoms referable Includes: Scalp lesion	to hair and scalp
	5km er	uption		1890.1	Too little hair
		s: ivy (2825.0) oak (2825.0)			Includes: Alopecia Baldness
	1860.1	Diaper rash			Falling out Losing hair
1865.0	Skin lesion, NOS			1890.2	Unwanted hair
	Includes Blister Face Papule Pustule Raw ar				Includes: Abnormal hairiness Hirsutism Superfluous hair
	Sore			1890.3	Dryness, flaky scalp, dry scalp
	Ulcer			1890.4	Itching
1870.0	Skin irritations, NEC		1895.0	Navel problems	
	1870.1	Pain		Includes	5:
	1870.2	Itching			
1875.0	Swelling of skin			Protru	icus not healing ision
	Includes Bumps Nodule	, lumps		OMS REFERABLE 7 I (1900-1999)	FO THE MUSCULOSKELETAL
	Welts, Tumor	except hives (2825.0) skin	These co Module.)		s (See Injuries and Adverse Effects
1880.0	Other symptoms refe	rable to skin			d be used with categories when there is adequate information
	Exclude Navel	s: problems (1895.0)	given:		
		· · ·	.1	pain, ache, soreness	
	1880.1	Oiliness	.2 .3	cramps, contracture limitation of moven	-
	1880.2	Dryness, peeling, scaliness, roughness	.4 .5	weakness swelling	
	1880.3	Wrinkles	.6	lump, mass, tumor	
1995 0			1900.0	Neck symptoms	
1885.0	Symptoms referable		1905.0	Back symptoms	
	1885.1	Infected	1910.0	Low back symptoms	3
	1885.2	Ingrown	1915.0	Hip symptoms	
	1885.3	Brittle, breaking, splitting, cracked, ridged	1920.0	Leg symptoms	
			1925.0	Knee symptoms	
			1930.0	Ankle symptoms	
			1935.0	Foot and toe sympto	ms
				ind too sympto	-

1940.0 Shoulder symptoms

PAGE 123

2006 NAMCS MICRO-DATA FILE DOCUMENTATION

1945.0	Arm symptoms	2015.0	Viral diseases
1950.0	Elbow symptoms		Includes:
1955.0	Wrist symptoms		Chickenpox Genital warts
1960.0	Hand and finger symptoms		German measles (rubella) Hepatitis (infectious and NOS)
170010	Includes:		Herpes simplex
	Ring stuck on finger		Infectious mononucleosis
	8		Measles
1965.0	Symptoms of unspecified muscles		Meningitis Mumps
1970.0	Symptoms of unspecified joints		Plantar's warts Poliomyelitis
1975.0	Musculoskeletal deformities		Rabies Respiratory syncytival virus (RSV)
	Excludes:		Shingles (Herpes zoster)
	Clubfoot (2960.0)		Smallpox, NOS
	Curvature of spine (2910.0)		Venereal warts
	1975.1 Bowlegged, knock-kneed		Verruca
			2015.1 Human immunodeficiency virus
	1975.2 Posture problems		(HIV) with or without associated conditions
	1975.3 Pigeon-toed, feet turn in		Includes: Acquired immunodeficiency
1980.0	Other musculoskeletal symptoms		syndrome AIDS
	Includes:		AIDS-like syndrome
	Bone pain		AIDS-related complex
	Stump pain		ARC
			HIV positive
	DISEASE MODULE		Excludes: Results, follow-up of test for HIV (6106.0)
INFECT	TIVE AND PARASITIC DISEASES (2001-2099)		
2005.0	Intestinal infectious diseases		2015.2 Hemorrhagic fevers
2005.0	intestinui intectious discuses		Includes:
	Includes:		Botulism
	Cholera		Ebola
	Dysentery		Fever, Hemorrhagic
	Enteritis		Marburg
	Gastroenteritis		
	Giardia Salmonella	2020.0	Sexually transmitted diseases
			Includes:
2010.0	Streptococcal infection		Chlamydia
			Gonorrhea
	Includes:		Syphilis
	Streptococcal tonsillitis		
	Scarlet fever	2025.0	Fungus infections (mycoses)
			Includes:
			Athlete's foot
			Candidiasis monilia
			Dermatophytoses
			Moniliasis

Moniliasis Ringworm Thrush Tinea Yeast infection

2030.0	Parasitic diseases Includes:	2125.0	Cancer, male genital tract
	Ascaris		Includes:
	Leeches		Epididymitis
	Lice		Penis
			Prepuce (foreskin)
	Maggots		
	Pinworms		Prostate
	Scabies		Scrotum
			Spermatic Cord
2031.0	Sepsis, septicemia		Testes
2035.0	Other and unspecified infectious and parasitic diseases	2126.0	Cancer of urinary tract
	Includes:		Includes:
	Cattleman's disease		Bladder
	Lyme disease		Kidney
	PCP (pneumocystis carinii)		Renal pelvis
	Plague		Ureter
			Urethra
	Staphylococcal infections		Oretilira
	Trichomonas vaginitis		
	Tuberculosis		
	Tularemia	2130.0	Other malignant neoplasms
NEOPL	ASMS (2100-2199)		Includes:
			Bone cancer
<u>Malignar</u>	nt neoplasms:		Metastatic carcinoma
			Brain tumor
2100.0	Cancer, gastrointestinal tract		Carcinoma-in-situ, NOS
	Includes:	2135.0	Hodgkin's disease, lymphomas, leukemias
	Colon		0 11
	Esophagus		Includes:
	Liver		Cancer of blood
	Small intestine		Lymphosarcoma
	Stomach		
	Stomach		Multiple myeloma
2105.0	Cancer, respiratory tract		Polycythemia vera
2105.0	Called, respiratory fract	Benign a	nd uncertain nature neoplasms:
	Includes:		
	Bronchus	2140.0	Fibroids and other uterine neoplasms
	Larynx		Includes:
	Lung		Cervical polyp
	Throat		Leiomyomata
	Trachea		Myoma
	Tracilea		
0110.0			Nabothian cyst
2110.0	Cancer, skin and subcutaneous tissues	21150	
		2145.0	Other benign neoplasms
	Includes:		Includes:
	Basal cell carcinoma		Bartholin's cyst
	Melanoma		Dermoid cyst (ovary)
	Squamous cell carcinoma		Hemangioma
			Lipoma
2115.0	Cancer, breast		Nasal polyp
			Nevus
2120.0	Cancer, female genital tract		Ovarian cyst
2120.0	Cancer, remaie genitar tract		Rectal polyp
	Includes:		1 11
	Includes:		Vaginal inclusion
	Cervix		Vocal cord
	Endometrium		
	Fallopian tube(s)		Excludes:
	Ovary(ies)		Cyst, NOS (1855.0)
	Uterus		Epidermoid cyst (2825.0)
	Vagina		Pilonidal cyst (2825.0)
	Vulva		Sebaceous cyst (2825.0)

2150.0 Neoplasm of uncertain nature

Excludes:

Brain tumor (2130.0)

ENDOCRINE, NUTRITIONAL, METABOLIC AND **IMMUNITY DISEASES (2200-2249)**

2200.0 Diseases of the thyroid gland

> Includes: Goiter Hyperthyroidism Hypothyroidism Myxedema Thyroid nodule Thyrotoxicosis

2205.0 Diabetes mellitus

2210.0 Gout, hyperuricemia

2215.0 Other endocrine, nutritional, metabolic and immunity diseases

Includes: Amyloidosis Barter's Syndrome Calcium deficiency Cystinosis Disorders of intestinal absorption Electrolyte imbalance Female hormone deficiency Hematochromatosis HL, elevated Hormone imbalance Hypercholesterolemia Hyperlipidemia Hypoglycemia Impaired immune system Iron deficiency Low blood sugar Malnutrition Ovarian dysfunction Poor nutrition

DISEASES OF THE BLOOD AND BLOOD-FORMING ORGANS (2250-2299)

2250.0	Anemia		
	Includes:		
	Anemia, NOS		
	Iron deficiency anemia		
	Pernicious anemia		
	Sickle cell anemia	2325.0	N
2255.0	Other diseases of blood and blood-forming organs		
	Includes:		
	Hemophilia		
	Thrombocytopenia		

Thrombocytopenia von Willebrand's disease

2006 NAMCS MICRO-DATA FILE DOCUMENTATION

MENTAL DISORDERS (2300-2349)

- 2300.0 Organic psychoses Includes: Alcoholic psychoses Drug withdrawal Organic brain syndromes Senile dementia
- 2305.0 Functional psychoses

Includes: Autism Bipolar disease Depression, Major Manic-depressive psychoses Paranoid states Psychosis, NOS Schizophrenia, all types

2310.0 Neuroses

Includes: Anxiety reaction Depressive neurosis Depressive reaction Neurosis, NOS Obsessive compulsive neurosis

Excludes: Anxiety (1100.0) Depression (1110.0)

- 2315.0 Personality and character disorders
- 2320.0 Alcoholism

Includes: Alcohol dependence

Excludes: Adverse effect of alcohol (5915.0) Alcohol abuse (1145.0) Alcohol-related problems (1145.0)

2321.0 Drug dependence

Includes: Drug addiction

Excludes: Abnormal drug usage (1150.0) Adverse effect of drug abuse (5910.0) Overdose, intentional (5820.1)

Mental retardation

2330.0	Other and unspecified mental disorders	2405.0	Refractive error (continued) Excludes:
	Includes:		Test for refractive errors (3230.0)
	Adolescent adjustment reaction		
	Attention deficit disorder (ADD)	2410.0	Cataract
	Attention deficit hyperactivity disorder		
	(ADHD)	2415.0	Glaucoma
	Note: Use additional code (1125.0) for		Includes:
	hyperactivity.		Hypertensive ocular disease
	Bruxism		Increased ocular pressure
	Dyslexia, Mental		
	Grief reaction	2420.0	Other diseases of the eye
	Sexual deviations		·
	Transient situational disturbances		Includes:
			Amblyopia

DISEASES OF THE NERVOUS SYSTEM (2350-2399)

- 2350.0 Multiple sclerosis 2355.0 Parkinson's disease (paralysis agitans) 2360.0 Epilepsy 2365.0 Migraine headache
- 2370.0 Other and unspecified diseases of the nervous system
 - Includes: Alzheimer's disease Bell's palsy Carpal tunnel syndrome Cerebral palsy Demyelinating disease Meningitis Morton's neuroma Muscular dystrophy Myasthenia gravis Neuropathy Paralysis, NEC Phantom leg/limb pain Thoracic outlet syndrome Tourette's syndrome

Aphakia Color blindness Esotropia Exotropia Krukenberg's spindle Macular degeneration Pterygium Retinal detachment Strabismus

DISEASES OF THE EAR (2450-2499)

- 2450.0 Otitis media
- Other diseases of the ear 2455.0

Includes: Abscess Labyrinthitis Ruptured tympanic membrane

Excludes: Deafness (1345.1) Infection, NOS (1355.2)

DISEASES OF THE CIRCULATORY SYSTEM (2500-2599)

2500.0 Rheumatic fever and chronic rheumatic heart disease

> Includes: Chorea

2505.0 Hypertension with involvement of target organs

> Includes: HCD HCVD Hypertensive cardiovascular disease Hypertensive heart disease Pulmonary hypertension Renal hypertension

2510.0 Hypertension, hypertensive

> Includes: High blood pressure

DISEASES OF THE EYE (2400-2449)

2400.0 Inflammatory diseases of the eye

> Includes: Blepharitis Conjunctivitis Ophthalmia Iritis Keratitis (includes sicca) Sty Ulcer

Excludes: Infection, NOS (1315.0)

2405.0 Refractive error

> Includes: Anisometropia Astigmatism Hyperopia, farsightedness Myopia, nearsightedness Presbyopia

2515.0	Ischemic heart disease Includes: Angina pectoris Arteriosclerotic cardiovascular disease (ACVD) Arteriosclerotic heart disease (ASHD) Coronary Coronary artery disease	2550.0	Other disease of circulatory system Includes: Aneurysm Blood clots Pulmonary embolism Heart disease, NOS Infarct(s), NOS Lymphadenitis Lymphadenopathy
	Heart attack Myocardial infarction		Stasis dermatitis Temporal arteritis Vasculitis Venous insufficiency
2520.0	Other heart disease		(chous insufficiency
	Includes:	DISEAS	ES OF THE RESPIRATORY SYSTEM (2600-2649)
	Aortic valve stenosis Arrhythmia, NOS Atrial fibrillation	2600.0	Upper respiratory infections except tonsillitis
	Cardiac arrhythmia		Includes:
	Cardiac dysrhythmias		Croup
	Cardiomyopathy		Laryngitis
	Cardiomyopathy (congestive)		Pharyngitis
	Congestive heart failure		Rhinitis
	Cor pulmonale Heart failure		Sinusitis
	Heart murmur		Excludes:
	Mitral valve prolapse		Allergic rhinitis (2635.0)
	Mitral valve regurgitation		Cold (1445.0)
	Paroxysmal tachycardia		Nose infection, NOS (1405.3)
	Premature ventricular contractions		Sinus infection, NOS (1410.2)
	(PVCs)		Throat infection, NOS (1455.3)
	Ventricular tachycardia	2605.0	m 111.7
2525.0	Cerebrovascular disease	2605.0	Tonsillitis
2323.0	Cerebrovascular disease	2610.0	Bronchitis
	Includes:	2010.0	Dionemitis
	Carotid stenosis		Includes:
	Cerebral arteriosclerosis		Acute bronchitis
	Cerebral hemorrhage		Bronchitis, NOS
	Cerebral stenosis		Chronic bronchitis
	Cerebrovascular accident (CVA)	2(20.0	
	Stroke TIA	2620.0 2625.0	Emphysema Asthma
	IIA	2623.0	Pneumonia
2530.0	Atherosclerosis	2030.0	1 noumoniu
			Includes:
	Includes:		Bacterial pneumonia
	Arteriosclerosis		Bronchopneumonia
	Hardening of the arteries		Pneumonitis
	Encluder		Viral pneumonia
	Excludes: Cerebral arteriosclerosis (2525.0)	2635.0	Hay fever
	Cerebrar arterioscierosis (2525.0)	2035.0	Hay level
2535.0	Phlebitis, thrombophlebitis		Includes:
			Allergic rhinitis
	Includes:		Allergy to:
	Phlebothrombosis		Dust
			Pollen
2540.0	Varicose veins		Animals
2545.0	Hammanda a' da		Ragweed
2545.0	Hemorrhoids		Nasal allergy Pollenosis
	Includes:		FUICIOSIS
	Perineal tags		
	i onnour ugo		

2640.0 Other respiratory diseases

Includes: Bronchospasm Chronic obstructive pulmonary disease Deviated nasal septum Hemothorax Pleurisy Pneumothorax Pulmonary edema Respiratory failure SARS

DISEASES OF THE DIGESTIVE SYSTEM (2650-2699)

2650.0 Diseases of the esophagus, stomach, and duodenum

Includes: Barrett's esophagus Duodenal ulcer Esophageal ulcer Esophagitis Gastritis GERD Peptic ulcer Stomach ulcer

Excludes: Gastroenteritis (2005.0) Stomach flu (1540.0)

- 2655.0 Appendicitis, all types
- 2660.0 Hernia of abdominal cavity
 - Includes: Abdominal Femoral Hiatus Inguinal Umbilical Ventral

2665.0 Diseases of the intestine and peritoneum

Includes: Abscess, rectal Adhesions Crohn's disease Diverticulitis Diverticulosis Fissure - rectal, anal Fistula - rectal, anal Ileitis Irritable bowel syndrome Proctitis Small bowel obstruction Spastic colitis Ulcerative colitis

Excludes: Intestinal virus (1540.0) Includes: Biliary colic Cholecystitis Cholelithiasis (gallstones) Cirrhosis Liver diseases Pancreatitis

2675.0 Other diseases of digestive system, NEC Includes: Mandibular cyst

> 2675.1 Dental abscess 2675.2 Dental cavities 2675.3 Canker sore 2675.4 Stomatitis 2675.5 Temperomandibular joint (TMJ) pain, Temperomandibular joint (TMJ) syndrome

DISEASES OF THE GENITOURINARY SYSTEM (2700-2799)

2700.0 Cystitis

Excludes: Bladder infection (1665.2)

- 2705.0 Urinary tract disease except cystitis
 - Includes: Bladder stones Glomerulonephritis Glomerulonephrosis Kidney stones Neurogenic bladder Pyelonephritis Renal failure Ureteral calculus Urethritis

Excludes:

Bladder infection (1665.2) Kidney infection, NOS (1670.2) Passed stones (1680.0) Urinary tract infection (1675.0)

2710.0 Diseases of the male genital organs

Includes: Benign prostatic hypertrophy (BPH) Epididymitis Hydrocele Peyronie's disease Phimosis Prostatitis

Excludes: Prostate infection (1710.2) 2715.0 Fibrocystic and other diseases of breast Includes: Abscess 2800.0 Mastitis 2805.0 Excludes: Infection (1810.0) Cancer (2115.0) 2720.0 Pelvic inflammatory disease (PID) 2815.0 Includes: 2820.0 Oophoritis 2825.0 Pelvic peritonitis Salpingitis Excludes: Pelvic infection, NOS (1775.3) 2725.0 Cervicitis, vaginitis Includes: Cervical erosion Vulvovaginitis 2730.0 Other diseases of female reproductive system Includes: Cervical dysplasia Cystocele Dysfunctional uterine bleeding Endometriosis Polycystic ovaries Procidentia uteri Prolapse of uterus Rectal-vaginal fistula Rectocele Vulvitis 2900.0 2735.0 Diagnosed complications of pregnancy and puerperium Includes: Advanced maternal age Diabetes during pregnancy Ectopic pregnancy Edema of pregnancy Fetal death in utero 2905.0 High blood pressure during pregnancy High risk pregnancy Hyperemesis Intrauterine growth retardation (IUGR) Miscarriage (if patient is pregnant) Multiple pregnancy Placenta previa

2006 NAMCS MICRO-DATA FILE DOCUMENTATION

DISEASES	OF	THE	SKIN	AND	SUBCUTANEO	DUS	TISSUE
(2800-2899)							

- 2800.0 Carbuncle, furuncle, boil, cellulitis, abscess, NEC
- 2805.0 Impetigo
- 2810.0 Seborrheic dermatitis Includes: Dandruff
- 2815.0 Eczema and dermatitis, NOS
- 2820.0 Psoriasis2825.0 Other diseases of the skin
 - Includes: Allergic skin reactions Epidermal inclusion cyst Folliculitis Hidradenitis Hives Keloid Keratosis Lupus erythematosus, NOS Paronychia Pilonidal cyst Poison ivy Poison oak Rosacea Sebaceous cyst Urticaria

Excludes: Acne (1830.0) Cyst, NOS (1855.0)

DISEASES OF THE MUSCULOSKELETAL SYSTEM AND CONNECTIVE TISSUE (2900-2949)

2900.0 Arthritis

Includes: Osteoarthritis Rheumatism, NOS Rheumatoid arthritis Septic

2905.0 Nonarticular rheumatism

Includes: Bursitis Ganglion cyst Lumbago Myositis Radiculitis/Radiculopathy Synovitis Tendinitis Tenosynovitis

Excludes: Rheumatism, NOS (2900.0)

2736.0 Other diseases of the genitourinary system, NEC

Post dates

Toxemia

Excludes:

RH sensitization

Spontaneous abortion

Abortion induced (3520.0)

Threatened abortion

2910.0 Other musculoskeletal or connective tissue disease

Includes: Baker's cyst Bone cysts Bone spur Bunions Cervical myelopathy Curvatures of spine Degenerative disc diseases Dupuytren's contracture Exostosis Kyphoscoliosis Kyphosis Osteomyelitis Osteoporosis Paget's Plantar fistula Scleroderma Scoliosis Sjogen's Slipped disc Spondylosis Spur, NOS Systemic lupus erythematosus

CONGENITAL ANOMALIES (2950-2979)

- 2950.0 Congenital anomalies of heart and circulatory system
- 2955.0 Undescended testicles

Includes: Hypospadias

2960.0 Other and unspecified congenital anomalies

Includes: Absence of organs Blocked tear duct Cleft palate Cleft lip Clubfoot Congenital dislocation of hip Deformed earlobe Down syndrome Duplication of organs Dysmorphic Harelip Turner's Syndrome

PERINATAL MORBIDITY AND MORTALITY CONDITIONS (2980-2999)

2980.0 Prematurity

Includes: Late effects of prematurity Premature infant

2990.0 All other perinatal conditions

DIAGNOSTIC, SCREENING, AND PREVENTIVE MODULE

GENERAL EXAMINATIONS (3100-3199)

3100.0 General medical examination

Includes: Annual exam Checkup, NOS Checkup, routine Evaluation, NOS General exam Healthy adult Healthy child History and physical (H&P) Multiphasic screening exam Physical exam Preventive Regular exam Routine exam

Excludes: Administrative exam (7100.0-7140.0) Followup visit (4800.0) Gynecological exam (3225.0) Pre-op exam (4200.0) Prenatal exam (3205.0) Progress visit (4800.0)

- 3105.0 Well baby examination (any child under 1 year of age)
- 3130.0 General psychiatric or psychological examination

Includes: Psychological testing

Excludes: Court- or school-ordered examination (7140.0)

SPECIAL EXAMINATIONS (3200-3299)

- 3200.0 Pregnancy, unconfirmed
 - Includes: HCG Late menses Late menstruation Might be pregnant Missed period Period late Possible pregnancy Pregnancy test

3205.0 Prenatal examination, routine

Includes: Normal antepartum visit Pregnancy, NOS Routine obstetrical care

3215.0 Postpartum examination, routine

3220.0 3225.0	Breast examination Excludes: Breast thermography (3340.0) Mammography (3340.0) Xerography (3340.0) Gynecological examination	3305.0	Skin immunity test Includes: PPD test Tuberculin test Excludes: To check results of skin tests (6600.0)
5225.0	Syneeoiogical examination	3310.0	Glucose level determination
	Includes: Pelvic exam Excludes: Examination for birth control medication (3505.0)		Includes: Blood sugar test Check sugar Glucose tolerance test Test for diabetes
	Examination for birth control, NOS (3500.0) Examination involving IUD (3510.0) Repeat or abnormal Pap smear (6300.0)	3314.0	Human immunodeficiency virus (HIV) test Includes: AIDS test
3230.0	Eye examination Includes: Check contacts Check glasses		Excludes: To check results of human immunodeficiency virus test (6106.0)
	For contacts For glasses Glasses, NOS Need new glasses Routine ophthalmologic exam Test for nearsightedness, farsightedness To test my eyes Vision test Visual field test Excludes:	3315.0	Other blood test Includes: Blood alcohol Blood count Blood culture Blood test, NOS Blood thinning test Check cholesterol Prothrombin time Sickle cell anemia test
	Fitting glasses or contacts (4515.0)		Excludes: Premarital blood test (7135.1)
3235.0	Heart examination Includes:		3315.1 Blood test for sexually transmitted disease
3240.0	Cardiac checkup Heart checkup Other special examination	3320.0	Blood pressure test Includes: Blood pressure check Check blood pressure
	Includes: AICD check Check tubes Examination of functioning internal prosthetic devices: implants, stents,shunts, etc. Hearing aid ICD check Neurological exam Thyroid	3325.0 3330.0	Urine test Includes: Estriol for fetal evaluation Test urine for sugar Urinalysis Urine culture Diagnostic endoscopies
DIAGNO	STIC TESTS (3300-3399)		Includes:
3300.0	Sensitization test Includes: Allergy test Excludes: To check results of skin tests (6600.0)	3335.0	Arthroscopy Cystoscopy Laparoscopy Proctoscopy Sigmoidoscopy Biopsies
	· · ·		

3340.0	Mammography, xero	ography, breast thermography	OTHER SCREENING AND PREVENTIVE PROCEDURES (3400-3499)	
	Exclude Breast	es: examination (3220.0)	3400.0	Prophylactic inoculations
3345.0	Diagnostic radiolog	y		Includes:
	Include	c.		Flu shot Immunization
		s. gram/angiography		Influenza shot
	Bones			Rhogam
		osalpingogram		Tetanus shot
	IVP			Vaccination
	MRI Myelo	oram	3405.0	Exposure to sexually transmitted disease (STD)
		isotope scanning	5105.0	Exposure to sexually transmitted discuse (01D)
	Venog			Includes:
	X-ray			Check for STD
2250.0	EVC ECC algotres	andiagram transferill strange testing		May have STD
3350.0	EKG, ECG, electroc	cardiogram, treadmill, stress testing	3408.0	Possible HIV
3355.0	EEG, electroenceph	alogram	5100.0	
3360.0	Hearing test	C	3409.0	Exposure to human immunodeficiency virus (HIV)
				Includes:
	Include			Exposed to AIDS
3365.0		ng exam	3410.0	Exposure to other infectious diseases
5505.0	Pap smear			Includes:
3366.0	Nasal swab			Chickenpox
				Infectious hepatitis
3370.0	Other and unspecified diagnostic tests			Measles
	Include			Mumps
	Centes	ocentesis		Pathogens Tuberculosis
		screening		Tuberculosis
		onic fetal monitoring	3415.0	Exposure to bodily fluids of another person, NOS
		st, NOS		
		nary function test		Includes:
	Spinal	tap		Blood exposure Exposure to another's secretions
	3370.1	Glaucoma test		Exposure to another's secretions
		Includes:	FAMIL	Y PLANNING (3500-3599)
		ATN check		
		Check intraocular pressure	3500.0	Family Planning, NOS
	3370.2	Throat culture		Includes:
	2270.2			Birth control, NOS
	3370.3	Heart catheterization		Counseling, examinations, and general advice
	3370.4	Other cultures		regarding:
		Includes:		Genetics
		Skin		Sterilization
				Fertility, NOS
				Unwanted pregnancy, contraceptive, NOS Excludes:
				Procedures performed [See Counseling
				and examinations for pregnancy
				interruption (3515.0) through Artificial
				insemination (3530.0)]
				Specified types of birth control:
				Birth control medication
				(3505.0) IUD (3510.0)
				10D (3310.0)

3505.0 Contraceptive medication TREATMENT MODULE Includes: MEDICATIONS (4100-4199) Depo Provera Examinations, instructions, and advice 4100.0 Allergy medication regarding: Birth control pills Includes: Contraceptive implants Allergy shots Allergy treatments Foams, jellies Oral contraceptives Renewing pill prescription Excludes: Norplant checkup Allergy testing (3300.0) Norplant insertion/removal (also code 4520.0) 4110.0 Injections 3510.0 Contraceptive device Includes: Antibiotics Includes: Fat Diaphragm insertion, removal, checkup Hormones IUD insertion, removal, checkup Injections, NOS Iron 3515.0 Counseling and examinations for pregnancy Lupron Depot Shots, NOS interruption Steroid Includes: Vitamins Evaluation for an arrangement for Excludes: abortion Wants abortion Allergy shots (4100.0) 3520.0 Abortion to be performed (at this visit) Immunizations (3400.0) Inoculations (3400.0) Sterilization and sterilization reversal to be performed 3525.0 Vaccinations (3400.0) (at this visit) 4111.0 Noncompliance with medication therapy Includes: Male - vasectomy 4115.0 Medication, other and unspecified kinds Female - tubal ligation Includes: Antibiotics, NOS 3530.0 Artificial insemination (at this visit) Check medication Includes: Drug studies For medication Assisted reproductive technologies Fetal reduction Medication for pain Intrauterine insemination Oral In vitro fertilization Prescribe medication Renew prescription Preconception counseling and education 3535.0 Renew scripts Includes: Request prescription Counseling, examinations, and general Scripts advice regarding: Artificial insemination Excludes: Desires pregnancy Egg donor (4110.0) Infertility Semen analysis

Sperm donor

Sperm washing

Antibiotic medication injections Birth control medication (3505.0) Eyeglass prescription (see Eye examination (3230.0) and Fitting glasses and contact lenses (4515.0))

PREOPERATIVE AND POSTOPERATIVE CARE (4200-

4299)

4200.0 Preoperative visit for specified and unspecified types of surgery

> Includes: Discussion of cosmetic surgery Pre-op examination Surgical consultation

4205.0 Postoperative visit

- Includes: Check graft Check implant Check shunt Check stoma Check surgical wound Clotted graft/shunt Endoscopy follow-up Postop care Postop pain Postop suture removal Suture removal follow-up
- Excludes: Complications of surgical or medical procedures and treatments (5930.0)

SPECIFIC TYPES OF THERAPY (4400-4499)

- 4400.0 Physical medicine and rehabilitation
 - Includes: Back adjustment Cardiac rehabilitation Heat therapy Hydrotherapy Occupational therapy Physical therapy Pulmonary rehabilitation Recreational therapy Speech therapy Therapeutic exercises Vocational rehabilitation

4401.0 Cardiopulmonary resuscitation (CPR)4405.0 Respiratory therapy

Includes: Asthma treatment Inhalation therapy Inhaler/breathing treatment

4410.0 Psychotherapy

Includes: Group counseling Includes: 12 Step programs (e.g. AA, Overeaters Anonymous, etc.) Group therapy Psychoanalysis

4415.0	Radiation therapy
	Includes treatment of s/p

- 4420.0 Acupuncture
- 4425.0 Chemotherapy

SPECIFIC THERAPEUTIC PROCEDURES (4500-4599)

4500.0 Tube insertion

Includes: Chest tube Flushed catheter PEG, Replacement Port-a-cath placement

Excludes: Flushed urinary catheter 4510.0

- 4505.0 Cauterization, all sites
- 4507.0 IV therapy, infusion
- 4510.0 Urinary tract instrumentation and catheterization

Includes: Flushed urinary catheter Urethral dilation Urinary catheterization

Excludes: Cystoscopy [see Diagnostic endoscopies (3330.0)]

4515.0 Fitting glasses and contact lenses

Includes: Broken or lost glasses or contacts Clean glasses or contacts Pick up glasses or contacts Prescription renewal

Excludes: Eye examination (3230.0)

4518.0 Detoxification

4518.1 Alcohol

4518.2 Drug

Minor surgery 4520.0 4556.0 Cosmetic injection, NOS Includes: 4556.1 Botox injection Ear tube removal 4556.2 Collagen injection Ears pierced 4560.0 Joint manipulation Other specific therapeutic procedures, NEC Norplant insertion/removal (also code Includes: 3505.0) Adjust device Cryotherapy Tattoo removal Tube removal Debridement Enema 4520.1 Wart removed Epidural Eye exercises 4521.0 Major surgery Nerve block Pessary, Change/Clean Phototherapy Includes: Skin rejuvenation Aspiration bone marrow TENS unit. NOS Balloon angiogram Ultraviolet treatment Cholecystectomy Wound care, NOS Laser surgery, eye Lens extraction Excludes: Liver biopsy Pinched nerve (1240.0) Percutaneous transluminal angiogram Polypectomy 4565.0 Transplants, NOS PTCA (balloon) Includes: 4525.0 Kidney dialysis Stem cell 4529.0 Internal prosthetic devices (fit, adjust, remove) 4565.1 Failure Includes: Breast implants Includes: Cardiac pacemaker Bone marrow Joint prostheses 4565.2 Rejection Excludes: Complications of surgical or medical MEDICAL COUNSELING (4600-4699) procedures and treatments (5930.0)4600.0 Diet and nutritional counseling Includes: 4530.0 External prosthetic devices, artificial body parts (fit, Check weight adjust, remove) Counseling for weight reduction 4604.0 Human immunodeficiency virus (HIV) counseling Excludes: Prosthetic complications (5930.0) Includes: 4535.0 Corrective appliances AIDS counseling AIDS information, education ARC counseling Includes: Fitting and adjusting: Worried, concerned about getting, Back brace transmitting AIDS Hearing aid Leg brace Neck brace Orthopedic shoes Walking cane 4540.0 Cast, splint - application, removal 4545.0 Dressing, bandage - application, change

- 4550.0 Irrigation, lavage
- 4555.0 Suture insertion, removal

4605.0	Medical Counseling, NOS	4715.0	Other problems of family relationship	
	Includes: Alcohol Disease counseling Drug Drug rehabilitation		Includes: Aged parents or in-laws Divorced parents Family fights and disruptions Problems with relatives	
	Medical consultation New patient Patient education	4720.0	Educational problems	
	Personal problem Referral Second opinion To learn about a condition To meet doctor Trouble toilet training		Includes: Absenteeism, truancy Hates school Problems with teachers School behavior problems	
	Wants to talk to doctor	4725.0	Occupational problems	
	4605.1 Family history of cardiovascular disease4605.2 Family history of cancer		Includes: Job dissatisfaction Out of work Problem with boss or coworkers Unable to work	
	4605.3 Family history of diabetes		Unemployment	
	4605.4 Family history of other disease or condition	4730.0	Social adjustment problems	
SOCIAL	PROBLEM COUNSELING (4700-4799)		Includes: Discrimination problems Don't have any friends	
4700.0	Economic problem Includes: Can't pay bills		Loneliness Neighborhood and community relations problems Social isolation	
4702.0	Too little income	4735.0	Legal problems	
4702.0	Problem with access to medical care Includes: Blocked access to medical care Limited access to medical care		Includes: Imprisonment, prosecution Lawsuits, litigation 4735.1 Police involvement in	
4705.0	Marital problems		outpatient visit circumstances	
	Includes: Alcoholic spouse Custody battle		Includes: Brought in by police Police called	
	Divorce, desertion, separation Marriage counseling, NOS Premarital counseling Problem with husband, wife	4740.0	Other social problems Includes: Disabled	
4710.0	Parent-child problems Includes: Adopted or foster child Concern about childhood behavior Discipline Maturation problems Working mother		Disasters Housing and clothing problems Pregnancy out-of-wedlock Problem with boyfriend or girlfriend Problems of aging	

PROGRESS VISIT, NEC (4800-4899) 5025.0 Ankle 4800.0 Progress visit, NOS (Use only when the only 5030.0 Foot and toes information given is progress or followup) 5035.0 Arm Includes: Chronic, NOS Includes: Followup, NOS Elbow Getting better Humerus I'm better Radius Shoulder I'm the same I'm worse Ulna Monthly visit Ongoing treatment, NOS 5040.0 Wrist Recheck Routine followup 5045.0 Hand and fingers Same problems, NOS Touching base 5050.0 Fracture, other and unspecified Excludes: Sprains and strains: Followup, disease (Code to disease) Followup, injury (Code to injury) 5105.0 Cervical spine, neck Followup, symptom (Code to symptom) Followup, test results (Code to 6100.0-Includes: 6700.0) Whiplash General checkup (3100.0) 5110.0 Back Postoperative followup (4205.0) Preventive medicine (3100.0) 5115.0 Knee 5120.0 Ankle INJURIES AND ADVERSE EFFECTS MODULE 5125.0 Wrist **INJURY BY TYPE AND/OR LOCATION (5001-5799)** 5130.0 Sprain or strain, other and unspecified Fractures and dislocations: Lacerations and cuts: 5005.0 Head and face 5205.0 Head and neck area Includes: Facial bones Excludes: Face (5210.0) Jaw Nose Skull 5210.0 Facial area Includes: Eye 5010.0 Spinal column Ear Forehead Includes: Lip Back Nose Neck 5215.0 Trunk area Vertebrae Includes: 5015.0 Perineum Trunk area, except spinal column

5220.0

5225.0

Lower extremity

Upper extremity

Includes:

Ankle

Includes:

Fingers

Arm

Hand

Wrist

Foot

Includes:

Rib

Includes: Femur

Fibula

Hip

Knee

Tibia

Leg

5020.0

Clavicle Collarbone

Pelvic scapula

Laceration and cuts, site unspecified

Head, neck and facial area

Trunk area

5230.0

5305.0

5310.0

Puncture wounds:

5520.0	Chest and abdomen
	Includes: Internal injuries
5525.0	Hip
5530.0	Leg
5535.0	Knee
5540.0	Ankle

5510.0		5530.0	Leg
5315.0	Lower extremity	5535.0	Knee
5320.0	Upper extremity	5540.0	Ankle
5325.0	Puncture wound, site unspecified	5545.0	Foot and toe(s)
	Includes: Needlestick, NOS	5550.0	Shoulder
Contusior	ns, abrasions, and bruises:	5555.0	Arm
5405.0	Head, neck, and face	5560.0	Elbow
	Excludes:	5565.0	Wrist
5410.0	Eye (5410.0)	5570.0	Hand and finger(s)
5410.0	Eye Includes:	5575.0	Injury, multiple or unspecified Includes post-traumatic (NOS) headache
	Black eye Contusion	Foreign	(and 1210.0) body:
	Corneal abrasion Trunk area	5600.0	Eye
5415.0		5605.0	Nose
	Includes: Injury to scrotum	5610.0	Skin
5420.0	Lower extremity	5615.0	Digestive tract
5425.0	Upper extremity		Includes: Mouth
5430.0	Contusion, abrasion, bruise, site unspecified		Rectum Throat
Injury, otl	her and unspecified type:	5616.0	Respiratory tract
5505.0	Head, neck, and face	5620.0	Other and unspecified sites
	Includes: Post concussive syndrome Tooth fracture	Burns, al	ll degrees:
	Tooth knocked out Traumatic brain injury (TBI)	5705.0	Head, neck, and face Includes eyes
	Excludes: Loose tooth (no injury) 1500.0	5710.0	Trunk area
5510.0	Eye	5715.0	Extremities
5515.0	Back		Includes: Lower Upper
	Includes: Tail bone	5720.0	Burn, site unspecified

5750.0	Sunburn, windburn		5820.0	Suicide attempt Includes:		
	Exclude Sun po	s: isoning 5920.0		Found in car with motor running Hanging oneself Slashed wrists		
Bites:				Code also: Laceration of wrists (5225.0)		
5755.0	Insect			Stabbed oneself		
	Includes Sting Tick	:		5820.1 Overdose, intentional Excludes: Unintentional overdose (5910.0)		
5760.0	Animal ,snake, huma	n	5830.0	Rape		
INJURY,	INJURY, NOS (5800-5899)			Includes: Sexual assault		
5800.0	Late effects of an old	l injury		5830.1 Sexual abuse		
	Includes Deforn			Includes:		
	Scars			Molestation		
5805.0	Motor vehicle accide	ent, type of injury unspecified	5835.0	Dead on arrival (DOA)		
	Includes	:	5655.0	Dead on arrival (DOA)		
		ccident		Includes: Death		
	Car acc Motor	ycle accident		Death		
5810.0	Accident, NOS			Excludes: Cardiac arrest (5837.0) Cardiopulmonary arrest (5839.0)		
	Includes			Respiratory arrest (5836.0)		
		pe or location of injury ecified				
			5836.0	Respiratory arrest		
5815.0	Violence, NOS			Excludes:		
	Includes	:		Cardiac arrest (5837.0)		
	Abuse			Cardiopulmonary arrest (5839.0)		
	Beat uj In a fig			Dead on arrival (5835.0) Drowning (5838.0)		
	Stabbin			Near drowning (5838.0)		
	Exclude	s:	5837.0	Cardiac arrest		
		ce against oneself (5818.0,		Includes: Code blue		
	5815.1	Child abuse or neglect		Excludes:		
				Cardiopulmonary arrest (5839.0)		
		Excludes: Child sexual abuse (5830.1)		CPR (4401.0) Dead on arrival (5835.0)		
		ennu sexual abuse (5656.1)		Respiratory arrest (5836.0)		
	5815.2	Battered spouse	5838.0	Drowning		
	5815.3	Elder abuse	202010	Includes:		
	5815.4	Gunshot wound		Near drowning		
			5839.0	Cardiopulmonary arrest		
5818.0	Intentional self-muti	lation		Excludes: Cardiac arrest (5837.0)		
Includes:			Respiratory arrest (5836.0)			
	Self-abuse Tried to hurt self					
	Exclude					
		s: e attempt (5820.0)				

5840.0	Unconscious on arrive	al	5915.0	Adverse effect of alcohol
	Includes: Coma Found u Knocke Shock Stupor	inconscious d out	5920.0	Includes: Acute intoxication Drunk Intoxication Adverse effects of environment
	Unrespo	onsive	5720.0	
5841.0	State of consciousnes Includes:	s not specified		Includes: Air pollution Frostbite Hypothermia
	Brought Found c	in by ambulance		Noise pollution Sun damage
		y unresponsive		Sun poisning Water pollution
5842.0	Altered level of consc	iousness, NOS	5922.0	Adverse effects of terrorism and bioterrorism
		: effect of alcohol 5915.0 effect of drug abuse 5910.0		Includes: Anthrax, skin Anthrax, respiratory (inhalation)
POISON		EFFECTS (5900-5999)		Bombing Food/water contamination Smallpox
5900.0	Unintentional poisoni	ng	NT	•
	5900.1	Food poisoning	or disease	se an additional code to identify the complaint, symptom, e, if any.
	5900.2	Ingestion, inhalation, or exposure to potentially poisonous products	5925.0	Adverse effects, other and unspecified Includes: Seasickness
		Includes: Household products Chemicals Drugs	5930.0	Complications of surgical or medical procedures and treatments
		Gas Smoke Lead Mace in eyes		Includes: Artificial openings (ostomies, stoma) Catheter Foreign body (accidentally left during
5905.0	Adverse effect of mec Includes: Allergy			surgery e.g. sponge, instrument) Medical complication, NOS Non-healing surgical wound Post-op fever
	Anaphy Bad rea	lactic shock ction to prescribed medication in allergy		Post-op hemorrhage (bleeding) Post-op infection or inflammation Post-op sepsis (septicemia) Shunt
5910.0	Adverse effect of drug Includes: Bad trip	-		Tubes Wound dehiscence
	Combin (nonst Drug-in	ation of drugs and alcohol aicidal) duced hallucinations out on drugs		Use additional code to identify condition Such as: UTI (1675.0) Fever (1010.0)
	Ingestio purpo	n of drugs for nonmedicinal		Excludes: Postpartum conditions (1791.0 and 1810.2) Complication of transplant organs
	Excludes Intentio	: nal overdose (5820.1)		(4565.1-4565.2)

2006 NAMCS MICRO-DATA FILE DOCUMENTATION

TEST RESULTS MODULE		6700.0	For other and unspecified test results	
(Includ	les all abnormal test results and followups for test results) For results of blood glucose tests Includes: Abnormal glucose tolerance test Elevated blood sugar Glucose control High blood sugar Hyperglycemia Sugar in blood	7100.0	Abnorr Abnorr Abnorr Results To disc Ultraso ADMINISTR	: nal EEG nal lab test results, NOS nal scans nal pulmonary function test of fetal evaluation tests uss test results with physician nography results NTIVE MODULE a required for school or
6105.0	For results of cholesterol and triglyceride tests Includes: High cholesterol		employment 7100.1	Physical examination required for employment
6106.0	For results of test for human immunodeficiency virus (HIV) Includes: Results of AIDS test			Includes: Preemployment examination Required company physical Return to work checkup Teacher's certificate physical
	Excludes: History of positive HIV test findings (2015.1)		7100.2 7100.3	Executive physical examination Physical examination required for school
6110.0	For other findings of blood tests Includes: Elevated sed rate Low potassium Positive blood culture Positive serology, VDRL			Includes: College Day care center Grade school High school Nursery school
6200.0	For results of urine tests Includes: Abnormal urinalysis Positive urine culture Sugar in urine		7100.4	Physical examination for extracurricular activities Includes: Athletics Boy Scouts or Girl Scouts Camp
6300.0	For cytology findings Includes: Atypical Pap smear For results of Pap smear of cervix or other area Positive Pap smear Repeat Pap smear	7120.0 7125.0 7130.0	Driver's license exan Insurance examinatio Disability examinatio Includes	on on
6400.0	For radiological findings Includes: Abnormal X-ray	7131.0	Evalua	tion of disability Security examination
6500.0	X-ray results Xeromammography results For results of EKG, Holter monitor review	7135.0	Premarital examinati 7135.1	on Premarital blood test

6600.0 For results of skin tests

7137.0 Direct admission to hospital

Includes: Admit to hospital Direct admit For admission Here for admission Involuntary commitment Pre admission exam Voluntary commitment

7140.0 Other reason for visit required by party other than the patient or the health care provider

Includes: Physical examination for adoption Psychiatric examination required by court

UNCODABLE ENTRIES

- 8990.0 Problems, complaints, NEC
- 8991.0 Patient unable to speak English
- 8993.0 Patient (or patient's spokesperson) refused care

Includes: Left AMA Walked out

8997.0 Entry of "none" or "no complaint"

Includes: Asymptomatic, NOS Doing well

- 8998.0 Insufficient information
- 8999.0 Illegible entry

SPECIAL CODE

90000 Blank

APPENDIX III

A. GENERIC CODES AND NAMES IN NUMERIC ORDER

This list reflects the new classification being used to code drugs reported in the NAMCS. Starting with 2006 data, the Multum Lexicon Plus system was used to classify drugs in the NAMCS. Drugs starting with a "d" prefix are those for which a match was found in the Multum Lexicon Plus[®], a proprietary database of Cerner Multum, Inc., and the code reflects the Multum code for the drug. Drugs starting with an "a" prefix are those for which a match could not be found in Multum but for which ingredients could be identified. Drugs starting with a "c" prefix are those for which ingredients could not be determined. Drugs starting with "a" or "c" were assigned codes by NCHS. Ingredients are separated by semi-colons.

a10000 ACACIA GUM; ALOE VERA TOPICAL; GUM GHATTI a10001 ACACIA GUM; HYDROCORTISONE; LEVONORGESTREL; NEOMYCIN; POLYMYXIN B SULFATE a10003 ACETONE; CASTOR OIL; COLLODION; PODOPHYLLUM RESIN TOPICAL; SALICYLIC ACID TOPICAL a10004 ACETONE; ETHANOL; FUCHSIN; PHENOL TOPICAL; RESORCINOL TOPICAL a10005 ACETONE; CALENDULA; CAPSAICIN TOPICAL; ECHINACEA; MENTHOL TOPICAL a10032 ANETHOLE; BENZOCAINE TOPICAL; DEXTROMETHORPHAN; MENTHOL; PEPPERMINT a10042 BENACTYZINE; MEPROBAMATE a10049 BENZYL ALCOHOL; DIMETHICONE; PETROLATUM TOPICAL a10051 BENZYL ALCOHOL; SOYBEAN OIL; STARCH TOPICAL a10054 BENZYL ALCOHOL; LIDOCAINE a10068 ASCORBIC ACID; BIOTIN; VITAMIN B COMPLEX a10085 BISMUTH ANTI-DIARRHEA; KAOLIN; OPIUM; PECTIN a10096 ASPIRIN; BUFFERS a10105 CALCIUM REPLACEMENT; MAGNESIUM ANTACIDS; POTASSIUM ACIDIFYING; SODIUM CHLORIDE a10111 CALCIUM REPLACEMENT; SODIUM FLUORIDE a10114 CALCIUM REPLACEMENT; ERGOCALCIFEROL; PHOSPHORUS a10125 CALCIUM REPLACEMENT; ERGOCALCIFEROL a10127 CALCIUM REPLACEMENT; CHOLECALCIFEROL a10133 CALCIUM ION; CHLORIDE ION; MAGNESIUM ANTACIDS; POTASSIUM ION; SODIUM ION a10135 CALCIUM ION; CHLORIDE ION; POTASSIUM ION; SODIUM ACETATE; SODIUM ION a10136 CALCIUM ION; CHOLECALCIFEROL; IRON PREPARATIONS; VITAMIN A; VITAMIN B COMPLEX a10138 CALCIUM ION; IRON PREPARATIONS; MULTIVITAMIN a10140 CALCIUM ION: MAGNESIUM CHLORIDE: POTASSIUM ION: SODIUM CHLORIDE a10143 CALCIUM PANTOTHENATE; NIACIN; PYRIDOXINE; RIBOFLAVIN; THIMEROSAL a10150 CANTHARIDIN; PODOPHYLLUM RESIN TOPICAL; SALICYLIC ACID TOPICAL a10154 BENZOCAINE TOPICAL; CARMELLOSE; GELATIN; MINERAL OIL; PECTIN a10156 ALGINIC ACID; BORIC ACID TOPICAL; CARMELLOSE; GLYCERIN TOPICAL; PROPYLENE GLYCOL a10159 CASEIN; COCONUT OIL; CORN OIL; MULTIVITAMIN; SUCROSE a10160 CASEIN; COCONUT OIL; MAGNESIUM AMINO ACIDS CHELATE; SUCROSE; TAPIOCA a10161 CASEIN; CORN OIL; MULTIVITAMIN; PHENYLALANINE; PROTEIN a10162 CASEIN; CORN OIL; LECITHIN; MULTIVITAMIN; SODIUM ION a10163 CASEIN; MULTIVITAMIN; SAFFLOWER OIL; SOYBEAN OIL; SUCROSE a10166 CERESIN WAX; MINERAL OIL; PETROLATUM TOPICAL; WOOLWAX ALCOHOL a10172 CETEARETH; PETROLATUM TOPICAL; PROPYLENE GLYCOL; SORBITOL a10179 CETYL ALCOHOL; PROPYLENE GLYCOL; SODIUM LAURYL SULFATE; STEARYL ALCOHOL a10181 CETYL ALCOHOL; LANOLIN TOPICAL; MULTIVITAMIN; PROPYLENE GLYCOL; PURIFIED WATER a10193 BENZOCAINE TOPICAL; BENZOIC ACID; CHLOROBUTANOL; CHLOROTHYMOL; SALICYLIC ACID TOPICAL a10224 COLLODION; ETHANOL; ETHER; SALICYLIC ACID TOPICAL; ZINC TOPICAL AGENTS, EXTERNAL USE a10230 CYSTINE; METHIONINE; UREA TOPICAL a10240 CALCIUM ACETATE; DEXTROSE; ELECTROLYTES; MAGNESIUM AMINO ACIDS CHELATE a10241 DEXTROSE; ELECTROLYTES; MAGNESIUM AMINO ACIDS CHELATE a10242 DEXTROSE; FRUCTOSE; PHOSPHORIC ACID a10244 DEXTROSE; MAGNESIUM ACETATE; POTASSIUM REPLACEMENT SOLUTIONS; SODIUM CHLORIDE

a10249	DEXTROSE; RINGERS LACTATED
	DEXTROSE; NORMAL SALINE
a10253	DEXTROSE; LACTATED RINGERS
	DEXTROSE; LACTATED RINGERS; POTASSIUM CHLORIDE
	DEXTROSE; NITROGLYCERIN
	DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE
	DEXTROSE; SODIUM CHLORIDE
	DEXTROSE; STERILE WATER
	BETAINE; DIASTASE; OX BILE EXTRACT; PANCREATIN; PAPAIN TOPICAL
a10282	DICHLOROPHENE; HEXACHLOROPHENE TOPICAL; TETRACAINE TOPICAL; UNDECYLENIC ACID
	TOPICAL; ZINC TOPICAL AGENTS, EXTERNAL USE
	DIMETHICONE; GLYCERIN; METHYLPARABEN; PETROLATUM TOPICAL
	ALOE VERA TOPICAL; DIMETHICONE; ETHANOL; GLYCERIN TOPICAL; MICONAZOLE TOPICAL
	ALOE VERA TOPICAL; DIMETHICONE; ETHANOL; GLYCERIN TOPICAL; PETROLATUM TOPICAL
a10296	CAMPHOR TOPICAL; CAPSICUM; DIPROPYLENE GLYCOL SALICYLATE; METHYL NICOTINATE; METHYL SALICYLATE TOPICAL
o10300	ASCORBIC ACID; ELECTROLYTES; MINERALS; VITAMIN B COMPLEX
	ELECTROLYTES; MAGNESIUM AMINO ACIDS CHELATE
	ELECTROLYTES; POLYETHYLENE GLYCOL 3350
	ETHANOL; EUCALYPTUS OIL; MENTHOL TOPICAL; METHYL SALICYLATE TOPICAL; THYMOL
	BENZOIN TOPICAL; CAMPHOR TOPICAL; EUCALYPTUS OIL; MENTHOL TOPICAL; THYMOL
	CAMPHOR TOPICAL; EUCALYPTUS OIL; MENTHOL TOPICAL; METHYL SALICYLATE TOPICAL
	FIBRINOLYSIN; FIBRINOLYSIN AND DESOXYRIBONUCLEASE TOPICAL
	CALCIUM CARBONATE; CITRIC ACID; GLUCONIC ACID; MAGNESIUM CARBONATE; MAGNESIUM
	CITRATE
a10338	GLYCINE; IMMUNE GLOBULIN INTRAMUSCULAR
a10340	FENNEL; GLYCYRRHIZA; SENNA; SUCROSE; SULFUR TOPICAL
a10348	ASCORBIC ACID; HESPERIDIN
	HYDROCORTISONE TOPICAL; IODOCHLORHYDROXYQUIN; PRAMOXINE TOPICAL
	HYDROCORTISONE TOPICAL; IODOCHLORHYDROXYQUIN
	IRON PREPARATIONS; MINERALS; MULTIVITAMIN
	IRON PREPARATIONS; VITAMIN B COMPLEX
	IRON PREPARATIONS; VITAMINS
	ETHINYL ESTRADIOL; IRON PREPARATIONS; NORETHINDRONE
	CALCIUM CARBONATE; FOLIC ACID; IRON PREPARATIONS; MULTIVITAMIN; NIACIN
	ASCORBIC ACID; FOLIC ACID; IRON PREPARATIONS; PYRIDOXINE; VITAMIN A
	CYANOCOBALAMIN; FOLIC ACID; IRON PREPARATIONS ASCORBIC ACID; CYANOCOBALAMIN; FOLIC ACID; IRON PREPARATIONS
	FOLIC ACID; IRON PREPARATIONS; MULTIVITAMIN
	IRON PREPARATIONS; NIACIN; PYRIDOXINE; RIBOFLAVIN; THIAMINE
	ASCORBIC ACID; CHOLECALCIFEROL; IRON PREPARATIONS; VITAMIN A; VITAMIN E
	ASCORBIC ACID; CHOLECALCIFEROL; FLUORIDE; IRON PREPARATIONS; VITAMIN A
	ASCORBIC ACID; ERGOCALCIFEROL; IRON PREPARATIONS; VITAMIN A
	CYANOCOBALAMIN; IRON PREPARATIONS; PYRIDOXINE; RIBOFLAVIN; THIAMINE
	ASCORBIC ACID; IRON PREPARATIONS; MULTIVITAMIN; RIBOFLAVIN; THIAMINE
	CYANOCOBALAMIN; IRON PREPARATIONS; PYRIDOXINE
	ASCORBIC ACID; IRON PREPARATIONS
	FLUORIDE; IRON PREPARATIONS; MULTIVITAMIN
a10439	DOCUSATE; IRON PREPARATIONS
a10442	IRON PREPARATIONS; MULTIVITAMIN
	BREWER'S YEAST; IRON PREPARATIONS
	CHLORPHENIRAMINE; ISOPROPAMIDE; PHENYLPROPANOLAMINE
	LACTOSE; NORETHINDRONE
	LACTOSE; MOMETASONE NASAL
	EPLERENONE; LACTOSE
	ALUMINUM HYDROXIDE; DIPHENHYDRAMINE TOPICAL; LIDOCAINE; MAGNESIUM ANTACIDS
a10464	ASPIRIN: CALCIUM CARBONATE: MAGNESIUM ANTACIDS

a10464 ASPIRIN; CALCIUM CARBONATE; MAGNESIUM ANTACIDS

PAGE 1	46 2006 NAMCS MICRO-DATA FILE DOCUMENTATION, APPENDIX III – GENERIC LIST
a10465	ALUMINUM HYDROXIDE; ASPIRIN; MAGNESIUM ANTACIDS
	ALUMINUM HYDROXIDE; MAGNESIUM ANTACIDS; PHENOBARBITAL
	ALUMINUM HYDROXIDE; CALCIUM CARBONATE; MAGNESIUM ANTACIDS
	ALUMINUM HYDROXIDE; MAGNESIUM ANTACIDS
	ALUMINUM HYDROXIDE; MAGNESIUM ANTACIDS; SIMETHICONE
	ALLANTOIN TOPICAL; ALLIUM CEPA; METHYLPARABEN; POLYETHYLENE GLYCOL 3350; SORBIC
	ACID
	LANOLIN TOPICAL; METHYLPARABEN; MULTIVITAMIN; PETROLATUM TOPICAL; ZINC OXIDE TOPICAL
	MINERALS; VITAMINS
a10514	CALCIUM CASEINATE; MINERALS; MULTIVITAMIN; WATER
a10529	MINERALS; MULTIVITAMIN; PYRIDOXINE; RIBOFLAVIN
a10530	MINERALS; MULTIVITAMIN
a10533	CAMPHOR TOPICAL; ISOPROPYL ALCOHOL TOPICAL; MENTHOL TOPICAL; METHYL SALICYLATE TOPICAL; MUSTARD OIL
a10537	BENZOCAINE TOPICAL; NUTMEG OIL; PETROLATUM TOPICAL; ZINC TOPICAL AGENTS, EXTERNAL USE
a10543	ALOE VERA TOPICAL; CALENDULA; OLIVE OIL; OREGON GRAPE
	GLYCERIN TOPICAL; LACTIC ACID TOPICAL; OLEIC ACID; PROPYLENE GLYCOL
	HYDROQUINONE TOPICAL; OCTYL METHOXYCINNAMATE; OXYBENZONE; PADIMATE O
	MISCELLANEOUS TOPICAL AGENTS; OXYBENZONE
	ANTIPYRINE OTIC; BENZOCAINE TOPICAL; GLYCERIN; OXYQUINOLONE
	CYANOCOBALAMIN; NIACIN; PANTHENOL; RIBOFLAVIN
	GREEN TEA: PANTOTHENIC ACID; VITAMINS
	NIACIN; PANTOTHENIC ACID; PYRIDOXINE; RIBOFLAVIN; THIAMINE
	MINERAL OIL; PEANUT OIL
	BENZOCAINE TOPICAL; NIACIN; PENTYLENETETRAZOL; PHENIRAMINE
	PETROLEUM DISTILLATE; PIPERONYL BUTOXIDE TOPICAL; PYRETHRINS TOPICAL
	ASPIRIN; CAFFEINE; PHENACETIN; PHENOBARBITAL
	ASPIRIN; CAFFEINE; PHENACETIN; PROPOXYPHENE
	ASPIRIN; CAFFEINE; PHENACETIN
	ASPIRIN; BUTALBITAL; CAFFEINE; PHENACETIN
	PHOSPHORUS; POTASSIUM REPLACEMENT SOLUTIONS; SODIUM CHLORIDE
	POTASSIUM REPLACEMENT SOLUTIONS; SODIUM CHLORIDE
	IODINE; POTASSIUM REPLACEMENT SOLUTIONS
	POTASSIUM ION; SODIUM CHLORIDE
	POTASSIUM ACIDIFYING; SODIUM ACID PHOSPHATE MINERAL SPIRITS; OCTYLPHENOXY; POLYETHOXYETHANO; POLYETHYLENE GLYCOL 3350;
a10059	PROPYLENE GLYCOL; SOAP
a10662	GLYCOLIC ACID; POLYQUATERNIUM; 10; PROPYLENE GLYCOL
	HP GUAR; POLYETHYLENE GLYCOL 3350; PROPYLENE GLYCOL; SODIUM BORATE TOPICAL
	AVOCADO OIL; LIQUID PARAFFIN; PROPYLENE GLYCOL; PURIFIED WATER; TROLAMINE
410000	SALICYLATE TOPICAL
a10678	CARBOHYDRATES; MULTIVITAMIN; PROTEIN SUPPLEMENT
	ASCORBIC ACID; CALCIUM ACETATE; PYCNOGENOL; QUERCETIN; RUTIN
	ETHANOL; GLYCERIN; MAGNESIUM CARBONATE; SACCHARIN; TOLU BALSAM
	GINSENG; MEADOWFOAM OIL; PETROLATUM TOPICAL; SAFFLOWER OIL; SESAME OIL
	MINERAL OIL; PETROLATUM TOPICAL; PHENYLEPHRINE TOPICAL; SHARK LIVER OIL
	BALSAM PERU TOPICAL; MINERAL OIL; SILICONE; ZINC TOPICAL AGENTS, EXTERNAL USE
	MISCELLANEOUS TOPICAL AGENTS; SILICONE
	SOAP; WATER
	CAMPHOR TOPICAL; SOAP
	MULTIVITAMIN; SODIUM FLUORIDE
	ERTAPENEM; SODIUM BICARBONATE; SODIUM HYDROXIDE
	CITRIC ACID; SODIUM CITRATE; SODIUM ION
	MENTHOL TOPICAL; METHYL SALICYLATE TOPICAL; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PERBORATE
a10726	POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM
	CHLORIDE; SODIUM SULFATE

a10732	CORN STARCH TOPICAL; LANOLIN TOPICAL; PETROLEUM; STEARYL ALCOHOL; ZINC OXIDE
	TOPICAL
a10738	AMPICILLIN; SULBACTIN SODIUM
	SULFABENZAMIDE; SULFACETAMIDE SODIUM TOPICAL; SULFATHIAZOLE
a10751	LANOLIN TOPICAL; MULTIVITAMIN; PETROLATUM TOPICAL; TALC; ZINC TOPICAL AGENTS,
	EXTERNAL USE
	TALC; ZINC OXIDE TOPICAL
a10754	ASCORBIC ACID; MAGNESIUM; TARTRAZINE; VITAMIN B COMPLEX; ZINC SULFATE
a10771	ASCORBIC ACID; ERGOCALCIFEROL; RIBOFLAVIN; THIMEROSAL; VITAMIN A
	CALCIUM CARBONATE; CHOLECALCIFEROL; VITAMIN K
	PETROLATUM TOPICAL; WAX; ZINC TOPICAL AGENTS, EXTERNAL USE
	CAMPHOR TOPICAL; MINERAL OIL; PETROLATUM TOPICAL; WAX
	ASCORBIC ACID; ZINC TOPICAL AGENTS, EXTERNAL USE
	DIPERODON TOPICAL; PHENYLEPHRINE; PYRILAMINE; ZINC TOPICAL AGENTS, EXTERNAL USE
	ETHANOL; FORMALDEHYDE TOPICAL; ZINC TOPICAL AGENTS, EXTERNAL USE
a10816	BALSAM PERU TOPICAL; BENZYL BENZOATE TOPICAL; BISMUTH RESORCIN TOPICAL; BISMUTH
	SUBGALLATE; ZINC TOPICAL AGENTS, EXTERNAL USE
a10826	CALAMINE TOPICAL; RESORCINOL TOPICAL; ZINC TOPICAL AGENTS, EXTERNAL USE
	BALSAM PERU TOPICAL; BENZYL BENZOATE TOPICAL; ZINC TOPICAL AGENTS, EXTERNAL USE
	CYANOCOBALAMIN; FOLIC ACID; VITAMIN B
	VITAMIN B; VITAMIN E
	ASCORBIC ACID; VITAMIN B; VITAMIN B COMPLEX
	ASCORBIC ACID; FOLIC ACID; IRON; VITAMIN B COMPLEX
	ASCORBIC ACID; CALCIUM ACETATE; FOLIC ACID; VITAMIN A; VITAMIN B COMPLEX
	ASCORBIC ACID; FOLIC ACID; VITAMIN B COMPLEX
a10850	CALCIUM ACETATE; FOLIC ACID; VITAMIN B COMPLEX
a10851	ASCORBIC ACID; CHOLECALCIFEROL; VITAMIN A; VITAMIN B COMPLEX; VITAMIN E
	ASCORBIC ACID; CALCIUM ACETATE; CHOLECALCIFEROL; VITAMIN B COMPLEX; VITAMIN E
	ASCORBIC ACID; VITAMIN B COMPLEX
	ASCORBIC ACID; LIVER DERIVATIVE COMPLEX; VITAMIN B COMPLEX
	CARBOHYDRATES; FAT EMULSION, ORAL; MAGNESIUM AMINO ACIDS CHELATE; MULTIVITAMIN;
a10004	
40000	
	CARBOHYDRATES; FAT EMULSION, ORAL; PROTEIN
	FAT EMULSION, ORAL; IRON; LINOLEIC ACID; POTASSIUM ACETATE; PROTEIN
	MULTIVITAMIN; PROTEIN
a10870	ARGININE; ASCORBIC ACID; CARBOHYDRATES; POTASSIUM CITRATE; VITAMIN E
a10871	IRON; VITAMINS
a10872	CHORIONIC GONADOTROPIN (HCG); FOLLICLE STIMULATING HORMONE; LEUTENIZING
	HORMONE
a10873	FOLLICLE STIMULATING HORMONE; LEUTENIZING HORMONE
	GLUCOSAMINE; METHYLSULFONYL; METHANE
	BALSAM PERU TOPICAL; PETROLEUM; ZINC OXIDE TOPICAL
	PENICILLIN; PENICILLIN G BENZATHINE
	DOCOSAHEXAENOIC ACID; EICOSAPENTAENOIC ACID; VITAMIN E
	CLINDAMYCIN TOPICAL; METHYL PARABEN
a10897	HOMATROPINE METHYL BROMIDE; HYDROCODONE
a10899	ESTRADIOL; ESTRIOL; ESTRONE
a10900	ESTRADIOL; ESTRIOL
	ASCORBIC ACID; COPPER GLUCONATE; LUTEIN; VITAMIN E; ZINC
	BETA; CAROTENE; BILBERRY; LUTEIN; LYCOPENE; VITAMIN E
	ACONITUM NAPELLUS; ARNICA TOPICAL; BELLADONNA; CHAMOMILE; COMFREY
	ADRENALINE; TETRACAINE TOPICAL; XYLOCAINE
	CALCIUM ACETATE; CHOLECALCIFEROL; COPPER GLUCONATE; MAGNESIUM; ZINC
	CALCIUM ACETATE; COPPER GLUCONATE; IRON; MULTIVITAMIN; ZINC
	BLACK COHOSH; BORIC ACID TOPICAL; ISOFLAVONES; KAVA; MULTIVITAMIN
a10927	EDETATE DISODIUM (EDTA); METRONIDAZOLE TOPICAL; PARABENS
10000	BENZONATATE; PARABENS

a10928 BENZONATATE; PARABENS

a10929 DOCUSATE; PARABENS; SORBITOL a10934 GYMNEMA SYLVESTRE; LIPOIC ACID; MAGNESIUM CITRATE; PYRIDOXINE; VANADIUM a10935 CHROMIUM PICOLINATE; MAGNESIUM AMINO ACIDS CHELATE; PYRIDOXINE; VANADIUM a10937 ADRENALINE; LIDOCAINE; TETRACAINE TOPICAL a10938 ADRENALINE; COCAINE TOPICAL; TETRACAINE TOPICAL a10941 CITRIC ACID; COLLAGEN PROTEIN; POTASSIUM SORBATE; TRYPTOPHAN; WATER a10944 CADEXOMER IODINE; POLYETHYLENE GLYCOL 3350 a10950 CHORIOGONADOTROPIN ALFA; MANNITOL; ORTHOPHOSPHORIC ACID a10956 CHLORPHENIRAMINE; HYDROCODONE POLISTIREX a10959 ANGELICA ROOT; ARECA PEEL; PERILLA LEAF; WRINKLED GIANT HYSSOP a10961 BUROW'S SOLUTION; CAMPHOR TOPICAL; MENTHOL TOPICAL; PHENOL TOPICAL a10962 BENZOCAINE TOPICAL; BUTYL AMINOBENZOATE; TETRACAINE TOPICAL a10966 ASPIRIN; CAFFEINE; DOVER'S POWDER a10968 MINERAL OIL; MINERAL WAX; PETROLATUM TOPICAL; WOOLWAX ALCOHOL a10971 ACETIC ACID TOPICAL; PROPYLENE GLYCOL DIACETATE; SODIUM ACETATE a10972 ACETIC ACID TOPICAL; HYDROCORTISONE OTIC; PROPYLENE GLYCOL DIACETATE; SODIUM ACETATE a10973 ALUMINUM HYDROXIDE; DONNATAL; LIDOCAINE; MAGNESIUM HYDROXIDE; SIMETHICONE a10975 DIBASIC SODIUM PHOSPHATE; SODIUM PHOSPHATE a10976 BETA; SISTEROL; LYCOPENE; MULTIVITAMIN; PYGEUM AFRICANUM; SAW PALMETTO a10978 DIPHTHERIA TOXOID; FILAMENTOUS HEMAGGLUTININ; PERTACTIN; PERTUSSIS, ACELLULAR; **TETANUS TOXOID** a10983 ERGOTAMINE; L; ALKALOIDS OF BELLADONNA; PHENOBARBITAL a10986 MULTIVITAMIN; WHEY a10988 L; METHYLFOLATE; METHYLCOBALAMIN; PYRIDOXINE a10989 CALCIUM ACETATE; GLUCOSAMINE; MAGNESIUM OXIDE; METHYLCOBALAMIN; MULTIVITAMIN a10990 ASCORBIC ACID; CALCIUM CHLORIDE; CALCIUM PHOSPHATE, TRIBASIC; MG GLYCEROPHOSPHATE; PYRIDOXINE a10991 CHICORY ROOT EXTRACT; LACTOBACILLUS GG a10994 ALUMINUM ACETATE TOPICAL; MAGNESIUM; SIMETHICONE a10995 CALCIUM ACETATE; MAGNESIUM a11003 ALLANTOIN TOPICAL; CALCIUM LACTATE; CHOLINE BITARTRATE; PORCINE STOMACH a11006 FLAVOCOXID; MALTODEXTRIN a11007 ASCORBIC ACID; MALTODEXTRIN a11009 FOLIC ACID; IRON; NIACINAMIDE; PANTOTHENATE; PYRIDOXINE a11010 ASCORBIC ACID; CYANOCOBALAMIN; FOLIC ACID; IRON a11011 CALCIUM ACETATE; FOLIC ACID; IRON; MULTIVITAMIN a11013 IRON; MULTIVITAMIN a11020 ASCORBIC ACID; CALCIUM SULFATE; CHOLECALCIFEROL; VITAMIN A; VITAMIN E a11022 AMYLASE; CELLULASE; GLUCOAMYLASE; LIPASE; PROTEASE a11025 FIBRINOGEN; THROMBIN TOPICAL a11027 ACETAMINOPHEN; MISCELLANEOUS ANALGESICS a11029 LAXATIVES; SENNA a11030 CONTRACEPTIVES; NORETHINDRONE a11031 MISCELLANEOUS UNCATEGORIZED AGENTS; PHENTOLAMINE a11033 ANTISEPTIC AND GERMICIDES; ETHANOL a11034 MISCELLANEOUS TOPICAL AGENTS; PETROLATUM TOPICAL a11036 COAL TAR TOPICAL; MISCELLANEOUS TOPICAL AGENTS a11037 GLYCERIN TOPICAL; MISCELLANEOUS TOPICAL AGENTS; POLYETHYLENE GLYCOL 3350 a11040 ARGININE; CEFTAZIDIME a11041 CIPROFLOXACIN; DEXAMETHASONE a11042 CIPROFLOXACIN; HYDROCORTISONE a11047 ACETAMINOPHEN; CAFFEINE; CODEINE; SALICYLAMIDE a11055 CHLORPHENIRAMINE; CODEINE; PHENYLEPHRINE a11072 CITRIC ACID; CODEINE; PHENIRAMINE; PYRILAMINE a11082 ABACAVIR; AMPRENAVIR; LAMIVUDINE; ZIDOVUDINE a11084 CYCLOPHOSPHAMIDE; FLUOROURACIL; METHOTREXATE a11087 CYCLOPHOSPHAMIDE; DOXORUBICIN; MITOMYCIN a11088 CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; VINCRISTINE a11089 CYCLOPHOSPHAMIDE; PREDNISONE; VINCRISTINE

a11092	ERYTHROMYCIN; NEOMYCIN
	ACETAMINOPHEN; CHLORPHENIRAMINE; PHENYLPROPANOLAMINE; PHENYLTOLOXAMINE
	ACETAMINOPHEN; PHENYLPROPANOLAMINE
	ACETAMINOPHEN; PHENYLPROPANOLAMINE; PHENYLTOLOXAMINE
	ATROPINE; HYOSCYAMINE; LIDOCAINE; PHENOBARBITAL; SCOPOLAMINE
	BUPIVACAINE; LIDOCAINE
	BACITRACIN; LIDOCAINE; NEOMYCIN; POLYMYXIN B SULFATE
	LIDOCAINE; SODIUM BICARBONATE
	ALUMINUM HYDROXIDE; LIDOCAINE; MAGNESIUM HYDROXIDE; SIMETHICONE
	EPINEPHRINE TOPICAL; LIDOCAINE; TETRACAINE TOPICAL
	HYDROXYZINE; PREDNISOLONE
	GENTAMICIN OPHTHALMIC; PREDNISOLONE
	ATROPINE; HYOSCYAMINE; METHENAMINE; METHYLENE BLUE; PHENYL SALICYLATE
	ATROPINE; BENZOIC ACID; METHENAMINE; METHYLENE BLUE; PHENYL SALICYLATE
	HYOSCYAMINE; METHENAMINE; METHYLENE BLUE; PHENYL SALICYLATE; SODIUM PHOSPHATE
	HYOSCYAMINE; METHENAMINE; METHYLENE BLUE; PHENYL SALICYLATE; SODIUM BIPHOSPHATE
	BELLADONNA; METHENAMINE; SALICYLAMIDE
	POLYMYXIN B SULFATE; TRIMETHOPRIM
	DORZOLAMIDE OPHTHALMIC; TIMOLOL
	EPHEDRINE; GUAIFENESIN; PHENOBARBITAL; THEOPHYLLINE
	ASPIRIN; CAFFEINE; CINNAMEDRINE
	ASPIRIN; CALCIUM ACETATE
	ATROPINE; CHLORPHENIRAMINE; HYOSCYAMINE; PHENYLEPHRINE; PHENYLPROPANOLAMINE
	ATROPINE; MORPHINE
	ATROPINE; HYOSCYAMINE; PHENAZOPYRIDINE; SCOPOLAMINE
	ALUMINUM HYDROXIDE; ATROPINE; HYOSCYAMINE; PHENOBARBITAL; SCOPOLAMINE
	ATROPINE; PHYSOSTIGMINE
	BUPIVACAINE; TRIAMCINOLONE
	CARBOPLATIN; CISPLATIN; FLUOROURACIL
	AMMONIUM CHLORIDE; CHLORPHENIRAMINE; GUAIFENESIN; PHENYLEPHRINE; SODIUM CITRATE
	CHLORPHENIRAMINE; HYDROCODONE; PHENYLEPHRINE; PSEUDOEPHEDRINE; PYRILAMINE
	CHLORPHENIRAMINE; PHENYLEPHRINE; SALICYLAMIDE; SCOPOLAMINE
	CARAMIPHEN; CHLORPHENIRAMINE; PHENYLPROPANOLAMINE
	CYTARABINE; DAUNORUBICIN
	DEXAMETHASONE; TRIAMCINOLONE
	AMMONIUM CHLORIDE; DEXTROMETHORPHAN
	DEXTROMETHORPHAN; PSEUDOEPHEDRINE; SORBITOL
	DEXTROMETHORPHAN; IODINATED GLYCEROL
	DEXTROMETHORPHAN; DOXYLAMINE; ETHANOL; SODIUM CITRATE
	ALUMINUM HYDROXIDE; DIPHENHYDRAMINE; MAGNESIUM HYDROXIDE; SIMETHICONE
	ALOE VERA TOPICAL; DIPHENHYDRAMINE; ETHANOL; ZINC ACETATE TOPICAL
	ETHINYL ESTRADIOL; FERROUS FUMARATE; NORETHINDRONE
	FLUOROURACIL; IRINOTECAN; LEUCOVORIN
a11286	FLUOROURACIL; LEUCOVORIN; OXALIPLATIN
a11287	FLUOROURACIL; MITOXANTRONE; VINCRISTINE
	CYANOCOBALAMIN; FOLIC ACID; PYRIDOXINE
	CYANOCOBALAMIN; FOLIC ACID
	ASCORBIC ACID; CARBONYL IRON; CYANOCOBALAMIN; FOLIC ACID
	FOLIC ACID; MULTIVITAMIN; SODIUM CHLORIDE; THIAMINE
	FOLIC ACID; MAGNESIUM SULFATE; MULTIVITAMIN; THIAMINE
a11300	FOLIC ACID; MULTIVITAMIN
a11302	
	FOLIC ACID; NICOTINAMIDE TOPICAL; ZINC OXIDE TOPICAL COLISTIN SULFATE OTIC: HYDROCORTISONE: NEOMYCIN: THONZONIUM BROMIDE OTIC

a11306 COLISTIN SULFATE OTIC; HYDROCORTISONE; NEOMYCIN; THONZONIUM BROMIDE OTIC

	INSULIN; INSULIN ISOPHANE
	MANNITOL; PEMETREXED
	AZACITIDINE; MANNITOL
	NEOMYCIN; POLYMYXIN B SULFATE
	BACITRACIN TOPICAL; NEOMYCIN; POLYMYXIN B SULFATE
	BACITRACIN OPHTHALMIC; NEOMYCIN; POLYMYXIN B SULFATE
a11330	BACITRACIN OPHTHALMIC; HYDROCORTISONE OPHTHALMIC; NEOMYCIN; POLYMYXIN B
	SULFATE
	DEXAMETHASONE OPHTHALMIC; NEOMYCIN; POLYMYXIN B SULFATE
	HYDROCORTISONE OTIC; NEOMYCIN; POLYMYXIN B SULFATE
	HYDROCORTISONE OTIC; NEOMYCIN; POLYMYXIN B OPHTHALMIC
	ERGOCALCIFEROL; NIACIN; RIBOFLAVIN; VITAMIN A
	ERGOCALCIFEROL; NIACIN; RIBOFLAVIN; THIAMINE; VITAMIN A
	ASCORBIC ACID; DOCUSATE; ERGOCALCIFEROL; NIACIN; VITAMIN A
	ASCORBIC ACID; NIACIN; RIBOFLAVIN; THIAMINE; VITAMIN E CYANOCOBALAMIN; NIACIN; PYRIDOXINE; RIBOFLAVIN
	CYANOCOBALAMIN, NIACIN, PTRIDOXINE, RIBOFLAVIN CYANOCOBALAMIN; NIACIN; PYRIDOXINE; RIBOFLAVIN; THIAMINE
	DEXPANTHENOL; NIACIN; PYRIDOXINE; RIBOFLAVIN; THIAMINE
	NIACIN; PYRIDOXINE; RIBOFLAVIN; THIAMINE
	PHENOBARBITAL; PROPANTHELINE
	EPHEDRINE; PHENOBARBITAL
	HYOSCYAMINE; PHENOBARBITAL; THIAMINE; VALERIAN
	HOMATROPINE; PHENOBARBITAL
	BACITRACIN TOPICAL; POLYMYXIN B SULFATE
	DEXAMETHASONE OPHTHALMIC; NEOMYCIN OPHTHALMIC; POLYMYXIN B SULFATE
	VITAMIN A; VITAMIN E
a11415	ERGOCALCIFEROL; RIBOFLAVIN; THIAMINE; VITAMIN A; VITAMIN E
	ASCORBIC ACID; VITAMIN A; VITAMIN E
	ASCORBIC ACID; ERGOCALCIFEROL; VITAMIN A; VITAMIN E
	CYANOCOBALAMIN; PYRIDOXINE; RIBOFLAVIN; VITAMIN A
	CYANOCOBALAMIN; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A
	ERGOCALCIFEROL; PYRIDOXINE; RIBOFLAVIN; VITAMIN A
	ASCORBIC ACID; ERGOCALCIFEROL; RIBOFLAVIN; THIAMINE; VITAMIN A
	ASCORBIC ACID; CHOLECALCIFEROL; FLUORIDE; VITAMIN A
	ASCORBIC ACID; ERGOCALCIFEROL; VITAMIN A ERGOCALCIFEROL; VITAMIN A
	CHOLECALCIFEROL; VITAMIN A
	ALLANTOIN TOPICAL; ALOE VERA TOPICAL; CALAMINE TOPICAL; CHOLECALCIFEROL; VITAMIN A
	ASCORBIC ACID; VITAMIN E
	ASCORBIC ACID; CYANOCOBALAMIN; PYRIDOXINE; RIBOFLAVIN; THIAMINE
a11447	CYANOCOBALAMIN; L; METHYLFOLATE; PYRIDOXINE; RIBOFLAVIN
	CHOLINE; CYANOCOBALAMIN; INOSITOL; RIBOFLAVIN; THIAMINE
	CYANOCOBALAMIN: PYRIDOXINE
	PANCREATIN; PYRIDOXINE
	DOXYLAMINE; PYRIDOXINE
a11466	CYANOCOBALAMIN; MULTIVITAMIN
a11471	CALCIUM CARBONATE; CALCIUM CITRATE; MAGNESIUM CITRATE; MAGNESIUM OXIDE
a11472	CALCIUM CARBONATE; CHOLECALCIFEROL
a11473	CALCIUM CARBONATE; MAGNESIUM GLUCONATE; MAGNESIUM OXIDE
	ASCORBIC ACID; CARBONYL IRON
	FLUORIDE; MULTIVITAMIN
	CHONDROITIN; GLUCOSAMINE; MANGANESE SULFATE
	SODIUM ACETATE; SODIUM CHLORIDE
	SODIUM CHLORIDE; SODIUM PHOSPHATE
	SODIUM CHLORIDE; STERILE WATER
	SODIUM BICARBONATE; SODIUM CHLORIDE NASAL
a11509	AMMONIUM CHLORIDE; SODIUM CITRATE

a11511 ALOE VERA TOPICAL; CYSTEINE; GRAPE SEED OIL; MULTIVITAMIN; SELENIUM a11514 MULTIVITAMIN; OMEGA; 3 POLYUNSATURATED FATTY ACIDS a11518 CONJUGATED ESTROGENS; PROGESTERONE a11519 PROGESTERONE; TESTOSTERONE a11520 NYSTATIN; TRIAMCINOLONE a11522 CAMPHOR TOPICAL; TRIAMCINOLONE a11523 NYSTATIN TOPICAL; TRIAMCINOLONE a11524 EDETATE DISODIUM (EDTA); UREA TOPICAL a11525 BENZOYL PEROXIDE TOPICAL; EDETATE DISODIUM (EDTA); GLYCERIN TOPICAL; UREA TOPICAL a11526 CHLOROPHYLLIN COPPER COMPLEX TOPICAL; PAPAIN TOPICAL; UREA TOPICAL a11531 CAFFEINE; EPHEDRINE; PHENYLPROPANOLAMINE a11549 EDETATE DISODIUM (EDTA); RIFAXIMIN a11550 SODIUM POLYSTYRENE SULFONATE; SORBITOL a11551 GUAIFENESIN; PHENIRAMINE; PHENYLPROPANOLAMINE; PYRILAMINE a11555 DIHYDROCODEINE; PHENYLPROPANOLAMINE a11556 PROMETHAZINE; PSEUDOEPHEDRINE a11558 NAPHAZOLINE OPHTHALMIC; PHENIRAMINE a11559 OXYMETAZOLINE NASAL: TETRACAINE TOPICAL a11563 GUAIFENESIN: POTASSIUM IODIDE a11564 CAFFEINE; MAGNESIUM SALICYLATE; PHENYLTOLOXAMINE a11576 ANTIPYRINE OTIC; BENZOCAINE TOPICAL a11585 BENZOCAINE TOPICAL; RESORCINOL TOPICAL a11602 CAPSICUM; CASCARA SAGRADA; PHENOLPHTHALEIN a11608 BALSAM PERU TOPICAL; BORIC ACID TOPICAL; CASTOR OIL; PETROLATUM TOPICAL; ZINC OXIDE TOPICAL a11610 BARIUM SULFATE; BISACODYL a11611 DOCUSATE; MINERAL OIL a11612 GLYCERIN TOPICAL: HYDROCORTISONE TOPICAL; MINERAL OIL; PETROLATUM TOPICAL a11614 MINERAL OIL; PETROLATUM TOPICAL a11615 LANOLIN TOPICAL; MINERAL OIL; PETROLATUM TOPICAL a11621 AMMONIUM LACTATE TOPICAL; MINERAL OIL a11622 CAPSICUM; MINERAL OIL; PEPPERMINT a11627 CHARCOAL; IPECAC a11630 HAEMOPHILUS B CONJUGATE VACCINE (OBSOLETE); HEPATITIS B VACCINE a11631 DIPHTHERIA TOXOID; HAEMOPHILUS B CONJUGATE VACCINE (OBSOLETE); PERTUSSIS, ACELLULAR; TETANUS TOXOID a11632 HEPATITIS A VACCINE (OBSOLETE); HEPATITIS B VACCINE a11640 COAL TAR; SALICYLIC ACID TOPICAL; SODIUM HYALURONATE OPHTHALMIC a11642 BORIC ACID TOPICAL; ISOPROPYL ALCOHOL TOPICAL a11646 DEXTRAN, LOW MOLECULAR WEIGHT; HYDROXYPROPYL METHYLCELLULOSE OPHTHALMIC a11648 CHLORHEXIDINE TOPICAL; ISOPROPYL ALCOHOL TOPICAL a11651 ALOE VERA TOPICAL; BENZOYL PEROXIDE TOPICAL a11654 FLUOCINOLONE TOPICAL; HYDROQUINONE TOPICAL; TRETINOIN a11663 PETROLATUM TOPICAL; SALICYLIC ACID TOPICAL a11664 ALUMINUM SULFATE TOPICAL; CAMPHOR TOPICAL; LACTOBACILLUS ACIDOPHILUS; MENTHOL TOPICAL; SALICYLIC ACID TOPICAL a11669 LANOLIN TOPICAL; SALICYLIC ACID TOPICAL; SULFUR TOPICAL a11670 COLLOIDAL OATMEAL TOPICAL; SALICYLIC ACID TOPICAL; SULFUR TOPICAL a11671 LACTIC ACID TOPICAL; SALICYLIC ACID TOPICAL a11674 TANNIC ACID TOPICAL; THIMEROSAL TOPICAL a11684 BENZALKONIUM CHLORIDE TOPICAL; BROMFENAC a11686 ALBUMIN HUMAN; PACLITAXEL a11687 IODINE; IOPAMIDOL a11689 DEXTRAN 1; METHYLCELLULOSE a11692 AMYLASE; LIPASE; PROTEASE a11693 AMYLASE; PAPAIN TOPICAL a11702 CHOLECALCIFEROL; MULTIVITAMIN a11703 CALCIUM ACETATE; CHOLECALCIFEROL

a11706 a11714 a11715 a11717 a11721 a11724 a11725 a11726 a11732 a11738	CALCIUM ACETATE; MULTIVITAMIN CETYLPYRIDINIUM TOPICAL; ETHANOL MICONAZOLE TOPICAL; PETROLATUM TOPICAL; ZINC OXIDE TOPICAL MENTHOL TOPICAL; ZINC OXIDE TOPICAL BETAMETHASONE TOPICAL; CLOTRIMAZOLE TOPICAL HYDROCORTISONE TOPICAL; NYSTATIN TOPICAL BACITRACIN TOPICAL; NEOMYCIN TOPICAL; POLYMYXIN B OPHTHALMIC LACTIC ACID TOPICAL; VITAMIN E TOPICAL ACETIC ACID TOPICAL; ALUMINUM ACETATE TOPICAL LANOLIN TOPICAL; PETROLATUM TOPICAL CAMPHOR TOPICAL; MENTHOL TOPICAL; PHENOL TOPICAL BACITRACIN TOPICAL; POLYMYXIN B OPHTHALMIC				
			ORTISONE OTIC; PRAMOXINE	OTIC	
	RITONAVIR; TENOFOVIR			0110	
	ATAZANAVIR; RITONAVIR				
	MAGNESIUM AMINO ACIDS C				
			IN TOPICAL; HYALURONIC AC	ID	
	MANNITOL; PHENYLALANINE				
			THOXYCINNAMATE; OXYBEN	ZONE	
	CARBOMER 940; ISOPROPYL				
	DIPHTHERIA TOXOID; PERTA HYDROCORTISONE TOPICAL				
			OCULAR LUBRICANT; SODIUN		IDE
			RIN; HYDROCODONE; PARABE		IDE
	ASCORBIC ACID; BIOTIN; FOI				
a11770	ASCORBIC ACID: CHOI FCAL		; GLYCERIN TOPICAL; VITAMIN		PLEX
a50520	BENZETHONIUM	a52885	IRON	a54655	POTASSIUM
	CHLORIDE		PREPARATIONS		REPLACEMENT
a50620	BIOTIN	a52968	KELP		SOLUTIONS
a50770	CALCIUM	a52990	LACTOSE	a54705	POTASSIUM
	REPLACEMENT	a53040	LEVALLORPHAN		HYDROXIDE
a50912	CARBOXYMETHYL-	a53155	LYPRESSIN	a54735	POTASSIUM
	CELLULOSE	a53175	MAGNESIUM		ACIDIFYING
a51080	CHLOROFORM		ANTACIDS	a54900	PROPYHEXEDRINE
a51185	CHOLESTEROL	a53298	MEGLUMINE	a54922	PROTEIN
a51209	CHROMIUN	a53315	MENINGOCOCCAL		SUPPLEMENT
a51225		~50075		a55075	RESCINNAMINE RINGERS LACTATED
ab 1325		abbb/b		abb115	
a51590	SOLUTION	a557 10	NONEAT	a55145	
a51495		a53723	; GLYCERIN TOPICAL; VITAMIN IRON PREPARATIONS KELP LACTOSE LEVALLORPHAN LYPRESSIN MAGNESIUM ANTACIDS MEGLUMINE MENINGOCOCCAL VACCINE MERBROMIN MILK SOLIDS NONFAT MINERALS MOXALACTAM	a55300	SODIUM BROMIDE
a51675	CYCLOTHIAZIDE DEXTROSE	a53778	MOXALACTAM	a55310	SODIUM CARBONATE
	DIETARY		MOXALACTAM MYRRH		SODIUM FLUORIDE
	SUPPLEMENT		NITROGEN		SODIUM LAURYL
a51770	DIGITALIS	a54015	OINTMENT		SULFATE
	ELECTROLYTES		HYDROPHILIC	a55400	SODIUM SUCCINATE
	ETHER		OLIVE OIL		SOYBEAN OIL
	ETHOPROPAZINE		OXYGEN		SUCCINLYCHOLINE
	FOOD SUPPLEMENT		PENTAERYTHRITOL		SUCROSE
	GALLAMINE	a54325	PERTUSSIS IMMUNE		SULFATHIAZOLE
	GELATIN	- 5 40 5 0	GLOBULIN		SURFACTANT
ao2475	GOLD SODIUM THIOSULFATE		PHENACETIN PNEUMOCOCCAL	a55645	TALC
252525	HAMAMELIS WATER	804000	VACCINE		VALPROTIC ACID
	HYDROCHLORIC	254565	POISON IVY		VEGETABLE OIL
a52040	ACID	a0-1000	EXTRACT		VEGETABLE OIL VITAMIN K
a52775	INFANT FORMULA	a54575	POLIO VACCINE		ZINC TOPICAL
	INTERFERON ALFA		POTASSIUM	200200	AGENTS, EXTERNAL
	IODOCHLOR-		BROMIDE		USE
-	HYDROXYQUIN			a56275	ZOMEPIRAC

a56340	VITAMIN B	a
a56345	VITAMIN B COMPLEX	a
a56580	POLOXAMER 188	- C
a56615	RETINOIC ACID	a
a56740	INTERFERON BETA	e
a56800	SODIUM	
0000066		a
	TETRABORATE	a
	DECAHYDRATE	
a57001	BLOOD SUGAR	a
	DIAGNOSTIC	
a57014	ERYTHROPOIETIN	a
a57024	MAGNESIUM ION	a
a57034	PHOSPHORUS	
a57040	MECLOCYCLINE	a
a57050	HYDROACTIVE	
	DRESSING	a
a57084	COLLAGEN	a
a57092	RECOMBINANT	a
	HUMAN	a
	DEOXYRIBO-	a
	NUCLEASE	a
a57154		a
a57158		a
a57188	LOVERSOL	- C
a57194		
a57204		a
aj1204	VACCINE	
a59603	HEPATITIS VACCINE	a
a59603 a59611	THYROID	a
a59611	-	a
	STIMULATING	a
	HORMONE	
a59632	DEHYDROEPI-	a
	ANDROSTERENE	a
a59717	ANDROGENS	
a59812	DOMPERIDONE	
a59813	FOLLITROPIN BETA	a
a59814	FOLLITROPIN ALPHA	a
a59841	GRAPESEED	a
a70009	HYALURONIC ACID	a
a70010		a
a70046	PENICILLIN G	a
	BENZATHINE	a
a70048	OIL OF EVENING	a
	PRIMROSE	a
a70062	FENRETINIDE	a
a70064	TETRABENAZINE	a
a70105	HAWTHORN	a
a70113	PERINDOPRIL	C
	ERBUMINE	C
a70116	SOY	C
a70123	BISMUTH	
a70123 a70159	SILVER	c
a70139 a70181	GLUTAMINE	c
a70161 a70194		
a/0194		C
	COPOLYMER	-
a70203	RACEMIC	C
~70004	EPINEPHRINE	
a70204	ACEMANNAN	

a70385	SILYBUM
a70465	SUPER OXIDE
	DISMUTASE
a70476	VIGABATRIN
a70479	BORAGE OIL
a70480	ALPHA LIPOIC ACID
a70484	CARBOXYMETHYL-
	CELLULOSE SODIUM
a70491	HYOSCYNAMINE
a/0491	
	SULFATE
a70550	SOLUMET
a70607	OXYQUINOLONE
u. 0001	SULFATE
a70674	TOTAL
	UNDECYLENATE
a70699	LYCOPENE
a70725	ASPARTAME
a70732	EPIDURAL
a70747	PROLINE
a70759	ALFALFA
	MAGNESIUM
a70799	
a70832	OAT BRAN
a70836	GAMMA;
	AMINOBUTRYIC
	ACID
a70841	POLOXAMER 331
a70886	IRON
a70891	HYDROGEL
	PREGNENOLONE
a70996	
a70998	ACETYLSALICYLIC
	ACID
a71002	FLOXACILLIN
a71002	TECHNETIUM TC 99M
a/1006	
	MERTIATIDE
	INJECTION
a71021	HISTERLIN
a71034	DECLABEN
a71036	GLIFLUMIDE
a71037	POLY; LACTIC ACID
a71042	NISOXETINE
a71045	
a71048	FLUZINAMIDE
a71057	CITRULLINE
a71058	D; RIBOSE
a71063	CODOXIME
a71065	CLOBAZAM
a71066	DEFLAZACORT
c00007	ANTIVIRAL AGENTS
c00009	CEPHALOSPORINS
c00003	MISCELLANEOUS
00012	
	ANTIBIOTICS
c00014	QUINOLONES
c00015	SULFONAMIDES
c00025	MISCELLANEOUS
00023	
	ANTINEOPLASTICS
c00027	RADIO-
	PHARMACEUTICALS
	PHARMACEUTICALS

c00039	MISCELLANEOUS
c00040	BIOLOGICALS CARDIOVASCULAR
c00042	AGENTS ANGIOTENSIN
00042	CONVERTING
	ENZYME
	INHIBITORS
c00045	ANTIANGINAL
-00040	AGENTS
c00046	ANTIARRHYTHMIC AGENTS
c00047	BETA; ADRENERGIC
-00040	BLOCKING AGENTS
c00048	CALCIUM CHANNEL BLOCKING AGENTS
c00049	DIURETICS
c00043	PERIPHERAL
	VASODILATORS
c00055	ANTIHYPERTENSIVE
	COMBINATIONS
c00057	CENTRAL NERVOUS
	SYSTEM AGENTS
c00059	MISCELLANEOUS
	ANALGESICS
c00061	NONSTEROIDAL ANTI-
	INFLAMMATORY
	AGENTS
c00065	ANTIEMETIC;
	ANTIVERTIGO
	AGENTS
c00067	ANXIOLYTICS,
	SEDATIVES, AND
	HYPNOTICS
c00068	BARBITURATES
c00070	MISCELLANEOUS ANXIOLYTICS,
	SEDATIVES AND
	HYPNOTICS
c00072	GENERAL
	ANESTHETICS
c00076	MISCELLANEOUS
	ANTIDEPRESSANTS
c00077	
	MISCELLANEOUS
	ANTIPSYCHOTIC
-00080	ANTIPSYCHOTIC AGENTS
c00080	ANTIPSYCHOTIC AGENTS MISCELLANEOUS
c00080	ANTIPSYCHOTIC AGENTS MISCELLANEOUS CENTRAL NERVOUS
	ANTIPSYCHOTIC AGENTS MISCELLANEOUS CENTRAL NERVOUS SYSTEM AGENTS
c00080 c00082 c00085	ANTIPSYCHOTIC AGENTS MISCELLANEOUS CENTRAL NERVOUS
c00082	ANTIPSYCHOTIC AGENTS MISCELLANEOUS CENTRAL NERVOUS SYSTEM AGENTS ANTICOAGULANTS MISCELLANEOUS COAGULATION
c00082 c00085	ANTIPSYCHOTIC AGENTS MISCELLANEOUS CENTRAL NERVOUS SYSTEM AGENTS ANTICOAGULANTS MISCELLANEOUS COAGULATION MODIFIERS
c00082	ANTIPSYCHOTIC AGENTS MISCELLANEOUS CENTRAL NERVOUS SYSTEM AGENTS ANTICOAGULANTS MISCELLANEOUS COAGULATION MODIFIERS GASTROINTESTINAL
c00082 c00085 c00087	ANTIPSYCHOTIC AGENTS MISCELLANEOUS CENTRAL NERVOUS SYSTEM AGENTS ANTICOAGULANTS MISCELLANEOUS COAGULATION MODIFIERS GASTROINTESTINAL AGENTS
c00082 c00085	ANTIPSYCHOTIC AGENTS MISCELLANEOUS CENTRAL NERVOUS SYSTEM AGENTS ANTICOAGULANTS MISCELLANEOUS COAGULATION MODIFIERS GASTROINTESTINAL

2006 NAMCS MICRO-DATA FILE DOCUMENTATION, APPENDIX III - GENERIC LIST

c00095 c00096	LAXATIVES MISCELLANEOUS GI
c00098	AGENTS ADRENAL CORTICAL
	STEROIDS
c00099	ANTIDIABETIC AGENTS
c00100	MISCELLANEOUS HORMONES
c00102	CONTRACEPTIVES
c00105	MISCELLANEOUS AGENTS
c00109	LOCAL INJECTABLE ANESTHETICS
c00110	MISCELLANEOUS UNCATEGORIZED AGENTS
c00115	NUTRITIONAL PRODUCTS
c00117	MINERALS AND ELECTROLYTES
c00119	VITAMINS
c00123	ANTIHISTAMINES
c00124	ANTITUSSIVES
c00127	DECONGESTANTS
c00129	MISCELLANEOUS
	RESPIRATORY
	AGENTS
c00131	ANTIASTHMATIC COMBINATIONS
c00132	UPPER
	RESPIRATORY
	COMBINATIONS
c00135	ANTISEPTIC AND
c00135	
c00135 c00137	ANTISEPTIC AND GERMICIDES TOPICAL ANTI-
	ANTISEPTIC AND GERMICIDES TOPICAL ANTI- INFECTIVES
c00137 c00138	ANTISEPTIC AND GERMICIDES TOPICAL ANTI-
c00137	ANTISEPTIC AND GERMICIDES TOPICAL ANTI- INFECTIVES TOPICAL STEROIDS MISCELLANEOUS
c00137 c00138 c00140	ANTISEPTIC AND GERMICIDES TOPICAL ANTI- INFECTIVES TOPICAL STEROIDS MISCELLANEOUS TOPICAL AGENTS
c00137 c00138	ANTISEPTIC AND GERMICIDES TOPICAL ANTI- INFECTIVES TOPICAL STEROIDS MISCELLANEOUS TOPICAL AGENTS TOPICAL ACNE
c00137 c00138 c00140 c00143	ANTISEPTIC AND GERMICIDES TOPICAL ANTI- INFECTIVES TOPICAL STEROIDS MISCELLANEOUS TOPICAL AGENTS TOPICAL ACNE AGENTS
c00137 c00138 c00140	ANTISEPTIC AND GERMICIDES TOPICAL ANTI- INFECTIVES TOPICAL STEROIDS MISCELLANEOUS TOPICAL AGENTS TOPICAL ACNE AGENTS OPHTHALMIC
c00137 c00138 c00140 c00143 c00164	ANTISEPTIC AND GERMICIDES TOPICAL ANTI- INFECTIVES TOPICAL STEROIDS MISCELLANEOUS TOPICAL AGENTS TOPICAL ACNE AGENTS OPHTHALMIC GLAUCOMA AGENTS
c00137 c00138 c00140 c00143	ANTISEPTIC AND GERMICIDES TOPICAL ANTI- INFECTIVES TOPICAL STEROIDS MISCELLANEOUS TOPICAL AGENTS TOPICAL ACNE AGENTS OPHTHALMIC GLAUCOMA AGENTS OPHTHALMIC
c00137 c00138 c00140 c00143 c00164	ANTISEPTIC AND GERMICIDES TOPICAL ANTI- INFECTIVES TOPICAL STEROIDS MISCELLANEOUS TOPICAL AGENTS TOPICAL ACNE AGENTS OPHTHALMIC GLAUCOMA AGENTS OPHTHALMIC LUBRICANTS AND
c00137 c00138 c00140 c00143 c00164 c00168	ANTISEPTIC AND GERMICIDES TOPICAL ANTI- INFECTIVES TOPICAL STEROIDS MISCELLANEOUS TOPICAL AGENTS TOPICAL AGENTS TOPICAL ACNE AGENTS OPHTHALMIC GLAUCOMA AGENTS OPHTHALMIC LUBRICANTS AND IRRIGATIONS
c00137 c00138 c00140 c00143 c00164	ANTISEPTIC AND GERMICIDES TOPICAL ANTI- INFECTIVES TOPICAL STEROIDS MISCELLANEOUS TOPICAL AGENTS TOPICAL AGENTS TOPICAL ACNE AGENTS OPHTHALMIC GLAUCOMA AGENTS OPHTHALMIC LUBRICANTS AND IRRIGATIONS MISCELLANEOUS
c00137 c00138 c00140 c00143 c00164 c00168	ANTISEPTIC AND GERMICIDES TOPICAL ANTI- INFECTIVES TOPICAL STEROIDS MISCELLANEOUS TOPICAL AGENTS TOPICAL AGENTS TOPICAL ACNE AGENTS OPHTHALMIC GLAUCOMA AGENTS OPHTHALMIC LUBRICANTS AND IRRIGATIONS MISCELLANEOUS OPHTHALMIC
c00137 c00138 c00140 c00143 c00164 c00168 c00169	ANTISEPTIC AND GERMICIDES TOPICAL ANTI- INFECTIVES TOPICAL STEROIDS MISCELLANEOUS TOPICAL AGENTS TOPICAL AGENTS OPHTHALMIC GLAUCOMA AGENTS OPHTHALMIC LUBRICANTS AND IRRIGATIONS MISCELLANEOUS OPHTHALMIC AGENTS
c00137 c00138 c00140 c00143 c00164 c00168	ANTISEPTIC AND GERMICIDES TOPICAL ANTI- INFECTIVES TOPICAL STEROIDS MISCELLANEOUS TOPICAL AGENTS TOPICAL AGENTS OPHTHALMIC GLAUCOMA AGENTS OPHTHALMIC LUBRICANTS AND IRRIGATIONS MISCELLANEOUS OPHTHALMIC AGENTS MISCELLANEOUS
c00137 c00138 c00140 c00143 c00164 c00168 c00169 c00172	ANTISEPTIC AND GERMICIDES TOPICAL ANTI- INFECTIVES TOPICAL STEROIDS MISCELLANEOUS TOPICAL AGENTS TOPICAL AGENTS OPHTHALMIC GLAUCOMA AGENTS OPHTHALMIC LUBRICANTS AND IRRIGATIONS MISCELLANEOUS OPHTHALMIC AGENTS MISCELLANEOUS OTIC AGENTS
c00137 c00138 c00140 c00143 c00164 c00168 c00169	ANTISEPTIC AND GERMICIDES TOPICAL ANTI- INFECTIVES TOPICAL STEROIDS MISCELLANEOUS TOPICAL AGENTS TOPICAL AGENTS OPHTHALMIC GLAUCOMA AGENTS OPHTHALMIC LUBRICANTS AND IRRIGATIONS MISCELLANEOUS OPHTHALMIC AGENTS MISCELLANEOUS OTIC AGENTS MISCELLANEOUS
c00137 c00138 c00140 c00143 c00164 c00168 c00169 c00172	ANTISEPTIC AND GERMICIDES TOPICAL ANTI- INFECTIVES TOPICAL STEROIDS MISCELLANEOUS TOPICAL AGENTS TOPICAL AGENTS OPHTHALMIC GLAUCOMA AGENTS OPHTHALMIC LUBRICANTS AND IRRIGATIONS MISCELLANEOUS OPHTHALMIC AGENTS MISCELLANEOUS OTIC AGENTS MISCELLANEOUS ANTIHYPERLIPI-
c00137 c00138 c00140 c00143 c00164 c00168 c00169 c00172 c00172	ANTISEPTIC AND GERMICIDES TOPICAL ANTI- INFECTIVES TOPICAL STEROIDS MISCELLANEOUS TOPICAL AGENTS TOPICAL AGENTS OPHTHALMIC GLAUCOMA AGENTS OPHTHALMIC LUBRICANTS AND IRRIGATIONS MISCELLANEOUS OPHTHALMIC AGENTS MISCELLANEOUS OTIC AGENTS MISCELLANEOUS ANTIHYPERLIPI- DEMIC AGENTS
c00137 c00138 c00140 c00143 c00164 c00168 c00169 c00172	ANTISEPTIC AND GERMICIDES TOPICAL ANTI- INFECTIVES TOPICAL STEROIDS MISCELLANEOUS TOPICAL AGENTS TOPICAL AGENTS OPHTHALMIC GLAUCOMA AGENTS OPHTHALMIC LUBRICANTS AND IRRIGATIONS MISCELLANEOUS OPHTHALMIC AGENTS MISCELLANEOUS OTIC AGENTS MISCELLANEOUS ANTIHYPERLIPI- DEMIC AGENTS SKELETAL MUSCLE
c00137 c00138 c00140 c00143 c00164 c00168 c00169 c00172 c00172 c00174	ANTISEPTIC AND GERMICIDES TOPICAL ANTI- INFECTIVES TOPICAL STEROIDS MISCELLANEOUS TOPICAL AGENTS TOPICAL AGENTS OPHTHALMIC GLAUCOMA AGENTS OPHTHALMIC LUBRICANTS AND IRRIGATIONS MISCELLANEOUS OPHTHALMIC AGENTS MISCELLANEOUS OTIC AGENTS MISCELLANEOUS ANTIHYPERLIPI- DEMIC AGENTS SKELETAL MUSCLE RELAXANTS
c00137 c00138 c00140 c00143 c00164 c00168 c00169 c00172 c00172	ANTISEPTIC AND GERMICIDES TOPICAL ANTI- INFECTIVES TOPICAL STEROIDS MISCELLANEOUS TOPICAL AGENTS TOPICAL AGENTS OPHTHALMIC GLAUCOMA AGENTS OPHTHALMIC LUBRICANTS AND IRRIGATIONS MISCELLANEOUS OPHTHALMIC AGENTS MISCELLANEOUS OTIC AGENTS MISCELLANEOUS ANTIHYPERLIPI- DEMIC AGENTS SKELETAL MUSCLE RELAXANTS MISCELLANEOUS
c00137 c00138 c00140 c00143 c00164 c00168 c00169 c00172 c00172 c00174	ANTISEPTIC AND GERMICIDES TOPICAL ANTI- INFECTIVES TOPICAL STEROIDS MISCELLANEOUS TOPICAL AGENTS TOPICAL AGENTS OPHTHALMIC GLAUCOMA AGENTS OPHTHALMIC LUBRICANTS AND IRRIGATIONS MISCELLANEOUS OPHTHALMIC AGENTS MISCELLANEOUS OTIC AGENTS MISCELLANEOUS ANTIHYPERLIPI- DEMIC AGENTS SKELETAL MUSCLE RELAXANTS

000130	AGENTS
c00198	MISCELLANEOUS
000100	ANTIEMETICS
c00204	MISCELLANEOUS
	ANTICONVULSANTS
c00219	NUTRACEUTICAL
	PRODUCTS
c00220	HERBAL PRODUCTS
c00254	IMMUNOLOGIC
	AGENTS
c00269	MISCELLANEOUS
	VAGINAL AGENTS
c00286	MYDRIATICS
c00296	INHALED
	CORTICOSTEROIDS
c00304	MACROLIDES
c00899	PHARMACEUTICAL
400001	
d00001 d00002	ACYCLOVIR AMIODARONE
d00002	AMPICILLIN
d00003	ATENOLOL
d00004	CAPTOPRIL
d000007	CEFAZOLIN
d00008	CEFOTAXIME
d00009	CEFTAZIDIME
d00010	CEFTIZOXIME
d00011	CIPROFLOXACIN
d00012	CODEINE
d00013	ENALAPRIL
d00014	GENTAMICIN
d00015	IBUPROFEN
d00016	LABETALOL
d00017	MEPERIDINE
d00018	NADOLOL
d00019	NAPROXEN
d00020	QUINIDINE
d00021	RANITIDINE
d00022	WARFARIN
d00023	
d00024	AZATHIOPRINE FENOPROFEN
d00028 d00027	HALOPERIDOL
d00027 d00028	KETOPROFEN
d00020	NAFCILLIN
d00020	PENTAMIDINE
d00031	PROBENECID
d00032	PROPRANOLOL
d00033	SULINDAC
d00034	ZIDOVUDINE
d00035	CHLOROQUINE
d00036	CYCLOPHOS-
	PHAMIDE
d00037	DOXYCYCLINE
d00039	INDOMETHACIN
d00040	OXAZEPAM
d00041	TETRACYCLINE
d00042	CHLORPROPAMIDE
d00043	CLINDAMYCIN

c00193 ANTIMIGRAINE

d00044 d00045 d00046 d00047	CLONIDINE DILTIAZEM ERYTHROMYCIN RIFAMPIN
d00048	VERAPAMIL
d00049	ACETAMINOPHEN
d00050	METHADONE
d00051 d00052	NIFEDIPINE CEFTRIAXONE
d00052	CEPHRADINE
d00054	TOLMETIN
d00055	CEFOTETAN
d00056	CEFUROXIME
d00057 d00058	PIPERACILLIN CARBAMAZEPINE
d00058	LIDOCAINE
d00060	METHOTREXATE
d00061	LITHIUM
d00064	CHLORPROMAZINE
d00066 d00067	GANCICLOVIR AZTREONAM
d00068	ETHAMBUTOL
d00069	TOBRAMYCIN
d00070	FUROSEMIDE
d00071	FLUCONAZOLE
d00072 d00073	CEFIXIME CEFPROZIL
d00075	PROCAINAMIDE
d00077	AMPHOTERICIN B
d00078	DIDANOSINE
d00079	CYCLOSPORINE
d00080	
d00081 d00082	CEFACLOR IMIPENEM:
000002	CILASTATIN
d00084	PREDNISOLONE
d00085	RIBAVIRIN
d00086 d00087	AMANTADINE AMIKACIN
d00087	AMOXICILLIN
d00089	AMOXICILLIN;
	CLAVULANATE
d00091	AZITHROMYCIN
d00094 d00095	CEFOXITIN CEFPODOXIME
d00095	CEPHALEXIN
d00097	CLARITHROMYCIN
d00098	DAPSONE
d00100	GRISEOFULVIN
d00101	ISONIAZID
d00102 d00103	ITRACONAZOLE KETOCONAZOLE
d00104	LOMEFLOXACIN
d00105	LORACARBEF
d00106	METHENAMINE
d00107	METHICILLIN METRONIDAZOLE
d00108 d00109	METRONIDAZOLE
d00109	MINOCYCLINE
d00112	NITROFURANTOIN

 2006 NAMCS MICRO-DATA FILE DOCUMENTATION, APPENDIX III – GEN

 d00113
 NORFLOXACIN
 d00181
 BURPROPION

 d00114
 OFLOXACIN
 d00182
 BUSPIRONE

 d00115
 OXACILLIN
 d00183
 BUSULFAN

 d00117
 PENICILLIN
 d00186
 CEPHALDTHIN

 d00118
 SULFADAZINE
 d00186
 CEPHALOTHIN

 d00120
 SULFA
 d00180
 CHLORAMBUCIL

 d00121
 CLARCILLIN;
 d00180
 CHLORAMBUCIL

 d00122
 SULFA
 d00191
 CHLORAMINEE

 d00123
 SULFA
 d00193
 CHLORAMINEE

 d00124
 SULFA
 d00193
 CHLORAMINEE

 d00125
 VANCOMYCIN
 d00193
 CLORAZEPAM

 d00126
 AUCTARABINE
 d00190
 CLORAZEPATE

 d00127
 ZALCITABINE
 d00200
 CRAMOLYN

 d00138
 GUANABENZ
 d00200
 CRAMOLYN

 d00139
 GUANABENZ
 d00200
 CRAMOLYN

 d00130
 GUANABENZ
 d00200
 CACARBAZINE
 </t

d00253	HYDROCHLORO- THIAZIDE
d00254	HYDROCORTISONE
d00255	HYDROMORPHONE
d00257	IFOSFAMIDE
d00259	IMIPRAMINE
d00260 d00262	INDAPAMIDE INSULIN
d00262	IPRATROPIUM
d00267	ISOFLURANE
d00268	ISOSORBIDE
100000	DINITRATE
d00269	ISOSORBIDE MONONITRATE
d00270	ISRADIPINE
d00272	KETAMINE
d00273	KETOROLAC
d00275	LEUCOVORIN
d00276 d00277	LEVAMISOLE LEVODOPA
d00277 d00278	LEVODOPA
d00279	LINCOMYCIN
d00280	LOVASTATIN
d00282	MANNITOL
d00283	MECLOFENAMATE
d00284	MEDROXY- PROGESTERONE
d00285	MEFENAMIC ACID
d00286	MEFLOQUINE
d00287	MELPHALAN
d00288	MEPROBAMATE
d00289 d00290	MERCAPTOPURINE METHIMAZOLE
d00290	METHYL-
	PREDNISOLONE
d00297	METIPRANOLOL
-100000	OPHTHALMIC
d00298 d00299	METOCLOPRAMIDE METOLAZONE
d00233	MEXILETINE
d00301	MIDAZOLAM
d00303	MISOPROSTOL
d00305	MITOMYCIN
d00306 d00308	MITOXANTRONE MORPHINE
d00308	NABUMETONE
d00311	NALOXONE
d00312	NEOMYCIN
d00313	NEOSTIGMINE
d00314 d00315	NIACIN NICARDIPINE
d00315 d00316	NICOTINE
d00318	NIMODIPINE
d00321	NITROGLYCERIN
d00322	NIZATIDINE
d00323 d00325	NOREPINEPHRINE OMEPRAZOLE
d00325 d00328	OXYBUTYNIN

2006 NAMCS MICRO-DATA FILE DOCUMENTATION, APPENDIX III - GENERIC LIST

d00329 OXYCODONE d00330 PANCURONIUM d00333 PENICILLAMINE d00334 PENTAZOCINE d00335 PENTOBARBITAL d00336 PENTOXIFYLLINE d00337 PHENAZOPYRIDINE d00340 PHENOBARBITAL d00343 PIROXICAM d00344 POLYMYXIN B SULFATE d00345 POTASSIUM CHLORIDE d00346 POVIDONE IODINE TOPICAL d00348 PRAVASTATIN d00350 PREDNISONE d00351 PRIMAQUINE d00352 PRIMIDONE d00354 PROCARBAZINE d00355 PROCHLOR-PERAZINE d00358 PROPAFENONE d00359 PROPANTHELINE d00360 PROPOXYPHENE d00361 PROPYLTHIOURACIL d00362 PROTAMINE d00363 PYRIDOSTIGMINE d00364 PYRIMETHAMINE d00365 QUINAPRIL d00366 QUININE d00367 RESERPINE d00370 OCTREOTIDE d00371 SOTALOL d00373 SPIRONOLACTONE d00377 SUCRALFATE d00378 SUFENTANIL d00379 SULFASALAZINE d00381 TAMOXIFEN d00384 TEMAZEPAM d00386 TERAZOSIN d00387 TERFENADINE d00388 THIOPENTAL d00389 THIORIDAZINE d00390 THIOTEPA d00391 THIOTHIXENE d00393 TOLAZAMIDE d00394 TOLBUTAMIDE d00395 TRAZODONE d00396 TRIAMTERENE d00397 TRIAZOLAM d00399 VECURONIUM d00400 VINBLASTINE d00401 VINCRISTINE d00402 VITAMIN A d00405 VITAMIN E d00409 RIBOFLAVIN d00412 PYRIDOXINE d00413 CYANOCOBALAMIN

d00425	CALCIUM
	CARBONATE
d00426	ASCORBIC ACID
d00428	FLUORIDE
d00438	SODIUM CHLORIDE
d00440	SODIUM
	BICARBONATE
d00468	MAGNESIUM
	SULFATE
d00471	SODIUM ACETATE
d00475	SODIUM PHOSPHATE
d00485	IODINE TOPICAL
d00488	LYSINE
d00489	METHIONINE
d00491	LEVOCARNITINE
d00492	CHOLINE
	SALICYLATE
d00497	OMEGA-3
	POLYUNSAT-
	URATED FATTY
	ACIDS
d00512	FILGRASTIM
d00513	SARGRAMOSTIM
d00514	TICLOPIDINE
d00521	ALTEPLASE
d00525	ANTIHEMOPHILIC
	FACTOR
	(OBSOLETE)
d00527	FACTOR IX COMPLEX
	(OBSOLETE)
d00528	AMINOCAPROIC ACID
d00534	ESTRONE
d00537	ESTRADIOL
d00541	CONJUGATED
	ESTROGENS
d00543	ESTROPIPATE
d00545	QUINESTROL
d00550	PROGESTERONE
d00555	NORETHINDRONE
d00557	LEVONORGESTREL
d00558	TESTOSTERONE
d00563	FINASTERIDE
d00566	OXANDROLONE
d00568	NANDROLONE
d00569	CLOMIPHENE
d00570	UROFOLLITROPIN
d00571	MENOTROPINS
d00572	CHORIONIC
	GONADOTROPIN
	(HCG)
d00576	SOMATREM
d00577	SOMATROPIN
d00578	ARGININE
d00583	DESMOPRESSIN
d00584	OXYTOCIN
d00587	METHYLER-
100	GONOVINE
d00589	DINOPROSTONE
100500	TOPICAL
d00592	METYRAPONE

400500	
	CLUCACON
d00593	GLUCAGON
d00598	CALCITONIN
d00599	ETIDRONATE
d00601	PAMIDRONATE
d00604	CORTICOTROPIN
d00608	FLUDROCORTISONE
d00609	CORTISONE
d00620	TRIAMCINOLONE
d00626	DEXAMETHASONE
000020	
	TOPICAL
d00640	METHAZOLAMIDE
d00649	ETHACRYNIC ACID
	UREA TOPICAL
d00651	
d00652	GLYCERIN
d00653	ISOSORBIDE
d00655	THYROID
000000	
	DESICCATED
d00658	LIOTHYRONINE
d00683	LIDOCAINE TOPICAL
d00688	BEPRIDIL
d00689	AMLODIPINE
d00693	ISOXSUPRINE
d00695	PAPAVERINE
d00697	ISOPROTERENOL
d00699	EPINEPHRINE
d00700	
	EPHEDRINE
d00702	METARAMINOL
d00704	PHENYLEPHRINE
d00708	CARTEOLOL
d00709	BISOPROLOL
d00717	GUANFACINE
d00726	DOXAZOSIN
d00728	RAMIPRIL
d00730	RAMIPRIL BENAZEPRIL
d00730	
d00730 d00732	BENAZEPRIL LISINOPRIL
d00730 d00732 d00735	BENAZEPRIL LISINOPRIL METYROSINE
d00730 d00732	BENAZEPRIL LISINOPRIL METYROSINE TRIMETHAPHAN
d00730 d00732 d00735	BENAZEPRIL LISINOPRIL METYROSINE
d00730 d00732 d00735 d00738	BENAZEPRIL LISINOPRIL METYROSINE TRIMETHAPHAN CAMSYLATE
d00730 d00732 d00735	BENAZEPRIL LISINOPRIL METYROSINE TRIMETHAPHAN CAMSYLATE SODIUM
d00730 d00732 d00735 d00738	BENAZEPRIL LISINOPRIL METYROSINE TRIMETHAPHAN CAMSYLATE SODIUM POLYSTYRENE
d00730 d00732 d00735 d00738	BENAZEPRIL LISINOPRIL METYROSINE TRIMETHAPHAN CAMSYLATE SODIUM POLYSTYRENE SULFONATE
d00730 d00732 d00735 d00738	BENAZEPRIL LISINOPRIL METYROSINE TRIMETHAPHAN CAMSYLATE SODIUM POLYSTYRENE SULFONATE
d00730 d00732 d00735 d00738 d00743 d00744	BENAZEPRIL LISINOPRIL METYROSINE TRIMETHAPHAN CAMSYLATE SODIUM POLYSTYRENE SULFONATE COLESTIPOL
d00730 d00732 d00735 d00738 d00743 d00744 d00744	BENAZEPRIL LISINOPRIL METYROSINE TRIMETHAPHAN CAMSYLATE SODIUM POLYSTYRENE SULFONATE COLESTIPOL SIMVASTATIN
d00730 d00732 d00735 d00738 d00743 d00744 d00744 d00746 d00749	BENAZEPRIL LISINOPRIL METYROSINE TRIMETHAPHAN CAMSYLATE SODIUM POLYSTYRENE SULFONATE COLESTIPOL SIMVASTATIN ALBUTEROL
d00730 d00732 d00735 d00738 d00743 d00744 d00744	BENAZEPRIL LISINOPRIL METYROSINE TRIMETHAPHAN CAMSYLATE SODIUM POLYSTYRENE SULFONATE COLESTIPOL SIMVASTATIN
d00730 d00732 d00735 d00738 d00743 d00744 d00746 d00749 d00750	BENAZEPRIL LISINOPRIL METYROSINE TRIMETHAPHAN CAMSYLATE SODIUM POLYSTYRENE SULFONATE COLESTIPOL SIMVASTATIN ALBUTEROL METAPROTERENOL
d00730 d00732 d00735 d00738 d00743 d00744 d00746 d00749 d00750 d00752	BENAZEPRIL LISINOPRIL METYROSINE TRIMETHAPHAN CAMSYLATE SODIUM POLYSTYRENE SULFONATE COLESTIPOL SIMVASTATIN ALBUTEROL METAPROTERENOL TERBUTALINE
d00730 d00732 d00735 d00738 d00743 d00744 d00746 d00749 d00750 d00752 d00755	BENAZEPRIL LISINOPRIL METYROSINE TRIMETHAPHAN CAMSYLATE SODIUM POLYSTYRENE SULFONATE COLESTIPOL SIMVASTATIN ALBUTEROL METAPROTERENOL TERBUTALINE PIRBUTEROL
d00730 d00732 d00735 d00738 d00743 d00744 d00746 d00749 d00750 d00752	BENAZEPRIL LISINOPRIL METYROSINE TRIMETHAPHAN CAMSYLATE SODIUM POLYSTYRENE SULFONATE COLESTIPOL SIMVASTATIN ALBUTEROL METAPROTERENOL TERBUTALINE
d00730 d00732 d00735 d00738 d00743 d00744 d00746 d00749 d00750 d00752 d00755 d00758	BENAZEPRIL LISINOPRIL METYROSINE TRIMETHAPHAN CAMSYLATE SODIUM POLYSTYRENE SULFONATE COLESTIPOL SIMVASTATIN ALBUTEROL METAPROTERENOL TERBUTALINE PIRBUTEROL AMINOPHYLLINE
d00730 d00732 d00735 d00738 d00743 d00744 d00746 d00749 d00750 d00752 d00755 d00758 d00758	BENAZEPRIL LISINOPRIL METYROSINE TRIMETHAPHAN CAMSYLATE SODIUM POLYSTYRENE SULFONATE COLESTIPOL SIMVASTATIN ALBUTEROL METAPROTERENOL TERBUTALINE PIRBUTEROL AMINOPHYLLINE
d00730 d00732 d00735 d00738 d00743 d00744 d00746 d00749 d00750 d00752 d00755 d00755 d00758 d00759 d00760	BENAZEPRIL LISINOPRIL METYROSINE TRIMETHAPHAN CAMSYLATE SODIUM POLYSTYRENE SULFONATE COLESTIPOL SIMVASTATIN ALBUTEROL METAPROTERENOL TERBUTALINE PIRBUTEROL AMINOPHYLLINE BECLOMETHASONE
d00730 d00732 d00735 d00738 d00743 d00744 d00746 d00749 d00750 d00752 d00755 d00755 d00758 d00759 d00760 d00762	BENAZEPRIL LISINOPRIL METYROSINE TRIMETHAPHAN CAMSYLATE SODIUM POLYSTYRENE SULFONATE COLESTIPOL SIMVASTATIN ALBUTEROL METAPROTERENOL TERBUTALINE PIRBUTEROL AMINOPHYLLINE BECLOMETHASONE ACETYLCYSTEINE
d00730 d00732 d00735 d00738 d00743 d00744 d00746 d00749 d00750 d00752 d00755 d00755 d00758 d00759 d00760	BENAZEPRIL LISINOPRIL METYROSINE TRIMETHAPHAN CAMSYLATE SODIUM POLYSTYRENE SULFONATE COLESTIPOL SIMVASTATIN ALBUTEROL METAPROTERENOL TERBUTALINE PIRBUTEROL AMINOPHYLLINE BECLOMETHASONE ACETYLCYSTEINE
d00730 d00732 d00735 d00738 d00743 d00744 d00746 d00749 d00750 d00752 d00755 d00755 d00758 d00759 d00760 d00762 d00769	BENAZEPRIL LISINOPRIL METYROSINE TRIMETHAPHAN CAMSYLATE SODIUM POLYSTYRENE SULFONATE COLESTIPOL SIMVASTATIN ALBUTEROL METAPROTERENOL TERBUTALINE PIRBUTEROL AMINOPHYLLINE BECLOMETHASONE ACETYLCYSTEINE PSEUDOEPHEDRINE
d00730 d00732 d00735 d00738 d00743 d00744 d00746 d00749 d00750 d00752 d00755 d00755 d00758 d00759 d00760 d00762	BENAZEPRIL LISINOPRIL METYROSINE TRIMETHAPHAN CAMSYLATE SODIUM POLYSTYRENE SULFONATE COLESTIPOL SIMVASTATIN ALBUTEROL METAPROTERENOL TERBUTALINE PIRBUTEROL AMINOPHYLLINE BECLOMETHASONE ACETYLCYSTEINE PSEUDOEPHEDRINE NAPHAZOLINE
d00730 d00732 d00735 d00738 d00743 d00744 d00746 d00749 d00750 d00752 d00755 d00758 d00758 d00759 d00760 d00762 d00769 d00771	BENAZEPRIL LISINOPRIL METYROSINE TRIMETHAPHAN CAMSYLATE SODIUM POLYSTYRENE SULFONATE COLESTIPOL SIMVASTATIN ALBUTEROL METAPROTERENOL TERBUTALINE PIRBUTEROL AMINOPHYLLINE BECLOMETHASONE ACETYLCYSTEINE PSEUDOEPHEDRINE NAPHAZOLINE OPHTHALMIC
d00730 d00732 d00735 d00738 d00743 d00744 d00746 d00749 d00750 d00752 d00755 d00755 d00758 d00759 d00760 d00762 d00769	BENAZEPRIL LISINOPRIL METYROSINE TRIMETHAPHAN CAMSYLATE SODIUM POLYSTYRENE SULFONATE COLESTIPOL SIMVASTATIN ALBUTEROL METAPROTERENOL TERBUTALINE PIRBUTEROL AMINOPHYLLINE BECLOMETHASONE ACETYLCYSTEINE PSEUDOEPHEDRINE NAPHAZOLINE
d00730 d00732 d00735 d00738 d00743 d00744 d00746 d00749 d00750 d00752 d00755 d00758 d00758 d00759 d00760 d00762 d00769 d00771	BENAZEPRIL LISINOPRIL METYROSINE TRIMETHAPHAN CAMSYLATE SODIUM POLYSTYRENE SULFONATE COLESTIPOL SIMVASTATIN ALBUTEROL METAPROTERENOL TERBUTALINE PIRBUTEROL AMINOPHYLLINE BECLOMETHASONE ACETYLCYSTEINE PSEUDOEPHEDRINE NAPHAZOLINE OPHTHALMIC
d00730 d00732 d00735 d00738 d00743 d00744 d00746 d00749 d00750 d00752 d00755 d00758 d00759 d00760 d00762 d00769 d00771 d00772	BENAZEPRIL LISINOPRIL METYROSINE TRIMETHAPHAN CAMSYLATE SODIUM POLYSTYRENE SULFONATE COLESTIPOL SIMVASTATIN ALBUTEROL METAPROTERENOL TERBUTALINE PIRBUTEROL AMINOPHYLLINE BECLOMETHASONE ACETYLCYSTEINE PSEUDOEPHEDRINE NAPHAZOLINE OPHTHALMIC OXYMETAZOLINE NASAL
d00730 d00732 d00735 d00738 d00743 d00744 d00746 d00749 d00750 d00752 d00755 d00758 d00758 d00759 d00760 d00762 d00769 d00771	BENAZEPRIL LISINOPRIL METYROSINE TRIMETHAPHAN CAMSYLATE SODIUM POLYSTYRENE SULFONATE COLESTIPOL SIMVASTATIN ALBUTEROL METAPROTERENOL TERBUTALINE PIRBUTEROL AMINOPHYLLINE BECLOMETHASONE ACETYLCYSTEINE PSEUDOEPHEDRINE NAPHAZOLINE OPHTHALMIC OXYMETAZOLINE NASAL TETRAHY-
d00730 d00732 d00735 d00738 d00743 d00744 d00746 d00749 d00750 d00752 d00755 d00758 d00759 d00760 d00762 d00769 d00771 d00772	BENAZEPRIL LISINOPRIL METYROSINE TRIMETHAPHAN CAMSYLATE SODIUM POLYSTYRENE SULFONATE COLESTIPOL SIMVASTATIN ALBUTEROL METAPROTERENOL TERBUTALINE PIRBUTEROL AMINOPHYLLINE BECLOMETHASONE ACETYLCYSTEINE PSEUDOEPHEDRINE NAPHAZOLINE OPHTHALMIC OXYMETAZOLINE NASAL TETRAHY- DROZOLINE
d00730 d00732 d00735 d00738 d00743 d00744 d00746 d00749 d00750 d00752 d00755 d00758 d00759 d00760 d00762 d00769 d00771 d00772	BENAZEPRIL LISINOPRIL METYROSINE TRIMETHAPHAN CAMSYLATE SODIUM POLYSTYRENE SULFONATE COLESTIPOL SIMVASTATIN ALBUTEROL METAPROTERENOL TERBUTALINE PIRBUTEROL AMINOPHYLLINE BECLOMETHASONE ACETYLCYSTEINE PSEUDOEPHEDRINE NAPHAZOLINE OPHTHALMIC OXYMETAZOLINE NASAL TETRAHY- DROZOLINE OPHTHALMIC
d00730 d00732 d00735 d00738 d00743 d00744 d00746 d00749 d00750 d00752 d00755 d00758 d00759 d00760 d00762 d00769 d00771 d00772	BENAZEPRIL LISINOPRIL METYROSINE TRIMETHAPHAN CAMSYLATE SODIUM POLYSTYRENE SULFONATE COLESTIPOL SIMVASTATIN ALBUTEROL METAPROTERENOL TERBUTALINE PIRBUTEROL AMINOPHYLLINE BECLOMETHASONE ACETYLCYSTEINE PSEUDOEPHEDRINE NAPHAZOLINE OPHTHALMIC OXYMETAZOLINE NASAL TETRAHY- DROZOLINE

d00806PHENTERMINEd00809PHENDIMETRAZINEd00810DIETHYLPROPIONd00812FENFLURAMINEd00813BENZOCAINE TOPICALd00817HYDROXY- CHLOROQUINEd00818AURANOFINd00824OPIUMd00838BUTORPHANOLd00839NALBUPHINEd00840BUPRENORPHINEd00841SODIUM SALICYLATEd00842SALSALATEd00843SODIUM SALICYLATEd00844SODIUM SALICYLATEd00845DICLOFENACd00856PERPHENAZINEd00857THIETHYLPERAZINEd00858PERPHENAZINEd00859MECLIZINEd00861DIMENHYDRINATEd00862TRIMETHO- BENZAMIDEd00863ONDANSETRONd00873TRIMIPRAMINEd00874AMOXAPINEd00875SERTRALINEd00880SERTRALINEd00881SIOCARBOXAZIDd00882ISOCARBOXAZIDd00883PHENELZINEd00884TRANYLCYPROMINEd00884TRANYLCYPROMINEd00884TRANYLCYPROMINEd00889PIMOZIDEd00889PIMOZIDEd00890REIFLUOPERAZINEd00891PEMOLINEd00892PIMOZIDEd00893PIMOZIDEd00894PIMOZIDEd00895PIMOZIDEd00896PIMOZIDEd00897LOXAPINEd00898PIMOZIDEd00899PIMOLINEd00	d00785 d00786 d00787 d00790 d00794 d00796 d00797 d00800 d00801 d00803 d00804	BROMPHENIRAMINE TRIPROLIDINE PROMETHAZINE CYPROHEPTADINE ASTEMIZOLE BENZONATATE GUAIFENESIN POTASSIUM IODIDE CAFFEINE AMPHETAMINE DEXTROAMPHET- AMINE
d00810DIETHYLPROPIONd00812FENFLURAMINEd00813BENZOCAINE TOPICALd00817HYDROXY- CHLOROQUINEd00818AURANOFINd00824OPIUMd00838BUTORPHANOLd00839NALBUPHINEd00840BUPRENORPHINEd00842SALSALATEd00843SODIUM SALICYLATEd00844SODIUMd00845SALSALATEd00846MAGNESIUM SALICYLATEd00847DICLOFENACd00848DICLOFENACd00851ETODOLACd00855PERPHENAZINEd00856PERPHENAZINEd00857THIETHYLPERAZINEd00861DIMENHYDRINATEd00862TRIMETHO- BENZAMIDEd00863ONDANSETRONd00873TRIMIPRAMINEd00874AMOXAPINEd00875SERTRALINEd00880SERTRALINEd00881SIOCARBOXAZIDd00883PHENELZINEd00884TRANYLCYPROMINEd00884TRANYLCYPROMINEd00883PHENELZINEd00884TRANYLCYPROMINEd00884TRANYLCYPROMINEd00885PIMOZIDEd00886PIMOZIDEd00897LOXAPINEd00898PIMOZIDEd00898PIMOZIDEd00898PIMOZIDEd00899PEROLINEd00890RETHYLPHENIDATEd00891PEMOLINEd00892ERGOLOID		
d00812FENFLURAMINEd00813BENZOCAINE TOPICALd00817HYDROXY- CHLOROQUINEd00818AURANOFINd00824OPIUMd00838BUTORPHANOLd00839NALBUPHINEd00840BUPRENORPHINEd00842SALSALATEd00843SODIUM SALICYLATEd00844SODIUMd00845SALSALATEd00846MAGNESIUM SALICYLATEd00847DICLOFENACd00848DICLOFENACd00851ETODOLACd00855PERPHENAZINEd00856PERPHENAZINEd00867THIETHYLPERAZINEd00861DIMENHYDRINATEd00862TRIMETHO- BENZAMIDEd00863ONDANSETRONd00873TRIMIPRAMINEd00874AMOXAPINEd00880SERTRALINEd00881SIOCARBOXAZIDd00882ISOCARBOXAZIDd00883PHENELZINEd00884TRANYLCYPROMINEd00884TRANYLCYPROMINEd00884TRANYLCYPROMINEd00884TRANYLCYPROMINEd00885PIMOZIDEd00896MOLINDONEd00897LOXAPINEd00898PIMOZIDEd00898PIMOZIDEd00898PIMOZIDEd00900RETHYLPHENIDATEd00901PEMOLINEd00902ERGOLOID		
d00813BENZOCAINE TOPICALd00817HYDROXY- CHLOROQUINEd00818AURANOFINd00824OPIUMd00838BUTORPHANOLd00839NALBUPHINEd00840BUPRENORPHINEd00842SALSALATEd00843SODIUM SALICYLATEd00844SODIUMd00845SODIUM SALICYLATEd00846MAGNESIUM SALICYLATEd00847DICLOFENACd00851ETODOLACd00853OXAPROZINd00855PERPHENAZINEd00856PERPHENAZINEd00861DIMENHYDRINATEd00862TRIMETHO- BENZAMIDEd00866DRONABINOLd00877MACAPINEd00873TRIMIPRAMINEd00874AMOXAPINEd00875SERTRALINEd00880SERTRALINEd00871MAPROTILINEd00881FRANYLCYPROMINEd00882ISOCARBOXAZIDd00883PHENELZINEd00884TRANYLCYPROMINEd00885PIMOZIDEd00896MOLINDONEd00897LOXAPINEd00898PIMOZIDEd00898PIMOZIDEd00898PIMOZIDEd00900METHYLPHENIDATEd00901PEMOLINEd00902ERGOLOID		
TOPICALd00817HYDROXY- CHLOROQUINEd00818AURANOFINd00824OPIUMd00838BUTORPHANOLd00839NALBUPHINEd00840BUPRENORPHINEd00842SALSALATEd00843SODIUM SALICYLATEd00844SODIUMd00845SODIUM SALICYLATEd00846MAGNESIUM SALICYLATEd00847DICLOFENACd00848DICLOFENACd00851ETODOLACd00853OXAPROZINd00855PERPHENAZINEd00856PERPHENAZINEd00861DIMENHYDRINATEd00862TRIMETHO- BENZAMIDEd00863ONDANSETRONd00873TRIMIPRAMINEd00874AMOXAPINEd00875SERTRALINEd00880SERTRALINEd00881SIOCARBOXAZIDd00882ISOCARBOXAZIDd00883PHENELZINEd00884TRANYLCYPROMINEd00885PIMOZIDEd00886PIMOZIDEd00887LOXAPINEd00888PIMOZIDEd00889PIMOZIDEd00898PIMOZIDEd00898PIMOZIDEd00898PIMOZIDEd00890RETHYLPHENIDATEd00891PEMOLINEd00892ERGOLOID		_
d00817HYDROXY- CHLOROQUINEd00818AURANOFINd00824OPIUMd00838BUTORPHANOLd00839NALBUPHINEd00840BUPRENORPHINEd00842SALSALATEd00843SODIUM SALICYLATEd00844SODIUMd00845SODIUM SALICYLATEd00846MAGNESIUM SALICYLATEd00847DICLOFENACd00848DICLOFENACd00851ETODOLACd00855PERPHENAZINEd00856PERPHENAZINEd00857THIETHYLPERAZINEd00861DIMENHYDRINATEd00862TRIMETHO- BENZAMIDEd00863ONDANSETRONd00873TRIMIPRAMINEd00874AMOXAPINEd00875SERTRALINEd00880SERTRALINEd00881SIOCARBOXAZIDd00883PHENELZINEd00884TRANYLCYPROMINEd00883PHENELZINEd00884TRANYLCYPROMINEd00889INOZIDEd00896MOLINDONEd00897LOXAPINEd00898PIMOZIDEd00898PIMOZIDEd00898PIMOZIDEd00900METHYLPHENIDATEd00901PEMOLINEd00902ERGOLOID	000010	
CHLOROQUINEd00818AURANOFINd00824OPIUMd00838BUTORPHANOLd00839NALBUPHINEd00840BUPRENORPHINEd00842SALSALATEd00843SODIUM SALICYLATEd00844SODIUMd00845SODIUM SALICYLATEd00846MAGNESIUMmuiceSALICYLATEd00847DICLOFENACd00848DICLOFENACd00851ETODOLACd00855PERPHENAZINEd00856PERPHENAZINEd00857THIETHYLPERAZINEd00861DIMENHYDRINATEd00862TRIMETHO- BENZAMIDEd00863ONDANSETRONd00873TRIMIPRAMINEd00874AMOXAPINEd00875SERTRALINEd00880SERTRALINEd00881SIOCARBOXAZIDd00883PHENELZINEd00884TRANYLCYPROMINEd00884TRANYLCYPROMINEd00885PIMOZIDEd00896MOLINDONEd00897LOXAPINEd00898PIMOZIDEd00898PIMOZIDEd00898PIMOZIDEd00898PIMOZIDEd00900METHYLPHENIDATEd00901PEMOLINEd00902ERGOLOID	d00817	
d00818AURANOFINd00824OPIUMd00838BUTORPHANOLd00839NALBUPHINEd00840BUPRENORPHINEd00842SALSALATEd00843SODIUM SALICYLATEd00844SODIUMd00845SODIUM SALICYLATEd00846MAGNESIUMmusclereSALICYLATEd00847DICLOFENACd00851ETODOLACd00853OXAPROZINd00855PERPHENAZINEd00856PERPHENAZINEd00861DIMENHYDRINATEd00862TRIMETHO- BENZAMIDEd00863ONDANSETRONd00873TRIMIPRAMINEd00874AMOXAPINEd00875SERTRALINEd00880SERTRALINEd00871MAPROTILINEd00880SERTRALINEd00881FIANYLCYPROMINEd00882ISOCARBOXAZIDd00883PHENELZINEd00884TRANYLCYPROMINEd00896MOLINDONEd00897LOXAPINEd00898PIMOZIDEd00898PIMOZIDEd00898PIMOZIDEd00900METHYLPHENIDATEd00901PEMOLINEd00902ERGOLOID		
d00838BUTORPHANOLd00839NALBUPHINEd00840BUPRENORPHINEd00842SALSALATEd00843SODIUM SALICYLATEd00844SODIUM SALICYLATEd00844SODIUMd00845SODIUM SALICYLATEd00846MAGNESIUMSALICYLATEd00847d00847DICLOFENACd00851ETODOLACd00853OXAPROZINd00855PERPHENAZINEd00857THIETHYLPERAZINEd00859MECLIZINEd00861DIMENHYDRINATEd00862TRIMETHO- BENZAMIDEd00863ONDANSETRONd00873TRIMIPRAMINEd00874AMOXAPINEd00875SERTRALINEd00880SERTRALINEd00881ISOCARBOXAZIDd00882ISOCARBOXAZIDd00883PHENELZINEd00884TRANYLCYPROMINEd00890TRIFLUOPERAZINEd00891LOXAPINEd00892PIMOZIDEd00893PIMOZIDEd00900METHYLPHENIDATEd00901PEMOLINEd00902ERGOLOID	d00818	
d00839NALBUPHINEd00840BUPRENORPHINEd00842SALSALATEd00843SODIUM SALICYLATEd00844SODIUMd00844SODIUMd00846MAGNESIUMSALICYLATEd00847d00847DICLOFENACd00851ETODOLACd00853OXAPROZINd00855PERPHENAZINEd00856PERPHENAZINEd00857THIETHYLPERAZINEd00861DIMENHYDRINATEd00862TRIMETHO- BENZAMIDEd00866DRONABINOLd00877ONDANSETRONd00873TRIMIPRAMINEd00874AMOXAPINEd00880SERTRALINEd00881ISOCARBOXAZIDd00882ISOCARBOXAZIDd00883PHENELZINEd00890TRIFLUOPERAZINEd00891LOXAPINEd00892ISOCARBOXAZIDd00893PHENELZINEd00894TRANYLCYPROMINEd00895PIMOZIDEd00896PIMOZIDEd00897LOXAPINEd00898PIMOZIDEd00900METHYLPHENIDATEd00901PEMOLINEd00902ERGOLOID	d00824	
d00840BUPRENORPHINEd00842SALSALATEd00843SODIUM SALICYLATEd00844SODIUMd00844SODIUMd00846MAGNESIUMSALICYLATEd00848d00847DICLOFENACd00851ETODOLACd00853OXAPROZINd00855PERPHENAZINEd00857THIETHYLPERAZINEd00859MECLIZINEd00861DIMENHYDRINATEd00862TRIMETHO- BENZAMIDEd00863ONDANSETRONd00864DRONABINOLd00873TRIMIPRAMINEd00874AMOXAPINEd00880SERTRALINEd00881SIOCARBOXAZIDd00882ISOCARBOXAZIDd00884TRANYLCYPROMINEd00890TRIFLUOPERAZINEd00891LOXAPINEd00892PIMOZIDEd00893PIMOZIDEd00900METHYLPHENIDATEd00901PEMOLINEd00902ERGOLOID	d00838	BUTORPHANOL
d00842SALSALATEd00843SODIUM SALICYLATEd00844SODIUMd00844SODIUMTHIOSALICYLATEd00846MAGNESIUMSALICYLATEd00848DICLOFENACd00851ETODOLACd00853OXAPROZINd00855PERPHENAZINEd00857THIETHYLPERAZINEd00859MECLIZINEd00861DIMENHYDRINATEd00862TRIMETHO- BENZAMIDEd00866DRONABINOLd00877ONDANSETRONd00873TRIMIPRAMINEd00874AMOXAPINEd00875SERTRALINEd00880SERTRALINEd00881ISOCARBOXAZIDd00883PHENELZINEd00884TRANYLCYPROMINEd00890TRIFLUOPERAZINEd00891LOXAPINEd00892PIMOZIDEd00893PIMOZIDEd00900METHYLPHENIDATEd00901PEMOLINEd00902ERGOLOID		-
d00843SODIUM SALICYLATEd00844SODIUMTHIOSALICYLATEd00846MAGNESIUMSALICYLATEd00848DICLOFENACd00851ETODOLACd00853OXAPROZINd00855PERPHENAZINEd00857THIETHYLPERAZINEd00861DIMENHYDRINATEd00862TRIMETHO-d00863ONDANSETRONd00864DRONABINOLd00865ONDANSETRONd00873TRIMIPRAMINEd00874AMOXAPINEd00875SERTRALINEd00880SERTRALINEd00881ISOCARBOXAZIDd00883PHENELZINEd00884TRANYLCYPROMINEd00896MOLINDONEd00897LOXAPINEd00898PIMOZIDEd00898PIMOZIDEd00900METHYLPHENIDATEd00901PEMOLINE		
d00844SODIUM THIOSALICYLATEd00846MAGNESIUM SALICYLATEd00848DICLOFENACd00851ETODOLACd00853OXAPROZINd00855PERPHENAZINEd00857THIETHYLPERAZINEd00859MECLIZINEd00861DIMENHYDRINATEd00862TRIMETHO- BENZAMIDEd00866DRONABINOLd00877ONDANSETRONd00873TRIMIPRAMINEd00874AMOXAPINEd00875SERTRALINEd00880SERTRALINEd00881SOCARBOXAZIDd00883PHENELZINEd00884TRANYLCYPROMINEd00890TRIFLUOPERAZINEd00891LOXAPINEd00892PIMOZIDEd00893PIMOZIDEd00900METHYLPHENIDATEd00901PEMOLINEd00902ERGOLOID		
THIOSALICYLATE d00846 MAGNESIUM SALICYLATE d00848 DICLOFENAC d00851 ETODOLAC d00853 OXAPROZIN d00855 PERPHENAZINE d00857 THIETHYLPERAZINE d00859 MECLIZINE d00861 DIMENHYDRINATE d00862 TRIMETHO- BENZAMIDE d00866 DRONABINOL d00867 ONDANSETRON d00873 TRIMIPRAMINE d00874 AMOXAPINE d00876 CLOMIPRAMINE d00877 MAPROTILINE d00880 SERTRALINE d00882 ISOCARBOXAZID d00883 PHENELZINE d00884 TRANYLCYPROMINE d00890 TRIFLUOPERAZINE d00890 TRIFLUOPERAZINE d00890 MOLINDONE d00897 LOXAPINE d00898 PIMOZIDE d00900 METHYLPHENIDATE d00901 PEMOLINE		
d00846MAGNESIUM SALICYLATEd00848DICLOFENACd00851ETODOLACd00853OXAPROZINd00855PERPHENAZINEd00857THIETHYLPERAZINEd00859MECLIZINEd00861DIMENHYDRINATEd00862TRIMETHO- BENZAMIDEd00866DRONABINOLd00877ONDANSETRONd00873TRIMIPRAMINEd00874AMOXAPINEd00880SERTRALINEd00881SOCARBOXAZIDd00882ISOCARBOXAZIDd00883PHENELZINEd00884TRANYLCYPROMINEd00890TRIFLUOPERAZINEd00891LOXAPINEd00892PIMOZIDEd00893PIMOZIDEd00900METHYLPHENIDATEd00901PEMOLINEd00902ERGOLOID	000844	
SALICYLATE d00848 DICLOFENAC d00851 ETODOLAC d00853 OXAPROZIN d00855 PERPHENAZINE d00857 THIETHYLPERAZINE d00857 THIETHYLPERAZINE d00861 DIMENHYDRINATE d00862 TRIMETHO- BENZAMIDE d00866 DRONABINOL d00867 ONDANSETRON d00873 TRIMIPRAMINE d00874 AMOXAPINE d00876 CLOMIPRAMINE d00877 MAPROTILINE d00880 SERTRALINE d00882 ISOCARBOXAZID d00883 PHENELZINE d00884 TRANYLCYPROMINE d00884 TRANYLCYPROMINE d00890 TRIFLUOPERAZINE d00890 TRIFLUOPERAZINE d00890 TRIFLUOPERAZINE d00890 PIMOZIDE d00898 PIMOZIDE d00900 METHYLPHENIDATE d00901 PEMOLINE	d00846	
d00848DICLOFENACd00851ETODOLACd00853OXAPROZINd00855PERPHENAZINEd00857THIETHYLPERAZINEd00859MECLIZINEd00861DIMENHYDRINATEd00862TRIMETHO- BENZAMIDEd00866DRONABINOLd00867ONDANSETRONd00873TRIMIPRAMINEd00874AMOXAPINEd00875CLOMIPRAMINEd00880SERTRALINEd00881SOCARBOXAZIDd00882ISOCARBOXAZIDd00883PHENELZINEd00890TRIFLUOPERAZINEd00890TRIFLUOPERAZINEd00891LOXAPINEd00892PIMOZIDEd00900METHYLPHENIDATEd00901PEMOLINEd00902ERGOLOID		
d00853OXAPROZINd00855PERPHENAZINEd00857THIETHYLPERAZINEd00859MECLIZINEd00861DIMENHYDRINATEd00862TRIMETHO-d00866DRONABINOLd00867ONDANSETRONd00873TRIMIPRAMINEd00874AMOXAPINEd00880SERTRALINEd00882ISOCARBOXAZIDd00883PHENELZINEd00884TRANYLCYPROMINEd00890TRIFLUOPERAZINEd00891LOXAPINEd00892PIMOZIDEd00893PIMOZIDEd00900METHYLPHENIDATEd00901PEMOLINEd00902ERGOLOID	d00848	
d00855PERPHENAZINEd00857THIETHYLPERAZINEd00859MECLIZINEd00861DIMENHYDRINATEd00862TRIMETHO-bENZAMIDEBENZAMIDEd00866DRONABINOLd00867ONDANSETRONd00873TRIMIPRAMINEd00874AMOXAPINEd00875CLOMIPRAMINEd00880SERTRALINEd00882ISOCARBOXAZIDd00883PHENELZINEd00884TRANYLCYPROMINEd00890TRIFLUOPERAZINEd00891LOXAPINEd00892PIMOZIDEd00900METHYLPHENIDATEd00901PEMOLINEd00902ERGOLOID	d00851	ETODOLAC
d00857THIETHYLPERAZINEd00859MECLIZINEd00861DIMENHYDRINATEd00862TRIMETHO- BENZAMIDEd00866DRONABINOLd00867ONDANSETRONd00873TRIMIPRAMINEd00874AMOXAPINEd00875CLOMIPRAMINEd00880SERTRALINEd00882ISOCARBOXAZIDd00883PHENELZINEd00884TRANYLCYPROMINEd00890TRIFLUOPERAZINEd00891LOXAPINEd00892PIMOZIDEd00900METHYLPHENIDATEd00901PEMOLINEd00902ERGOLOID		
d00859MECLIZINEd00861DIMENHYDRINATEd00862TRIMETHO- BENZAMIDEd00866DRONABINOLd00867ONDANSETRONd00873TRIMIPRAMINEd00874AMOXAPINEd00875CLOMIPRAMINEd00876CLOMIPRAMINEd00880SERTRALINEd00882ISOCARBOXAZIDd00883PHENELZINEd00884TRANYLCYPROMINEd00890TRIFLUOPERAZINEd00891LOXAPINEd00892PIMOZIDEd00900METHYLPHENIDATEd00901PEMOLINEd00902ERGOLOID		
d00861DIMENHYDRINATEd00862TRIMETHO- BENZAMIDEd00866DRONABINOLd00867ONDANSETRONd00873TRIMIPRAMINEd00874AMOXAPINEd00875CLOMIPRAMINEd00876CLOMIPRAMINEd00877MAPROTILINEd00880SERTRALINEd00882ISOCARBOXAZIDd00883PHENELZINEd00884TRANYLCYPROMINEd00890TRIFLUOPERAZINEd00891LOXAPINEd00892PIMOZIDEd00900METHYLPHENIDATEd00901PEMOLINEd00902ERGOLOID		
d00862TRIMETHO- BENZAMIDEd00866DRONABINOLd00867ONDANSETRONd00873TRIMIPRAMINEd00874AMOXAPINEd00875CLOMIPRAMINEd00876CLOMIPRAMINEd00877MAPROTILINEd00880SERTRALINEd00882ISOCARBOXAZIDd00883PHENELZINEd00884TRANYLCYPROMINEd00890TRIFLUOPERAZINEd00891LOXAPINEd00892PIMOZIDEd00900METHYLPHENIDATEd00901PEMOLINEd00902ERGOLOID		
BENZAMIDE d00866 DRONABINOL d00867 ONDANSETRON d00873 TRIMIPRAMINE d00874 AMOXAPINE d00876 CLOMIPRAMINE d00877 MAPROTILINE d00880 SERTRALINE d00882 ISOCARBOXAZID d00883 PHENELZINE d00884 TRANYLCYPROMINE d00890 TRIFLUOPERAZINE d00890 TRIFLUOPERAZINE d00897 LOXAPINE d00898 PIMOZIDE d00900 METHYLPHENIDATE d00901 PEMOLINE d00902 ERGOLOID		
d00866DRONABINOLd00867ONDANSETRONd00873TRIMIPRAMINEd00874AMOXAPINEd00876CLOMIPRAMINEd00877MAPROTILINEd00880SERTRALINEd00882ISOCARBOXAZIDd00883PHENELZINEd00884TRANYLCYPROMINEd00890TRIFLUOPERAZINEd00897LOXAPINEd00898PIMOZIDEd00900METHYLPHENIDATEd00901PEMOLINEd00902ERGOLOID	000602	
d00867ONDANSETRONd00873TRIMIPRAMINEd00874AMOXAPINEd00876CLOMIPRAMINEd00877MAPROTILINEd00880SERTRALINEd00882ISOCARBOXAZIDd00883PHENELZINEd00884TRANYLCYPROMINEd00890TRIFLUOPERAZINEd00897LOXAPINEd00898PIMOZIDEd00898PIMOZIDEd00900METHYLPHENIDATEd00901PEMOLINEd00902ERGOLOID	400866	
d00873TRIMIPRAMINEd00874AMOXAPINEd00876CLOMIPRAMINEd00877MAPROTILINEd00880SERTRALINEd00882ISOCARBOXAZIDd00883PHENELZINEd00884TRANYLCYPROMINEd00890TRIFLUOPERAZINEd00896MOLINDONEd00897LOXAPINEd00898PIMOZIDEd00900METHYLPHENIDATEd00901PEMOLINEd00902ERGOLOID		
d00874AMOXAPINEd00876CLOMIPRAMINEd00877MAPROTILINEd00880SERTRALINEd00882ISOCARBOXAZIDd00883PHENELZINEd00884TRANYLCYPROMINEd00890TRIFLUOPERAZINEd00896MOLINDONEd00897LOXAPINEd00898PIMOZIDEd00900METHYLPHENIDATEd00901PEMOLINEd00902ERGOLOID		
d00877MAPROTILINEd00880SERTRALINEd00882ISOCARBOXAZIDd00883PHENELZINEd00884TRANYLCYPROMINEd00890TRIFLUOPERAZINEd00896MOLINDONEd00897LOXAPINEd00898PIMOZIDEd00900METHYLPHENIDATEd00901PEMOLINEd00902ERGOLOID		
d00880SERTRALINEd00882ISOCARBOXAZIDd00883PHENELZINEd00884TRANYLCYPROMINEd00890TRIFLUOPERAZINEd00896MOLINDONEd00897LOXAPINEd00898PIMOZIDEd00900METHYLPHENIDATEd00901PEMOLINEd00902ERGOLOID	d00876	CLOMIPRAMINE
d00882ISOCARBOXAZIDd00883PHENELZINEd00884TRANYLCYPROMINEd00890TRIFLUOPERAZINEd00896MOLINDONEd00897LOXAPINEd00898PIMOZIDEd00900METHYLPHENIDATEd00901PEMOLINEd00902ERGOLOID	d00877	
d00883PHENELZINEd00884TRANYLCYPROMINEd00890TRIFLUOPERAZINEd00896MOLINDONEd00897LOXAPINEd00898PIMOZIDEd00900METHYLPHENIDATEd00901PEMOLINEd00902ERGOLOID		
d00884TRANYLCYPROMINEd00890TRIFLUOPERAZINEd00896MOLINDONEd00897LOXAPINEd00898PIMOZIDEd00900METHYLPHENIDATEd00901PEMOLINEd00902ERGOLOID		
d00890TRIFLUOPERAZINEd00896MOLINDONEd00897LOXAPINEd00898PIMOZIDEd00900METHYLPHENIDATEd00901PEMOLINEd00902ERGOLOID		
d00896MOLINDONEd00897LOXAPINEd00898PIMOZIDEd00900METHYLPHENIDATEd00901PEMOLINEd00902ERGOLOID		
d00897LOXAPINEd00898PIMOZIDEd00900METHYLPHENIDATEd00901PEMOLINEd00902ERGOLOID		
d00898PIMOZIDEd00900METHYLPHENIDATEd00901PEMOLINEd00902ERGOLOID		
d00900 METHYLPHENIDATE d00901 PEMOLINE d00902 ERGOLOID		
d00901 PEMOLINE d00902 ERGOLOID		-
d00902 ERGOLOID		
		MESYLATES

d00904 d00907 d00910 d00915 d00919 d00929 d00933 d00934 d00957 d00960 d00962 d00963 d00964 d00965 d00966 d00967 d00968 d00967 d00972 d00970 d00972 d00976 d00977 d00978 d00984 d00984 d00985 d00988 d00988 d00991 d00992 d00977 d00978 d00977 d00978 d00977 d00978 d00977 d00978 d00977 d00978 d00977 d00978 d00977 d00978 d00984 d00985 d00985 d00986 d00985 d00985 d00986 d00977 d00978 d00977 d00978 d00977 d00978 d00977 d00978 d00977 d00978 d00977 d00978 d00984 d00985 d00986 d00985 d00986 d00985 d00986 d00977 d00978 d00977 d00978 d00977 d00978 d00977 d00978 d00977 d00978 d00977 d00978 d00977 d00978 d00977 d00978 d00986 d00985 d00986 d00988 d00991 d00977 d00978 d00977 d00978 d00970 d00977 d00978 d00970 d00977 d00978 d00970 d00977 d00978 d00970 d00970 d00977 d00978 d00988 d00988 d00988 d00991 d00970 d00970 d00970 d00970 d00970 d00970 d00970 d00970 d00970 d00978 d00988 d00980 d00991 d0092 d00970 d00070 d00077 d00	PSYLLIUM MINERAL OIL DOCUSATE
001008	DEMEGLOGIGLINE

d01070	OXYTETRACYCLINE
d01097	RIFABUTIN
d01104	PAROMOMYCIN
d01113	COLISTIMETHATE
d01115	BACITRACIN
d011120	ATOVAQUONE
	IMMUNE GLOBULIN
d01133	
104404	INTRAVENOUS
d01134	CYTOMEGALOVIRUS
	IMMUNE GLOBULIN
d01135	IMMUNE GLOBULIN
	INTRAMUSCULAR
d01137	TETANUS IMMUNE
	GLOBULIN
d01138	VARICELLA ZOSTER
	IMMUNE GLOBULIN
d01139	RHO (D) IMMUNE
401100	GLOBULIN
d01147	RABIES VACCINE
uu 1 1 4 7	
-104440	(OBSOLETE)
d01148	RABIES IMMUNE
	GLOBULIN, HUMAN
d01150	BCG
d01154	CHOLERA VACCINE
d01156	TYPHOID VACCINE,
	INACTIVATED
d01158	HAEMOPHILUS B
	CONJUGATE
	VACCINE
	(OBSOLETE)
d01159	MEASLES VIRUS
	VACCINE
d01160	RUBELLA VIRUS
401100	VACCINE
d01161	MUMPS VIRUS
001101	VACCINE
d01164	INFLUENZA VIRUS
001104	
104405	INACTIVATED
d01165	YELLOW FEVER
	VACCINE
d01166	HEPATITIS B
	VACCINE
d01168	TETANUS TOXOID
d01171	TUBERCULIN
	PURIFIED PROTEIN
	DERIVATIVE
d01184	DIPIVEFRIN
	OPHTHALMIC
d01185	APRACLONIDINE
201100	OPHTHALMIC
d01187	LEVOBUNOLOL
001107	OPHTHALMIC
d01100	
d01189	CARBACHOL
401404	
d01191	PILOCARPINE
	OPHTHALMIC

2006 NAMCS MICRO-DATA FILE DOCUMENTATION, APPENDIX III – GENERIC LIST

-104405	
d01195	ECHOTHIOPHATE IODIDE
104400	OPHTHALMIC
d01199	HOMATROPINE
401200	OPHTHALMIC
d01200	TROPICAMIDE OPHTHALMIC
d01201	CYCLOPENTOLATE
001201	OPHTHALMIC
d01204	SUPROFEN
	OPHTHALMIC
d01208	SULFACETAMIDE
	SODIUM
-104040	OPHTHALMIC
d01213	NATAMYCIN OPHTHALMIC
d01215	TRIFLURIDINE
001210	OPHTHALMIC
d01217	TETRACAINE
d01218	PROPARACAINE
	OPHTHALMIC
d01219	FLUORESCEIN
	OPHTHALMIC
d01222	SODIUM
	HYALURONATE
-104005	
d01225 d01226	BORIC ACID TOPICAL HYDROXYPROPYL
001220	METHYLCELLULOSE
	OPHTHALMIC
d01227	BOTULINUM TOXIN
	TYPE A
d01231	CHLORHEXIDINE
104000	TOPICAL
d01232	CARBAMIDE PEROXIDE TOPICAL
d01234	BUTOCONAZOLE
001204	TOPICAL
d01236	CLOTRIMAZOLE
d01238	TERCONAZOLE
	TOPICAL
d01239	GENTIAN VIOLET
d01240	
001240	SULFANILAMIDE TOPICAL
d01241	CLINDAMYCIN
	TOPICAL
d01242	NONOXYNOL 9
	TOPICAL
d01244	TRETINOIN TOPICAL
d01245	ISOTRETINOIN
d01246	BENZOYL PEROXIDE TOPICAL
d01254	ANTHRALIN TOPICAL
d01257	NITROFURAZONE
	TOPICAL
d01258	MAFENIDE TOPICAL
d01259	SILVER
	SULFADIAZINE
	TOPICAL

d01263	PYRITHIONE ZINC
	TOPICAL
d01265	SULFACETAMIDE
	SODIUM TOPICAL
d01267	MUPIROCIN TOPICAL
d01271	ECONAZOLE
	TOPICAL
d01272	CICLOPIROX
	TOPICAL
d01274	TOLNAFTATE
	TOPICAL
d01277	NAFTIFINE TOPICAL
d01278	LINDANE TOPICAL
d01279	PERMETHRIN
	TOPICAL
d01280	CROTAMITON
	TOPICAL
d01282	ALCLOMETASONE
	TOPICAL
d01283	AMCINONIDE
	TOPICAL
d01288	CLOBETASOL
	TOPICAL
d01289	CLOCORTOLONE
	TOPICAL
d01290	DESONIDE TOPICAL
d01291	DESOXIMETASONE
	TOPICAL
d01292	DIFLORASONE
	TOPICAL
d01293	FLUOCINOLONE
	TOPICAL
d01294	FLUOCINONIDE
	TOPICAL
d01295	FLURANDRENOLIDE
	TOPICAL
d01298	HALOBETASOL
	TOPICAL
d01301	DIBUCAINE TOPICAL
d01303	PRAMOXINE
	TOPICAL
d01305	DYCLONINE TOPICAL
d01306	COCAINE TOPICAL
d01307	SALICYLIC ACID
	TOPICAL
d01308	PODOPHYLLUM
	RESIN TOPICAL
d01309	PODOFILOX TOPICAL
d01312	DICHLOROACETIC
	ACID TOPICAL
d01313	TRICHLOROACETIC
	ACID TOPICAL
d01315	COLLAGENASE
	TOPICAL
d01319	HYDROQUINONE
	TOPICAL
d01321	CAPSAICIN TOPICAL

d01322	ALUMINUM
001522	
	CHLORIDE
	HEXAHYDRATE
	TOPICAL
d01325	ARNICA TOPICAL
d01332	HEXACHLOROPHENE
	TOPICAL
d01333	BENZALKONIUM
	CHLORIDE TOPICAL
-104005	
d01335	SODIUM
	HYPOCHLORITE
	TOPICAL
d01339	MECHLORETHAMINE
d01342	CARMUSTINE
d01344	FLOXURIDINE
d01345	THIOGUANINE
d01346	FLUDARABINE
d01348	MEGESTROL
d01353	LEUPROLIDE
d01354	GOSERELIN
d01369	INTERFERON
001309	
	ALFA-2B
d01372	ALTRETAMINE
d01373	HYDROXYUREA
d01375	ALDESLEUKIN
d01376	PACLITAXEL
d01379	ASPARAGINASE
d01382	ETHANOLAMINE
001002	OLEATE
104000	-
d01383	SODIUM
	TETRADECYL
	SULFATE
d01384	MORRHUATE
uu 1364	
	SODIUM
d01385	BETA; CAROTENE
d01387	ALPROSTADIL
d01388	CHYMOPAPAIN
d01389	DISULFIRAM
d01394	PROCAINE
d01395	CHLOROPROCAINE
d01398	MEPIVACAINE
d01406	NALTREXONE
d01407	FLUMAZENIL
d01409	
d01/11	PRALIDOXIME
d01411	MESNA
d01416	MESNA TRIENTINE
	MESNA
d01416 d01417	MESNA TRIENTINE SUCCIMER
d01416 d01417 d01423	MESNA TRIENTINE SUCCIMER POTASSIUM CITRATE
d01416 d01417 d01423 d01425	MESNA TRIENTINE SUCCIMER POTASSIUM CITRATE FLAVOXATE
d01416 d01417 d01423 d01425 d01427	MESNA TRIENTINE SUCCIMER POTASSIUM CITRATE FLAVOXATE BETHANECHOL
d01416 d01417 d01423 d01425	MESNA TRIENTINE SUCCIMER POTASSIUM CITRATE FLAVOXATE BETHANECHOL ACETOHYDROXAMIC
d01416 d01417 d01423 d01425 d01427	MESNA TRIENTINE SUCCIMER POTASSIUM CITRATE FLAVOXATE BETHANECHOL ACETOHYDROXAMIC
d01416 d01417 d01423 d01425 d01427 d01433	MESNA TRIENTINE SUCCIMER POTASSIUM CITRATE FLAVOXATE BETHANECHOL ACETOHYDROXAMIC ACID
d01416 d01417 d01423 d01425 d01427 d01433 d01445	MESNA TRIENTINE SUCCIMER POTASSIUM CITRATE FLAVOXATE BETHANECHOL ACETOHYDROXAMIC ACID BARIUM SULFATE
d01416 d01417 d01423 d01425 d01427 d01433 d01445 d01456	MESNA TRIENTINE SUCCIMER POTASSIUM CITRATE FLAVOXATE BETHANECHOL ACETOHYDROXAMIC ACID BARIUM SULFATE IOHEXOL
d01416 d01417 d01423 d01425 d01427 d01433 d01445	MESNA TRIENTINE SUCCIMER POTASSIUM CITRATE FLAVOXATE BETHANECHOL ACETOHYDROXAMIC ACID BARIUM SULFATE IOHEXOL IOPAMIDOL
d01416 d01417 d01423 d01425 d01427 d01433 d01445 d01456	MESNA TRIENTINE SUCCIMER POTASSIUM CITRATE FLAVOXATE BETHANECHOL ACETOHYDROXAMIC ACID BARIUM SULFATE IOHEXOL IOPAMIDOL
d01416 d01417 d01423 d01425 d01427 d01433 d01445 d01456 d01461 d01473	MESNA TRIENTINE SUCCIMER POTASSIUM CITRATE FLAVOXATE BETHANECHOL ACETOHYDROXAMIC ACID BARIUM SULFATE IOHEXOL IOPAMIDOL DIATRIZOATE
d01416 d01417 d01423 d01425 d01427 d01433 d01445 d01456 d01461 d01473 d02374	MESNA TRIENTINE SUCCIMER POTASSIUM CITRATE FLAVOXATE BETHANECHOL ACETOHYDROXAMIC ACID BARIUM SULFATE IOHEXOL IOPAMIDOL DIATRIZOATE DESFLURANE
d01416 d01417 d01423 d01425 d01427 d01433 d01445 d01456 d01461 d01473	MESNA TRIENTINE SUCCIMER POTASSIUM CITRATE FLAVOXATE BETHANECHOL ACETOHYDROXAMIC ACID BARIUM SULFATE IOHEXOL IOPAMIDOL DIATRIZOATE DESFLURANE PLASMA PROTEIN
d01416 d01417 d01423 d01425 d01427 d01433 d01445 d01456 d01461 d01473 d02374	MESNA TRIENTINE SUCCIMER POTASSIUM CITRATE FLAVOXATE BETHANECHOL ACETOHYDROXAMIC ACID BARIUM SULFATE IOHEXOL IOPAMIDOL DIATRIZOATE DESFLURANE
d01416 d01417 d01423 d01425 d01427 d01433 d01445 d01456 d01461 d01473 d02374	MESNA TRIENTINE SUCCIMER POTASSIUM CITRATE FLAVOXATE BETHANECHOL ACETOHYDROXAMIC ACID BARIUM SULFATE IOHEXOL IOPAMIDOL DIATRIZOATE DESFLURANE PLASMA PROTEIN FRACTION

d02377	DEXTRAN 1
d03001	CLADRIBINE
d03007	MEASLES; MUMPS;
	RUBELLA VIRUS
	VACCINE
d03008	INTERFERON
005000	GAMMA-1B
100044	÷
d03041	ENOXAPARIN
d03050	LORATADINE
d03052	HYDROCHLORO-
	THIAZIDE;
	TRIAMTERENE
d03054	AMYLASE
d03061	BUTALBITAL
d03071	DIPHENOXYLATE
d03075	HYDROCODONE
d03078	KAOLIN
d03080	LIPASE
d03081	MALT SOUP
	EXTRACT
d03085	PEPSIN
d03096	SODIUM BENZOATE
d03098	SODIUM CITRATE
d03110	DIPHTH; PERTUSSIS,
	ACEL; TETANUS
	(OBSOLETE)
d03112	NEDOCROMÍL
d03126	CALCITRIOL
d03128	ERGOCALCIFEROL
d03129	CHOLECALCIFEROL
d03130	THIAMINE
d03130	HYDROXO-
uus 155	
-100405	COBALAMIN
d03135	PHYTONADIONE
d03137	CALCIUM; VITAMIN D
d03140	MULTIVITAMIN
d03148	MULTIVITAMIN,
	PRENATAL
d03154	DOXYLAMINE
d03157	PAROXETINE
d03158	RIMANTADINE
d03158 d03160	
d03160	RIMANTADINE SUMATRIPTAN
d03160 d03162	RIMANTADINE SUMATRIPTAN ETHANOL
d03160	RIMANTADINE SUMATRIPTAN ETHANOL PIPERACILLIN;
d03160 d03162 d03165	RIMANTADINE SUMATRIPTAN ETHANOL PIPERACILLIN; TAZOBACTAM
d03160 d03162 d03165 d03166	RIMANTADINE SUMATRIPTAN ETHANOL PIPERACILLIN; TAZOBACTAM CISAPRIDE
d03160 d03162 d03165 d03166 d03169	RIMANTADINE SUMATRIPTAN ETHANOL PIPERACILLIN; TAZOBACTAM CISAPRIDE TRIMETREXATE
d03160 d03162 d03165 d03166 d03169 d03170	RIMANTADINE SUMATRIPTAN ETHANOL PIPERACILLIN; TAZOBACTAM CISAPRIDE TRIMETREXATE FELBAMATE
d03160 d03162 d03165 d03166 d03169 d03170 d03171	RIMANTADINE SUMATRIPTAN ETHANOL PIPERACILLIN; TAZOBACTAM CISAPRIDE TRIMETREXATE FELBAMATE GRANISETRON
d03160 d03162 d03165 d03166 d03169 d03170 d03171 d03180	RIMANTADINE SUMATRIPTAN ETHANOL PIPERACILLIN; TAZOBACTAM CISAPRIDE TRIMETREXATE FELBAMATE GRANISETRON RISPERIDONE
d03160 d03162 d03165 d03166 d03169 d03170 d03171 d03180 d03181	RIMANTADINE SUMATRIPTAN ETHANOL PIPERACILLIN; TAZOBACTAM CISAPRIDE TRIMETREXATE FELBAMATE GRANISETRON RISPERIDONE VENLAFAXINE
d03160 d03162 d03165 d03166 d03169 d03170 d03171 d03180 d03181 d03182	RIMANTADINE SUMATRIPTAN ETHANOL PIPERACILLIN; TAZOBACTAM CISAPRIDE TRIMETREXATE FELBAMATE GRANISETRON RISPERIDONE VENLAFAXINE GABAPENTIN
d03160 d03162 d03165 d03166 d03169 d03170 d03171 d03180 d03181 d03182 d03183	RIMANTADINE SUMATRIPTAN ETHANOL PIPERACILLIN; TAZOBACTAM CISAPRIDE TRIMETREXATE FELBAMATE GRANISETRON RISPERIDONE VENLAFAXINE GABAPENTIN FLUVASTATIN
d03160 d03162 d03165 d03166 d03169 d03170 d03171 d03180 d03181 d03182 d03183 d03189	RIMANTADINE SUMATRIPTAN ETHANOL PIPERACILLIN; TAZOBACTAM CISAPRIDE TRIMETREXATE FELBAMATE GRANISETRON RISPERIDONE VENLAFAXINE GABAPENTIN FLUVASTATIN TORSEMIDE
d03160 d03162 d03165 d03166 d03169 d03170 d03171 d03180 d03181 d03182 d03183	RIMANTADINE SUMATRIPTAN ETHANOL PIPERACILLIN; TAZOBACTAM CISAPRIDE TRIMETREXATE FELBAMATE GRANISETRON RISPERIDONE VENLAFAXINE GABAPENTIN FLUVASTATIN TORSEMIDE OXICONAZOLE
d03160 d03162 d03165 d03166 d03169 d03170 d03171 d03180 d03181 d03182 d03183 d03189	RIMANTADINE SUMATRIPTAN ETHANOL PIPERACILLIN; TAZOBACTAM CISAPRIDE TRIMETREXATE FELBAMATE GRANISETRON RISPERIDONE VENLAFAXINE GABAPENTIN FLUVASTATIN TORSEMIDE OXICONAZOLE TOPICAL
d03160 d03162 d03165 d03166 d03169 d03170 d03171 d03180 d03181 d03182 d03183 d03189	RIMANTADINE SUMATRIPTAN ETHANOL PIPERACILLIN; TAZOBACTAM CISAPRIDE TRIMETREXATE FELBAMATE GRANISETRON RISPERIDONE VENLAFAXINE GABAPENTIN FLUVASTATIN TORSEMIDE OXICONAZOLE
d03160 d03162 d03165 d03166 d03169 d03170 d03171 d03180 d03181 d03182 d03183 d03189 d03190	RIMANTADINE SUMATRIPTAN ETHANOL PIPERACILLIN; TAZOBACTAM CISAPRIDE TRIMETREXATE FELBAMATE GRANISETRON RISPERIDONE VENLAFAXINE GABAPENTIN FLUVASTATIN TORSEMIDE OXICONAZOLE TOPICAL

d03192 d03193	ZINC OXIDE TOPICAL AMILORIDE; HYDROCHLORO-
d03195	THIAZIDE MICONAZOLE TOPICAL
d03196	GENTAMICIN TOPICAL
d03197	BETAMETHASONE
d03200	ERYTHROMYCIN
d03203 d03204	MINOXIDIL TOPICAL FLUOROURACIL
d03205	TOPICAL HYDROCORTISONE
d03206	TOPICAL TRIAMCINOLONE
d03208	TOPICAL METRONIDAZOLE
d03210	TOPICAL SELENIUM SULFIDE TOPICAL
d03211	CIPROFLOXACIN
d03220	FLURBIPROFEN
d03221	PREDNISOLONE
d03222	TOBRAMYCIN OPHTHALMIC
d03225	PREDNICARBATE
d03227	FLUOROMETHOLONE
d03228	LODOXAMIDE OPHTHALMIC
d03229	LEVOCABASTINE OPHTHALMIC
d03231	TRIPLE SULFA TOPICAL
d03233 d03238	VITAMIN E TOPICAL ETHINYL ESTRADIOL;
d03241	NORETHINDRONE ETHINYL ESTRADIOL;
d03242	NORGESTREL ETHINYL ESTRADIOL;
d03244	LEVONORGESTREL CONJUGATED
d03245	ESTROGENS; METHYLTES- TOSTERONE ESTERIFIED ESTROGENS; METHYLTES- TOSTERONE

d03247	HYDROCHLORO- THIAZIDE; SPIRO-
d03250	NOLACTONE CHLOROTHIAZIDE; RESERPINE
d03253	METHYCLOTHIAZIDE; RESERPINE
d03256	HYDRALAZINE; HYDROCHLOROTHIA ZIDE; RESERPINE
d03257	HYDRALAZINE; HYDROCHLORO- THIAZIDE
d03258	ATENOLOL; CHLORTHALIDONE
d03259	BENDRO- FLUMETHIAZIDE;
d03263	NADOLOL HYDROCHLORO- THIAZIDE;
d03265	METHYLDOPA BENAZEPRIL; HYDRO- CHLOROTHIAZIDE
d03266	HYDROCHLORO- THIAZIDE;
d03280	LISINOPRIL EPHEDRINE; PHENOBARBITAL;
d03287	THEOPHYLLINE EPHEDRINE; PB; K IODIDE;
d03289	THEOPHYLLINE ACETAMINOPHEN; PSEUDOEPHEDRINE
d03292	IBUPROFEN; PSEUDOEPHEDRINE
d03293	APAP; ASA; PPA
d03296	ACETAMINOPHEN;
	CHLORPHEN- IRAMINE
d03297	ACETAMINOPHEN; PHENYLTOLOX-
d03298	AMINE CHLORPHEN- IRAMINE;
d03299	PSEUDOEPHEDRINE CHLORPHEN- IRAMINE; PHENYLPRO-
d03300	PANOLAMINE CHLORPHEN- IRAMINE;
d03301	PHENYLEPHRINE BROMPHENIRAMINE; PSEUDOEPHEDRINE

2006 NAMCS MICRO-DATA FILE DOCUMENTATION, APPENDIX III - GENERIC LIST

d03302 BROMPHENIRAMINE; PHENYLPROPANOL-AMINE d03306 CHLORPHEN-IRAMINE; PE; PHENYLTOLOX-AMINE d03309 BROMPHENIRAMINE; PHENYLEPHRINE; PPA d03310 CHLOR-PHENIRAMINE; PE; PPA: PHENYLTOLOX-AMINE d03311 BROMPHENIRAMINE; PHENYLEPHRINE d03313 CHLORPHEN-**IRAMINE:** PHENYLEPHRINE; **PYRILAMINE** d03314 CHLORPHEN-IRAMINE; PHENYLEPHRINE; PPA d03315 CHLORPHEN-IRAMINE: PHENYLEPHRINE; PPA; PYRILAMINE d03316 PSEUDOEPHEDRINE; TRIPROLIDINE d03317 PHENYLEPHRINE; PROMETHAZINE d03318 PHENIRAMINE; PPA; **PYRILAMINE** d03319 APAP; CHLORPHEN-IRAMINE; PHENYLPRO-PANOLAMINE d03320 APAP; CHLORPHEN-IRAMINE; **PSEUDOEPHEDRINE** d03331 APAP: CHLORPHEN-IRAMINE; PHENYLEPHRINE d03338 CHLORPHEN-IRAMINE; METHSCOPOL-AMINE; PE d03340 HOMATROPINE; HYDROCODONE d03347 APAP; CHLORPHEN-IRAMINE; DEXTROMETHOR-PHAN; PSE

d03349	APAP;
	DEXTROMETHOR-
	PHAN; DOXYLAMINE;
	PSE
-100050	_
d03352	HYDROCODONE;
	PSEUDOEPHEDRINE
d03353	HYDROCODONE;
	PHENYLPROPANO-
	LAMINE
d03354	DEXTROMETHOR-
	PHAN:
	PSEUDOEPHEDRINE
400057	
d03357	CODEINE;
	PROMETHAZINE
d03359	CHLORPHEN-
	IRAMINE;
	DEXTRO-
	METHORPHAN
d03360	DEXTRO-
000000	
	METHORPHAN;
	PROMETHAZINE
d03361	CHLORPHEN-
	IRAMINE;
	HYDROCODONE;
	PHENYLEPHRINE
d03364	CODEINE;
	PHENYLEPHRINE;
	PROMETHAZINE
-100000	
d03368	BROMPHENIRAMINE;
	DEXTROMETHOR-
	PHAN; PSE
d03369	CHLORPHEN-
	IRAMINE;
	DEXTROMETHORP;
	PHENYLEPHRINE
d03370	CHLORPHEN-
400010	IRAMINE;
	DEXTROMETHOR-
100070	PHAN; PSE
d03372	BROMPHENIRAMINE;
	DEXTROMETHOR-
	PHAN; PPA
d03379	GUAIFENESIN;
	PSEUDOEPHEDRINE
d03381	GUAIFENESIN;
	PHENYLEPHRINE
d03382	GUAIFENESIN;
000002	-
	PHENYLPROPANOL-
100000	AMINE
d03383	GUAIFENESIN;
	PHENYLEPHRINE;
	PPA
d03388	ETHINYL ESTRADIOL;
	ETHYNODIOL
d03389	ESTRADIOL;
400000	TESTOSTERONE
d03392	CHLORPHENI-
000092	RAMINE;
	GUAIFENESIN;
	PHENYLEPHRINE

d03393 CODEINE: **GUAIFENESIN** d03394 CODEINE; **IODINATED** GLYCEROL d03396 GUAIFENESIN; **HYDROCODONE** d03398 CODEINE; GUAIFENESIN; PSE d03400 DEXTROMETHOR-PHAN; GUAIFENESIN d03403 GUAIFENESIN; HYDROCODONE; PHENYLEPHRINE d03404 GUAIFENESIN; HYDROCODONE: **PSEUDOEPHEDRINE** d03408 DEXTROMETHOR-PHAN: GUAIFENESIN; PHENYLEPHRINE d03409 DEXTROMETHOR-PHAN; GUAIFENESIN; **PSEUDOEPHEDRINE** DEXTROMETHORd03411 PHAN: **GUAIFENESIN; PPA** d03416 CHLORPHEN-**IRAMINE:** HYDROCODONE; PSE d03419 CHLORPHEN-IRAMINE; DM; GUAIFENESIN: PHENYLEPHRINE d03423 ACETAMINOPHEN: CODEINE d03424 ASPIRIN; CODEINE d03425 APAP; BUTALBITAL; CAFFEINE; CODEINE d03426 ASA; BUTALBITAL; CAFFEINE; CODEINE d03428 ACETAMINOPHEN: **HYDROCODONE** d03429 ASPIRIN; **HYDROCODONE** d03431 ACETAMINOPHEN; OXYCODONE d03432 ASPIRIN; OXYCODONE d03433 MEPERIDINE; PROMETHAZINE d03434 ACETAMINOPHEN; PROPOXYPHENE d03437 APAP; ASA; CAFFEINE: SALICYLAMIDE d03439 APAP; ASA; CAFFEINE

2006 NAMCS MICRO-DATA FILE DOCUMENTATION, APPENDIX III - GENERIC LIST

d03445 ACETAMINOPHEN: d03521 CYCLOPENTOLATE; DIPHENHYDRAMINE d03449 ASPIRIN; CAFFEINE d03455 APAP; BUTALBITAL; CAFFEINE d03456 ACETAMINOPHEN; BUTALBITAL d03457 ASA; BUTALBITAL; CAFFEINE d03458 ASPIRIN; BUTALBITAL d03459 APAP; DICHLORALPHEN-AZONE; **ISOMETHEPTENE** d03462 AMITRIPTYLINE; CHLORDIAZEP-OXIDE d03463 AMITRIPTYLINE: PERPHENAZINE d03468 ASPIRIN; METHOCARBAMOL d03469 ASPIRIN; CARISOPRODOL d03472 ASA; CAFFEINE; ORPHENADRINE d03473 CARBIDOPA; **LEVODOPA** d03474 ALUMINUM HYDROXIDE; MAGNESIUM **HYDROXIDE** d03478 AL HYDROXIDE; MG HYDROXIDE: SIMETHICONE d03485 ATROPINE; HYOSCYAMINE; PB; SCOPOLAMINE d03490 ATROPINE; PHENOBARBITAL d03492 CHLORDIAZEPOXIDE; CLIDINIUM d03495 BELLADONNA; ERGOTAMINE: PHENOBARBITAL d03496 DOCUSATE; SENNA d03498 CASANTHRANOL; DOCUSATE d03505 ATROPINE; DIFENOXIN d03506 ATROPINE; DIPHENOXYLATE d03508 ISONIAZID; RIFAMPIN d03509 ERYTHROMYCIN;

SULFISOXAZOLE d03510 OXYTETRACYCLINE;

PHENAZOPYRIDINE; SULFAMETHIZOL

000021	PHENYLEPHRINE
	OPHTHALMIC
d03525	GRAMICIDIN;
	NEOMYCIN;
	POLYMYXIN B
	OPHTHALMIC
d03536	DEXAMETHASONE;
	TOBRAMYCIN
	OPHTHALMIC
d03541	PREDNISOLONE;
	SULFACETAMIDE
	SODIUM
	OPHTHALMIC
d03546	HYDROCORTISONE;
	PRAMOXINE
	TOPICAL
d03555	HYDROCORTISONE;
	NEOMYCIN TOPICAL
d03561	BETAMETHASONE;
	CLOTRIMAZOLE
	TOPICAL
d03566	CAPTOPRIL;
400000	HYDROCHLORO-
	THIAZIDE
d03569	CARBINOXAMINE
d03570	CARBINOXAMINE:
400010	PSEUDO-
	EPHEDRINE
d03572	CARAMIPHEN;
000072	PHENYLPROPANOL-
	AMINE
d03574	CARBETAPENTANE;
400011	CPM; EPHEDRINE;
	PHENYLEPHRINE
d03577	CARBINOXAMINE;
000011	DEXTROMETHOR-
	PHAN; PSE
d03613	PSYLLIUM; SENNA
d03618	HYOSCYAMINE;
	METHENAM; M;
	BLUE; PHENYL
	SALICYL
d03620	ANTAZOLINE;
	NAPHAZOLINE
	OPHTHALMIC
d03623	ACETIC ACID
400020	TOPICAL
d03624	ANTIPYRINE OTIC
d03634	BENZOCAINE;
200001	
	CETYLPYRIDINIUM
	CETYLPYRIDINIUM TOPICAL
d03640	TOPICAL
d03640 d03641	TOPICAL BUDESONIDE NASAL
	TOPICAL BUDESONIDE NASAL PETROLATUM
	TOPICAL BUDESONIDE NASAL PETROLATUM TOPICAL
d03641	TOPICAL BUDESONIDE NASAL PETROLATUM

d03646	LACTOBACILLUS ACIDOPHILUS AND
	BULGARICUS
d03647	ISOPROPYL
u03047	ALCOHOL TOPICAL
402640	BENZOIN TOPICAL
d03649	
d03652	COLCHICINE;
	PROBENECID
d03653	CALAMINE TOPICAL
d03655	LIDOCAINE;
	PRILOCAINE
	TOPICAL
d03656	ETHYL CHLORIDE
	TOPICAL
d03663	LECITHIN
d03664	PHENOL TOPICAL
d03665	MENTHOL TOPICAL
d03667	METHACHOLINE
d03669	METHYL
	SALICYLATE;
	MENTHOL TOPICAL
d03676	NALOXONE;
400010	PENTAZOCINE
d03680	ASA; CITRIC ACID;
000000	NA BICARB
d03682	ACETAMINOPHEN;
000002	PENTAZOCINE
d03684	THROMBIN TOPICAL
d03687	ALUMINUM ACETATE
u03007	TOPICAL
402600	CALCIUM ACETATE
d03689 d03690	ALUMINUM SULFATE;
003690	CALCIUM ACETATE;
-100000	
d03692	BENZYLPENI-
	CILLOYL;
100700	POLYLYSINE
d03703	COAL TAR TOPICAL
d03707	ALOE VERA TOPICAL
d03708	LANOLIN; MINERAL
	OIL TOPICAL
d03735	TRIETHANOLAMINE
	POLYPEPTIDE
	OLEATE OTIC
d03740	ENALAPRIL;
	HYDROCHLORO-
	THIAZIDE
d03744	BISOPROLOL;
	HYDROCHLORO-
	THIAZIDE
d03751	DEXBROM-
	PHENIRAMINE;
	PSEUDOEPHEDRINE
d03752	TACROLIMUS
d03754	ACRIVASTINE;
	PSEUDOEPHEDRINE
d03756	BACITRACIN
400700	TOPICAL
	IUTIOAL

2006 NAMCS MICRO-DATA FILE DOCUMENTATION, APPENDIX III - GENERIC LIST

d03829 AMLODIPINE;

d03759	SALMETEROL
d03761	LANOLIN TOPICAL
d03766	ROCURONIUM
d03768	OCULAR LUBRICANT
d03770	EMOLLIENTS,
	TOPICAL
d03773	STAVUDINE
d03774	DOXEPIN TOPICAL
d03775	FAMCICLOVIR
d03778	CHLOROTHIAZIDE;
003778	
	METHYLDOPA
d03780	DESOGESTREL
d03781	ETHINYL ESTRADIOL;
003761	
	NORGESTIMATE
d03782	DESOGESTREL;
	ETHINYL
	ESTRADIOL
d03783	BUPIVACAINE;
000700	
	EPINEPHRINE
d03784	EPINEPHRINE;
	LIDOCAINE
d03788	CALCIPOTRIENE
	TOPICAL
d03790	POTASSIUM
005750	
	PHOSPHATE
d03796	MAGNESIUM
	CHLORIDE
100707	
d03797	MAGNESIUM OXIDE
d03798	MAGNESIUM
	GLUCONATE
100004	
d03804	FLUVOXAMINE
d03805	DORZOLAMIDE
	OPHTHALMIC
100000	
d03806	ALBENDAZOLE
d03807	METFORMIN
d03808	NEFAZODONE
d03809	LAMOTRIGINE
d03810	VINORELBINE
d03811	ABCIXIMAB
d03812	DALTEPARIN
d03814	RIMEXOLONE
	OPHTHALMIC
100040	
d03818	LORATADINE;
	PSEUDOEPHEDRINE
d03819	CONJUGATED
000013	
	ESTROGENS;
	MEDROXYPROGES-
	TERONE
100000	
d03820	HEPATITIS A
	VACCINE
	(OBSOLETE)
100004	
d03821	LOSARTAN
d03822	FERROUS
	GLUCONATE
d03823	IRON
	POLYSACCHARIDE
d03825	NISOLDIPINE
d03826	TRAMADOL
d03827	CETIRIZINE
d03828	LANSOPRAZOLE

003629	
100000	BENAZEPRIL
d03830	HYDROCHLORO-
	THIAZIDE;
	LOSARTAN
d03832	VARICELLA VIRUS
	VACCINE
d03833	DIVALPROEX
000000	SODIUM
402025	MOEXIPRIL
d03835	-
d03836	ACITRETIN
d03838	VALACYCLOVIR
d03839	MYCOPHENOLATE
	MOFETIL
d03841	DEXRAZOXANE
d03845	SEVOFLURANE
d03846	ACARBOSE
d03847	CARVEDILOL
d03848	AZELAIC ACID
003040	
100040	TOPICAL
d03849	ALENDRONATE
d03850	BICALUTAMIDE
d03857	BENZOYL PEROXIDE;
	ERYTHROMYCIN
	TOPICAL
d03858	LAMIVUDINE
d03860	SAQUINAVIR
d03861	MAGNESIUM
400001	LACTATE
d03862	MAGNESIUM AMINO
000002	ACIDS CHELATE
402004	
d03864	GLIMEPIRIDE
d03866	CALCIUM CITRATE
d03868	AMIFOSTINE
d03869	RILUZOLE
d03873	ANASTROZOLE
d03874	CEFTIBUTEN
d03875	CISATRACURIUM
d03879	CANNABIS
	(SCHEDULE I
	SUBSTANCE)
d03882	CEFEPIME
d03884	-
	SALICYLATE
	TOPICAL
d03894	KAOLIN; PECTIN
d03896	AMYLASE;
	CELLULASE; LIPASE;
	PROTEASE
d03897	LACTASE
d03904	
400004	CASTOR OIL;
	TRYPSIN TOPICAL
402000	APAP; CHLORPHEN-
d03908	
	IRAMINE;
	DEXTROMETHOR-
	PHAN; PPA

d03911	CHLORPHEN-
	IRAMINE;
	METHSCOPO-
100045	LAMINE; PSE
d03915	HYDROCODONE; POTASSIUM
	GUAIACOL-
	SULFONATE
d03922	ACETAMINOPHEN;
	CAFFEINE
d03927	BACITRACIN
d03929	OPHTHALMIC AMINOPHYLLINE;
000020	AMOBARBITAL;
	EPHEDRINE
d03952	CITRIC ACID;
402000	SODIUM CITRATE DEXAMETHASONE
d03968	OPHTHALMIC
d03971	EPINEPHRINE
	OPHTHALMIC
d03973	ERYTHROMYCIN
100074	OPHTHALMIC
d03974	GENTAMICIN OPHTHALMIC
d03977	OFLOXACIN
	OPHTHALMIC
d03979	SCOPOLAMINE
100000	OPHTHALMIC
d03982	TETRACAINE TOPICAL
d03984	RITONAVIR
d03985	INDINAVIR
d03990	CARBAMIDE PEROXIDE OTIC
d03994	COLLOIDAL
	OATMEAL TOPICAL
d03996	DIENESTROL
d03997	TOPICAL EPINEPHRINE;
u03997	ETIDOCAINE
d03998	STERILE WATER
d04000	PIPERONYL
	BUTOXIDE TOPICAL
d04001	PYRETHRINS
404000	TOPICAL
d04002	PIPERONYL BUTOXIDE;
	PYRETHRINS
	TOPICAL
d04003	HYDROGEN
404000	PEROXIDE TOPICAL
d04006	
d04008	TRANDOLAPRIL
d04009	DOCETAXEL
d04010	GEMCITABINE
d04011	INTERFERON BETA-
404040	
d04012 d04014	TERBINAFINE TOPOTECAN
004014	IUFUIEUAN

d04015	
uu4015	ADAPALENE
	TOPICAL
d04017	LATANOPROST
u0 4 017	OPHTHALMIC
404000	
d04022	PENTAGASTRIN
d04025	MIRTAZAPINE
d04026	
d04027	MEROPENEM
d04029	NEVIRAPINE
d04032	SULFACETAMIDE
	SODIUM; SULFUR
	TOPICAL
d04035	AMPHETAMINE;
401000	DEXTROAMPHET-
	AMINE
404027	
d04037	TIMOLOL
10 4000	OPHTHALMIC
d04038	BETAXOLOL
	OPHTHALMIC
d04039	CARTEOLOL
	OPHTHALMIC
d04040	FEXOFENADINE
d04041	FOSPHENYTOIN
d04047	MIDODRINE
d04048	BRIMONIDINE
	OPHTHALMIC
d04049	AMMONIUM LACTATE
401010	TOPICAL
d04050	
d04050 d04051	ROPIVACAINE
d04052	PENTOSAN
	POLYSULFATE
10 40 5 4	SODIUM
d04054	PENCICLOVIR
	TOPICAL
d04056	ZINC GLUCONATE
d04056 d04057	ZINC GLUCONATE
	ZINC GLUCONATE ZINC SULFATE MELATONIN
d04057	ZINC GLUCONATE ZINC SULFATE MELATONIN
d04057 d04058	ZINC GLUCONATE ZINC SULFATE
d04057 d04058 d04063	ZINC GLUCONATE ZINC SULFATE MELATONIN BUTENAFINE TOPICAL
d04057 d04058	ZINC GLUCONATE ZINC SULFATE MELATONIN BUTENAFINE TOPICAL TRANDOLAPRIL;
d04057 d04058 d04063 d04065	ZINC GLUCONATE ZINC SULFATE MELATONIN BUTENAFINE TOPICAL TRANDOLAPRIL; VERAPAMIL
d04057 d04058 d04063	ZINC GLUCONATE ZINC SULFATE MELATONIN BUTENAFINE TOPICAL TRANDOLAPRIL; VERAPAMIL ALBUTEROL;
d04057 d04058 d04063 d04065 d04066	ZINC GLUCONATE ZINC SULFATE MELATONIN BUTENAFINE TOPICAL TRANDOLAPRIL; VERAPAMIL ALBUTEROL; IPRATROPIUM
d04057 d04058 d04063 d04065 d04066 d04067	ZINC GLUCONATE ZINC SULFATE MELATONIN BUTENAFINE TOPICAL TRANDOLAPRIL; VERAPAMIL ALBUTEROL; IPRATROPIUM RETEPLASE
d04057 d04058 d04063 d04065 d04066 d04067 d04068	ZINC GLUCONATE ZINC SULFATE MELATONIN BUTENAFINE TOPICAL TRANDOLAPRIL; VERAPAMIL ALBUTEROL; IPRATROPIUM RETEPLASE AZELASTINE NASAL
d04057 d04058 d04063 d04065 d04066 d04067	ZINC GLUCONATE ZINC SULFATE MELATONIN BUTENAFINE TOPICAL TRANDOLAPRIL; VERAPAMIL ALBUTEROL; IPRATROPIUM RETEPLASE AZELASTINE NASAL CHLORPHENIRAMINE
d04057 d04058 d04063 d04065 d04066 d04067 d04068 d04079	ZINC GLUCONATE ZINC SULFATE MELATONIN BUTENAFINE TOPICAL TRANDOLAPRIL; VERAPAMIL ALBUTEROL; IPRATROPIUM RETEPLASE AZELASTINE NASAL CHLORPHENIRAMINE ; EPINEPHRINE
d04057 d04058 d04063 d04065 d04066 d04067 d04068	ZINC GLUCONATE ZINC SULFATE MELATONIN BUTENAFINE TOPICAL TRANDOLAPRIL; VERAPAMIL ALBUTEROL; IPRATROPIUM RETEPLASE AZELASTINE NASAL CHLORPHENIRAMINE ; EPINEPHRINE LACTIC ACID
d04057 d04058 d04063 d04065 d04066 d04067 d04068 d04079 d04090	ZINC GLUCONATE ZINC SULFATE MELATONIN BUTENAFINE TOPICAL TRANDOLAPRIL; VERAPAMIL ALBUTEROL; IPRATROPIUM RETEPLASE AZELASTINE NASAL CHLORPHENIRAMINE ; EPINEPHRINE LACTIC ACID TOPICAL
d04057 d04058 d04063 d04065 d04066 d04067 d04068 d04079	ZINC GLUCONATE ZINC SULFATE MELATONIN BUTENAFINE TOPICAL TRANDOLAPRIL; VERAPAMIL ALBUTEROL; IPRATROPIUM RETEPLASE AZELASTINE NASAL CHLORPHENIRAMINE ; EPINEPHRINE LACTIC ACID TOPICAL HYDROCORTISONE;
d04057 d04058 d04063 d04065 d04066 d04067 d04068 d04079 d04090	ZINC GLUCONATE ZINC SULFATE MELATONIN BUTENAFINE TOPICAL TRANDOLAPRIL; VERAPAMIL ALBUTEROL; IPRATROPIUM RETEPLASE AZELASTINE NASAL CHLORPHENIRAMINE ; EPINEPHRINE LACTIC ACID TOPICAL HYDROCORTISONE; IODOQUINOL
d04057 d04058 d04063 d04065 d04066 d04067 d04068 d04079 d04090	ZINC GLUCONATE ZINC SULFATE MELATONIN BUTENAFINE TOPICAL TRANDOLAPRIL; VERAPAMIL ALBUTEROL; IPRATROPIUM RETEPLASE AZELASTINE NASAL CHLORPHENIRAMINE ; EPINEPHRINE LACTIC ACID TOPICAL HYDROCORTISONE; IODOQUINOL TOPICAL
d04057 d04058 d04063 d04065 d04066 d04067 d04068 d04079 d04090	ZINC GLUCONATE ZINC SULFATE MELATONIN BUTENAFINE TOPICAL TRANDOLAPRIL; VERAPAMIL ALBUTEROL; IPRATROPIUM RETEPLASE AZELASTINE NASAL CHLORPHENIRAMINE ; EPINEPHRINE LACTIC ACID TOPICAL HYDROCORTISONE; IODOQUINOL TOPICAL IMIGLUCERASE
d04057 d04058 d04063 d04065 d04066 d04067 d04068 d04079 d04090 d04093	ZINC GLUCONATE ZINC SULFATE MELATONIN BUTENAFINE TOPICAL TRANDOLAPRIL; VERAPAMIL ALBUTEROL; IPRATROPIUM RETEPLASE AZELASTINE NASAL CHLORPHENIRAMINE ; EPINEPHRINE LACTIC ACID TOPICAL HYDROCORTISONE; IODOQUINOL TOPICAL
d04057 d04063 d04065 d04066 d04067 d04068 d04079 d04090 d04090	ZINC GLUCONATE ZINC SULFATE MELATONIN BUTENAFINE TOPICAL TRANDOLAPRIL; VERAPAMIL ALBUTEROL; IPRATROPIUM RETEPLASE AZELASTINE NASAL CHLORPHENIRAMINE ; EPINEPHRINE LACTIC ACID TOPICAL HYDROCORTISONE; IODOQUINOL TOPICAL IMIGLUCERASE DONEPEZIL
d04057 d04063 d04065 d04066 d04067 d04068 d04079 d04090 d04090 d04093	ZINC GLUCONATE ZINC SULFATE MELATONIN BUTENAFINE TOPICAL TRANDOLAPRIL; VERAPAMIL ALBUTEROL; IPRATROPIUM RETEPLASE AZELASTINE NASAL CHLORPHENIRAMINE ; EPINEPHRINE LACTIC ACID TOPICAL HYDROCORTISONE; IODOQUINOL TOPICAL IMIGLUCERASE DONEPEZIL IVERMECTIN
d04057 d04063 d04065 d04066 d04067 d04068 d04079 d04090 d04090	ZINC GLUCONATE ZINC SULFATE MELATONIN BUTENAFINE TOPICAL TRANDOLAPRIL; VERAPAMIL ALBUTEROL; IPRATROPIUM RETEPLASE AZELASTINE NASAL CHLORPHENIRAMINE ; EPINEPHRINE LACTIC ACID TOPICAL HYDROCORTISONE; IODOQUINOL TOPICAL IMIGLUCERASE DONEPEZIL IVERMECTIN TIZANIDINE

d04105	ATORVASTATIN
d04107	AMLEXANOX
004107	-
104400	TOPICAL
d04109	LEVOFLOXACIN
d04110	MIGLITOL
d04111	GLATIRAMER
d04112	CABERGOLINE
d04113	VALSARTAN
d04115	TOPIRAMATE
d04117	OLOPATADINE
001117	OPHTHALMIC
d04118	NELFINAVIR
d04118 d04120	CAFFEINE;
004120	
10 4 4 0 4	ERGOTAMINE
d04121	TAMSULOSIN
d04125	IMIQUIMOD TOPICAL
d04126	ANAGRELIDE
d04134	POLYMYXIN B
	OPHTHALMIC
d04138	TAZAROTENE
	TOPICAL
d04141	HYDROCHLORO-
004141	THIAZIDE;
	MOEXIPRIL
404445	
d04145	-
d04150	
d04153	PHENAZOPYRIDINE;
	SULFISOXAZOLE
d04156	
d04159	SORBITOL
d04160	SODIUM
	BIPHOSPHATE;
	SODIUM
	PHOSPHATE
d04165	APAP;
	DEXTROMETHOR-
	PHAN;
	DIPHENHYDRAMINE;
	PSE
-10.4.4.0.0	
d04168	,
	DIPHENHYDRAMINE;
	PSEUDOEPHEDRINE
d04172	CALAMINE;
	PRAMOXINE
	TOPICAL
d04178	CALCIUM
	HYDROXIDE
	TOPICAL
d04186	PHENYLEPHRINE
404100	NASAL
d04190	PAPAIN TOPICAL
d04191	PAPAIN; UREA TOPICAL
10 4 9 9 9	
d04200	
004200	CALCIUM
004200	CALCIUM GLYCEROPHOS-
	CALCIUM GLYCEROPHOS- PHATE
d04207	CALCIUM GLYCEROPHOS-
	CALCIUM GLYCEROPHOS- PHATE

d04208	SILVER NITRATE TOPICAL
d04209	METHOXSALEN
	TOPICAL
d04212	GLYCERIN TOPICAL
d04214	DOLASETRON
d04215	ROPINIROLE
d04219	LAMIVUDINE:
004219	
	ZIDOVUDINE
d04220	QUETIAPINE
d04221	TIAGABINE
d04222	IRBESARTAN
d04223	MOMETASONE
004220	NASAL
404005	
d04225	HYDROCODONE;
	IBUPROFEN
d04233	TRIAMCINOLONE
	NASAL
d04242	SODIUM CHLORIDE
u0+2+2	
	NASAL
d04244	CHARCOAL;
	SIMETHICONE
d04245	HYDROCHLORO-
	THIAZIDE:
	IRBESARTAN
-10.40.40	GREPAFLOXACIN
d04246	
d04248	METHYLCELLULOSE
d04253	ZOLMITRIPTAN
d04255	RITUXIMAB
d04256	CEFDINIR
d04257	FENOLDOPAM
d04258	CLOPIDOGREL
d04260	SIBUTRAMINE
d04261	RALOXIFENE
d04262	DACLIZUMAB
d04264	BECAPLERMIN
40.20.	TOPICAL
404000	
d04266	EPROSARTAN
d04267	REPAGLINIDE
d04269	APAP; CAFFEINE;
	DIHYDROCODEINE
d04270	FEXOFENADINE;
40.210	PSEUDOEPHEDRINE
404074	
d04271	DICLOFENAC;
	MISOPROSTOL
d04272	AMOXICILLIN;
	CLARITHROMYCIN;
	LANSOPRAZOLE
d04274	FOMEPIZOLE
d04275	BECLOMETHASONE
	NASAL
d04276	BUDESONIDE
d04279	FLUNISOLIDE NASAL
d04282	TOLCAPONE
d04283	FLUTICASONE
007200	
-10.400.4	NASAL
d04284	FLUTICASONE
	TOPICAL

d04285 NARATRIPTAN d04286 FENOFIBRATE d04289 MONTELUKAST d04292 LOTEPREDNOL **OPHTHALMIC** d04293 HYDROCHLORO-THIAZIDE; VALSARTAN d04294 TOLTERODINE d04295 OXYMETHOLONE d04299 SILDENAFIL d04300 RISEDRONATE d04301 BRINZOLAMIDE OPHTHALMIC d04311 CAPECITABINE d04312 PARICALCITOL d04315 TIROFIBAN d04316 EPTIFIBATIDE d04317 DIPHTHERIA TOXOID d04322 CANDESARTAN d04323 PALIVIZUMAB d04328 RIZATRIPTAN d04329 SODIUM HYALURONATE d04331 THALIDOMIDE d04332 CITALOPRAM d04337 PRAMOXINE OTIC d04342 INFLIXIMAB d04344 ROTAVIRUS VACCINE d04349 LEFLUNOMIDE d04355 EFAVIRENZ d04357 TRASTUZUMAB d04363 SEVELAMER d04364 TELMISARTAN d04365 ETANERCEPT d04368 TANNIC ACID TOPICAL d04370 INSULIN ISOPHANE d04375 ESTRADIOL; NORETHINDRONE d04376 ABACAVIR d04378 MODAFINIL d04380 CELECOXIB d04382 CILOSTAZOL d04387 SODIUM FERRIC GLUCONATE COMPLEX d04395 CLOTRIMAZOLE TOPICAL d04399 NYSTATIN TOPICAL d04400 DIMETHYL SULFOXIDE TOPICAL d04404 TAZOBACTAM d04405 CLAVULANATE d04411 GARLIC d04412 GINSENG d04413 GINKGO d04416 VALERIAN

d04417	CREATINE
	-
d04418	GLUCOSAMINE
d04419	CHONDROITIN
d04420	CHONDROITIN:
u04420	,
	GLUCOSAMINE
d04422	KAVA
d04423	
d04425	DEHYDROEPI-
	ANDROSTERONE
d04427	LEVALBUTEROL
d04428	AMPRENAVIR
d04429	ORLISTAT
d04432	CARBONYL IRON
d04433	ROFECOXIB
d04434	ROSIGLITAZONE
d04435	
d04436	MALATHION TOPICAL
d04441	KETOTIFEN
dorrrr	
	OPHTHALMIC
d04442	PIOGLITAZONE
d04443	ZANAMIVIR
d04445	,
	CHLORPHENIRAMINE;
	PHENYLEPHRINE
-04440	
d04446	,
	PYRILAMINE
d04447	GANIRELIX
	•••••
d04448	_
d04451	
d04452	ZALEPLON
d04453	
d04459	DOFETILIDE
d04460	ENTACAPONE
d04461	
	EXEMESTANE
d04462	OSELTAMIVIR
d04468	CLOVE
d04472	
d04476	BILBERRY
d04483	DANDELION
d04497	-
u04497	
	DIPYRIDAMOLE
d04499	LEVETIRACETAM
d04500	
d04503	
	OPHTHALMIC
d04504	
	GATEL ()XACIN
	GATIFLOXACIN
d04506	ESTRADIOL;
d04506	ESTRADIOL; NORGESTIMATE
d04506 d04507	ESTRADIOL; NORGESTIMATE BEXAROTENE
d04506	ESTRADIOL; NORGESTIMATE BEXAROTENE HYDROCHLORO-
d04506 d04507	ESTRADIOL; NORGESTIMATE BEXAROTENE HYDROCHLORO- THIAZIDE;
d04506 d04507	ESTRADIOL; NORGESTIMATE BEXAROTENE HYDROCHLORO- THIAZIDE;
d04506 d04507 d04509	ESTRADIOL; NORGESTIMATE BEXAROTENE HYDROCHLORO- THIAZIDE; QUINAPRIL
d04506 d04507 d04509 d04512	ESTRADIOL; NORGESTIMATE BEXAROTENE HYDROCHLORO- THIAZIDE; QUINAPRIL CEVIMELINE
d04506 d04507 d04509 d04512 d04513	ESTRADIOL; NORGESTIMATE BEXAROTENE HYDROCHLORO- THIAZIDE; QUINAPRIL CEVIMELINE OXCARBAZEPINE
d04506 d04507 d04509 d04512 d04513	ESTRADIOL; NORGESTIMATE BEXAROTENE HYDROCHLORO- THIAZIDE; QUINAPRIL CEVIMELINE OXCARBAZEPINE
d04506 d04507 d04509 d04512 d04512 d04513 d04514	ESTRADIOL; NORGESTIMATE BEXAROTENE HYDROCHLORO- THIAZIDE; QUINAPRIL CEVIMELINE OXCARBAZEPINE PANTOPRAZOLE
d04506 d04507 d04509 d04512 d04513 d04514 d04516	ESTRADIOL; NORGESTIMATE BEXAROTENE HYDROCHLORO- THIAZIDE; QUINAPRIL CEVIMELINE OXCARBAZEPINE PANTOPRAZOLE ALOSETRON
d04506 d04507 d04509 d04512 d04512 d04513 d04514	ESTRADIOL; NORGESTIMATE BEXAROTENE HYDROCHLORO- THIAZIDE; QUINAPRIL CEVIMELINE OXCARBAZEPINE PANTOPRAZOLE ALOSETRON MEQUINOL;
d04506 d04507 d04509 d04512 d04513 d04514 d04516	ESTRADIOL; NORGESTIMATE BEXAROTENE HYDROCHLORO- THIAZIDE; QUINAPRIL CEVIMELINE OXCARBAZEPINE PANTOPRAZOLE ALOSETRON MEQUINOL;
d04506 d04507 d04509 d04512 d04513 d04514 d04516 d04519	ESTRADIOL; NORGESTIMATE BEXAROTENE HYDROCHLORO- THIAZIDE; QUINAPRIL CEVIMELINE OXCARBAZEPINE PANTOPRAZOLE ALOSETRON MEQUINOL; TRETINOIN TOPICAL
d04506 d04507 d04509 d04512 d04513 d04513 d04514 d04516 d04523	ESTRADIOL; NORGESTIMATE BEXAROTENE HYDROCHLORO- THIAZIDE; QUINAPRIL CEVIMELINE OXCARBAZEPINE PANTOPRAZOLE ALOSETRON MEQUINOL; TRETINOIN TOPICAL UBIQUINONE
d04506 d04507 d04509 d04512 d04513 d04514 d04516 d04519	ESTRADIOL; NORGESTIMATE BEXAROTENE HYDROCHLORO- THIAZIDE; QUINAPRIL CEVIMELINE OXCARBAZEPINE PANTOPRAZOLE ALOSETRON MEQUINOL; TRETINOIN TOPICAL UBIQUINONE

404532	MELOXICAM
d04532	
d04534	LINEZOLID
d04537	RIVASTIGMINE
d04538	INSULIN GLARGINE
d04541	AZELASTINE
	OPHTHALMIC
d04547	ATOVAQUONE;
u04547	
	PROGUANIL
d04572	FORMOTEROL
d04611	FLUTICASONE;
	SALMETEROL
d04694	TENECTEPLASE
d04695	COLESEVELAM
d04696	TRIPTORELIN
d04697	INSULIN ASPART
d04700	BALSALAZIDE
d04703	GLYBURIDE;
	METFORMIN
d04704	EFLORNITHINE
401101	TOPICAL
404709	ZOLEDRONIC ACID
d04708	
d04711	CANDESARTAN;
	HYDROCHLORO-
	THIAZIDE
d04716	LOPINAVIR
d04717	LOPINAVIR;
uo	RITONAVIR
404704	
d04721	ESTRADIOL;
	MEDROXY-
	PROGESTERONE
d04725	IRON SUCROSE
d04727	ABACAVIR;
	LAMIVUDINE;
	ZIDOVUDINE
d04737	HYDROCHLORO-
u04737	
	THIAZIDE;
	TELMISARTAN
d04740	TACROLIMUS
	TOPICAL
d04742	BENZOYL PEROXIDE;
	CLINDAMYCIN
	TOPICAL
104740	
d04743	NATEGLINIDE
d04746	PEGINTERFERON
	ALFA-2B
d04747	ZIPRASIDONE
d04749	ESOMEPRAZOLE
d04750	GALANTAMINE
d04752	CARBINOXAMINE;
u04752	HYDROCODONE;
	PSEUDOEPHEDRINE
d04753	TRAVOPROST
	OPHTHALMIC
d04754	BIMATOPROST
	OPHTHALMIC
d04755	VALGANCICLOVIR
d04756	ALEMTUZUMAB
d04757	ALMOTRIPTAN
d04758	IMATINIB
d04759	DROSPIRENONE

d04760	DROSPIRENONE;	d04836	CYCLOSPORINE	d04933	TELITHROMYCIN
	ETHINYL		OPHTHALMIC		ACAMPROSATE
	ESTRADIOL	d04839	INSULIN ASPART;		BETAMETHASONE;
d04763	NESIRITIDE	004000	INSULIN ASPART	000011	CALCIPOTRIENE
			PROTAMINE		TOPICAL
004764	CETIRIZINE;	-10.4.0.4.4		405047	
	PSEUDOEPHEDRINE	au4844	CAMPHOR;		PEMETREXED
d04766	ACETAMINOPHEN;		MENTHOL TOPICAL	d05048	AMLODIPINE;
	TRAMADOL		ELETRIPTAN		ATORVASTATIN
d04767	CEFDITOREN	d04851	ROSUVASTATIN	d05101	CETUXIMAB
d04771	DARBEPOETIN ALFA	d04853	ENFUVIRTIDE	d05214	BEVACIZUMAB
	ETHINYL ESTRADIOL;		APREPITANT	d05217	MYCOPHENOLIC
	ETONOGESTREL		BOTULISM		ACID
d04774	TENOFOVIR		ANTITOXIN	d05218	CINACALCET
	ANAKINRA	404850	GEMIFLOXACIN		ALGINIC ACID
	FROVATRIPTAN		DIPHENHYDRAMINE;		HYALURONAN
		u04001			
d04777	DEXMETHYL-	10 40 00	PHENYLEPHRINE		RIFAXIMIN
	PHENIDATE	d04862	BROMPHENIRAMINE;	d05338	DIPHTHERIA;
	VALDECOXIB		DM; GUAIFENESIN;		TETANUS TOXOIDS
d04779	ETHINYL ESTRADIOL;		PSE	d05348	EZETIMIBE;
	NORELGESTROMIN	d04864	CARBETAPENTANE;		SIMVASTATIN
d04782	BOSENTAN		PSEUDOEPHEDRINE	d05350	POLYETHYLENE
d04783	ERTAPENEM	d04868	GEFITINIB		GLYCOL 3350
d04784	PIMECROLIMUS		BORTEZOMIB	d05351	
401101	TOPICAL		ATROPINE; CPM;		PHENYLTOLOX-
d04785	DESLORATADINE	001012	HYOSCYAMINE; PE;		AMINE;
	LOVASTATIN; NIACIN		SCOPOLAMINE		SALICYLAMIDE
		404077		405252	EMTRICITABINE;
	DUTASTERIDE	004877	CARBIDOPA;	005552	
	PEGFILGRASTIM		ENTACAPONE;	105054	TENOFOVIR
	ALFUZOSIN		LEVODOPA	d05354	ABACAVIR;
	TEGASEROD	d04878	HYDROCHLORO-		LAMIVUDINE
d04799	FULVESTRANT		THIAZIDE;		DULOXETINE
d04801	OLMESARTAN		OLMESARTAN	d05357	IBANDRONATE
d04803	VORICONAZOLE	d04880	BROMPHENIRAMINE;	d05361	CARBETAPENTANE;
d04804	CHARCOAL;		HYDROCODONE;		GUAIFENESIN
	SORBITOL		PSEUDOEPHEDRINE	d05395	LANTHANUM
d04806	SODIUM OXYBATE	d04881	OMALIZUMAB		CARBONATE
	OXALIPLATIN		ATAZANAVIR	d05411	CHLORPHEN-
	ESCITALOPRAM		EMTRICITABINE	000411	IRAMINE:
					,
	ADEFOVIR		PALONOSETRON		METHSCO-
	EPLERENONE		MIGLUSTAT	105440	POLAMINE
d04818	DEXCHLOR-		VARDENAFIL		ERLOTINIB
	PHENIRAMINE;		DAPTOMYCIN	d05413	SOLIFENACIN
	DEXTRO-		TADALAFIL		NATALIZUMAB
	METHORPHAN; PSE	d04898	EPINASTINE	d05415	IBUPROFEN;
d04819	BUPRENORPHINE;		OPHTHALMIC		OXYCODONE
	NALOXONE	d04899	MEMANTINE	d05419	CARBINOXAMINE;
d04820	METFORMIN;		FOSAMPRENAVIR		PHENYLEPHRINE
			BROMPHENIRAMINE;	d05421	ESZOPICLONE
	RUSIGUUAZUNE				
d04823	ROSIGLITAZONE	004900			
d04823	GLIPIZIDE;	004900	DEXTROMETHORPH	d05422	DARIFENACIN
	GLIPIZIDE; METFORMIN		DEXTROMETHORPH ; PHENYLEPHRINE	d05422	DARIFENACIN LOTEPREDNOL;
d04824	GLIPIZIDE; METFORMIN EZETIMIBE		DEXTROMETHORPH ; PHENYLEPHRINE LANSOPRAZOLE;	d05422	DARIFENACIN LOTEPREDNOL; TOBRAMYCIN
d04824 d04825	GLIPIZIDE; METFORMIN EZETIMIBE ARIPIPRAZOLE	d04913	DEXTROMETHORPH ; PHENYLEPHRINE LANSOPRAZOLE; NAPROXEN	d05422 d05425	DARIFENACIN LOTEPREDNOL; TOBRAMYCIN OPHTHALMIC
d04824 d04825 d04826	GLIPIZIDE; METFORMIN EZETIMIBE ARIPIPRAZOLE NITAZOXANIDE	d04913	DEXTROMETHORPH ; PHENYLEPHRINE LANSOPRAZOLE; NAPROXEN SERTACONAZOLE	d05422 d05425 d05436	DARIFENACIN LOTEPREDNOL; TOBRAMYCIN OPHTHALMIC INSULIN DETEMIR
d04824 d04825 d04826 d04827	GLIPIZIDE; METFORMIN EZETIMIBE ARIPIPRAZOLE NITAZOXANIDE ATOMOXETINE	d04913 d04915	DEXTROMETHORPH ; PHENYLEPHRINE LANSOPRAZOLE; NAPROXEN SERTACONAZOLE TOPICAL	d05422 d05425 d05436	DARIFENACIN LOTEPREDNOL; TOBRAMYCIN OPHTHALMIC INSULIN DETEMIR DESLORATADINE;
d04824 d04825 d04826 d04827	GLIPIZIDE; METFORMIN EZETIMIBE ARIPIPRAZOLE NITAZOXANIDE	d04913 d04915	DEXTROMETHORPH ; PHENYLEPHRINE LANSOPRAZOLE; NAPROXEN SERTACONAZOLE TOPICAL FLUOXETINE;	d05422 d05425 d05436 d05473	DARIFENACIN LOTEPREDNOL; TOBRAMYCIN OPHTHALMIC INSULIN DETEMIR DESLORATADINE; PSEUDOEPHEDRINE
d04824 d04825 d04826 d04827 d04828	GLIPIZIDE; METFORMIN EZETIMIBE ARIPIPRAZOLE NITAZOXANIDE ATOMOXETINE	d04913 d04915	DEXTROMETHORPH ; PHENYLEPHRINE LANSOPRAZOLE; NAPROXEN SERTACONAZOLE TOPICAL	d05422 d05425 d05436 d05473	DARIFENACIN LOTEPREDNOL; TOBRAMYCIN OPHTHALMIC INSULIN DETEMIR DESLORATADINE;
d04824 d04825 d04826 d04827 d04828 d04829	GLIPIZIDE; METFORMIN EZETIMIBE ARIPIPRAZOLE NITAZOXANIDE ATOMOXETINE TERIPARATIDE	d04913 d04915	DEXTROMETHORPH ; PHENYLEPHRINE LANSOPRAZOLE; NAPROXEN SERTACONAZOLE TOPICAL FLUOXETINE; OLANZAPINE	d05422 d05425 d05436 d05473 d05488	DARIFENACIN LOTEPREDNOL; TOBRAMYCIN OPHTHALMIC INSULIN DETEMIR DESLORATADINE; PSEUDOEPHEDRINE
d04824 d04825 d04826 d04827 d04828 d04829 d04831	GLIPIZIDE; METFORMIN EZETIMIBE ARIPIPRAZOLE NITAZOXANIDE ATOMOXETINE TERIPARATIDE TIOTROPIUM	d04913 d04915 d04917	DEXTROMETHORPH ; PHENYLEPHRINE LANSOPRAZOLE; NAPROXEN SERTACONAZOLE TOPICAL FLUOXETINE; OLANZAPINE	d05422 d05425 d05436 d05473 d05488 d05508	DARIFENACIN LOTEPREDNOL; TOBRAMYCIN OPHTHALMIC INSULIN DETEMIR DESLORATADINE; PSEUDOEPHEDRINE PRAMLINTIDE

2006 NAMCS MICRO-DATA FILE DOCUMENTATION, APPENDIX III - GENERIC LIST

d05537 d05538 d05540	TIGECYCLINE TIPRANAVIR HYDRALAZINE;	d05647	FERRIC SUBSULFATE TOPICAL	d05736 d05748 d05776	BREWER'S YEAST IODINE
	ISOSORBIDE DINITRATE	d05657	M; CRESYL ACETATE OTIC	d05813	ZOSTER VACCINE
d05578	RAMELTEON	d05659	DEFERASIROX	d05817	HUMAN
d05612	RASAGILINE	d05668	CARBINOXAMINE;		PAPILLOMAVIRUS
d05633	NEPAFENAC		HYDROCODONE;		VACCINE
	OPHTHALMIC		PHENYLEPHRINE	d05847	EFAVIRENZ;
d05635	METFORMIN;	d05674	GLIMEPIRIDE;		EMTRICITABINE;
	PIOGLITAZONE		ROSIGLITAZONE		TENOFOVIR
d05645	MEASLES; MUMPS;	d05691	SORAFENIB	d05866	GUAR GUM
	RUBELLA;	d05696	LENALIDOMIDE	d05896	SITAGLIPTIN
	VARICELLA VIRUS	d05702	METHYLSULFONYL-	d05963	COAGULATION
	VACCINE		METHANE		FACTOR IX
d05646	SACCHAROMYCES	d05717	SUNITINIB	d06848	LUTEIN
	BOULARDII LYO	d05719	RANOLAZINE		

B. DRUG ENTRY CODES AND NAMES IN NUMERIC ORDER

 B. DRUG ENTRY CODES AND NAMES IN NUMERIC ORDER

 00002 TAMIFLU
 00096 OSTEO-BIFLEX
 00184 KEPPRA

 00003 DITROPAN XL
 00096 ALOCRI
 0117 OPHTHALMIC DROPS

 00004 LIDODERM PATCH
 00101 ASA
 00180 TAMIFLU

 00005 VTMP-SMZ DS
 00111 ISSOGRBIDE DINITRATE
 00180 TAMIFLU

 00101 ISSOGRBIDE
 00117 ISSOGRBIDE
 00181 ENOZAPARIN SODIUM

 00101 IFAN
 00101 ISSOGRBIDE
 00180 TAMIFLU

 00101 IFAN
 00101 ISSOGRBIDE
 00180 TACOL

 00101 IFAN
 00101 ROSIGLITAZONE
 00200 MEPENIOLATE

 00101 IFANTHORN
 00101 URSODIOL
 00211 FORDEX

 00117 ISRCINUUS
 00117 ISRCINUS
 00117 ISRCINUS

 00121 LOTROPEX
 00112 MEDERMA
 00211 CARBARDERY

 00222 PREVNAR
 00113 ANDROGEL
 00211 CARBANDERS

 00223 PREVNAR
 00113 DURADRIN
 00221 CHINESE HERAL MEDS

 00222 PREVNAR
 00113 CANDESARTAN
 00221 CHINESE HERAL MEDS

 00223 PREVNAR
 00123 CANDESARTAN
 00224 MILK AND MOALSSES

 00232 SONATA
 00132 CALMAG
 00233 SCHAREAL MEDS

 00232 CALTRAY
 00

 1005
 2005 NAMES DECOMPACT ALL DECOMPACTATION - APPENDIX II, DRUGE DATURED

 1005
 1005
 ALLERAY BELLER OR SHOTS
 0090
 ALLERAY BELLER OR SHOTS
 01084
 LWINGAW

 1005
 ALLERAY BELLER OR SHOTS
 0090
 ALLERAY BELLER OR SHOTS
 01084
 LWINGAW

 1005
 ALLERAY BELLER OR SHOTS
 0090
 ALLERAY BELLER OR SHOTS
 01084
 LWINGAW

 1005
 ALLERAY BELLERAY
 01090
 ALLERAY BELLERAY
 01084
 LWINGAW

 1005
 PERTADERS
 0107
 TICSYN
 01084
 ALWINGAW

 1005
 TICSYN
 01097
 TICSYN
 01084
 CHINGAW

 10015
 DICTIC TICSYN
 01097
 TICSYN
 01014
 CHINGAW

 10015
 DICTIC TICSYN
 01015
 DICTIC TICSYN
 01014
 CHINGAW

 10015
 DICTIC TICSYN
 0109
 DICTIC TICSYN
 01014
 DICTIC TICSYN

 10015
 DICTIC TICSYN
 01015
 MINTERSYN
 01014
 DICTIC TICSYN

 10015
 DICTICSYN
 01015
 DICTIC TICSYN

W/HYDROCORTISONE

<page-header>2004 MARCH MURCED CALCULATE CONCUMENTATION APPENDIX UNDERCEMPT2004 MARCH MURCED CALCULATE1111PULKINGON1111PULKINGON1111PULKINGON1112PULKING1112PULKINGON<tr

 PAGE 170
 2006 NAMES MICRO-DATA FILE DOCUMENTATION - APPENDIX III, DRUG ENTRY LIST

 02125
 ANTIACID
 02214
 NULEY
 0233
 LIPRAM-CR5

 02129
 ELNIZONATATE
 02217
 XANASSP
 0233
 BERZONATATE

 02129
 CUMMERRAZOLE
 02217
 XANASSP
 0233
 BERZONATATE

 02131
 ENMERRAZOLE
 02227
 ZATANASP
 0233
 BERZONATATE

 02131
 ENMERRAZOLE
 02227
 ZATANASP
 0233
 BERZONATATE

 02131
 ENMERRAZOLE
 02227
 ZATANA
 0234
 LACANO

 02132
 ENTITATO
 02233
 BERZONA
 0234
 LACANO

 02132
 ENTITATO
 02233
 ENTITATO
 0234
 LACANO

 02133
 MALACON
 VUSCUS
 0234
 BALANCON
 0235
 ENTITA

 02144
 OTTATO
 0235
 ENTITATO
 0236
 ENTITATO
 0236
 ENTITATO

 02144
 OTTATO
 0234
 INTROLOCANE
 0236
 ENTITATO
 0236 02208MYTUSSIN DAC LIQUIDSULFATES/02982ATROPINE SULF/02209NOVOLOGHYDROCORT02987AUGMENTIN 12502212AMBROTOSE02332PANCRECARB MS-802995AURALGAN02213ELIDEL02333ROXICODONE03000AURASOL

 2000 NUMCAS MICRO-DATA FILE DOCUMENTATION, APPENDIX II - DRUG ENTRY OF
 0311
 METRO REAL
 0311
 METRO REAL
 0311
 METRO REAL

 03001
 VAQTA
 0310
 METRO REAL
 0311
 METRO REAL
 0311
 METRO REAL

 03001
 VAQTA
 0310
 METRO REAL
 0310
 METRO REAL
 0311
 METRO REAL

 03001
 METRO REAL
 0310
 METRO REAL
 0310
 METRO REAL
 0311
 METRO REAL

 03001
 METRO REAL
 0310
 METRO REAL
 0310
 METRO REAL
 0311
 METRO REAL

 03001
 METRO REAL
 0310
 METRO REAL
 0310
 METRO REAL
 0311
 METRO REAL

 03001
 METRO REAL
 0310
 METRO REAL
 0310
 METRO REAL
 0311
 METRO REAL

 03001
 METRO REAL
 0310
 METRO REAL
 0310
 METRO REAL
 0310
 METRO REAL

 03001
 METRO REAL
 0310
 METRO REAL
 0310
 METRO REAL
 0310
 METRO REAL
 0310
 METRO REAL</t

<page-header>
 MARCHEN AND ALCON ALL ALCON ALL

<page-header>2004 MACK MARCADATA FLE DOCUMENTATION, APPENDIX IN CRUIC CHARACTER, CALL04190CALCILLM MARCENEUR04191CALCILLM TARD04192CALCILLM TARD04193CALCILLM TARD0419CALCILLM TARD0419CALCILLM

<page-header>

 PAGE 162
 2000 MACCO CACA CLE DOCUMENTATION - APPENDIX UN DRUG CACAT CLE DATA

 0111
 GUNADO TROPANSA
 06198
 VITALERT
 06271
 MINIPLI,

 0113
 GUNADO TROPANSA
 06198
 VITALERT
 06271
 MINIPLI,

 0113
 GUNADO TROPANSA
 06198
 VITALERT
 06271
 MINIPLI,

 0114
 CATA CLARANT
 06270
 PARCHARAT
 06271
 MINIPLI,

 0114
 CATA CLARANT
 06270
 PARCHARAT
 06271
 MINIPLI,

 0114
 CATARAT
 06270
 PARCHARAT
 06271
 MINIPLI,
 06271
 MINIPLI,

 0114
 CATARAT
 06270
 PARCHARAT
 06271
 MINIPLI,
 06271
 MINIPLI,
 06271
 MINIPLI,
 06271
 MINIPLI,
 <

<page-header>2000 MARCE MARCENAL PLACED CONCENTRATION APPENDIX DE DECAMENTARIA2000 MARCENAL0000 DE CARLER07755CORTER0800 DE PLANAMENT0000 DE CARLER07755CORTER0800 DE PLANAMENT0000 DE CARLER07755CORTER0800 DE PLANAMENT0000 DE CARLER07755CORTER0800 DE PLANAMENT0000 DE CARLER07855CORTER0800 DE PLANAMENT0000 DE CARLER07855DE CARLER0800 DE PLANAMENT0000 DE

<page-header>1002 101

 2000 NUMCS MICRO-DATA FILE DOCUMENTATION, APPENDIX II - DRUG ENTRY LIN
 1000

 12770 FLUGROURAGIL
 1400
 HALOPERIDAL
 1500

 12780 FLUGRENCIL
 1400
 HALOPERIDAL
 1500
 HUPPENZINE

 12780 FLUGRENCIL
 1400
 HALOPERIDAL
 1500
 HUPPENZINE

 1280 FLUGRENCIL
 1400
 HEAL ON
 1500
 HUPPENZINE

 1280 FLUGRENCIL
 1400
 HEAL ON
 1500
 HUPPENZINE

 1280 FLUGRENCI
 1400
 HUPPENZINE
 1500
 HUPPENZINE

<page-header>PAGE 102200 AMACCAURACTURATION CAURACTURATION CAURACTURATION CAURACTURATION1947 SALANTAR1758 SILVARA1947 SALANTAR1758 SILVARA1948 SILVARA1758 SILVARA1948 SILVARA1758 SILVARA1949 SILVARA1758 SILVARA1949 SILVARA1758 SILVARA1949 SILVARA1758 SILVARA1949 SILVARA1758 SILVARA1949 SILVARA1758 SILVARA1940 SILVARA1758 SILVARA

<page-header>2000 MUCRY CONCENTRATION OF PENDENCIP CONCENTRATION2001 MUCRY CONCENTRATION1983 MICRA COLE2005 MUCRY CONSTANT1983 MICRA COLE2005 MUCRY CONSTANT1983 MICRA COLE2005 MUCRY CONSTANT1983 MICRA COLE2005 MUCRY CONSTANT1984 MICRA CONSTANT2005 MUCRY CONSTANT1985 MICRA CONSTANT2005 MUCRY CONSTANT1986 MICRA CONSTANT2005 MUCRY CONSTANT1987 MUCRY CONSTANT2005 MUCRY CONSTANT1988 MICRA CONSTANT2005 MUCRY CONSTANT1989 MICRA CONSTANT2005 MUCRY CONSTANT1980 MUCRY CONSTANT2005 MUCRY CONSTANT1980 MUCRY CONSTANT2005 MUCRY CONSTANT1980 MUCRY CONSTANT2005 MUCRY CONSTANT<

<page-header>2004 NAME & CRUCE DECIDENCE CONTROL OF CRUCE DECIDENCE DECIDE DECIDENCE DECIDENCE DECIDENCE DECIDENCE

<page-header>PAGE 162DescriptionPage 17 is a construction of the construction of the

<page-header>2004 NAMES AND CONCENTRATION APPENDIX I DECIGATION OF CONCENTRATION3222UNEXAMINE2005 TRIVINE LOR3222UNEXAMINE3222UNEXAMINE2016 TRIVINE LOR3222UNEXAMINE3222UNEXAMINE2016 TRIVINE LOR3222UNEXAMINE3222UNEXAMINE2016 TRIVINE LOR3232UNEXAMINE3232UNEXAMINE2017 TRIVINE LOR3335UNEXAMINE3335UNEXAMINE2018 TRIVINE LOR3335UNEXAMINE3335UNEXAMINE2019 TRIVINE LOR3335UNEXAMINE3335UNEXAMINE2019 TRIVINE LOR3335UNEXAMINE3335UNEXAMINE2020 TRIVINE LOR3335UNEXAMINE3335UNEXAMINE2021 TRIVINE LOR3335UNEXAMINE3335UNEXAMINE2023 TRIVINE LOR3336UNEXAMINE3336UNEXAMINE2024 TRIVINE LOR3336UNEXAMINE3336UNEXAMINE2025 TRIVINE LOR3336UNEXAMINE3336UNEXAMINE2026 TRIVINE LOR3336UNEXAMINE3336UNEXAMINE2026 TRIVINE LOR3336UNEXAMINE3336UNEXAMINE2026 TRIVINE LOR3336UNEXAMINE3336UNEXAMINE2026 TRIVINE LOR3336UNEXAMINE3336UNEXAMINE2026 TRIVINE LOR3336UNEXAMINEUNEXAMINE3336UNEXAMINE2026 TRIVINE LOR3336UNEXAMINEUNEXAMINEUNEXAMINE2026 TRIVINE LOR3336UNEXAMINEUNEXAMINE<

<page-header>2021 2000 Control Control

<page-header>
 MARCINE MARCHARACTERIC DOCUMENTATION APPENDIX DE CONCENCIÓN DE CONCENCIÓ

<page-header>PAGE 182200 CAUCCIONACIA LE DOCUMENTATION - APPENDIX I, DUCUENTATION - APPEN

<page-header>2000 MARCMACADATA FLE DOCUMENTATION APPENDIX IN CARCENT3411 PC3110 20003225 CARREDOLUTION3111 20003300 DENDION3111 20003311 DEDUTAMINE3111 20003320 PORTOPIN3111 20003320 PORTOPIN3111 20003330 DENDIAMINE3111 2000</t

<page-header>PAGE 130200 ALCMICE9142 4CHORE STYRAUME9032 MITRATE9428 5SHARPEO9142 4CHORE STYRAUME9032 MITRATE9429 5SHARPEO9142 6CHORE STYRAUME9032 MITRATE9429 5SHARPEO9142 6CHORE STYRAUME9032 MITRATE9429 5SHARPEO9142 6CHORE STYRAUME9032 MITRATE9429 5SHARPEO9142 6CHORE STYRAUME9032 MITRATE9439 5ACCORE9142 6CHORE STYRAUME9032 MITRATE9439 5ACCORE STYRAUME9142 6CHORE STYRAUME9032 MITRATE9439 5ACCORE STYRAUME9143 CARCER9143 CARCER9143 CARCER9439 5CHORE STYRAUME9143

<page-header>PAGE 162200 ADMIC SUBJIC9713CUMBRIN DURATION CONCURSION CONCURSION

Appendix III Multum Lexicon End-User License Agreement

1. Introduction

A. This License Agreement (the "License") applies to the Multum Lexicon database (the "Database"). This License does not apply to any other products or services of Cerner Multum, Inc. ("Multum"). A "work based on the Database" means either the Database or any derivative work under copyright law; i.e., a work containing the Database or a substantial portion of it, either verbatim or with modifications. A translation of the Database is included without limitation in the term "modification". Each end-user/licensee is addressed herein as "you".

B. Your use of the Database acknowledges acceptance of these restrictions, disclaimers, and limitations. You expressly acknowledge and agree that Multum is not responsible for the results of your decisions resulting from the use of the Database, including, but not limited to, your choosing to seek or not to seek professional medical care, or from choosing or not choosing specific treatment based on the Database.

C. Every effort has been made to ensure that the information provided in the Database is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive.

D. Multum does not assume any responsibility for any aspect of healthcare administered or not administered with the aid of information the Database provides.

2. Terms and Conditions for Copying, Distribution and Modification

A. You may copy and distribute verbatim copies of the Database as you receive it, in any medium, provided that you conspicuously and appropriately publish on each copy an appropriate copyright notice and disclaimer of warranty; keep intact all the notices that refer to this License and to the absence of any warranty; and give any other recipients of the Database a copy of this License (the readme.txt file) along with the Database and anything else that is part of the package, which should be identified.

B. You may modify your copy or copies of the Database or any portion of it to form a derivative work, and copy and distribute such modifications or work under the terms of Section 2.A. above, provided that you also meet all of these conditions:

i) You must cause the modified files to carry prominent notices stating that they are derived from the Multum Lexicon database from Cerner Multum, Inc. and that you changed the files and the date of any change(s).

ii) If you incorporate modified files into a computer program, you must cause it, when started running for interactive use in the most ordinary way, to print or display an announcement including an appropriate copyright notice, a notice that you have modified the Multum Lexicon database from Cerner Multum, Inc., and a notice that there is no warranty (or that you provide the warranty) and telling the user how to view a copy of this License.

C. It is not the intent of this section to claim rights or contest your rights to work written entirely by you; rather, the intent is to exercise the right to control the distribution of derivative or collective works based on the Database.

D. You may copy and distribute the Database (or a work based on it, under Section 2.B.) in an encoded form under the terms of Sections 2.A. and 2.B. above provided that you also do one of the following:

i) Accompany it with the complete corresponding machine-readable plain text, which must be distributed under the terms of Sections 2.A and 2.B. above on a medium customarily used for software interchange; or,

ii) Accompany it with a written offer to give any third party, for no charge, a complete machine-readable copy of the Database (and the entirety of your derivative work based on it, under Section 2.B.), to be distributed under the terms of Sections 2.A. and 2.B. above on a medium customarily used for software interchange.

E. You may not copy, modify, sublicense, or distribute the Database except as expressly provided under this License. Any attempt otherwise to copy, modify, sublicense or distribute the Database will automatically terminate your rights under this License. However, parties who have received copies, or rights, from you under this License will not have their licenses terminated so long as such parties remain in full compliance.

F. You are not required to accept this License. However, nothing else grants you permission to copy, modify or distribute the Database or its derivative works. These actions are prohibited by law if you do not accept this License. Therefore, by copying, modifying or distributing the Database (or any work based on the Database), you indicate your acceptance of this License to do so, and all its terms and conditions for copying, distributing or modifying the Database or works based on it.

G. Each time you redistribute the Database (or any work based on the Database), the recipient automatically receives a license from Multum to copy, distribute or modify the Database subject to these terms and conditions. You may not impose any further restrictions on the recipients' exercise of the rights granted herein. You are not responsible for enforcing compliance by third parties to this License.

3. Disclaimer of Warranties; Limitation of Damages

A. BECAUSE THE DATABASE IS LICENSED FREE OF CHARGE, THERE IS NO WARRANTY FOR THE PROGRAM OR DATA, TO THE EXTENT PERMITTED BY APPLICABLE LAW. EXCEPT WHEN OTHERWISE STATED IN WRITING. MULTUM AND/OR OTHER PARTIES PROVIDE THE DATABASE "AS IS" WITHOUT WARRANTY OF ANY KIND, EITHER EXPRESSED, STATUTORY OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, THE IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. THE ENTIRE RISK AS TO THE QUALITY AND PERFORMANCE OF THE DATABASE IS WITH YOU. SHOULD THE DATABASE PROVE DEFECTIVE, INCOMPLETE, OR INACCURATE, YOU ASSUME THE RESPONSIBILITY AND COST OF ALL NECESSARY SERVICING, REPAIR OR CORRECTION.

B. IN NO EVENT (UNLESS REQUIRED BY APPLICABLE LAW OR AGREED TO IN WRITING) WILL MULTUM, OR ANY OTHER PARTY WHO MAY MODIFY AND/OR REDISTRIBUTE THE DATABASE AS PERMITTED ABOVE, BE LIABLE FOR ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL, OR INDIRECT DAMAGES, INCLUDING DAMAGES FOR LOSS OF PROFITS, LOSS OF BUSINESS, OR DOWN TIME, EVEN IF MULTUM OR ANY OTHER PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.

C. IN ADDITION, WITHOUT LIMITING THE FOREGOING, THE DATABASE HAS BEEN DESIGNED FOR USE IN THE UNITED STATES ONLY AND COVERS THE DRUG PRODUCTS USED IN PRACTICE IN THE UNITED STATES. MULTUM PROVIDES NO CLINICAL INFORMATION OR CHECKS FOR DRUGS NOT AVAILABLE FOR SALE IN THE UNITED STATES AND CLINICAL PRACTICE PATTERNS OUTSIDE THE UNITED STATES MAY DIFFER SUBSTANTIALLY FROM INFORMATION SUPPLIED BY THE DATABASE. MULTUM DOES NOT WARRANT THAT USES OUTSIDE THE UNITED STATES ARE APPROPRIATE.

D. You acknowledge that updates to the Database are at the sole discretion of Multum. Multum makes no representations or warranties whatsoever, express or implied, with respect to the compatibility of the Database, or future releases thereof, with any computer hardware or software, nor does Multum represent or warrant the continuity of the features or the facilities provided by or through the Database as between various releases thereof.

E. Any warranties expressly provided herein do not apply if: (i) the end-user alters, mishandles or improperly uses, stores or installs all, or any part, of the Database, (ii) the end-user uses, stores or installs the Database on a computer system which fails to meet the specifications provided by Multum, or (iii) the breach of warranty arises out of or in connection with acts or omissions of persons other than Multum.

4. Assumption of Risk, Disclaimer of Liability, Indemnity

A. THE END-USER ASSUMES ALL RISK FOR SELECTION AND USE OF THE DATABASE AND CONTENT PROVIDED THEREON. MULTUM SHALL NOT BE RESPONSIBLE FOR ANY ERRORS, MISSTATEMENTS, INACCURACIES OR OMISSIONS REGARDING CONTENT DELIVERED THROUGH THE DATABASE OR ANY DELAYS IN OR INTERRUPTIONS OF SUCH DELIVERY.

B. THE END-USER ACKNOWLEDGES THAT MULTUM: (A) HAS NO CONTROL OF OR RESPONSIBILITY FOR THE END-USER'S USE OF THE DATABASE OR CONTENT PROVIDED THEREON, (B) HAS NO KNOWLEDGE OF THE SPECIFIC OR UNIQUE CIRCUMSTANCES UNDER WHICH THE DATABASE OR CONTENT PROVIDED THEREON MAY BE USED BY THE END-USER, (C) UNDERTAKES NO OBLIGATION TO SUPPLEMENT OR UPDATE CONTENT OF THE DATABASE, AND (D) HAS NO LIABILITY TO ANY PERSON FOR ANY DATA OR INFORMATION INPUT ON THE DATABASE BY PERSONS OTHER THAN MULTUM.

C. MULTUM SHALL NOT BE LIABLE TO ANY PERSON (INCLUDING BUT NOT LIMITED TO THE END-USER AND PERSONS TREATED BY OR ON BEHALF OF THE END-USER) FOR, AND THE END-USER AGREES TO INDEMNIFY AND HOLD MULTUM HARMLESS FROM ANY CLAIMS, LAWSUITS, PROCEEDINGS, COSTS, ATTORNEYS' FEES, DAMAGES OR OTHER LOSSES (COLLECTIVELY, "LOSSES") ARISING OUT OF OR RELATING TO (A) THE END-USER'S USE OF THE DATABASE OR CONTENT PROVIDED THEREON OR ANY EQUIPMENT FURNISHED IN CONNECTION THEREWITH AND (B) ANY DATA OR INFORMATION INPUT ON THE DATABASE BY END-USER, IN ALL CASES INCLUDING BUT NOT LIMITED TO LOSSES FOR TORT, PERSONAL INJURY, MEDICAL MALPRACTICE OR PRODUCT LIABILITY.

5. Miscellaneous

A. You warrant that you have authority within the organization you identified during registration for the Database to enter into license agreements with other organizations including Multum.

B. You agree that Multum may identify you and/or your organization by name as a "licensee", "licensed user", or "licensing organization" of the Database or a "client" of Multum in Multum's external market communications. You also agree that Multum may issue, if it desires, a press release stating that you and/or your organization have licensed the Database.

C. If conditions are imposed on you (whether by court order, agreement or otherwise) that contradict the conditions of this License, they do not excuse you from the conditions of this License. If you cannot distribute so as to satisfy simultaneously your obligations under this License and any other obligations, then as a consequence you may not distribute the Database at all.

D. If any portion of this License is held invalid or unenforceable under any particular circumstance, the balance of this License is intended to apply and the License as a whole is intended to apply in other circumstances.

E. If the distribution and/or use of the Database is or becomes restricted in certain countries either by patents or by copyrighted interfaces, Multum may add an explicit geographical distribution limitation excluding those countries, so that distribution is permitted only in or among countries not thus excluded. In such case, this License incorporates the limitation as if written in the body of this License.

Multum Lexicon Copyright (c) 1997, 1998, 1999, 2000, 2001, 2002, 2003, 2004, 2005, 2006, 2007 Cerner Multum, Inc. 2000 South Colorado Blvd, Suite 11000 Denver, Colorado 80222

APPENDIX III. MULTUM CLASSIFICATION OF THERAPEUTIC CLASSES (DRUG CATEGORIES)

Level 1			Level 2		Level 3		
CAT ID	CATEGORY NAME	CATID	CATEGORY NAME	CAT ID	CATEGORY NAME		
001	anti-infectives	002	amebicides				
001	anti-infectives	003	anthelmintics				
001	anti-infectives	004	antifungals	235	Polyenes		
001	anti-infectives	004	antifungals	236	azole antifungals		
001	anti-infectives	004	antifungals	237	miscellaneous antifungals		
001	anti-infectives	004	antifungals	310	echinocandins		
001	anti-infectives	005	antimalarial agents	238	antimalarial quinolines		
001	anti-infectives	005	antimalarial agents	239	miscellaneous antimalarials		
001	anti-infectives	005	antimalarial agents	328	antimalarial combinations		
001	anti-infectives	006	antituberculosis agents	230	aminosalicylates		
001	anti-infectives	006	antituberculosis agents	231	nicotinic acid derivatives		
001	anti-infectives	006	antituberculosis agents	232	rifamycin derivatives		
001	anti-infectives	006	antituberculosis agents	233	streptomyces derivatives		
001	anti-infectives	006	antituberculosis agents	234	miscellaneous antituberculosis agents		
001	anti-infectives	006	antituberculosis agents	329	antituberculosis combinations		
001	anti-infectives	007	antiviral agents	175	protease inhibitors		
001	anti-infectives	007	antiviral agents	176	NRTIS		
001	anti-infectives	007	antiviral agents	177	miscellaneous antivirals		
001	anti-infectives	007	antiviral agents	227	NNRTIS		
001	anti-infectives	007	antiviral agents	228	adamantane antivirals		
001	anti-infectives	007	antiviral agents	229	purine nucleosides		
001	anti-infectives	007	antiviral agents	281	neuraminidase inhibitors		
001	anti-infectives	007	antiviral agents	327	antiviral combinations		
001	anti-infectives	007	antiviral agents	330	antiviral interferons		
001	anti-infectives	007	antiviral agents	364	chemokine receptor antagonist		

	Level 1		Level 2		Level 3
CAT ID	CATEGORY NAME	CAT ID	CATEGORY NAME	CAT ID	CATEGORY NAME
001	anti-infectives	007	antiviral agents	366	integrase strand transfer inhibitor
001	anti-infectives	008	carbapenems		
001	anti-infectives	009	cephalosporins	159	first generation cephalosporins
001	anti-infectives	009	cephalosporins	160	second generation cephalosporins
001	anti-infectives	009	cephalosporins	161	third generation cephalosporins
001	anti-infectives	009	cephalosporins	162	fourth generation cephalosporins
001	anti-infectives	010	leprostatics		
001	anti-infectives	011	macrolide derivatives	304	macrolides
001	anti-infectives	011	macrolide derivatives	305	ketolides
001	anti-infectives	012	miscellaneous antibiotics		
001	anti-infectives	013	penicillins	222	penicillinase resistant penicillins
001	anti-infectives	013	penicillins	223	antipseudomonal penicillins
001	anti-infectives	013	penicillins	224	aminopenicillins
001	anti-infectives	013	penicillins	225	beta-lactamase inhibitors
001	anti-infectives	013	penicillins	226	natural penicillins
001	anti-infectives	014	quinolones		
001	anti-infectives	015	sulfonamides		
001	anti-infectives	016	tetracyclines		
001	anti-infectives	017	urinary anti-infectives		
001	anti-infectives	018	aminoglycosides		
001	anti-infectives	240	lincomycin derivatives		
001	anti-infectives	315	glycylcyclines		
020	antineoplastics	021	alkylating agents		
020	antineoplastics	022	antibiotics/antineoplastics		
020	antineoplastics	023	antimetabolites		
020	antineoplastics	024	hormones/antineoplastics		
020	antineoplastics	025	miscellaneous antineoplastics		
020	antineoplastics	026	mitotic inhibitors		

	Level 1		Level 2		Level 3
CAT ID	CATEGORY NAME	CATID	CATEGORY NAME	CAT ID	CATEGORY NAME
020	antineoplastics	323	antineoplastic monoclonal antibodies		
020	antineoplastics	324	antineoplastic interferons		
020	antineoplastics	343	tyrosine kinase inhibitors		
028	biologicals	030	antitoxins and antivenins		
028	biologicals	032	colony stimulating factors		
028	biologicals	034	in vivo diagnostic biologicals		
028	biologicals	036	recombinant human erythropoietins		
040	cardiovascular agents	041	agents for hypertensive emergencies		
040	cardiovascular agents	042	angiotensin converting enzyme inhibitors		
040	cardiovascular agents	043	antiadrenergic agents, peripherally acting		
040	cardiovascular agents	044	antiadrenergic agents, centrally acting		
040	cardiovascular agents	045	antianginal agents		
040	cardiovascular agents	046	antiarrhythmic agents		
040	cardiovascular agents	047	beta-adrenergic blocking agents	274	cardioselective beta blockers
040	cardiovascular agents	047	beta-adrenergic blocking agents	275	non-cardioselective beta blockers
040	cardiovascular agents	048	calcium channel blocking agents		
040	cardiovascular agents	049	diuretics	154	loop diuretics
040	cardiovascular agents	049	diuretics	155	potassium-sparing diuretics
040	cardiovascular agents	049	diuretics	156	thiazide diuretics
040	cardiovascular agents	049	diuretics	157	carbonic anhydrase inhibitors
040	cardiovascular agents	049	diuretics	158	miscellaneous diuretics
040	cardiovascular agents	050	inotropic agents		
040	cardiovascular agents	051	miscellaneous cardiovascular agents		
040	cardiovascular agents	052	peripheral vasodilators		
040	cardiovascular agents	053	vasodilators		
040	cardiovascular agents	054	vasopressors		
040	cardiovascular agents	055	antihypertensive combinations		
040	cardiovascular agents	056	angiotensin II inhibitors		

	Level 1		Level 2		Level 3
CAT ID	CATEGORY NAME	CAT ID	CATEGORY NAME	CAT ID	CATEGORY NAME
040	cardiovascular agents	303	agents for pulmonary hypertension		
040	cardiovascular agents	319	vasopressin antagonists		
040	cardiovascular agents	325	sclerosing agents		
040	cardiovascular agents	340	aldosterone receptor agonists		
040	cardiovascular agents	342	renin inhibitors		
057	central nervous system agents	058	analgesics	060	narcotic analgesics
057	central nervous system agents	058	analgesics	061	nonsteroidal anti-inflammatory agents
057	central nervous system agents	058	analgesics	062	Salicylates
057	central nervous system agents	058	analgesics	063	analgesic combinations
057	central nervous system agents	058	analgesics	191	narcotic analgesic combinations
057	central nervous system agents	058	analgesics	193	antimigraine agents
057	central nervous system agents	058	analgesics	278	cox-2 inhibitors
057	central nervous system agents	064	anticonvulsants	199	hydantoin anticonvulsants
057	central nervous system agents	064	anticonvulsants	200	succinimide anticonvulsants
057	central nervous system agents	064	anticonvulsants	201	barbiturate anticonvulsants
057	central nervous system agents	064	anticonvulsants	202	oxazolidinedione anticonvulsants
057	central nervous system agents	064	anticonvulsants	203	benzodiazepine anticonvulsants
057	central nervous system agents	064	anticonvulsants	204	miscellaneous anticonvulsants
057	central nervous system agents	064	anticonvulsants	311	dibenzazepine anticonvulsants
057	central nervous system agents	064	anticonvulsants	345	fatty acid derivative anticonvulsants
057	central nervous system agents	064	anticonvulsants	346	gamma-aminobutyric acid reuptake inhibitors
057	central nervous system agents	064	anticonvulsants	347	gamma-aminobutyric acid analogs
057	central nervous system agents	064	anticonvulsants	348	triazine anticonvulsants
057	central nervous system agents	064	anticonvulsants	349	carbamate anticonvulsants
057	central nervous system agents	064	anticonvulsants	350	pyrrolidine anticonvulsants
057	central nervous system agents	064	anticonvulsants	351	carbonic anhydrase inhibitor anticonvulsants

	Level 1		Level 2		Level 3
CAT ID	CATEGORY NAME	CAT ID	CATEGORY NAME	CAT ID	CATEGORY NAME
057	central nervous system agents	065	antiemetic/antivertigo agents	196	phenothiazine antiemetics
057	central nervous system agents	065	antiemetic/antivertigo agents	197	anticholinergic antiemetics
057	central nervous system agents	065	antiemetic/antivertigo agents	198	miscellaneous antiemetics
057	central nervous system agents	066	antiparkinson agents	205	anticholinergic antiparkinson agents
057	central nervous system agents	066	antiparkinson agents	206	miscellaneous antiparkinson agents
057	central nervous system agents	066	antiparkinson agents	276	dopaminergic antiparkinsonism agents
057	central nervous system agents	067	anxiolytics, sedatives, and hypnotics	068	Barbiturates
057	central nervous system agents	067	anxiolytics, sedatives, and hypnotics	069	Benzodiazepines
057	central nervous system agents	067	anxiolytics, sedatives, and hypnotics	070	miscellaneous anxiolytics, sedatives and hypnotics
057	central nervous system agents	071	CNS stimulants		
057	central nervous system agents	072	general anesthetics		
057	central nervous system agents	073	muscle relaxants	074	neuromuscular blocking agents
057	central nervous system agents	073	muscle relaxants	178	skeletal muscle relaxants
057	central nervous system agents	073	muscle relaxants	179	skeletal muscle relaxant combinations
057	central nervous system agents	080	miscellaneous central nervous system agents		
057	central nervous system agents	253	anorexiants		
057	central nervous system agents	312	cholinergic agonists		
057	central nervous system agents	313	cholinesterase inhibitors		
081	coagulation modifiers	082	anticoagulants	261	heparins
081	coagulation modifiers	082	anticoagulants	262	coumarins and indandiones
081	coagulation modifiers	082	anticoagulants	283	thrombin inhibitors
081	coagulation modifiers	082	anticoagulants	285	factor Xa inhibitors
081	coagulation modifiers	083	antiplatelet agents	211	platelet aggregation inhibitors
081	coagulation modifiers	083	antiplatelet agents	212	glycoprotein platelet inhibitors
081	coagulation modifiers	084	heparin antagonists		

	Level 1		Level 2		Level 3	
CAT ID	CATEGORY NAME	CAT ID	CATEGORY NAME	CAT ID	CATEGORY NAME	
081	coagulation modifiers	086	thrombolytics			
087	gastrointestinal agents	088	antacids			
087	gastrointestinal agents	090	antidiarrheals			
087	gastrointestinal agents	091	digestive enzymes			
087	gastrointestinal agents	092	gallstone solubilizing agents			
087	gastrointestinal agents	093	GI stimulants			
087	gastrointestinal agents	094	H2 antagonists			
087	gastrointestinal agents	095	laxatives			
087	gastrointestinal agents	096	miscellaneous GI agents			
087	gastrointestinal agents	272	proton pump inhibitors			
087	gastrointestinal agents	277	5-aminosalicylates			
087	gastrointestinal agents	354	H. pylori eradication agents			
087	gastrointestinal agents	355	functional bowel disorder agents	89	anticholinergics/antispasmodics	
087	gastrointestinal agents	355	functional bowel disorder agents	356	serotoninergic neuroenteric modulators	
087	gastrointestinal agents	355	functional bowel disorder agents	362	chloride channel activators	
097	hormones	098	adrenal cortical steroids	300	corticotrophin	
097	hormones	098	adrenal cortical steroids	301	glucocorticoids	
097	hormones	098	adrenal cortical steroids	302	mineralocorticoids	
097	hormones	100	miscellaneous hormones			
097	hormones	101	sex hormones	102	contraceptives	
097	hormones	101	sex hormones	182	androgens and anabolic steroids	
097	hormones	101	sex hormones	183	estrogens	
097	hormones	101	sex hormones	184	gonadotropins	
097	hormones	101	sex hormones	185	progestins	
097	hormones	101	sex hormones	186	sex hormone combinations	
097	hormones	101	sex hormones	187	miscellaneous sex hormones	
097	hormones	101	sex hormones	279	gonadotropin releasing hormones	

	Level 1		Level 2		Level 3
CAT ID	CATEGORY NAME	CAT ID	CATEGORY NAME	CAT ID	CATEGORY NAME
097	hormones	101	sex hormones	288	5-alpha-reductase inhibitors
097	hormones	103	thyroid drugs		
097	hormones	217	bisphosphonates		
097	hormones	295	growth hormones		
097	hormones	318	insulin-like growth factor		
097	hormones	357	growth hormone receptor blockers		
105	miscellaneous agents	106	antidotes		
105	miscellaneous agents	107	chelating agents		
105	miscellaneous agents	108	cholinergic muscle stimulatns		
105	miscellaneous agents	109	local injectable anesthetics		
105	miscellaneous agents	110	miscellaneous uncategorized agents		
105	miscellaneous agents	111	psoralens		
105	miscellaneous agents	113	genitourinary tract agents	263	impotence agents
105	miscellaneous agents	113	genitourinary tract agents	264	urinary antispasmodics
105	miscellaneous agents	113	genitourinary tract agents	265	urinary pH modifiers
105	miscellaneous agents	113	genitourinary tract agents	266	miscellaneous genitourinary tract agents
105	miscellaneous agents	114	illicit (street) drugs		
105	miscellaneous agents	192	antirheumatics		
105	miscellaneous agents	270	antipsoriatics		
105	miscellaneous agents	284	viscosupplementation agents		
105	miscellaneous agents	320	smoking cessation agents		
115	nutritional products	116	iron products		
115	nutritional products	117	minerals and electrolytes		
115	nutritional products	118	oral nutritional supplements		
115	nutritional products	119	vitamins		
115	nutritional products	120	vitamin and mineral combinations		
115	nutritional products	121	intravenous nutritional products		

	Level 1		Level 2		Level 3	
CAT ID	CATEGORY NAME	CAT ID	CATEGORY NAME	CAT ID	CATEGORY NAME	
122	respiratory agents	123	antihistamines			
122	respiratory agents	124	antitussives			
122	respiratory agents	125	bronchodilators	126	methylxanthines	
122	respiratory agents	125	bronchodilators	180	adrenergic bronchodilators	
122	respiratory agents	125	bronchodilators	181	bronchodilator combinations	
122	respiratory agents	125	bronchodilators	299	anticholinergic bronchodilators	
122	respiratory agents	127	decongestants		Ŭ Ŭ	
122	respiratory agents	128	expectorants			
122	respiratory agents	129	miscellaneous respiratory agents			
122	respiratory agents	130	respiratory inhalant products	296	inhaled corticosteroids	
122	respiratory agents	130	respiratory inhalant products	297	mucolytics	
122	respiratory agents	130	respiratory inhalant products	298	mast cell stabilizers	
122	respiratory agents	131	antiasthmatic combinations			
122	respiratory agents	132	upper respiratory combinations			
122	respiratory agents	243	leukotriene modifiers			
122	respiratory agents	273	lung surfactants			
133	topical agents	134	anorectal preparations			
133	topical agents	135	antiseptic and germicides			
133	topical agents	136	dermatological agents	137	topical anti-infectives	
133	topical agents	136	dermatological agents	138	topical steroids	
133	topical agents	136	dermatological agents	139	topical anesthetics	
133	topical agents	136	dermatological agents	140	miscellaneous topical agents	
133	topical agents	136	dermatological agents	141	topical steroids with anti-infectives	
133	topical agents	136	dermatological agents	143	topical acne agents	
133	topical agents	136	dermatological agents	144	topical antipsoriatics	
133	topical agents	136	dermatological agents	248	topical emollients	
133	topical agents	136	dermatological agents	290	topical antibiotics	
133	topical agents	136	dermatological agents	291	topical antivirals	

Level 1			Level 2		Level 3		
CAT ID	CATEGORY NAME	CATID	CATEGORY NAME	CAT ID	CATEGORY NAME		
133	topical agents	136	dermatological agents	292	topical antifungals		
133	topical agents	146	mouth and throat products				
133	topical agents	147	ophthalmic preparations	163	ophthalmic anti-infectives		
133	topical agents	147	ophthalmic preparations	164	ophthalmic glaucoma agents		
133	topical agents	147	ophthalmic preparations	165	ophthalmic steroids		
133	topical agents	147	ophthalmic preparations	166	ophthalmic steroids with anti- infectives		
133	topical agents	147	ophthalmic preparations	167	ophthalmic anti-inflammatory agents		
133	topical agents	147	ophthalmic preparations	168	ophthalmic lubricants and irrigations		
133	topical agents	147	ophthalmic preparations	169	miscellaneous ophthalmic agents		
133	topical agents	147	ophthalmic preparations	267	ophthalmic antihistamines and decongestants		
133	topical agents	147	ophthalmic preparations	286	mydriatics		
133	topical agents	147	ophthalmic preparations	287	ophthalmic anesthetics		
133	topical agents	147	ophthalmic preparations	321	ophthalmic diagnostic agents		
133	topical agents	147	ophthalmic preparations	322	ophthalmic surgical agents		
133	topical agents	147	ophthalmic preparations	353	anti-angiogenic ophthalmic agents		
133	topical agents	148	otic preparations	170	otic anti-infectives		
133	topical agents	148	otic preparations	171	otic steroids with anti-infectives		
133	topical agents	148	otic preparations	172	miscellaneous otic agents		
133	topical agents	150	sterile irrigating solutions				
133	topical agents	151	vaginal preparations	149	spermicides		
133	topical agents	151	vaginal preparations	268	vaginal anti-infectives		
133	topical agents	151	vaginal preparations	269	miscellaneous vaginal agents		
133	topical agents	247	nasal preparations	244	nasal lubricants and irrigations		
133	topical agents	247	nasal preparations	245	nasal steroids		
133	topical agents	247	nasal preparations	246	nasal antihistamines and decongestants		
133	topical agents	247	nasal preparations	344	nasal anti-infectives		

	Level 1		Level 2		Level 3
CAT ID	CATEGORY NAME	CAT ID	CATEGORY NAME	CAT ID	CATEGORY NAME
218	alternative medicines	219	nutraceutical products		
218	alternative medicines	220	herbal products		
218	alternative medicines	363	probiotics		
242	psychotherapeutic agents	249	antidepressants	76	miscellaneous antidepressants
242	psychotherapeutic agents	249	antidepressants	208	SSRI antidepressants
242	psychotherapeutic agents	249	antidepressants	209	tricyclic antidepressants
242	psychotherapeutic agents	249	antidepressants	250	monoamine oxidase inhibitors
242	psychotherapeutic agents	249	antidepressants	306	phenylpiperazine antidepressants
242	psychotherapeutic agents	249	antidepressants	307	tetracyclic antidepressants
242	psychotherapeutic agents	249	antidepressants	308	SSNRI antidepressants
242	psychotherapeutic agents	251	antipsychotics	77	miscellaneous antipsychotic agents
242	psychotherapeutic agents	251	antipsychotics	79	psychotherapeutic combinations
242	psychotherapeutic agents	251	antipsychotics	210	phenothiazine antipsychotics
242	psychotherapeutic agents	251	antipsychotics	280	thioxanthenes
242	psychotherapeutic agents	251	antipsychotics	341	atypical antipsychotics
254	immunologic agents	031	bacterial vaccines		
254	immunologic agents	037	toxoids		
254	immunologic agents	038	viral vaccines		
254	immunologic agents	039	miscellaneous biologicals		
254	immunologic agents	104	immunosuppressive agents		
254	immunologic agents	256	interferons		
254	immunologic agents	257	monoclonal antibodies		
331	radiologic agents	027	radiopharmaceuticals	338	diagnostic radiopharmaceuticals
331	radiologic agents	027	radiopharmaceuticals	339	therapeutic radiopharmaceuticals
331	radiologic agents	112	radiocontrast agents	333	iodinated contrast media
331	radiologic agents	112	radiocontrast agents	334	lymphatic staining agents
331	radiologic agents	112	radiocontrast agents	335	magnetic resonance imaging contrast media

Level 1			Level 2		Level 3
CAT ID	CATEGORY NAME	CAT ID	CATEGORY NAME	CAT ID	CATEGORY NAME
331	radiologic agents	112	radiocontrast agents	336	non-iodinated contrast media
331	radiologic agents	112	radiocontrast agents	337	ultrasound contrast media
331	radiologic agents	332	radiologic adjuncts		
358	metabolic agents	019	antihyperlipidemic agents	173	HMG-CoA reductase inhibitors
358	metabolic agents	019	antihyperlipidemic agents	174	miscellaneous antihyperlipidemic agents
358	metabolic agents	019	antihyperlipidemic agents	241	fibric acid derivatives
358	metabolic agents	019	antihyperlipidemic agents	252	bile acid sequestrants
358	metabolic agents	019	antihyperlipidemic agents	316	cholesterol absorption inhibitors
358	metabolic agents	019	antihyperlipidemic agents	317	antihyperlipidemic combinations
358	metabolic agents	099	antidiabetic agents	213	sulfonylureas
358	metabolic agents	099	antidiabetic agents	214	non-sulfonylureas
358	metabolic agents	099	antidiabetic agents	215	insulin
358	metabolic agents	099	antidiabetic agents	216	alpha-glucosidase inhibitors
358	metabolic agents	099	antidiabetic agents	271	thiazolidinediones
358	metabolic agents	099	antidiabetic agents	282	meglitinides
358	metabolic agents	099	antidiabetic agents	309	miscellaneous antidiabetic agents
358	metabolic agents	099	antidiabetic agents	314	antidiabetic combinations
358	metabolic agents	289	antihyperuricemic agents		
358	metabolic agents	293	glucose elevating agents		
358	metabolic agents	359	peripherally acting antiobesity agents		
358	metabolic agents	360	lysosomal enzymes		
358	metabolic agents	361	miscellaneous metabolic agents		
153	plasma expanders				
365	medical gas				